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ABSTRACT 
A. 1 Background 
The need to assess safety as well as clinical and economic effectiveness of health care 
innovations and thus prioritise health care provision, created the need for structured 
health technology assessment (HTA) programs [Gafni et al. 1993b; Henshall et al. 
1997; Stevens et al. 20041. Sleep apnoea hypopnoea syndrome (SAHS) affects 2-4% of the 
adult population[Young et al. 19931 who are disabled by daytime dysfunction [Hardinge 
et al. 1995; Johns 1993b; Mitler 1993; Sauter et al. 2oool and a heightened mortality and 
morbidity [Greenberg et al. 1995; Kiely et al. 2000; Peker et al. 1999; Sanner et al. 
1997; Tremel et al. 1999; Wilcox et al. 1998; Moruzzi et al 1999; Malone et al. 1991]. The 
advent of continuous positive airway pressure devices (CPAP) [Sullivan et al 1981] made 
it possible to treat safely, patients over a wider spectrum of disease severity [Borak et al. 
1996; Mar et al. 2003; Engleman et al igg7a], yet its diffusion and adoption appears to 
follow a heterogenous pattern. 
A. 2 Study design 
A retrospective case-control study of 603 SAHS patients was followed by a prospective, 
randomised, parallel group trial (RCT) of CPAP compared to lifestyle intervention 
(including weight reduction and sleep hygiene strategy) comparing clinical, health related 
quality of life (HRQL) and cost-utility ratios (CUR). The final study is a qualitative survey 
assessing the factors influencing the diffusion and adoption of CPAP among 303 Primary 
care trusts (PCT) and 261 Respiratory physicians in the UY- 
A. 3 Results 
SAHS patients had a (5x) higher risk of death and (2x) of hypertension, compared to 
controls. Among 71 SAHS patients in the RCT, those on CPAP demonstrated greater 
clinical effectiveness (sleep latency, apnoea hypopnoea index, excessive daytime 
sleepiness & neuropsychiatriefunction) and HRQL (social _functioning, mental 
health & 
energylvitality) compared to lifestyle intervention. Utilities improved on CPAP and the 
CUR were lower (E'716-E2027 vs. F-326444243). 
The diffusion survey demonstrated that the characteristics of CPAP as an innovation, 
would favour its adoption compared to alternative therapies, except in patient tolerability 
(PCT respondents). However there appeared to be no regular system for the diffusion of 
innovation knowledge within the NHS and hindrances in SAHS management due to 
deficiencies in resources, specialists and facilities. 
A. 4 Conclusions 
The results presented in this thesis provide a logical framework for the assessment of the 
progression of an innovation from the stage of establishing the clinical burden of disease 
and treatment needs, to its adoption and may help identify potentially modifiable factors 
in slow diffusion scenarios. 
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1.1 OVERVIEW 
Evolution of universal provision of healthcare by governments to their people [World 
Health Organization 1999] was made possible not only by a combination of Scientific 
discovery with technological advancement but also by the impact of global education and 
efforts to expand health services [World Health Organization 19991. The result of this 
combined strategy is reflected in the changes in life-expectancy [World Health 
Organization 19991 seen among industrialized nations between igio and 1998. Even 
among the developing countries, the average life-expectancy had improved from 40 years 
in 195o to 63 years in 199o. These improvements in population health not only translated 
into gains in well-being but also alleviated the economic burden posed by reduced 
productivity from unhealthy workers [Subramanian et al. 20021. 
The goal of healthcare provision was visualized, in the declaration of the 1978 World 
Health Assembly in Alma-Ata, 'Health for All by 2000'which envisaged, the attainment 
by all peoples of the world, a level of health that will allow them to lead a socially and 
economically productive life 132 WORLD HEALTH ASSEMBLY 19791. The primary 
purpose of any health care system or technology was thus to promote, preserve and 
restore health [WHO 19461. 
Patients' preferences and expectations from their health assume a paramount role in 
assessment of health and health care provision in the present day environment 
[Anonymous 1998c]. Such are the complexities of measuring a dynamic and multi- 
faceted state that any health technology assessment (HTA) method has not only to evolve 
scientific and reproducible mechanisms but also to evaluate the interaction of the various 
tiers of factors responsible for its promotion, restoration and preservation [Maynard et al. 
20031. 
1.1.1 Health technology assessment (HTA) 
Although the advancement in health care technologies allowed the possibility for the 
emancipation of large sections of humanity of many of its scourges, there were newer 
problems emerging. These were mainly in the form of the harmful effects of hitherto 
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unknown or little known technology and the burgeoning costs of their provision to the 
masses [Pelletier-Fleury et al. 1999]. 
The experience with the adverse effects of many of the industrial, agricultural and 
chemical processes created the understanding of the potential for similar effects of health 
care developments. There were some tragedies which fuelled the increasing regulation of 
the drugs sector like the Thalidomide related birth defects [Annas et al. 1999]. The 
intention of technology assessment in the 1970's was not only to quantify the first-order 
desirable effects of a new technology but also the unintended and undesirable higher 
order effects on social, economic and environmental systems [Morton et al. 20031- 
The rapid expansion of healthcare technologies had been fuelled by a common interest of 
clinicians and patients alike to take the advantage of what was and still is widely perceived 
as state-of-the-art in healthcare benefit, regardless of cost. The flow of technology has 
been increasingly modulated by a widening group of health care policy makers which 
include researchers, manufacturers, regulators, clinicians, patients, government leaders 
and politicians [McDaid 20031. Thus giving rise to a need for well-founded information to 
support decisions on how to develop and adopt new technology, pay for it, and to regulate 
it. Since its early years, HTA has been fuelled in part by the emergence and diffusion of 
technologies that have evoked social, ethical, legal, and political concerns. Some examples 
are contraceptives [Kohler 19971, organ transplantation [Rublee 19941, in vitro 
fertilisation, artificial organs, life-sustaining technologies for critically or terminally ill 
patients [Rettig 1991] and, more recently, genetic testing and genetic therapy [Mowatt et 
al. 1997a]. These technologies have challenged societal institutions, codes, and other 
norms regarding fundamental aspects of human life such as parenthood, heredity, birth, 
bodily sovereignty, freedom and control of human behaviour, and death. 
Although the ideal HTA conceptually encompasses the direct and indirect effects of a new 
technology, in practice often the need for speed and resource constraints has restricted 
the assessment to mainly safety, direct beneficial/ desirable effect quantification and 
economic impact studies [Goodman 19921. 
The outcome of any new HTA can be measured by a change in a health status measure or 
variable also known as the 'treatment effect' [Gafni et al. 1993a]. Such treatment effects 
can then be compared between old (or existing) treatment options and the new to assess 
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effectiveness of the new technology. The case of the continuous positive airway pressure 
devices (CPAP) [Sullivan et al. 1981] for the treatment of Sleep apnoea hypopnoea 
syndrome (SAHS) [American Academy of Sleep Medicine 1999] is an example where a 
relatively inexpensive technology was developed to alleviate the disability of chronic sleep 
deprivation in SAHS patients [Wright and White 2000]. 
1.1.2 SAHS & HTA 
The Oxford English Dictionary defines 'sleep' as, 'the condition of body and mind which 
normally recurs for several hours every night, in which the nervous system is inactive, the 
eyes closed, the postural muscles relaxed and consciousness practically 
suspended'[Anon. 1996]. Sleep is recognised as two distinct and essential states of 
existence, namely rapid eye movement (REM) and non- rapid eye movement sleep 
(NREM) [Rechtschaffen et al. 1968]. 
The role of sleep in normal human life and performance is borne out by consequences of 
sleep deprivation [Leproult et al. 19971- Sleep deprivation is known to be the cause of at 
least 56ooo, accidents annually on American roads directly as a result of driver fatigue/ 
sleepiness, leading to 1550 fatalities and is estimated to have cost just under 4o billion 
United States dollars (USD) in 1988, and 72o, billion USD for public transportation 
accidents [Leger 19941. In 199o, there were 2.5 million injuries with a loss Of 52 million 
work days [Leger 19941. In the UK, up to a third of serious road traffic accidents are 
related to sleep [Home & Reyner, 19951. Although these estimated figures are indicative 
but the full economic and societal impact of nocturnal sleep fragmentation or deprivation 
is difficult to investigate and quantify [Sleep Alliance. 20041. 
Sleep deprivation, whether it be a result of a deliberate lack of sleep, sleep restriction due 
to shift work or due to sleep disorders, has a common pathway in producing excessive 
daytime sleepiness (EDS) [Johns 19941, poor concentration, neuro-cognitive dysfunction 
[Engleman and Douglas 1993b] and an increased propensity for accidents [11oberes et al. 
20001. Apart from sleep deprivation and insomnia the predominant pathological cause of 
EDS is SAHS. Although the prevalence of nocturnal apnoeic or hypopnoeic events is high 
in the general population, the existence of the clinical syndrome is estimated at 2-4% 
among middle aged adults [Young et al. 19931. 
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SAHS is characterised by an episodic and repetitive closure/ collapse or narrowing of the 
naso-pharyngeal airway leading to arterial oxygen desaturation, hypercapnoea and an 
increased work of breathing [American Academy of Sleep Medicine 1999]. This in turn 
causes interruption of continuous sleep in the form of arousals leading to sleep 
fragmentation and EDS [American Academy of Sleep Medicine 1999]. 
SAHS is intimately associated with obesity [Kopelman 1984; Lindberg et al. 
2000; Shneerson et al. 20011 and lifestyle features (such as alcohol consumption, smoking, 
poor sleep hygiene, shift-work [Knutsson 20031) which are known to have an adverse 
effect on health. Early research has been plagued by a difficulty in extracting the effect of 
sleep fragmentation from the influence of these lifestyle factors on the individual. There is 
an observed increased prevalence of hypertension (HTN), Ischaemic heart disease (HID), 
Cerebrovascular disease (CVA)[Lattimore et al. 20031, mortality and diabetes (DM) 
[Punjabi et al. 2003] among SAHS sufferers. Current research in SAHS has begun 
establishing the decline in health related quality of life (HRQL) in untreated patients 
which can be reversed with continuous positive airways pressure (CPAP) therapy 
compared to placebo [Bolitschek et al. 1998; FlemonS 2004; Lacasse, et al. 2002a; Moyer et 
al. 2001; Stradling et al. 1996] or ineffective CPAP [Hein 2002; Jenkinson et al. 1999], 
there is still a considerable variability in the effects measured with varying range of HRQL 
tools [Jenkinson et al. 1997c] and little evidence on the effect of intervention in the 
adverse lifestyle features associated with SAHS [Wright and White 20001. 
The advent of new technology usually brings with it increased cost of diagnostic and 
treatment procedures and demands increased healthcare resource allotment [Banta 
1994; Maynard 1989; Neumann et al. 19911. It is estimated that diagnosis and treatment of 
SAHS in the USA in 1990 Cost 275 million USD and affecting 20 million Americans the 
estimated cost may reach 6o billion USD by the year 2000 [National Commission on 
Sleep Disorders Research 19931. 
Resource allocation is finite and determined largely by socio-economic, political and 
market forces [Freemantle 1995; Hurley et al. 1997; McKneally et al. 1997] and is 
constantly in need of prioritisation especially in the 'free at the point of delivery' system 
like the National Health Service (NHS) [Weale 1998] in the United Kingdom (UK) or 
Medicare health insurance system in the USA [Kinney 1989]. Allocation of resources to 
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competing technologies is facilitated by measuring the clinical and economic effectiveness 
using generic outcome variables (Gafni and Birch 1993a; Levine et al. 2002; Mehrez et al. 
1991; Pinto Prades 19971. 
SAHS patients report a variable degree of EDS and daytime dysfunction which does not 
often show a clear relationship with the severity of physiological sleep fragmentation 
[Punjabi et al. 2002]. Hence there exists a perceived need for more generic and 
comparable measures of effectiveness. These include generic quality of life measures, 
disease specific measures and health status outcomes, which assess the net effect of an 
intervention on the patient and allow for comparison between different populations and 
different disease groups [FlemonS 2000]. 
Over the last three decades, various techniques have been developed to treat patients with 
SAHS; lifestyle strategies of weight reduction and sleep hygiene improvement [Shneerson 
and Wright 20011, oral/ mandibular advancement devices (Marldund et al. 2004; Smith et 
al. 2002a], laser/ surgical approaches [Friedman et al. 2004; Littner et al. 20011 to 
modifying the naso-pharyngeal airway and CPAP [American Thoracic Society 
1994; Ballester et al. 1999; Scottish Intercollegiate Guidelines Network 20031. 
Since 199o, CPAP has been commercially available as a treatment option for SAHS 
sufferers [American Academy of Sleep Medicine 19991. A study by the Royal College of 
Physicians of UK (RCPUK) estimated that only a small proportion of potential patients 
with SAHS were being diagnosed and treated in the UY, demonstrating a mismatch in the 
patient needs and facilities available [Stradling et al. 19931- This report also identified the 
existence of a wide variation in the availability of diagnostic and treatment facilities 
within the UK and a lack of homogeneity in adoption of CPAP therapy [Gibson et al. 
1998] This assessment was further supported and updated with the Sleep: Impact on 
Society report by the Sleep Alliance in 2004 [Sleep Alliance. 20041 which demonstrated 
the heterogeneity in availability within the framework of health service (which is designed 
to deliver an equitable distribution of healthcare resources). 
The issues which may be influencing the variable availability of CPAP and its slower 
adoption in the UK maybe manifold; 
1. The lack of randomised studies establishing the clinical effectiveness prior to 1997 
[Wright et al. 1997b]. 
IITA ,v SAHS, PhD thesis bdraffilChakramrý, 2005 23 
Chapter I- BACKGROUND 
2. The absence of an objective and universal outcome measure preventing 
comparability with competing technologies [Jenkinson et aL1997c] 
3. The absence of a predictable, linear relationship between the pathophysiological 
measures of SAHS and sleep fragmentation with the (outcome) HRQL measures 
[Ballester et al. iggg]. 
The dearth of economic evaluation data [Anonymous 1998a; Moyer et al. 2001] in 
SAHS. 
The possible lack of widespread dissemination of research evidence and 
knowledge utilisation among secondary and primary care[Gibson et al. 
1998; Semple and Gibson 1993; Sleep Alliance. 20041. 
6. The inactivity of active patient self-help groups and professional champions and 
hence relative public apathy towards sleep disorders [Sleep Alliance. 20041. 
7. The absence of political and policy imperatives and national plan framework for 
SAHS [Sleep Alliance. 20041 compared to cancer diseases [Holmberg et al. 
1998; Waller et al. 19951. 
8. The innovation characteristics i. e. comfort [Beecroft et al. 2003; Pepin et al. 19951, 
complexity and user perceptions [Zozula et al. 2oolb] for CPAP. 
Using the case of CPAP use in SAHS, this thesis explores the HTA of a health care 
innovation and the factors influencing its diffusion and adoption in a managed care 
setting. It examines the clinical experience from the introduction of CPAP in 199o in a 
typical UK district general hospital (DGH), through a retrospective case control study of 
603 patients seen over 7 years, investigating their anthropometrics, clinical features, 
diagnostic modalities, mortality and morbidity as well as referral patterns and growth in 
numbers of patients and CPAP prescriptions. This then leads to the design and execution 
of a randomised, controlled trial (RCT) to assess the clinical effectiveness of CPAP 
therapy in SAHS compared to structured lifestyle intervention. This study also provided 
the opportunity to assess the sensitivity and reliability of different clinical, HRQL and 
health status outcome measures. 
This is then followed by an exploration of the techniques of economic evaluation of CPAP 
in the treatment of SAHS, measuring health status or utilities in order to produce a 
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generic outcome measure; the quality adjusted life year (QALY) which would allow the 
comparison of clinical and cost effectiveness of competing technologies. The final phase 
of this research explores the different factors influencing the diffusion and adoption of 
CPAP as an innovation and the processes of knowledge utilisation in this area. Results 
from this research may help recommend a logical framework for the assessment and 
adoption of health care innovations by a managed care sector in the future. 
1.2 HEALTH TECHNOLOGY ASSESSMENT 
1.2.1 Introduction 
The technological advancements in diagnosing diseases and measures to prolong 
life and restore health have fuelled public expectation for better health care 
provision, which in turn has resulted in a rise in the economic burden on nation 
states [Neumann and Weinstein iggil. Most countries, especially in the 
developing world, are increasingly forced to choose between infrastructural 
development for social, educational and economic growth, against improving the 
diagnostic facilities and treatment of diseases with newer technology [Reich 
19881. This paradigm may sometimes lead to a pressure for the adoption of less 
effective therapies at high cost before a complete evaluation. The pressure on 
finite economic resources leads to the emergence of rationing or priority setting 
in medical care provision, as the next logical step [Maynard et al. 1995; Weale 
1998]. Medical practice has varied locally, regionally, and internationally, e. g., 
patients with similar age and stage of cancer can receive very different levels of 
radiotherapy across Europe [Maynard and Bloor 1998]. For most interventions, 
the appropriate level of treatment may be asserted on 'clinical need' but is usually 
not based on cost effectiveness knowledge. Health policy analysts, like clinicians, 
tend to make assertions about competition and other health care reforms which 
are value- rather than knowledge-based [Maynard and Bloor 1998]. 
There has been a need not only to answer the questions of safety, and quality for 
emerging technologies but also to establish the efficacy and effectiveness of 
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currently available technological advances [Angus 19941. HTA was developed to 
provide this crucial information and has been evolving since [Battista 19921. 
HTA is designed to provide information to various agencies with varying 
perspectives on healthcare provision; i. e. Hospitals and health care providers are 
concerned with the safety and clinical effectiveness of new and evolving 
practices/ treatments; while to health care purchasers and medical insurers, HTA 
provides information on economic evaluation of clinical strategies; and for 
governmental agencies, it is a tool for the assessment of the public impact of 
existing and new technologies [Rutten et al. 19941. 
1.2.2 Definitions 
The Office of Technology Assessment was created in 1972 by the U. S. Congress to 
11 provide early indications of the probable beneficial and adverse impacts of the 
applications of technology [Blair 19941". HTA was defined as 'the drugs, devices, 
and medical and surgical procedures used in medical care, and the organizational 
and support systems within which such care is delivered. ' 
However recent definitions of HTA have evolved to include, 'all the methods used 
by health professionals to promote health, to prevent and treat disease, and to 
improve rehabilitation and long term care [NHS 1992]. ' 
Thus HTA is 'the systematic process by which the direct and indirect 
consequences of a particular technology are assessed: it is concerned with 
evaluating the safety, effectiveness, and cost- effectiveness, and (where 
appropriate) the social, ethical, and legal impact of a technology' [Szczepura et al. 
19941- 
1.2.3 History & evolution of HTA 
The concept of controlling for bias dates back to 1898 [Cheng 20041, the RCT, 
introduced in the late 1930's [Hammerschmidt 20041, was a landmark 
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development in the history of medicine [Jadad AR et al. 19981. It paved the way 
for the scientific approach to evaluating the safety and effectiveness of health care 
interventions and provided the most secure basis for valid causal inferences about 
the effects of treatments [Office of Technology Assessment 19831. 
This was followed by the rapid expansion of the pharmaceutical industry [Bloor et 
al. 1996; Maynard et al. 1997] and the rapid introduction of a great number of 
drugs being developed for treatment, with their potential for both beneficial and 
adverse effects. Many governments introduced tight controls with the 
requirement to prove the safety and efficacy of all new drugs prior to their 
licensing for public use [Maynard and Bloor 1997]. This control regime not only 
introduced a cost burden on the pharmaceutical industry which pushed up the 
cost of newer drugs or devices [Dimasi et al. iggi] it was also discovered that the 
efficacy of new drugs or new treatment protocols established in tightly controlled 
trial settings did not always translate to the same levels of efficacy when in 
general use. This may be due to lack of motivation, reduced compliance, co- 
morbidities and less adherence to protocol than in an RCT setting with motivated 
and supported trial participants. 
This led to the introduction of the concept of 'Effectiveness and efficiency'in 1972 
by Archie Cochrane [Cochrane 1972]. By this time cost-benefit analysis (CBA) was 
established alongside clinical or physiological data in trials assessing health care 
interventions (Levine et al. 2002; Nixon et al. 2000]. The economic appraisal of 
health care technologies evolved and expanded in the 198o's to encompass; cost 
of illness, cost-effectiveness and cost-utility studies [Torrance 1986a]. 
In 1972, the US Congress established the Office of Technology Assessment in 
order to gather information on all forms of technology and to inform policy 
making at government level [Blair 19941. The Health Program was established a 
year later, to synthesise existing knowledge from research evidence [Martin 1981]. 
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Governments in Europe followed a decade later, with the World Health 
Organisation 'Health for All' strategy urging member states to establish a 
mechanism for the systematic assessment of the effectiveness, efficiency, safety 
and acceptability of health care technologies. It is only in the last decade of the 
last millennium that countries and their governments began acknowledging the 
need for a uniform, scientific and systematic approach to health policy decision 
making about the adoption of new and existing technologies [Davies et al. 19941. 
However there is still evidence of a reluctance for the utilisation of such 
assessments in decision making [Maynard and McDaid 20031 except in the case 
of pharmaceutical companies (where the culture of increasing regulation is well 
established) who now have to provide evidence of cost-effectiveness along with 
clinical effectiveness [Maynard and Bloor 19971. Acceptance of economic 
appraisal information in decision making is also shown to be far slower and more 
reluctant in the devices and medical procedural sector [Maynard and McDaid 
20031. 
Public health establishments like the UK NHS are now widening the HTA 
horizons by establishing mechanisms to assess the influence of organizational 
structure and support systems [Woolf et al. 20oob; NHS 19921. The NHS HTA 
Group now undertakes annual white paper consultations from the NHS, the 
health care industry and the public on health technology issues and 
commissioning studies of safety, effectiveness and economic analysis [NHS 
1992; Woolf and Henshall 2ooob]. The data from such studies are intended to be 
fed back to the health care industry and the public to help diffusion and policy 
making [Woolf et al. 200oal. 
in the UK, a new body with the responsibility of recommending to the NHS on 
the clinical and cost effectiveness of new drugs and medical devices called the 
National Institute of Clinical Excellence (NICE), was established in 1999 [Taylor 
20021. A review looking at 32 appraisals conducted by NICE found that around 
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two-thirds of NICE appraisals had been of pharmaceuticals [Salazar 2002]. There 
was clear evidence of the use of cost-effectiveness criteria to restrict or reject 
technologies, although these were not the only criteria used in decision making 
[Salazar 20021. Although definitely considered to be a step in the right direction 
by most health care professionals, the opinion of the both manufacturers and 
NHS agencies remained mixed as the impact of NICE recommendations are 
continually scrutinised [Sitzia 2002]. Manufacturers remained concerned about 
the timing of referrals in the product life cycle and about the quality and 
consistency of the reviews of evidence undertaken by the academic groups for 
NICE. Within NHS there were concerns on whether the right technologies were 
being referred to NICE and also on the opportunity cost of positive NICE 
recommendations [Davies et al. 2002]. In a survey carried out among the 
Directors of Public Health in the UY, the majority were positive about NICE's role 
of providing high-quality appraisal and central guidance but negative about its 
influence on local priority setting. Major concerns remained about the 
affordability of competing national demands often by the lay public or politicians 
with a potential for creating difficulties in local priority setting [Sitzia 20021. 
Given the global budget constraints and the difficulty of withdrawing services, the 
NICE recommendations based on economic evaluation may pre-empt growth 
money that could be better used for more cost-effective purposes [Rosen et al. 
1998]. NICE also has a defined role in appraising established technologies that 
may not be cost effective and whose discontinuance could therefore release 
resources for other more cost-effective treatments [Rawlins 1999]. As the political, 
economic and social cost of health policy decision making can be immense and 
largely uncertain, there is still a perceived need for wider understanding, 
multidimensional participation in a more widespread structured strategy of HTA 
[Davies et al. 2ooob]. 
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1.2.4 Purpose of HTA 
HTA is the systematic evaluation of properties, effects and/or other impacts of 
health care technology. The main purpose of HTA is to inform technologym-related 
policymaking in health care at institutional, regional, national and international 
levels. HTA addresses the direct and intended consequences of technologies as 
well as their indirect and unintended consequences. 
HTA may be used to advise regulatory agencies whether or not to permit the 
commercial use (e. g., marketing) of a drug, device or other technology [Taylor 
20021. 
HTA may help health care payers and providers to determine which technologies 
should be included within the managed care framework or private health plans, 
addressing coverage (whether or not to pay) and/or reimbursement (how much 
to pay) policies [Taylor 2002]. 
HTA may be used to advise clinicians, providers and patients about the proper 
use of health care interventions for particular health problems (e. g., practice 
guidelines, disease management programs) [Perleth et al. 20011. 
Information from HTA may help managers of hospitals, health care networks and 
other health care organizations to make decisions regarding technology 
acquisition and management [Lee et al. 20031. 
HTA is used by governmental health departments in undertaking and 
commissioning public health programs (e. g., vaccination, screening and 
environmental protection programs) [Banta 2001]. 
HTA information supports health care product company decisions about product 
development and marketing [Siebert et al. 2002] [Schubert 2002]. 
HTA helps to set voluntary or mandatory standards regarding the manufacture, 
use, maintenance, reuse and other aspects of health care technologies, 
components and materials [Siebert et al. 20021. 
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Data analysis from HTA is used to advise state and national leaders about policies 
concerning technological innovation, research and development, regulation, 
payment and delivery of health care [Papatheofanis 2000]. 
HTA may also include user feedback, public and professional priorities 
[Johannesson et al. 2002] and socio-political aspects of new technologies in a 
more comprehensive assessment [Lehoux et al. 20001. 
1.2.5 Factors affecting the timing of HTA 
The pace of new technology development and the speed of widespread diffusion 
and application of a recently introduced instrument or method, determine how 
and when an HTA exercise needs to be undertaken to play a role in its adoption 
[Mowatt et al. 19981. This is especially true for new and fast-changing 
technologies. The factors that may influence the diffusion of uncvaluated medical 
technologies are cost, the presence of enthusiasts, lack of resistance, meeting 
perceived needs and ease of use [Rogers 19841. However there may be pressures 
on the evaluation process from rapid developments in a non-medical field, which 
may influence adoption through media and pressure groups [Stocking 19861. 
The life cycle of a new technology is considered to evolve through five different 
stages [Banta 1992]. 
'Future' is the anticipated or conceptual stage of development, when feasibility 
studies may be undertaken to assess potential benefit and risk. 
'Experimental/ emerging' stage usually involves laboratory testing or animal 
models for benefit / risk assessment. 
'Investigational/ new'is the stage when clinical evaluation is conducted in human 
volunteers before applying for general licensing (e. g. A third phase drug trial). 
A technology is considered to be 'established/ accepted' when it is licensed for 
generaluse. 
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Technology becomes 'obsolete', when it is superseded by later developments or 
considered ineffective or where risks outweigh benefits. 
Although technologies may evolve along the simplistic pathways, the real process 
can be very complex with no clear transition points. The rate of diffusion in this 
linear model was described by an S-shaped curve with an initial slow diffusion 
followed by a rapid acceptance till saturation is reached [Feeny 19851. Except for 
the highly restrictive world of ethical pharmaceuticals, medical technology rarely 
followed this orderly progression [Gelijns et al. 19941. Different centres 
modifying an emerging technology without evaluation may lead to projects 
becoming established procedures, despite the absence of formal evaluation 
[Deber 1992]. Timing of an HTA is further complicated by the fact that the stages 
of the development process are not only influenced by 'technologyýpush' from 
research but also by the 'demand-pull' i. e. market forces [Neumann and 
Weinstein 1991]. 
Parallel, rapid and non-medical development of a technology which is at an 
appropriate point transferred for medical use makes it difficult to institute 
appropriate assessment [Gelijns and Rosenberg 19941. There is also now diversity 
in the constitution of technology users beyond enthusiastic clinicians, as health 
planners, hospital managers and patient-bodies play an increasing role in 
exercising health-care choices [Mowatt et al. igg7b]. 
A fiirther complexity in the timing of HTA is due to the changes occurring in the 
early stages of adoption often in an uncontrolled public setting, generating an 
essential real-world feedback which then helps to reshape and develop it further. 
A cross-sectional HTA exercise in such cases may be inadequate and sometimes 
irrelevant to further diffusion and adoption [Gelijns and Rosenberg 19941. 
1.2.6 Cost of HTA 
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In its most well designed and regulatory form, the process of evaluating a new 
pharmaceutical product for clinical use may cost up to Eigo million [Dimasi, et. 
al. iggil. Though it is reasonably argued, that the societal costs of under- 
evaluated technologies adopted for common use and subsequently found to be 
unsafe or ineffective, can far outweigh the initial outlay on assessment and also 
protect the public from iatrogenic insults (e. g. the thalidomide example) [Annas 
and Elias 1999]. 
Interestingly surgical procedures, which involve some of the highest costs, were 
often found to have the most inadequate forms of systematic evaluation [Love 
19751. Love et al argued that parallels could not be drawn easily between the 
regulatory mechanism available for drugs and for surgical procedures, as typically 
surgical procedures evolved with experience and the attainment of manual skills. 
Thus such evaluation had traditionally taken place in the arena of clinicians' 
autonomy and evolved through clinical practice [Neumann and Weinstein 1991]. 
This lack of a systematic evaluation of clinical or surgical procedures perhaps 
more recently exposed the public to potential risks and the clinicians to libel 
action and a loss of confidence [Teasdale 2002]. 
The public perspective of new health care technology is in turn influenced by the 
media and patient self-help groups. Rigorous evaluation mechanisms impose 
restrictions on the wider availability of new technology for considerable periods 
of time. When a major new advance is contemplated over present practice the 
pressures for its rapid adoption from both the public and professionals can be 
immense, thus restricting the scope of evaluation. In the Viagra' versus the 
Health secretary case, public pressures for a cure for male impotence were so 
great that fearing a bankruptcy of the fragile NHS economics, the Health 
secretary introduced sweeping restrictions on its prescription and use [1(lein et al. 
20021. This led to animated debates, both in the public and professional domain, 
as the hastily drawn up restrictions infringed on the clinicians right to seek the 
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best treatment for their patients. This is a classic example of the importance of 
the potential role of an early HTA exercise, in both making new advances rapidly 
available and also to have in place instruments for continual evaluation during 
and after the adoption and diffusion. 
1.2.7 Methods of assessment 
1.2.7.1 Categories of HTA 
HTA may either be 'primary' involving a direct collection of clinical and cost data from or 
about patients (usually involves RCTs and epidemiological observation studies) or 
I secondary' when it makes use of existing data in the literature (involves systematic 
reviews and meta-analyses). While economic evaluation (cost-effectiveness or cost-benefit 
analysis) and ethical, social and legal assessments are carried out in both forms 
[Donaldson et al. 1992]. 
1.2.7.2 Assessment of clinical effects 
1.2.7.2.1 Population health & health care provision 
life is a primary determinant of health; hence the oldest measures of health included a 
measurement of the length of life. An intervention which prevents the mortality 
associated with certain diseases can thus be measured by the length of additional survival 
achieved. On a larger scale, the mortality rate from a certain disease or infirmity provided 
a measure of the health of a population group and the alteration of this rate by an 
intervention thus measured its effectiveness. Population health may be assessed in 
generic terms by measuring the overall mortality rate and hence the life expectancy. Some 
of the other determinants of health of populations are infant mortality rate, maternal 
mortality rate and the fertility rate. On the other hand healthcare provision can be 
assessed at various levels as shown in table 1.1. 
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Table U: The three main tiers of health care measurement 
Tier Measures 
Structure oIf health care Administrative, ' per capita, advanced 
delivery organizational and physical equipment, physician to 
facilities population ratio etc. 
Process Content of healthcare Bed utilization rates, length of 
hospital stay, adherence to 
guidelines 
Health status and well- 
being of patients 
1.2.7.2.2 Individual health 
Mortahty rate, quahty of life, 
morbidity 
The health of an individual has been traditionally assessed by measures such as life 
expectancy, the presence or absence of disease, physiological determinants (like systemic 
blood pressure), biochemical and haernatological. markers (blood haernoglobin, serum 
cholesterol levels) and pain. With a reduction in mortality from diseases such as microbial 
infections or parasite infestations achieved in the mid-twentieth century in some parts of 
the world, mortality as an endpoint became insensitive to the subsequent changes in the 
health states achieved by health care interventions. Hence the impact of chronic 
conditions on functioning became increasingly important [World Health Organization 
19991 [Byrne 1992]. 
The focus of health provision and its measurement then shifted from laboratory or clinical 
endpoints to patient-orientated outcomes, like quality of life, relief from pain, absence of 
anxiety or depression, mental health, physical and social functional capacity and general 
health status [Slevin et al. 1988]. As there were tools developed to measure these specific 
aspects affecting patients with cancer, chronic arthritis or lung diseases, others measured 
the overall impact of disease and infirmity on general health, physical, mental or both. An 
analysis of twenty three studies published between 1975 and 1979 measuring the 
effectiveness of new health technology using quality of life outcomes, was found to lack 
seriously in methodology (i. e. failing to represent subjective responses and hence only the 
professionals' assessment of the impact of treatment on the patient's quality of life) 
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[Najman et al. 1981]. Thus historically the art of measuring individual health has shifted 
from clinical or laboratory data through professional assessment of impact on patients 
quality of life to finally patient-based preferences or outcomes, without any influence 
from the provider of such healthcare. 
The inherently subjective nature of such data has been an issue of concern among medical 
scientists but as the fields of psychometric testing and clinimetrics developed 
simultaneously, rigorous methods for the development and testing of these quality of life 
tools have evolved at the same pace [Deyo et al. iggil. There were iooo articles 
measuring quality of life in 1995, as health professionals gave increasing attention to the 
preferences and wishes of patients towards their own healthcare [Rosenberg 1995]. 
In the current environment of transparency and accountability of medical professionals, 
health planners and ultimately of government policies to the public, patients rightfully 
expect to be involved not only in decisions about their individual care, but in formulating 
priorities and assessment of health care interventions [Siegrist et al. 1989). 
1.2.7.3 Health Related Quality of Life 
Defining quality of life in a form, which offers itself to scientific scrutiny and 
demonstrates qualities of consistency and reproducibility, is a challenging task. It also 
needs to encompass the full spectrum of the desirable aspects of life and well-being of all 
people. In the post World War II era, The Commission of National Goals set up by 
President Eisenhower of the United States included education, health and welfare, 
economic and industrial growth and the defence of the free world among the qualities of 
'good life' to material affluence and leisure [Anon. 1961]. 
Among all the attributes of a 'good life', health commands a paramount position and is a 
complex amalgam of satisfactory functioning in all almost all core domains of life, which 
include psychological, social, occupational and physical. Health technology, which 
improves quality of life, but has no direct influence on survival, is evaluated by measuring 
the change in quality of life. There are various tools developed for assessment of health 
related quality of life (HRQL) as illustrated in table 1.2. The various methods for assessing 
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quality of life are broadly classified as 'disease specific' or 'generic' allowing for 
comparisons between patient and disease groups. 
Table 1.2 Quality of life assessment tools [Fallowfield 199o] 
eý _f" T y"p' Description txample 
Performance index Observation scales Karnofsky Performance Index, 
usually completed by WHO Performance status 
carer/ physician 
Self-assessment Visual Analogue Scale Linear Analogue Self Assessment 
questionnaires Questionnaire Nottingham Health Profile, 
Short Form 36 
Scales for Mood States Assessment of Profile of mood states, 
emotionaL mental and Hospital Anxiety & Depression 
social well-being Scale 
In recent years, advances have been made in developing and validating measures of 
HRQL. These combine assessment of various facets of quality of life affected by health 
and produce aggregate scores allowing comparison and providing along with 
physiological measures of health a holistic picture [Bergner, 19891. 
1.2.7.4 Utility and health status 
Advances in medical technology have also created the problem of infinite health needs 
competing for finite financial resources. There was a need for creating a method of 
valuing life which combined both the qualitative and quantitative dimensions. Thus the 
origin of utilitarian theory of health and the delivery of health care is set within the 
economic limitations; a topic of extensive political, moral and ethical debate. Such an 
approach might result in the majority of the population being better off but demands that 
the some may be considerably worse off [Fallowfield 199o]. 
The Expected Utilitarian Theory was first published in 1944 as a way of rational decision 
making under uncertainty, included in a theory of games [von Neumann et al. 19441. This 
theory proposed how an individual ought to make a decision when faced with uncertain 
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outcomes based on certain axioms which have been rigorously debated over five decades 
and form the foundation of modem decision theory [Drummond et al. 19971. 
Axioms for the von Meumann and -Morzecnstern utft 
Mcgr 
1. Preferences exist and are transitiue 
For 2 risky prospects y and y; the individual may either prefer y to Y, or Y, to y or may be 
indifferent to both. In the case Of 3 choices- y, y' and y"; the individual may prefer y to Y, 
and y' is preferred to y" then y is preferred to y". If the individual is indifferent to y and Y, 
and y' to y" then y is indifferent to y". 
2. Independence 
This axiom suggests that an individual should be indifferent between a2 stage risky 
prospect and its probabilistic one stage equivalent. 
3. Continuity ofpreferences 
This axiom suggests that if an individual prefers an outcome x, to xý and x:, to X2, there is a 
probability p where he/ she becomes indifferent between outcomeX2with certainty or 
receiving the risky prospect made up of outcome x, with probability p and outcome x3 
with probability (i-p). 
There exist basic differences between the normative model to decision making as 
proposed by the utility theory and observed human behaviour which describes real 
human behaviour. Utility is a general concept for assessing the value a given individual 
might place on the consequences of different courses of action. This approach when 
applied to HRQL provides a numerical value (usually between o=death and 1=perfect 
health) to represent the quality or value of an individual's health at a given point in time. 
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Table 1.3 Methods of utility assessment [Torrance et al 1972b] 
Method 'Ption Descth 
Standard Gamble Requires patients choosing treatment 
options with varYing success to failure 
risks 
Time trade off/ Healthy year equivalents Trading off years in the present state for 
years at a better health state 
Health & Illness matrix Rosser & Kind, 
EuroQol were health states valued 
according to a population derived matrix 
The utility values yielded from the above methods combined with the life expectancy of 
each individual produced the quality adjusted life years (QALY). Hence, the effect of a 
healthcare intervention would be expressed by the number of QALYs gained. Although 
the current state of art in QALY measurement does not allow its unequivocal acceptance, 
it has rapidly become the crucial health measurement in health policy making and 
resource allocation circles. Unfortunately, even a huge amount of carefully conducted 
research in to the derivation of QALYs will still not have any relevance at individual level 
of health care need, specially in the life-saving emergency sector. QALYs may be 
inconsistent, biased for curative treatments, against the elderly and have different values 
depending on methods used to generate the utilities [Gafni 19891. There is also the fear of 
misapplication of QALY data to rationing of health care [Loomes et al. 19891. Even 
evidence from different economic scenarios like North America may be used 
inappropriately in the NHS in the UK [Neumann et al. 19971. Used for its original purpose 
to help evaluate the effectiveness of treatment or a new technology, utility measurement 
has a vital role to play, especially with subjective but structured input from patients 
[Johannesson et al. 19941. 
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1.2.7.5 Economics of health 
1.2.7.5.1 Introduction 
In its simplest form, health economics is a logical and explicit framework to aid health 
care workers, decision-makers, governments, or society at large to make choices about 
how best to use resources [Drummond 19941- Although the health service is envisaged to 
provide an equal and universal access to the best possible healthcare, the first real-world 
situation is that like other resources in society, health care is distributed equitably. It is 
often a population's view that nearly all health care needs must be provided for, no matter 
what the costs are. Health planners and purchasers often have to face the dilemma of 
which technology should be preferred and up to what point health needs can be met, with 
a majority perspective. Hence it is critical to have a system whereby all dimensions of 
evaluation are taken in to account in a multi-dimensional approach which includes equity 
and humanity, as well as effectiveness and economic efficiency [Drummond et al. 1996]. 
Economic appraisal of health technology forms an essential part of this theory. A 
microeconomic evaluation helps compare the resource implications of alternative health 
technologies to help assess the most effective solution for the benefit of the maximum 
number people. Hence, health economics involves a dynamic interaction between medical 
ethics, humanity and limited resources in a community care scenario [Johannesson et al. 
1996b]. 
1.2.7.5.2 Types of economic analyses 
At the end of the seventeenth century, Sir William Petty estimated the value of human life 
to be between F-6o and Ego [Petty 1662]. Nearly two centuries later, the value of 'human 
capital' was estimated as the present value of future earnings minus the maintenance 
costs to calculate the benefits of therapy [Fitz-enZ 20001. In the mid-twentieth century, 
the concept of calculating the cost-of-illness emerged followed by cost-benefit analysis 
(CBA) and cost-effectiveness analysis (CEA) which were developed as applications of 
classical economic theory to health care [Drummond and Jefferson 19961. 
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Table 1.4 Methods of economic evaluation prummond et al 19971 
Cost-nunuiusation Treatiiients with'equal'cffec'tiveness, to IL. 6d 
the cheapest option 
Cost-effectiveness Cost of treatment assessed per each unit of 
health gained 
Cost-utility CI ost I of treatment in relation to I ea , ch year'6f 
life gained, adjusted for quality 
Cost-benefit Cost of treatment in relation to benefits to 
patient or society 
C& eapes 
treatment 
option , 
Cost per 
QALY, days off 
work, days out 
of hospital etc. 
COst'per'oAtý 
Monetary units 
All methods of economic evaluation value inputs and consequences following the same 
three step approach of (i) identify inputs and consequences, (ii) measure them in physical 
units and Gii) and value them. 
The importance of conducting economic evaluation is increasing as patients clinicians 
and healthcare purchasers are rapidly realizing the need for optimizing treatment options 
in an increasingly cost-conscious environment and scarce resources. Of over 50,000 trials 
published between 1966 and 1988 only 121 (0.2%) included economic analyses [Adams et 
al. 1992]. This recognition to carry out economic analyses in almost all cases of new HTA 
development has only recently emerged. 
Although the demand for integrating economic evaluation techniques within RCTs is 
growing as part of healthcare research development, the best model for incorporating this 
into study design is yet to be established [Sculpher et al. 19971. There is an early 
introduction of economic analysis in the lifecycle of a new technology development and 
prior to its diffusion, hence in any carefully designed RCT, economic data is collected 
from an early stage. 
Estimating hidden costs, value of expertise and opportunity costs pose various difficulties 
in economic evaluation exercises [McNeil 2001]. Especially controversial is the concept of 
'discounting', which exists to allow a comparison of immediate costs with future potential 
benefits (Johannesson et al. 19941. This is based on the premise that an individual would 
agree to forgo a part of the future benefits if they are accrued now rather than in the 
uncertain future. Moreover all comparisons made in economic evaluation are based on 
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'marginal utflit-/ who assumes that costs vary according to the variation in the volume of 
services or units available and hence comparisons are only valid at a certain set level of 
variation. 
As outcomes are measured in disease specific parameters and usually differ from 
programme to programme, they cannot be used to make CEA comparisons [Neumann et 
al. 19941. There may be more than one parameter of interest to different groups of 
analysts. In order to standardise this approach the CUA was developed by integrating the 
net effect of various outcomes on the individual into a generic outcome measure. Thus 
named the 'generalized cost effectiveness analysis' or the 'utility maximization model'. 
The first coining of the term CUA was established in 1981 in the UK [Drummond et 
al. 1997] as the primary method of arriving at the individual preference weights is the 
utility (as defined by the Utility theory) and in Europe but is still referred to as CEA in the 
USA [Russell et al. 1996]. 
Randomised controlled trials are regarded as the cornerstone of clinical research 
[Drummond et al. 19911. Since randomisation not only adjusts for the effects of known 
biases but also for the unknown. Hence any efficacy claims generated from non-RCT 
research are currently viewed with caution. RCTs help distinguish between interventions 
providing moderate clinical benefits with mild deleterious effects (which is the 
commonest proffle of most modem technological advances). However organizing RCTs 
can be a very difficult logistical task involving huge time and resource allocation. In 
situations where technology advances rapidly a result from an elaborate RCT may become 
irrelevant by the time it is reported. Again RCTs are usually carried out on highly 
motivated and compliant patients in a highly specialized centre hence the results are 
difficult to generalize in a District General Hospital (DGH) setting, where patient 
motivation and compliance can vary considerably [Drummond et al. 19931. RCTs provide 
data on efficacy rather than effectiveness because often the results obtained in tightly 
controlled research protocols are not readily generisable to real life health care delivery 
scenarios. 
Critics of the RCT argue that in certain situations they may be unnecessary, inappropriate, 
impossible to implement or inadequate and their faults originate from their origin in the 
strict scientific methods required in pharmaceutical research. At best, RCTs; can form part 
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of an evaluative inventory which utilizes observational methods like case-control studies, 
cohort studies and retrospective analyses as appropriate. This concept was supported by 
Franklin in 1993 [Franklin 19931, who argued that neither RCT nor observational studies 
can address the complexities of HTA independently; hence they should be regarded as 
complementary and not competitive. In rapidly changing scenarios, where only a small 
window of opportunity exists, early observational studies may provide vital evidence to 
influence diffusion and identify possible implications of adoption [Stocking 1986]. 
Stocking's model suggests a pattern of clinical evaluation starting at the point when 
opinion leaders are becoming interested but not yet committed, with a quick inexpensive 
assessment to determine what potential benefits a new technology may have to offer, 
followed by observational studies and RCTs as appropriate [Stocking 1986). 
1.2.7.6 Non-clinical assessments 
In addition to clinical assessments, there is a need for evaluating the economic, legal, 
ethical and social issues accompanying the adoption of a new healthcare technology 
[Dolan et al. 19931. This involves a different toolkit and skills compared to clinical 
assessment. The legal, ethical and social assessment of a new technology may involve 
interviews with clinicians, public, patients, judiciary and the synthesis of such 
information in a qualitative analysis. There is an absence of rigorous models for such 
evaluation as the debate may involve the media, users of the technology and the 
regulatory authorities. This is especially true in cases for the use of genetic testing for 
disease potential [Blanck et al. 1996], genetic modification of food stuff [Uzogara 2000], 
pre-natal diagnosis [Bassett et al. 20041, organ transplantation [Southern 1989] and 
human cloning technology [Gilbert 20041. The Catholic Church has opposed human 
embryonic stem cell research and any kind of human cloning because they are contrary to 
the dignity of procreation, of conjugal union and of human embryos [Ohara 20031 
arguing on moral implications of health technology. The assessment process may involve 
discussion and debate [Curtis 20031 with the public and non-governmental agencies [Jin 
20001 on moral and ethical implications (LyngstadaaS 2002b] before such technology is 
widely adopted. 
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1.2.7.7 Assessing different types of technology 
Rigorous methods for assessing clinical efficacy through the RCT evolved within the strict 
regulatory atmosphere of pharmaceutical development and this approach has been 
professed in other types of health technology including surgical or clinical procedures, 
medical informatics and diagnostic techniques. However, this is not widely accepted and 
there are various guidelines proposed for the evaluation of diagnostic technologies, 
[Guyatt et al. 1986]medical imaging, surgical procedures, picture archiving and 
communication systems [Banta et al. 19941. 
1.2.7.8 Summary of HTA 
Governments are now faced with the impact of technology push with newer and more 
effective and inevitably expensive innovations for the purpose of improving health care. 
This is combined with the demand pull from public and professionals expecting the rapid 
and widespread implementation of innovative healthcare products. The balance with 
other competing priorities for public expenditure such as defence, education and 
infrastructure building tends to introduce the angle of societal and political imperatives 
on clinical and cost-effectiveness. Hence HTA programs are designed and implemented 
not only to identify new and emerging technologies with a potential of delivering 
improved health care to the general public, but also to ensure their safety and 
effectiveness and finally to ensure a 'value for money' for public expenditure. In times 
when the focus of health care provision has largely shifted from reducing mortality from 
infectious diseases to health promotion and primary prevention and the improvement in 
quality of life; the HTA of CPAP in SAHS patients gives an opportunity to formulate a 
generic pathway for assessment of similar technologies designed to improve primarily 
quality of life parameters in a large section of the adult public afflicted by chronic disease. 
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1.3 SLEEP APNOEA HVPOPNOEA SYNDROME 
1.3.1 Introduction 
This section reviews the various aspects of the SAHS covering the epidemiological, 
pathophysiological, and clinical, HRQL and economic issues. This will be followed by an 
analysis of the treatment pathways for patients and review the evidence available to date 
on the efficacy and effectiveness of various options, introducing the case of CPAP as a 
technological innovation. This will then set the scene for the HTA of CPAP in SAHS 
patients as has been researched and presented through this thesis. 
1.3.2 History of sleep apnoea research 
SAHS is characterised by repetitive partial or complete obstruction of the upper airway 
during sleep, leading to daytime consequences of hyper somnolence, an increased risk of 
accidents and impairment of general health status. The syndrome definition has evolved 
and expanded since the latter part of the nineteenth century. Sir Charles Dickens is 
credited with the most well-known and picturesque description of some of the features 
associated with this syndrome in the English language, in his sleepy red-faced boy Joe, in 
the novel ne Posthumous papers of the Pickwickian Club' published in 1837 [Dickens 
18371. 
The earliest scientific account of apnoeas during sleep dates back to W. H. Broadbent in 
1877 when he recognized and described a case of snoring and periodic breathing in a 
sleeping patient (Cheyne-Stokes respiration) following cerebral haemorrhage [Broadbent 
18771. It was eleven years later that Richard Caton presented a classical case-report of a 
37 year-old patient with daytime sleepiness, obesity and apnoeas in sleep, observed by the 
night nurse [Caton 1889]. In the same year, Morison reported chronic daytime sleepiness 
in a 63 year-old man, with his own observation of apnoeic events during sleep, 
disagreeing with Caton's diagnosis of narcolepsy for his patient [Morison 1889]. 
Even in 1889, Christopher Heath the president of the Clinical Society of London, 
recognized the characteristic similarity to sleepy Joe in the Dickens' novel with the case 
described by Richard Caton [Caton 1889; Lavie 19841. The term 'Pickwickian'was coined 
HTA in SA-HS, - PbD thens-Indrand Cbakravony 2005 45 
Chapter I- BACKGROLTAD 
by Osler in 1918 in association with obesity. Another early reference to the Dickensonian 
fat-boy Joe comes from the writing of Bramwell in 1909, when he describes a fat, 
somnolent postal delivery boy who tends to fall asleep on the box, raising the possibility of 
an accident and the grounds for a medico-legal dispute with the insurers, knowing of the 
boy's condition [Bramwell 19o9j. Thus by the turn of the twentieth century, the 
association of obesity, snoring, nocturnal respiratory disturbance and daytime 
somnolence was increasingly recognized. 
However considerable confusion and overlap existed for the next few decades with obesity 
related hypoventilation, Cheyne-stokes breathing, respiratory failure during sleep and 
narcolepsy. While Caton in 1889 mislabelled his patient with probable sleep apnoea as 
narcolepsy and Spitz in 1937, reported features of obesity, cyanosis, excessive daytime 
sleepiness and right-sided heart failure in 3 patients, who were also incorrectly labelled as 
tnarcoleptics' [Spitz 19371. Burwell et al in 1956, reported an obese, somnolent, 
polycythaemic patient as resembling the character Joe and hence having the 'Pickwickian 
syndrome'but without citing any nocturnal breathing disturbance [Burwell et al. 19561. 
Thus the hypothesis in the mid-twentieth century centred around obesity which increased 
the mechanical load on the respiratory system, which in turn blunted the respiratory 
centre resulting in hypoventilation. The hypercapnoea and hypoxaemia caused by 
hypoventilation in turn explained the consequences of daytime somnolence, cyanosis, 
periodic respiration, and polycythaemia and right-heart failure [Kryger 19831. 
The first scientific team to identify and record repeated apnoeas in sleep among patients 
labelled as having the 'Pickwickian syndrome'were Gastaut et al in 1966 [Gastaut et al. 
1966], who postulated the causative link with daytime consequences. They were also 
perhaps the first to suggest that obesity related cardio-respiratory syndrome was probably 
responsible for the cyanosis, polycythaemia and right-ventricular failure seen in the 
Pickwickian syndrome described by Burwell et al and was unrelated to apnoeas in sleep. 
Thus SAHS was established as a distinct physiological entity from obesity-related alveolar 
hypoventilation (or'Pickwickian syndrome'). 
In Hindu mythology, when Ravana wanted his brother Kumbhakamals help in his epic 
battle against Rama, it required the beating drums, piercing with sharp instruments and 
then finally a thousand elephants marching across his chest to wake him [Dharma 2000]. 
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The earliest recorded form of treatment for daytime somnolence, which was the most 
striking feature of patients with the sleep disordered breathing, dates back to the needles 
of Dionysius, the Heracleote, born in 36oBC. His physicians ordered a novel remedy to 
awake him from sleep and thus rid him of his shortness of breath and choking, by 
piercing his belly with very long and small needles till they had passed through the fat and 
reached firm flesh, and thus he felt it and awakened [Aelianus 1666]. 
Since the nineteenth century, extreme obesity has been linked with disease and death, 
hence weight loss was advocated and reportedly improved symptoms, in patients as far 
back as 1816, as reported by William Wadd in his 'Cursory remarks on Corpulence' 
[Wadd 1822]. Caton in 1889 treated his patient with considerable doses of naphthalene, 
iodoform and charcoal, which reduced drowsiness and his weight much to the delight of 
the patient who could then read a newspaper for half-an-hour at a time [Caton 1889]. 
Wells in 1898, identifying the link between obstructed nasal breathing and daytime 
somnolence, treated lo patients surgically removing the nasal obstruction with a relief of 
somnolence in each and everyone of them [Wells 18981. 
1.3.3 Definition 
Earlier definitions relied on the unmistakable apnoea caused by the upper airway collapse 
for the definition of 'Obstructive sleep apnoea' [Guilleminault et al. 19761. The 
recognition of partial closures or hypopnoeas causing arousals or sleep disruption led to 
their incorporation in the definition of the SAHS. Hypopnoeas are defined as a 50% 
reduction in oro-nasal airflow (or frequently estimated using surrogate measures such as 
change in temperature across oro-nasal thermistors, chest or abdominal excursions etc) 
from baseline lasting more than ten seconds. They may or may not be accompanied by a 
3-4% desaturation of arterial oxygenation and electroencephalographic evidence of 
arousal [Gould et al. 1988]. 
The net result of such compromise of the upper airway patency during sleep or significant 
increase in the upper airway resistance leads to repetitive disruption in the continuity of 
nocturnal sleep. This is manifest by a well-recognized alteration in the 
electroencephalogram recording known as arousals. Again, variation exists in the 
HTA in SAHS, PbD thesis Indranit Cbakramny 2005 47 
definition of arousals based on their duration ranging from 1.5 to lo seconds [Bonnet et al. 
19921. In turn nocturnal sleep disruption leads to daytime consequences primarily 
manifest as hyper somnolence. 
The most recent consensus document trying to define the syndrome is from the American 
Academy of Sleep Medicine published in 1999 which (detailed in Chapter III) defines 
SAHS as combination of the symptoms of sleep fragmentation (snoring and / EDS) in the 
presence of apnoeas / hypopnoeas of at least 5 hour-, during sleep [American Academy of 
Sleep Medicine 1999]. 
1.3.4 Epidemiology 
1.3.4.1 Prevalence of snoring, EDS and SAHS 
Population based studies of the prevalence of SAHS are closely interlinked with 
associated snoring and EDS as these are essential components of the syndrome definition. 
Habitual snoring is reported by 19-35%Of men and almost half of that in women. An AHI 
?-5 hour, was found in 11-24% of men and in 6-9% of women. Thus the prevalence of 
SAHS (EDS + AHI ý' 5 hour-') was 1-2% in women, 2-4% in men [Duran et al. 
2ooi; Jennum et al. 1992; Ohayon et al. 1997; Young et al. 19931. The percentage of 
subjects with EDS increased from 21% in subjects with AHI <5 to 35% in those with AHI 
ý* 30 [Gottlieb et al. 19991. 
Figure: 1.1 Venn diagram showing the overlap of EDS, Snoring and nocturnal 
breathing disturbance constituting SAHS 
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1.3.4.2 Under-diagnosis 
It is estimated that a large proportion of patients with clinically significant SAHS remain 
undiagnosed. In a sample Of 4,925 employed adults, questionnaire data on doctor- 
diagnosed SAHS was followed up to ascertain the prevalence of diagnosed SAHS with in- 
laboratory polysomnography on a subset of 1, o9o participants. In this population, 
without obvious barriers to health care for sleep disorders, it was estimated that 93% Of 
women and 82% of men with moderate to severe SAHS were not clinically diagnosed 
[Young et al. 1997c]- 
1.3.5 Clinical presentation 
1.3.5.1 Snoring 
The two most frequently reported symptom of SAHS are loud habitual snoring and EDS 
and hence often constitute the main reason for a patient seeking medical advice. Snoring 
is often described as a coarse, harsh respiratory sound typically caused by vibration of the 
uvula and the soft palate [American Thoracic Society 19891- Snoring represents a 
mechanical loading of the upper respiratory system that can produce sleep disruption. 
Snoring has been further categorised into mild, moderate and severe depending on 
frequency, intensity, body position and disturbance to others. 
Snoring is a common symptom in the community and increases in prevalence with male 
sex, age and a high body mass index (BMI), smoking, caffeine and the consumption of 
alcohol [Ohayon, et al. 1997; Stradling et al. 1989]. In later stages of SAHS, when 
respiratory control is impaired, the drive to breathe may be impaired allowing little or no 
respiratory effort being made and hence snoring is no longer produced [Gottlieb et al. 
2000]. Snoring is an independent risk factor for hypertension [Young et al. 1996a], 
Ischaemic heart disease and strokes [Shepard, Jr. 19921. 
1.3.5.2 Excessive daytime sleepiness 
EDS is the second most common symptom reported by patients with SAHS and essential 
for syndrome diagnosis. EDS is described as the urge to sleep and is not peculiar to SAHS 
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but a common phenomenon related to poor nocturnal sleep or sleep deprivation. Studies 
of sleep disruption induced by auditory tones in normal volunteers have indicated that 
minimal arousals reflected in electroencephalographic (EEG) criteria even without true 
awakening can impair daytime performance and cause daytime sleepiness. 
The pathophysiology of EDS in SAHS patients was initially thought to be a function of 
hypoxia and hypercapnoea which occurred as a result of upper airway occlusion via 
receptors in the medulla, carotid body and the nasopharynx. Arousal is thought to be 
caused by activation of the reticular activating system through neuronal inter-connections, 
however these postulates have been difficult to prove [Berry et al. 19971. Later studies 
have shown evidence that large intra-thoracic pressure swings generated when an apnoeic 
subject strains to breathe against a nearly closed gullet causes sleep fragmentation and 
EEG arousals [Wiegand et al. 1989]. This concept has now been extended to show that 
upper airway resistance (UAR) leading to an increased ventilatory effort during sleep is 
also associated with sleep fragmentation and hence daytime consequences on function 
and EDS similar to patients with SAHS [Montserrat et al. 20011. 
Unlike objective measures of EDS (i. e. multiple wakefulness test, multiple sleep latency 
test and less slow wave sleep) the severity of self-reported EDS is not linearly related to 
the degree of physiological SAHS (AHI) [Sauter et al. 2ooo] and may fail to discriminate 
between snorers and SAHS patients [Osman et al. 1999]. Thus aetiology of EDS in 
patients with SAIHS is not well established although sleep fragmentation and reduction in 
SWS are the most likely mechanisms (Punjabi et al. 1999]. Although poorly understood, 
there is some evidence that nocturnal sleep apnoea without daytime symptoms or 
deterioration in HRQL may not respond to treatment, strengthening the need for EDS in 
the syndrome definition [Barbe et al. 2001]. 
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Table 1.5: Presenting symptoms of SAHS [Stradling 1995a] 
Mýifcommon Less 6ommon' Raic 
Loud snoring Nocturnal choking 
F-ýcessiv'e dayttme sleepiness Reduced libido 
Restless sleep 
Un-refreshing sleep 
Nocturnal sweating 
Morning headaches 
Nocturia 
Personality changes 
Witnessed apnoeas 
1.3.6 SAHS & Co morbidity 
1.3.6.1 Obesity 
Enuresis 
Recurreiýt'ý' arousals/ 
insonmia , 
Noctumal cough 
Gastro-oesophageal reflux 
disease 
Overweight and obesity represent a rapidly growing threat to the health of nations 
replacing more traditional problems such as under-nutrition and infectious diseases as 
the most significant causes of ill-health. Obesity is associated with coronary artery disease 
(CAD), hypertension and stroke, types of cancer, non-insulin-dependent diabetes mellitus 
(NIDDM), gallbladder disease, dyslipidaemia, osteoarthritis and gout, and pulmonary 
diseases, including SAHS. A WHO sponsored international consultation exercise 
concluded; that the fundamental causes of the obesity epidemic were sedentary lifestyles 
and high-fat energyýdense diets [Anon. 2000]. 
Obesity and SAHS have been historically linked closely together and in turn are 
considered to be contributing to increased prevalence of hypertension, IHD and Insulin 
resistance in diabetes mellitus. In obese patients, upper airway soft tissue enlargement 
may play a more important role in the development of obstructive SAHS [Whittle et al. 
1999], whereas in non-obese patients, bony structure discrepancies may be the dominant 
contributing factors for SAHS [Sakakibara et al. 1999]. 
1.3.6.2 Systemic hypertension 
SAHS is an independent risk factor for the development of hypertension. Data from cross- 
sectional studies show a progressive increase in mean blood pressure with an increase in 
AHI suggesting a dose response link [Grote et al. 2001]. AHI has been shown to predict 
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daytime ambulatory diastolic blood pressure (DBP), nocturnal ambulatory systolic blood 
pressure (SBP) and DBP [Lavie et al. 2000]. SAHS is also a risk factor for drug resistant 
hypertension, independent of obesity and age [Lavie et al. 2001]. In the Sleep Heart 
Health Study with 6132 subjects the odds ratio for hypertension, comparing the highest 
category (of AHI 2t 3o hour-, ) with the lowest category (AHI < 1.5 hour-'), was 1.4 [Nieto et 
al. 2000]. 
Although age, obesity, smoking and alcohol consumption are known to confound the link 
between SAHS and hypertension in primary care based studies [Stradling et al. 199o], 
there is prospective randomised trial evidence linking SAHS with development of 
systemic hypertension, in normotensive patients with SAHS over 4-5 years [Wright, Jr. et 
al. 2001] [Peppard et al. 2000]. 
1.3.6.3 Cerebrovascular disease 
SAHS is more frequently reported in association with strokes and transient ischaemic 
attacks (TIA) [Bassetti et al. 1996]. SAHS is known to be frequent during the first night 
after cerebral infarction (62%) and is associated with early neurological worsening 
[Iranzo et al. 20021. Cerebral infarction onset during sleep is also associated with the 
presence of moderate to severe SAHS (AHI a25 hour, ) [Bassetti et al. 19991. 
SAHS is a well-established complication of stroke involving the brainstem. Diffuse 
cerebral symptoms such as cognitive deficits, depression or fatigue after a hemispheric 
stroke may mimic SAHS symptoms. Sleep is fragmented because of the presence of 
increased AHI (>5o hour') majority being obstructive apnoeas and associated with 
arterial oxygen desaturations (SaoJ and arousals (Mohesenin, 1995]_ In the Sleep Heart 
Health Study the risk of stroke was 1.6 times higher in SAHS (AHI>5 hour-iL) then normal 
subjects [Shahar et al. 2ooll although there is as yet no prospective evidence to suggest 
that SAHS is causally linked to strokes [Neau et al. 2002]. 
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1.3.7 Consequences of SAHS 
1.3.7.1 SAHS & Driving 
Sleepiness is recognised as a common cause of road traffic accidents (RTA) with a 
consequent human and economic cost to the individual and society. Sleepiness while 
driving maybe a manifestation of EDS and has a multi-factorial aetiology from sleep debt 
or deprivation and insomnia to sleep disorders causing sleep fragmentation [Aldrich 
1989; Home & Reyner 19951. Sleep related accidents are considered when there is no 
sign of avoidance or braking and are more commonly high speed, single-vehicle accidents. 
The proportion of patients with severe SAHS who had sleep-related accidents was almost 
2-7 times that of patients with mild or moderate SAHS, although MSLT sleep latency did 
not differ significantly in patients with accidents and those without [Haraldsson et al. 
1990; Teran-Santos et al. 19991. 
None of the clinical or physiological markers commonly used to define disease severity 
were able to discriminate those patients at higher risk of having an automobile accident 
[Barbe et al. 1998]. 
1.3.7.2 Health related quality of life 
SAHS is a cause of generalized fatigue, poor motivation and HRQL deterioration 
[D'Ambrosio et al. 19991. In a qualitative analysis using semi-directive interviews with a 
trained psychologist, patients with severe SAHS spoke mainly of abnormal fatigue and 
somnolence. Many bad problems with obesity, snoring related problems and depression. 
Patients had problems with relationships and sex and were concerned about loss of 
memory and the fear of dying [Veale et al. 2002]. SAHS has been reported to be an 
independent predictor of amount of sick leave, impaired work performance and divorce 
rate [Grunstein et al. 19951. 
All dimensions of HRQL were found to be significantly impaired when compared with an 
age- and gender-matched population [Bolitschek et. al. 1998]. SAHS not only affects the 
individual adversely but also partners who frequently report moderate to severe 
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disturbance from patient snoring/apnoeas/restlessness and had poor sleep quality and 
self- reported health status [McArdle et al. 200ibl. 
Participants in the US population- based Sleep Heart Health Study reported poorer 
HRQL scores on several Short Form 36 (SF-36) scales although energy/ vitality was the 
only subscale which correlated with AHI [Baldwin et al. 20011. Whereas it is 
advantageous to demonstrate the HRQL deterioration in SAHS patients utilizing already 
established generic HRQL instruments like the SF36, the problem lies in different 
countries using different approaches which have the potential to yield variable results. 
This in turn would make comparisons of effectiveness difficult due to a lack of consistency 
between the effect sizes obtained using different instruments. This is illustrated well by a 
study examining three generic approaches to the measurement of patient-reported health 
status: the Patient-generated Index (PGI), the European Quality of We Questionnaire 
(EuroQol) and the SF36. Of loo patients with mild to moderate SAHS approached, 86- 
89% responded with SF-36 summary scale scores being lower than those of the general 
population at baseline, but had improved to the normative levels after treatment. The 
EuroQol showed no decrement at baseline and no change with treatment and was 
considered to lack sensitivity to the type of HRQL decrements expected in SAHS patients 
Venkinson et al. 1997b]. 
When disease specific questionnaires have been used like the Calgary Sleep Apnoea 
Quality of Life Index (SAQLI), this was found to have a high responsiveness index of 1.9 
and an effect size of 1.1, which was much greater than the domains of the generic 
questionnaires like the SF-36 and the Functional Profile Quality of Life Index [Flemons et 
al. 2002]. 
HRQL data (whether generic or disease specific) has been now incorporated in assessing 
the effectiveness of therapy for SAHS, as the main goal of treatment in these patients 
tends to be symptomatic benefit. However there is no clear relationship demonstrated 
between the HRQL scores obtained with physiological parameters of nocturnal sleep 
disturbance, hence the causal mechanism of HRQL deterioration remain to be established 
[Barbe et. al. 2001]. The large overlap between the poor HRQL suffered by patients with 
obesity, depression and other co morbid diseases makes the interpretation of the HRQL 
changes difficult. Different generic measures of HRQL show variable effect sizes 
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depending on which measure is used and in which population. The therapeutic benefits 
measured in SAHS are not wholly conducive to comparison with gains obtained with 
competitive health care intervention strategies. This in turn makes the work of health 
policy prioritising difficult. 
1.3.7.3 Mortality 
SAHS has been implicated in epiderniologic studies as an important risk factor for 
cardiovascular disease which is the primary cause of death in males. There is a greater 
incidence of hypertension and atherosclerosis related diseases such as stroke, angina, and 
acute myocardial infarction [Mooe et al. 2001]. However, obesity is a common association 
and is argued by some to be the etiological factor for both SAHS and cardiovascular 
morbidity. There is shortened longevity seen in patients with untreated or inadequately 
treated SAHS [Fletcher 1996c] and there are pathophysiological factors thought to 
account for this early mortality, like sudden death during sleep (arrhythmia) or even 
fatalities from sleep related automobile accidents. The reason that the association 
between SAHS and cardiovascular disease remains unclear is that the relationship thus 
far is demonstrated only by epidemiological association and not yet convincingly by 
mechanisms showing a cause-effect relationship. Although the overall mortality among 
SAHS patients is reported to be similar to the general population, a significant excess of 
cardiovascular deaths and an excess of deaths from accidents and poisonings was found 
[Veale et al. 2000]. 
The presence of obesity can confound the interpretation of data obtained from un- 
controlled trials into the association of SAHS and mortality. Autopsy Of 34 obese men 
with sudden death demonstrated that those with a history of SAHS have a high risk of 
sudden cardiovascular death, despite the absence of other conventional risk factors 
[Rossner et al. 1991]. Cardiovascular cause of death was more common among those who 
snored habitually or often than among those who snored occasionally or never, while 
'habitual' snorers died more often while sleeping or in the early morning (Rajala et al. 
19911. 
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There is some evidence that increased mortality may be linked to the severity of nocturnal 
sleep disturbance, when other confounding variables have been accounted for [He et aL 
1988]. 
1.3.7.4 Neuro-cognitive dysfunction 
SAHS is most frequently associated with reduced concentration and recent memory 
(verbal, visual and spatial) loss, along with increased prevalence of mental stress, 
depression and anxiety [Borak et. al. 1996]. Patients also have longer reaction times and 
poor vigilance in driving simulation testing [Munoz et al. 20001. Appropriate treatment is 
reported to show either improvement in cognitive performance, vigilance, mental 
flexibility and attention [Henke et al. 2001]. 
As depression and neuro-cognitive dysfunction remain important determinants in SAHS, 
these are important issues to be addressed in any assessment of the benefits of health care 
intervention strategies. There are traditional instruments used in neuropsychiatric 
research as the Hospital Anxiety and Depressions Scale (HADS) [Bjelland et al. 20021 
and the General Health Questionnaire (GHQ) [Goldberg et al. 1988] which may provide a 
measure of the prevalence of psychiatric disorder and the effect of treatment. 
1.3.8 Treatment of SAHS 
1.3.8.1 Aims of treatment 
The primary goal of treatment in individual patients is to improve their EDS and daytime 
function [Scottish Intercollegiate Guidelines Network 20031. Treatment has an impact 
not only on HRQL [Ballester et al. 1999] but on morbidity and mortality associated with 
accidents both on the road and at work [Cassel et al. igg6a], although there is limited 
RCT evidence of this as yet [Wright and Dye 19951. Presently there is little evidence for 
treating otherwise healthy and asymptomatic individuals simply on the basis of a 
nocturnal sleep breathing disorder [Scottish Intercollegiate Guidelines Network 20031. 
However there is an epidemiological risk of developing hypertension [Peppard et 
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al. 20001 and secondary CAD in patients with SAHS [Peker et al. 19991, regardless of 
symptomatology. Patients already at increased risk with a combination of co-existent 
obesity, hypertension, cardiovascular and cerebrovascular disease along with diabetes are 
more likely to benefit from treatment of their concomitant SAHS [Wilcox et al. 1998], 
with improvement not only in HRQL [Flemons et al. 1997a] and daytime function 
[Engleman et al. 1994a] but perhaps also in a reduction in mortality [Fletcher 1996a]. 
1.3.8.2 Surgical treatment 
Surgical treatment for SAHS has ranged from early tracheostomy [Cohen et al. 20021 
with genioglossus mobilisation, maxillo-mandibular advancement [Cohen et al. 19981, 
and nasal surgery [Salib et al. 2000] to the more recent laser assisted 
Uvulopalatopharyngoplasty (UVPPP) [Ikeda et al. 19971- Although there is some evidence 
of improvement in symptoms and a reduction in AHI seen among these patients the 
impetus has currently shifted towards minimally invasive techniques. These include 
radiofrequency ablation of the uvula and soft palate to reduce the inherent collapsibility 
of the pharyngeal airway [Masood et al. 20011. There are no RCTs comparing surgical 
treatment in SAHS hence no evidence based recommendations which are free of 
statistical regression to mean errors [Scottish Intercollegiate Guidelines Network 20031. 
A meta-analysis of smaller studies of the effectiveness of UVPPP [Verse et al. 20001 
concluded that there was possibly a 50% benefit in 50% cases based on subjective 
measures, hence current best practice guidelines do not recommend routine use of 
surgical techniques for SAHS patients [Scottish Intercollegiate Guidelines Network 20031. 
The techniques and evidence surrounding these surgical treatment options are beyond 
the scope of this thesis and hence have not been discussed here. 
1.3.8.3 CPAP therapy 
CPAP therapy was first used in the treatment of SAHS in 1981 in Australia [Sullivan, Issa, 
Berthon-Jones, and Eves 1981]. CPAP dilates the upper airway using intra-luminal high 
pressure air during the breathing cycle, counteracting the normal predominantly 
collapsing forces in the pharynx, thus preventing airway narrowing and collapse. This 
high pressure is generated via a compressor and delivered to the patient through a tight 
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fitting nasal/ full face mask, which in the original experiment the nasal mask was fixed 
with a silicone adhesive each night. 
1.3.8.3.1 Benefits of CPAP therapy 
1. Sleep & symptoms of SAHS 
Sleep architecture in SAHS patients is characterized by a reduction in SWS in the early 
part of the night and this is correlated with a reduction in sleep latency recorded in the 
MSLT. After CPAP therapy, SAHS patients significantly increased their mean SWS in the 
first and second sleep cycles and restored a more physiologic decay of SWS across the 
night [Heinzer et al. 2001]. Patients on CPAP show significant reductions in the 
symptoms of EDS, restless sleep, heartburn, nocturia, enuresis, headache and nocturnal 
sweating [Kiely et al. 1999] [Tiihonen et al. 1998]. 
Although obesity is closely inter-linked with SAHS, patients on CPAP and conservative 
weight loss therapy were shown to have a six times higher odds ratio of successful 
treatment compared with weight loss alone [Ballester et al. 19991. 
In long term use more than 8o% Of 3225 respondents in a French population study 
reported that CPAP treatment had greatly improved their symptoms (based on 
Nottingham Health Profile scores) [Meslier et al. 1998]. Other studies demonstrated 
improvements in AHI, emotional reactions and energy [Sanner et al. 20ool and in HRQL 
(energy/ vitality, physical and mental component summary dimensions of the SF36 and 
the sleep and rest dimension of the FLP) [Stradling et. al. 19961. 
Asymptornatic patients with significant SAHS [Barbe et al. 20011 or symptomatic mild 
SAHS patients are reported not to show any improvement in EDS with treatment 
[Engleman et. al. 1997a], hence currently treatment is not recommended for 
asymptornatic patients [Scottish Intercollegiate Guidelines Network 20031. 
2. Cardiac Function 
Two different studies involving a total of 83 patients with SAHS demonstrated a 
significant improvement in left ventricular diastolic function and a drop in blood pressure 
in SAHS patients [Alchanatis et al. 2000; Fung et al. 20021. 
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3. Accidents 
CPAP treatment has been shown to reduce the rate of RTAs [Young et al. igg7b] 
including both real and near-miss accidents along with a reduction in accident related 
hospital stay [Kryger 19971. 
There are limitations in designing randomized studies to assess the benefit of treatment 
on real RTAs; hence studies have used surrogate performance measures in driving 
simulators [George et al. 1996]. Untreated SAHS patients, whose baseline performance 
had been worse than controls in all measures [Turkington et al. 20011, improved 
significantly after CPAP treatment, particularly in 'tracking error' which returned to the 
level of controls [George et al. 19971- 
4. Neuro-psychiatric function 
CPAP treatment has been shown to improve mood and cognitive performance especially 
in improved vigilance, mental flexibility (trail-making B time) and attention [Engleman et 
al. 1994b]. Some patients with affective disorders (anxiety & depression) have been 
shown to improve with CPAP treatment [Yamamoto et al. 20001 while others have 
reported no change in their emotional status [Borak et al. 19961. The cognitive 
dysfunction is shown to be more closely related to EDS then to underlying AHI [Cohen- 
Zion et al. 2001]. Deductive thinking and verbal attainment were more severely impaired 
in SAHS when compared to patients with Alzheimer's disease, while impairment in 
constructive ability and immediate memory were comparable [Antonelli Inc et al. 20041. 
1.3.8.4 Oral appliances for the treatment of SAHS 
Oral appliances present a useful alternative to CPAP, especially for patients with simple 
snoring and patients with SAHS who may not be able to tolerate CPAP therapy [Scottish 
Intercollegiate Guidelines Network 20031. They work on the principle of moving the 
mandible forward thus stretching open the oro-pharyngeal airway and positioning the 
tongue forward, preventing its inherent tendency to fall back and obstruct the airway 
[Marklund et al. 20041. This maybe titrated by advancing 1 mm every week until there is a 
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resolution of the symptoms and a reduction in the oxygen desaturation index (ODI) 
[Fleury et al. 20041. 
These tend to be more effective in female [Battagel et al. 19991, younger patients with 
normal BMI presenting with a history of snoring and/or mild hypopnoea [Liu et al. 
2000; Verse et al. 20031. Although the reduction in AHI was less when compared to CPAP 
[Barnes et al. 20041, patients reported improved EDS and preferred using an oral device 
over CPAP in a cross-over study [Clark et al. 1996]. 
A Cochrane review Of 7 trials involving 177 SAHS patients found that although it was less 
effective than CPAP, patients strongly preferred the oral appliance to CPAP (odds ratio 
9.5) [Wright and White 2000). 
When compared with UVPPP, mandibular advancement has been shown to be more 
effective but with less patient contentment [Wilhelmsson et al. 19991. 
1.3.8.5 Lifestyle Interventions in SAHS 
Sleep and SAHS are closely related to lifestyle influences from sleep opportunity, work, 
mental stress, jet travel, sleep hygiene factors, obesity, and consumption of alcohol, 
smoking and drug use. These lifestyle factors tend to cause EDS, generalised fatigability 
and confound intervention studies in SAHS [Shneerson and Wright 20011 if they are not 
specifically corrected for in analyses. There is as yet little evidence of the influence of 
lifestyle intervention in SAHS [Shneerson & Wright, 20oil and hence the next section 
reviews the current evidence and identifies the key features which may be incorporated 
into an intervention study. 
1.3.8.5.1 Sleep hygiene 
The daytime performance, EDS and chronic fatigue are in turn linked with the qualitative 
and quantitative aspects accompanying nocturnal sleep and the influences on it. Hence 
conservative measures to improve nocturnal sleep have an important contribution in the 
treatment of patients with SAHS. The evidence for sleep promotion measures comes from 
research into behavioural strategies for the treatment of insomnia but are equally 
applicable in other sleep disorders for promotion [Becker et aL 1993; Blake et al. 1998]. 
The factors affecting sleep quality and quantity are; 
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1.3.8.5.1.1 Psychological Factors 
Stress is considered by most sleep experts to be an important cause of short-term sleeping 
difficulties [Breslau et al. 19951. Common triggers include school or job-related pressures, 
family or marital problems, and serious illness or death in the family. Usually the sleep 
problem disappears when the stressful situation passes. However, if short-term sleep 
problems aren't managed properly right from the beginning, they can persist long after 
the original stress has passed and are increasingly associated with chronic depression 
[Breslau et al. 19951. 
1.3.8.5.1.2 Lifestyle Stressors 
These include drinking alcohol or beverages containing caffeine in the afternoon or 
evening [Taillard et al. 1999], exercising close to bedtime, following an irregular morning 
and night-time schedule [Knutsson 20031, and working or doing other mentally intense 
activities right before or after getting into bed. Jet lag [Brown et al. 20011 and shift work 
contribute adversely to the quality of sleep and subsequent performance. It is difficult to 
reset the internal circadian clock and not surprisingly 10- 20% of night shift workers 
report falling asleep on the job, usually during the second half of the shift [Harma 19961. 
They may also find it difficult to sleep during the day, even though they are tired [Phillips 
et al. 1991]. Hence adherence to a sleep routine is shown to help sleep. 
1.3.8.5.1.3 Environmental Interferences 
A distracting sleep environment such as a room that's too hot or cold, too noisy or too 
brightly lit [Schnelle et al. 1998], the comfort and size of beds [Ancoli-Israel 19971 and the 
habits of the sleep partner can be a barrier to sound sleep. In a study comparing 
structured sleep hygiene measures in combination with light therapy and exercise all 
subjects showed a trend toward improvement, independent of the treatment received 
[Guffleminault et al. 19951. 
1.3.8.5.1.4 Physical factors 
A number of physical problems can interfere with the ability to fall or stay asleep like 
arthritis and other conditions that cause pain or discomfort [Bloom et al. 2002] and so 
can breathing disorders such as asthma and Chronic obstructive airways disease (COPD) 
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[Bohadana et al. 2002], hormonal shifts including those that cause premenstrual 
syndrome [Lee-Chiong, 20041 or menopause [Empson et al. jL9991 and pregnancy 
[Maasilta et al. 2001]. 
1.3.8.5.1.5 Drugs & Alcohol 
In addition, certain commonly used drugs such as steroids, antihypertensives, 
bronchodilators and can cause sleeping difficulties [Obermeyer et al. 1996]. The effect of 
alcohol on sleep is dose dependant usually causing central nervous system stimulation 
and dis-inhibition in smaller quantities leading to a stuporous state in excess [Issa et al. 
19821. Typically, these individuals take a longer time to fall asleep and show decreased 
sleep efficiency, shorter sleep duration and reduced amounts of SWS when compared 
with healthy controls. Their sleep patterns are fragmented, and the typical time course of 
EEG delta wave activity is severely disrupted. The amount of REM sleep may be reduced 
or increased. Sleep changes can persist during months or years of abstinence, and recent 
studies indicate that certain alterations in sleep architecture, as well as subjective sleep 
complaints, predict relapse to alcoholism [Landolt & Gillin, 20011. Long term alcohol 
consumption causes significant interactions with Stage 1 sleep percentage, SAHS and 
periodic limb movements, with older subjects having the most disturbances [Brower et al. 
20011. 
1.3.8.5.1.6 Time for sleep 
Eveningness was associated with an irregular sleep/wake habit and greater caffeine 
consumption. Subjects built up a sleep debt during the week and extended their duration 
of sleep at the weekend [Taillard et al. iggg]. A temporal discrepancy between the 
endogenous sleep-wake cycle and the daily structure of the surrounding social network 
are characteristic for chronobiological sleep disturbances. Structuring daily activities by 
paying attention to natural daylight (dawn and dusk) and to the social routine strengthen 
the synchronizing effect of external timekeepers necessary for the concordance between 
inner and outer rhythmic phenomena. 
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Table 1.6: Advice on sleep hygiene adapted from the National Sleep 
Foundation, USA 1999 [Alward 1995; National Sleep Foundation 19991 
BEDTIMERITUALS 
Take a warm bath. 
Lower the room temperature (a cool environment improves sleep). 
Don't "activate" your brain by balancing a check book, reading a thriller, or doing other 
stressful activities or watching television in bed. 
LJGHT 
Light is one of the main sources of stimulus for the inherent chronobiological rhythm and 
simple measures to darken the bedroom and bathroom helps induce sleep and prevent early 
awakening. 
Install light blocking and sound absorbing curtains or shades. 
Wear eye shades. 
SOUND 
Wear ear plugs. 
Gentle soothing music or a white noise source (like a fan) may help to reduce the effect from 
other noises. 
Sound proofing of the bedroom allows less external interference (Install carpeting and 
drapes to absorb sound). 
Avoid interference from telephones etc. 
FOOD 
Avoid caffeine, nicotine or tannin (which are stimulants for the central nervous system) less 
than five hours before bedtime. 
Avoid alcohol before bedtime as it may help induce sleep but in the long term or in excess 
affects sleep architecture and worsens snoring and sleep apnoea. 
Light snack before bedtime is considered to be better than either extremes of an empty/ full 
stomach. 
EXERCISE 
Exercise promotes alertness and raises the body temperature and hence should be avoided 
for at least 3 hours before bedtime. 
Daytime naps usually reduce continuity of nocturnal sleep and should be avoided. 
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1.3.8.5.2 Impact of weight loss on SAHS 
The ideal management for an obese patient is the combination of a suitable calorie- 
restricted diet with a programme of physical exercise [Kopelman 19841. There appears to 
be a lack of consensus among physicians at all levels of care regarding the best approach 
to managing lifestyle changes including dietary strategies. Most primary care physicians 
do not treat obesity, citing lack of time, resources, insurance reimbursement, and 
knowledge of effective interventions as significant barriers. However there is evidence 
that a brief, physician-directed program with nutritionist support by telephone can be 
implemented in a busy primary care office [Bowerman et al. 2001]. 
Although weight reduction reduces apnoea severity and improves pulmonary function it 
is not known to be curative in most obese patients with sleep apnoea [Grunstein et al. 
1994; Largerstrand & Rossner 19931. Among morbidly obese patients (BMI ý40 kgM-2) 
vertical-banded gastroplasty and an intensified dietary regimen had variable results. Only 
those with significant reduction in BMI (27966) reported improvement in SAHS symptoms 
[Rajala et. al. 1991]. Although it is possible for various low calorie diet systems to achieve 
a reasonable weight loss, there is usually a weight gain in the long term. 
Appetite modification with amphetamine related products lead to pulmonary 
hypertension and valvular heart disease and have been severely restricted [Sobierai 19971. 
Sibutramine is an appetite suppressant with some evidence of sustained weight loss when 
used up to 2 years with some risk of increased blood pressure (Bray et al. 19961. 
Orlistat is an inhibitor of pancreatic lipase enzyme when administered with meals it 
results in a 3o% reduction in dietary fat absorption, which equals approximately 2oo kcal 
daily energy deficit [Ballinger 20001. In the long term, orlistat has been shown to be more 
effective than placebo in reducing body weight and serum total and low-density 
lipoprotein cholesterol levels [Foxcroft et al. 2000]. 
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1.3.9 Summary 
The review of the SAHS literature demonstrates that SAHS is a common condition [Young, 
et. al. 19931 with patients suffering socially debilitating symptoms of EDS [Johns 1993a), 
generalised fatigability, lack of motivation, depression [Flemons and Tsai 1997a] and 
neuro-psychiatric dysfunction [Cheshire et al. 1992; Engleman and Douglas 1993b]. 
Although there is a far wider prevalence of snoring, EDS, obesity and nocturnal apnoeas/ 
hypopnoea, the syndrome definition includes only patients with both symptoms and 
nocturnal sleep breathing abnormalities (AHIýt5 hour-) [American Academy of Sleep 
Medicine 1999] , who 
in turn are more likely to derive benefit from therapy [Barbe et 
al. 20011. The recent trial evidence demonstrates significant but variable reduction in 
HRQL measures associated with this condition [Bolitschek et al. 1998; Flemons 
2004; Lacasse, et al. 2002a; Moyer et al. 2001; Sanner et al. 2000; Stradling et al. 1996]; 
although the tools used vary in their effect sizes and sensitivity in measuring change with 
treatment [Jenkinson, et al. 1997c]. There is little correlation seen between disability 
levels reported by patients compared to the patho-physiological measures of nocturnal 
sleep apnoea [Barbe et al. 200i; Carrera et al. 1998; Monasterio et al. 2001a]. These in 
turn create difficulties in validating and comparing the impact of SAHS treatment with 
other health care interventions competing for scarce economic resources. 
The impact of untreated SAHS is considerable both at individual and societal level [Sleep 
Alliance. 20041. The economic burden of the disease and its consequences if measured at 
the societal level, with manpower and RTA implications, may far outweigh the cost of 
therapy provision[Rodenstein 2000] [Leger 19941 [Douglas et al. 20021 [Sassani et al. 
20041 [Pack et al. 20041 [Pelletier-Fleury et al. 20041. 
Therapy for SAHS includes surgical measures [Lang et al. 20041 or oral mandibular 
advancement devices in specific situations [Bennett et al. 1998]. However since 19go, 
CPAP [Sullivan et. al. 1981] is the most common treatment for the majority of SAHS 
patients with increasing evidence of success with minimum side effects [Scottish 
Intercollegiate Guidelines Network 20031. 
As a health technology innovation CPAP has certain characteristics and advantages over 
previously available treatment options for SAHS treatment. There is evidence of the 
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efficacy of CPAP in preventing the episodic collapse of the pharyngeal airway in SAHS 
patients, prevent snoring and also reduce the work of breathing in the mild SAHS and 
UAR patients [American Thoracic Society 1994; Engleman et al. 1997a] [Cassel et al. 
igg6b; Stradling et al. 1996]. However there are difficulties in assessing the clinical 
effectiveness of CPAP as the common measures of SAHS severity (i. e. AHI, Al, EDS) are 
not strongly correlated with improvement reported by symptoms [Barbe et al. 20011. One 
of the main shortcomings arises from the lack of a unified outcome measure in these 
patients which can be reliably used to measure the impact of treatment provision 
[Jenldnson et al. igg7c]. 
The other principal difficulty in assessment of CPAP is the need to adjust for the effect of 
confounding variables [Wright and Dye 19951. As almost half of patients with 
symptomatic SAHS, have either obesity of significant sleep hygiene abnormalities, careful 
attention to these factors with conservative measures may improve symptornatology in 
many patients precluding the need for more expensive or invasive strategies [Shneerson 
and Wright 2001]. 
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1.4 DIFFUSION OF INNOVATIONS 
1.4.1 Introduction 
The majority of growth in healthcare costs over the last fifty years has been attributable to 
technological innovations [Newhouse 19921 which have resulted in a net improvement in 
patient well-being [Cutler et al. 1998]. The goal of HTA exercise is to optimise patient 
outcome, both objective (clinical) and subjective (patient-cantered) [Berwick 1989]. This 
is achieved by developing consensus recommendations based on scientific evidence of 
efficacy and effectiveness as well as the tangible and even intangible impact on society 
[Sultz 1991]. HTA analysis usually provides evidence to support further resource 
allocations or decisions to restrict them [Feeny et al. 19871. An essential part of 
completing an HTA is then to help transmit the evidence of clinical and cost-effectiveness 
to the appropriate forums for incorporation into health policy and planning, by a process 
of knowledge utilisation [Booth-Clibborn et al. 2000] [Hillman 1986). 
Unfortunately the assumption that scientific evidence will be seamlessly incorporated into 
everyday practice and planning appears to be far from true in real life [Omery et al. 1999]. 
The classical example dates back to the slow adoption of evidence on the effectiveness of 
lemons in treating scurvy which was the scourge of sailors in the British Navy [Cheng 
20041; an innovation which took 264 years to diffuse to widespread use within the 
merchant naval ships at a great cost of life [Berwick 20031. More recently, there has been 
little demonstrable net effect on commissioning of healthcare or planning based on the 
availability of effectiveness data [Hailey et al. 2ool]. Thus the mere generation of an 
evidence based report may not transform practice as would be anticipated in an ideal 
setting. 
The forces which influence the process of the spread of an innovation within a social 
system play an important part in the final utilisation/ adoption and ensuring benefits 
reach society at large. This process of dif Tusion, according to the classical diffusion 
paradigm, may be seen as a linear communication from the innovator to the passive 
adopter [Rogers 19951. But this is often found to be far more complex and interactive a 
simple linear one between a change agent attempting to persuade a client to adopt an 
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innovation [Rogers 19951. One of the first to write about diffusion was Gabriel Tarde who 
in his book 'Laws of imitation' described the concept that individuals learn of an 
innovation by copying another individual's adoption behaviour [Tarde 19621. In any 
situation where an innovation maybe introduced there are usually certain uncertainties 
which exist with alternatives which offer a choice, thus adoption is in turn determined by 
information on technological innovations. 
HTA exercise is designed to gather this knowledge and make it available for policy makers. 
Although it is argued that health services are most inefficient among all sectors in their 
ability to extract the value of resources consumed [Newhouse 20021, it is Still suggested 
that health policy should be biased to encourage technological progress rather then be 
restrictive and focus only on avoiding waste by delaying the adoption of new technology 
[Cutler et al. 2001]. 
1.4.2 Elements of the Diffusion Process 
1.4.2.1 Innovation 
Innovation is an idea, practice or object which is perceived as new by an individual or 
other unit of adoption. The newness of an innovation may not involve dealing with 
objectively new knowledge and the individual may not have formed a favourable/ 
unfavourable attitude towards it or a decision to adopt [Rogers 19951. 
There are three phases within the lifecycle of an innovation; 
(i) technology development which includes invention, demonstrations and clinical 
trials; 
(ii) launch including approval by regulatory bodies and reimbursement decisions; 
and 
(iii) Dissemination includes experimentation / reinvention, acceptance, integration 
and post-launch trials [Coye et al. 20031. 
Research suggests that perceptions of the attributes of an innovation may account for 49- 
87'0/6 of the variance seen in their rate of diffusion and adoption, while compatibility with 
current social norms and relative advantage are shown to positively influence diffusion, 
complexity of an innovation has a negative influence [Tornatzky et al. 19821. The most 
consistent innovation characteristics which tend to determine rate of diffusion, identified 
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from diffusion studies, are listed in table 1-7 and are namely; economic advantage, 
effectiveness, observe ability, trial ability, comple)dty, compatibility, reliability, 
application, communality, and radical ness [Rogers 19951. 
In an exploratory investigation, Dearing et al suggested that when risky-innovations are 
disseminated, applicability and reliability are important attributes [Dearing et al. 19941. 
They also noted that accompanying these predictors was two or more traditional 
attributes, complexity and compatibility. Their research suggests that while the diffiision 
model provides a framework with which to study a given innovation, each innovation 
differs and should be conceptualized based on its specific attributes and the results are 
likely to be applicable to a specific social system. However, similar innovations could be 
compared on a set of attributes common to all of them [Dearing and Meyer 19941. 
Table 1.7: Characteristics of an innovation 
Relative Is the degree to which an innovation is perceived to be better than the idea 
advantage it supersedes 
Compatibility The degree to which it is considered to be consistent with the existing 
values, past experiences and the need for potential adopters 
Complexity The degree to which an innovation is perceived as difficult to understand 
and use 
Trial ability The degree to which an innovation may be experimented on a limited 
basis. Ile more divisible an innovation is the qtdcker and easier it will be 
I to try it and hence quicker diffusion. 
Observe ability I The degree to which the results of an innovation are visible to others. 'Me 
greater the visibility the quicker the diffusion and adoption occurs. 
Adapted from 'Elements of diffusion' chapter in Diffusion of innovations [Rogers 1995] 
When chemotherapy for tuberculosis was introduced as an innovation it provided a 
distinct advantage to the then current procedures of sanatorium stay and iatrogenic 
collapse of the affected lung. Even so, it did not diffuse well as it was viewed to be 
expensive and required taking unpalatable medication for extended periods of up to two 
years. Only with the later introduction of Rifampicin and the reduction of the 
chemotherapy period did this modality of treatment gain widespread acceptance in spite 
of its high cost [Reekie 1982]. Relative advantage over current therapy has been shown to 
be a primary factor in the adoption of pharmaceutical innovations like in the case of 
cardiovascular drugs adoption in Germany [Wieringa et al. 20011. 
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The lack of compatibility with current norms prevented the diffusion of the energy 
efficient compact fluorescent lamps in a market dominated by tungsten lamps. Their 
delayed start mechanism and cold light was perceived unfavourably by the market to a 
point where they were nearly withdrawn. Only a significant modification and adaptation 
to the warmer light helped them gain a market niche (Menanteau et al. 20001. Unlike 
other health technologies, most of health care innovations are developed as a partnership 
between users/ academic institutions in combination with industry. This gives them the 
advantage of being compatible with the intended adopters' needs and hence can allow for 
accelerated adoption in the absence of expensive marketing and product placement 
strategies [Tabak et al. 19991. 
Perceived complexity of an innovation may hinder or slow down the rate of diffusion. In a 
comparison of anticholinesterase inhibitor use in German patients with Alzheimer's 
disease, research showed only a 9% adoption among primary care physicians compared to 
45% among specialists although the drug was targeted equally in primary and secondary 
care; this was due to the perceived specialist nature of the treatment and the lack of 
personal knowledge and expertise [Ruof et al. 20021. In a computer based stroke 
management system set up to improve and standardise care within a hospital, the 
diffusion was slow until sustained education, round-the-clock support and system 
refinement was instituted [Lau et al. 1998]. A similar computerised physician order entry 
system was shown to have a slow diffusion although perceived to be beneficial allowing 
remote access to patient data, decreasing errors and allowing decision support due to 
complexity compared to paper based systems, lack of flexibility, user interaction and 
absence of perceived need by the end user [Ash et al. 20011. 
Findings suggest that relative advantage; compatibility with current practice, its 
complexity, and observe ability were the strongest predictors of likelihood to adopt 
genomic medicine innovation tasks into primary care practice in Texas [Suther et al. 
20041. 
Both observe ability and trial ability, may affect the diffusion of surgical technique 
innovations as shown in a Canadian study where areas using laparoscopic gastric surgery 
recorded an annual rise of 16% in cases compared to only 3% in areas still dependant on 
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open surgical technique [McMahon et al. 20001. The availability of the new technique 
encouraged new adopters to observe its use and trial themselves leading to a much 
greater adoption then in regions without this degree of availability. 
1.4.2.2 Innovators & innovativeness 
The process of innovation development usually begins with a perception of need or 
recognition of a problem / deficiency (economic/ institutional model). Innovations 
developed due to user needs tend to be more focussed and need less dissemination efforts 
[Roehrich 20041- On the other hand, in some cases there is a technological push where 
new products or innovations are seen to drive the diffasion process and create the need 
[Kaplan 2001] [Prater et al. 2002] [KrepS 2002]. 
The innovativeness of an individual is his/ her attitude towards experimenting with new 
knowledge and is determined by the rate at which he/ she are likely to adopt a new idea. 
Innovativeness is based on the assumption that adoption of innovation is desirable and 
enhances the performance or efficiency of an adopter [Dos Santos et al. 19951. Followers 
of the 'contingency theory' believe that the stimulus for adoption emanates from the 
environmental flux, and rate of diffusion is faster (individuals tend to be more innovative) 
in unstable environments on order to achieve an advantage over competitors [Lawrence 
et al. 19671 [Robertson et al. 1986]. 
While in stable environments innovativeness may be considered a wasted effort and 
individuals do not adopt early nor are they consistent in their attitude to innovation 
[Hambrick 19831- While traditionally health care provision in the UK has been non- 
competitive, there have been recent innovations to make individual hospital trusts 
compete for local priorities and funding, creating a marketplace environment to drive 
progress [Maynard 19931. 
An alternative theory is one of 'strategic decision making' which suggests that 
innovativeness is a function of strategic management where decision makers actively 
choose innovations for improving performance and efficiency [Child 1972] [Dougherty et 
al- 19941. According to this theory, adopters are classified as Trospectoe, 'Analyzee, 
'Defender' and 'Reactor'. individuals or firms who rapid adopters (prospector) were held 
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greater market share while slower adopters (defenders) were shown to be more profitable 
[Miles et al. IL978]. 
Tbus the rate of diffusion depends on the relative advantages offered by the innovation 
over current practice/ technology. 'Innovativeness' has also been defined as a multi- 
dimensional phenomenon based on the number of innovations adopted, time of adoption 
and consistency of adoption [Subramanian 1996]. 
It has been said that 'to create a future different from its past, health care needs leaders 
who understand innovation and how it spreads, who respect the diversity in change itself 
and who drawing on the best of social science for guidance, can nurture innovation in all 
its rich and many costumes' [Rogers 19951. Innovators are thus characterised by their 
venturous ness, fascination with novelty and willingness to step out of their systems to 
learn. 
It has been shown that frequent and consistent adopters tend to progress faster along the 
innovation learning curve and become more efficient than others [Pennings et al. 1992], 
giving them an inherent 'first mover' advantage [Dos Santos and Pfeffer 19951. The health 
care sector in the USA is characterized by a similar market based strategy of rapid 
technological progress fuelled in part by a reimbursement system that generously pays for 
the use of new and advanced therapies [Weisbrod 1991]. While new technologies such as 
implantable defibrillators [Greenberg et al. 2002], percutaneous coronary stent insertions 
[Booth-Clibborn, Packer, and Stevens 2ooo], drug eluding stents, gene therapy 
[LyngstadaaS 2002a] etc have diffused rapidly there have been others such as magnetic 
resonance imaging scanners [Baker 2001], neonatal intensive care units [Baker et al. 
20ool and proliferation of mammography screening units [Bryant 1996] which have been 
slower as a result of introduction of recent managed care regulatory strategies [Cutler and 
Sheiner 1998]. 
In a market driven health care sector changes in financial incentives, reduction in 
profitability [Reinganum 1989] and regulation have the same effect in slowing diffusion of 
expensive innovations [Baker 2001]. 
Socialist economies in the later part of the 20th century lacked market structures hence 
diffusion of innovations was led by factors such as personal creativity of academicians and 
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engineers and recognition of societal need and government encouragement [Achilladelis 
et al. 2ooi). 
Similarly in a completely managed health care sector like the NHS in the UY, the 
dynamics of diffusion are entirely different from the experience in the USA. At an 
individual level innovation decisions may be made on an optional or collective basis 
within small groups of individuals (like clinical groups or Primary Care Trusts). However 
decision making within managed care settings is done at a regional level (like the 
Regional Health Authorities [Pettigrew et al. 1989] and the recently formed Strategic 
Health Authorities [SHA] in the UK NHS). This is guided by national bodies for 
assessment of innovations and health care technologies [Rawlins 1999]. Decision making 
at SHA level is increasingly becoming dependant on formal systems of HTA (assessments 
and guidance from the National Institute of Clinical Excellence [Taylor 20021 [Davies and 
LittlejohnS 2002]), social-political imperative [Pettigrew, McKee, and Ferlie 19891 and 
mechanisms of identifying new and emerging technologies for appraisal. 
1.4.2.3 Communication 
This involves the transfer of a 'new idea' or innovation between an individual/body who 
has the knowledge or experience of this innovation, through communication channels to 
those who do not yet have the knowledge [Rogers 19951- Although mass media channels 
are usually the quickest way of disseminating knowledge to a large audience, the 
disadvantage is the lack of individual tailoring/ focus and the diversity of this large 
audience group [Gupta 1996]. Individuals tend to only take notice of mass media 
messages which they perceive to be relevant to them and hence a perception of need or 
prior knowledge is essential for them to be successful [Scullion 20021. Hence the people 
in a social system who are likely to be inclined to early adoption and are seeking 
knowledge about an innovation are likely to be influenced by mass media campaigns 
rather than the ones with the least knowledge [Scullion 2oo2]. 
Contrary to planned mass media communication campaigns, the media coverage of 
particular individual stories may have a great influence in shaping public perceptions and 
pressuring public spending policies. This is illustrated by the effect on prescription of 
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certain drugs like anti-influenza drug'Zanamivir' [Barnett 2001] and 'Sildenafil'for male 
sexual impotence [Smith 1998b]. Media may also have an adverse impact on adoption of 
even well-established technologies. In 1997, when a medical journal published research 
suggesting the link between a vaccine and the development of autism [Wakefield et al. 
1998], this was taken up by mass media leading to a sharp decline in the immunisation 
coverage in the UK, in spite of governmental efforts to reassure the public of its' safety 
[Ramsay 20011. This illustrated the impact of quantitative evidence in the absence of 
qualitative or philosophical insight and suggests the need for a combined approach in 
policymaking [Roberts et al. 2002]. 
On the other hand, for professionals research suggests that in the diffusion of innovations 
particularly among new pharmaceutical products, inter-personal communication 
channels are considered far more effective in persuading a potential adopter [Mahler et al. 
19991. There is empirical evidence that physicians tend to view information available in 
professional journals as appearing too late to be useful, as too positive, as providing too 
little information regarding complications and the transferability of results to their own 
practice [Greer et al. 19771. Instead they feel that the best source of information 
concerning the efficacy of new medical procedures or innovations is other physicians with 
first-hand experience [Stross et al. 19791. The experience of the introduction of 
Tetracycline is a classical example where the initial innovators only used a few 
prescriptions while late majority users wrote a much larger number of prescriptions when 
uncertainties about this new innovation were reduced with directly observed behaviour of 
peers [Coleman et al. 1966]. This dependence on the adoption behaviour of peers suggests 
that diffusion is a very interactive and social process. 
When diffusion of communication technologies is involved they can in turn accelerate the 
diffusion of newer technologies by boosting the communication infrastructure and the 
access to knowledge [Redmond 20041. 
The adoption process consists of several stages and not merely a function of knowledge 
acquisition but is shown to require also evaluation and trial. The diffusion of higher 
technology products may be faster in communities where it has arrived later [Gruber 
20011 and especially if many similar products are introduced simultaneously with synergy 
between the communication methods. 
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The impact of the social network approach on modern contraceptive use was shown to be 
almost double that of conventional field worker visits to individual homes after 
controlling for the effects of prior contraceptive use and intention, prior home visits, and 
selected socio-demographic characteristics [Kincaid 20001. The same approach may hold 
true for the diffusion of new technology using 'workshop' based learning methods in the 
health care sector as in the appropriate use of rapid diagnostic tests for Tuberculosis 
[Anon. 1997a]. 
Much of the information necessary to support the diffusion of an innovation flows 
through personal contacts. Although in the diffusion of medical knowledge much 
emphasis is placed on publication of information about an innovation in scientific 
journals, research has shown that most physicians depend on a subjective evaluation of 
an innovation by other physicians who have already adopted this [Elford et al. 20021 
[RappOlt 20021. Hence the closer the individuals are to each other in certain attributes, 
beliefs, education and social status the more effective the communication between them is 
likely to be (homophily). While in many situations, the heterophily of individuals makes it 
difficult to establish effective lines of communication, leading to a slower diffusion 
[Rogers 19951. 
Networks of interpersonal communication that link organisations developing new 
systems with those that are adopting technological innovations thus allowing for a free 
exchange of ideas and feedback are of considerable importance in the diffusion process 
[Debresson et al. 1991]. 
Networking appears to be essential for the development of a region's knowledge 
infrastructure [Tassey 1991] and network cohesiveness (defined as direct user-to-user 
influence) has a positive impact on the diffusion of industrial innovations [Midgley et al. 
1992]. 
Pressures from social emulation and a localised competitive environment lead 
organisations and even individuals to adopt a new technology in order to "stay in the 
game" [Ebadi et al. 19841. The pharmaceutical industry began with the commercial 
application of scientific research which was initially born within academic institutions. 
Since then it has flourished while maintaining a very close link with academic institutions 
which facilitate learning by use, interaction, credibility building and maintaining market 
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focus. The close sharing of information within pharmaceutical - academic networks leads 
to reduction in time to marketing and gives these firms a competitive advantage 
(Achilladelis and AntonakiS 2001]. 
1.4.2.4 Time 
The innovation-decision process is one by which an individual or decision making body 
passes from first knowledge of an innovation to developing an attitude towards the 
innovation which in turn determines its adoption. This process is conceptualized by 
Rogers into 5 steps; 1) knowledge 2) persuasion 3) decision 4) implementation and 5) 
confirmation [Rogers 19951- 
While the knowledge of an innovation is usually transmitted by mass communication 
channels it is at the persuasion and decision stages that individuals need information on 
cause-effect, consequences and innovation evaluation information. Inter-personal 
communication channels provide the information usually at this stage especially 
regarding applicability in individual microenvironments. Subjective evaluation in such 
situations has been shown to be very effective in establishment of firm attitudes. The time 
taken by an innovation to be adopted is known as the innovation-decision period [Rogers 
19951. 
When adoption behaviour is plotted as a histogram it has been shown to take the typical 
shape of a normal distribution curve. This has been divided according to mean and 
standard deviation into five different categories. Although individual innovations may 
demonstrate different variations depending on individual factors, Rogers has generalised 
these into 5 categories commonly found normal distribution. This was initially reported in 
a seminal study of the diffusion of hybrid corn among Iowa farmers in 1943 [Ryan et al. 
19431. These were innovators (2.5%), early adopters (13-5%), early majority (34%), late 
majority (34%) and laggards (16%). 
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Figure 1.2: S-shaped diffusion curves for non-interactive (solid line) and 
interactive (broken line) innovations [Mahler and Rogers 19991 
The rate of adoption measures the relative speed with which an innovation is adopted by 
members of a social system. When the diffusion of most common innovations are plotted 
in a cumulative graph over time it demonstrates an 'S' shaped curve [Beal et al. ig6o] 
with an early majority of adopters and a plateau effect late in the diffusion process. The 
rate of adoption i. e. the rate at which a certain percentage of individuals adopt an 
innovation is however dependant on many factors. 
The critical mass is defined as the minimal number of adopters of an interactive 
innovation for the further rate of adoption to be self-sustaining. The term critical mass 
comes originally from nuclear physics where it referred to the amount of radioactive 
material needed for a pile to 'go critical' in a self-sustaining reaction. Whether or not 
such a critical mass problem is involved in the diffusion of a health innovation depends in 
part on the innovation's degree of interactivity and the existence of social networks. In the 
early stages of the diffusion of an interactive innovation, when relatively few individuals 
have adopted, the rate of adoption proceeds extremely slowly. The cumulative rate of 
adoption is characterized by almost a straight line with a long tail to the left. But 
eventually enough adopters are reached when many individuals in the system perceive 
that 'everybody's doing it'. At this point enough other individuals have adopted so that an 
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individual considering adoption of the innovation perceives that the innovation would 
have sufficient utility to justify its adoption [Mahler and Rogers 19991. The critical mass 
point in the diffusion process is generally expected to occur approximately between io 
and 2o% adoption [Rogers 19951. 
The study carried out by Ryan and Gross [Ryan and Gross 1943] about the diffusion of 
hybrid corn in two Iowa communities is often considered as the starting point of the 
research on innovation diffusion. Their main problem was to understand why some 
farmers adopted earlier than others, among all who had an economic interest to adopt the 
innovation. They tried to capture these differences with variables such as social 
participation, education, cosmopolitanisms, and media consumption which were more 
highly correlated with the time to adopt than the size of the farm and the length of 
farming experience. Moreover, the data of cumulative adoption showed the typical S- 
shaped curve for the diffusion of innovation. 
This type of curve is explained by the risk of innovation adoption, and the uncertainty 
about the outcome of adoption. The observation of earlier adopters is a means for 
reducing this uncertainty. Therefore risk tends to force individuals to turn to their peers 
to gain more information and/or reassurance about the outcome of the adoption. [Rogers, 
1984] refers to contagion as the diffusion effect. When the number of adopters increases 
in the network of peers, the pressure for adoption also increases. However, the capacity to 
resist to this pressure varies among individuals. This led to the definition of the threshold 
models (Granovetter, 19781- An individual's threshold is the proportion of adopters in the 
considered group necessary to convince him to adopt. Originally this model was applied 
to the case where the group was considered to be seen globally by all individuals (the 
example of riots). 
The network approach led to refine the models and to define the personal network 
threshold models, corresponding to the proportion of adopters in the personal network 
(also called personal exposure) leading to adoption. The exposure can be calculated for 
direct links, or for indirect links divided by their length using the flow matrix [Freeman et 
al 1991]. The exposure at the first level is used to define a local threshold for adoption, 
corresponding to the proportion of adopters in this one step network which led to 
adoption. The threshold lag corresponds to the time necessary for adoption when the 
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threshold is reached (in general the adoption does not occur right when the threshold is 
reached). The more formal definition of the threshold is the point at which the perceived 
benefits exceed the perceived costs [Granovetter, 1978]. 
The network approach also led to reconsider the critical mass concept, and connect it to 
the different versions of the personal network threshold. This research shows that the 
critical mass varies with the threshold distribution of the population and with the social 
network structure. 
A historic example of a rapidly diffusing health technology innovation was the computed 
tomography (CT) scanner in the USA in the early 1970s. This was adopted at a rapid rate 
in the USA due to an early realisation and perception among radiologists, administrators 
and physicians alike of its immense benefits over conventional technology. However the 
scanners were purchased rapidly at great cost even for well resourced hospitals, when still 
undergoing rapid changes in development. Hence, most initial scanners became obsolete 
within 2 years. There was a second spate of purchases by tertiary hospitals so that 
diffusion reached a peak by four years from the introduction of this technology, before 
safety and effectiveness were established with traditional research methods. In some 
states this created a regulatory backlash and diffusion became variable geographically. 
Thus perhaps there was a need for a proper assessment of efficacy similar to those 
required for pharmaceutical innovations before being licensed for widespread adoption 
[Baker 19791. In a similar case of diffusion of Magnetic Resonance Imaging (MRI) 
scanners in the USA, the technical and financial uncertainties surrounding MRI had 
inhibited its diffusion compared with that of CT. Medicare's prospective reimbursement 
system and certificate-of-need regulation by states had reduced overall MRI diffusion and 
stimulated purchases of MRI by non-hospital organizations [Hillman et al. 19851. In 
England, MRI scanners were initially purchased six years after first availability with a 
subsequently slow rate of diffusion, and are still absent from some hospitals [Booth- 
Clibborn et al. 2000] their steep cost being the primary hindrance to adoption. 
While coronary stents were initially used six years after first availability, but within two 
years all responding hospitals in England reported using them, as their diffusion was 
accelerated by professional champions [Booth-Clibborn et al. 2000]. 
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1.4.2.5 The social system 
A social system is a set of interrelated units that are engaged in joint problem solving to 
accomplish a common goal [Rogers 19951. Individuals in a social system are different but 
usually work towards a common goal. The structure of a social system is the way the 
individual units are arranged in a system, i. e. primary, secondary and tertiary care health 
systems where there is usually a diffusion of innovation from the tertiary care 
establishments engaged in research or early implementation of an innovation through 
secondary care and finally at the grass roots level among primary care health workers. 
The advantage of a social structure is some predictability of the way the system might 
respond to a new idea/ innovation. In addition to a basic social structure there are well 
established channels of communication which determine how a set of individuals may or 
may not respond based on their inter-personal channels [Rogers 19951. 
Established patterns of behaviour (norms) are instrumental in influencing the variable 
way an innovation may diffuse in different subsets of the same social system with a 
homogenous exposure. In 1991, Hofstede suggested possible factors in different social 
structures which could be related to innovativeness; 1) individualism vs. collectivism or 
self-orientation, 2) femininity vs. masculinity or achievement orientation and 3) 
uncertainty avoidance or risk orientation. Social systems or cultures with individualism 
and masculinity were more likely to be early adopters than those with a conservative and 
risk aversion outlook [Hofstede 1991]. 
Social networks of potential users of a service have been used to determine the 
prioritisation of healthcare interventions and thus may have a role in influencing the 
diffusion of adoption of health care innovations. The Oregon Plan in the late ig8os and 
early 199os was an experiment to prioritise health care spending based on adopting 
public preferences to a combination of health care interventions ranked according to cost- 
utility ratios and professional prioritisiation. Although regarded initially as a progressive 
movement to explicit rationing of healthcare delivery influenced partly by user 
preferences, compared to the implicit rationing seen in other systems, there were inherent 
flaws due to factors such as the under-representation of minorities, the disabled and 
mental health patient groups in such user surveys [Brown 1991]. This led to the removal 
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of the potential user group influence on prioritising in the revised plan which was adopted 
later to fund 565/696 condition/treatment pairs [Sipes-Metzler 19941. 
The adoption of computers in hospitals demonstrates the flexibility and compatibility 
influencing its diffusion in two waves, initially as an administrative tool and later in 
clinical application areas. Hospitals were plagued by rapidly escalating workloads and 
costs and computers offered a solution for some of the major health-management 
problems and offered assistance to all individuals involved in health care. With the 
availability of personal computers, it became feasible for even small hospitals to have 
access to computer systems. However in the early days of the introduction of computers, 
diffusion was not being achieved across areas of clinical application. Most of the leading 
hospitals in the United States used to perceive and use computers only for administrative 
applications. The use of computers in clinical applications and patient care had not been 
exploited in the 1970s. 
Mahajan identified the need for focussing resources on the difftision of knowledge on 
computer-based clinical applications and links with teaching hospitals as change agents 
through communication networks to implement the difftision of computers in clinical 
applications [Mahajan 19791. Since then in the last two decades the use of personal 
computers (PCs) in clinical applications, telemedicine, digital imaging, electronic patient 
records, ordering of investigations, and the use of intra-nets for the dissemination of 
clinical practice guidelines have become the mainstay of hospital practice and their use 
has also expanded into primary care [Egan et al. 19951 [Majeed 20031. 
Systematic barriers are known to slow down the adoption of certain innovations as 
demonstrated in the slow market penetration of anti-cholinesterase inhibitors in 
Alzheimer's disease in the UK and in Germany. Although there were positive attitudes 
regarding the safety and efficacy of these drugs, the negative attitudes regarding the 
budgetary limitations to prescribing these drugs in particular seemed to inhibit the 
adoption of the innovation by the majority of General Practitioners (GPs). Budgetary 
systems such as those in the UK and Germany support short-term cost control behaviour 
and thus, do not encourage long-term disease management and cost saving strategies 
[Ruof et al. 20021. 
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1.4.2.6 Opinion leadership 
Although the most innovative individuals maybe virtually rejected by society as they are 
perceived to be mavericks and out of touch with their peers, others who function as 
opinion leaders have considerable influence on the adoption or rejection of new ideas. 
Opinion leaders are closer to early adopters then to being innovators themselves. This 
position is usually earned and maintained by an individual's competence, social 
accessibility and conformity to the system's norms [Rogers 19951. Characteristically 
opinion leaders are; 1) more exposed to all forms of external communication, 2) have a 
higher social status and 3) are usually more innovative. 
Opinion leaders are members of the social system and exemplify the norms of the social 
system and hence their innovativeness depends on the innovative behaviour of the social 
system. The behaviour of opinion leaders may influence the rate of adoption of an 
innovation within a social system and hence may be chosen for individual targeting by 
agencies seeking to influence adoption. Opinion leaders may be sought out by change 
agencies in order to learn about public perceptions to assist in removing hurdles and 
speeding up innovations. In the adoption of environmentally safe alternative energies, i. e. 
solar energy systems early adopters revealed high education and income levels; 
professional and executive occupations; economic, energy saving, and environmental 
concern as the principal purchase motivations; and high satisfaction levels. Their early 
adoption in turn set the example for ftirther adoption in their communities [Sawyer 1982]. 
In the early days of adoption of internet based systems in healthcare practices, studies 
among physician leaders identified six internet-enabled services as "essential" for the 
future success of their practice and indicated that reduced administrative costs, faster 
payments, and improved quality of care are the most important benefits derived from 
internet-enabled applications. Ninety-six percent of survey respondents estimated that 
internet-enabled technologies will have a significant, positive impact on the practice of 
medicine in general and will improve the quality of care [Coye et al. 2001]. 
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1.4.2.7 Change agents 
The external agents or professionals entrusted with the specific task of imparting 
knowledge about an innovation to members of a social system (e. g. medical 
representatives bringing news and technical information on new drugs to medical 
practitioners) are called 'change agents. Unlike the rural agricultural sectors or third 
world family planning programs, in the healthcare sector local implementation activities 
often capitalise on knowledge primed individuals (who are highly skilled and educated) 
by enabling and reinforcing the desired behavioural change [Lomas 19931. Direct 
marketing with medical representatives continues to be a common route used by 
pharmaceutical industry where the industry representative may act as a change agent and 
influence the behaviour and practice of individual clinicians towards more evidence based 
practice. This raises many potential ethical issues and may leave a danger for non- 
evidence based practice with increased cost and safety implications [Stryer et al. 19961 
[Lober 19931 [Lal 20011. However change agents can be useful as a mechanism for 
feedback of user perspectives to industry which may help to improve the innovation 
[Calfee 2002]. 
When a new technology is introduced in the market place there are several potential 
hurdles from established technologies such as relatively crudeness of a new technology in 
its early stages, lacking the benefit of cumulative learning and economies of scale in 
production. New technologies can be perceived as more expensive, and comparison 
against the established evaluation criteria may fail to highlight the advantages of the latter. 
There is also an inherent inertia to change among most adopters which may slow down 
diffusion significantly [Menanteau and Lefebvre 20001. 
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1.4.3 Summary (Diffusion & adoption of CPAP) 
CPAP as an innovation provided certain advantages over older technologies (i. e. surgery) 
by having less adverse effects, being safer, reversible, reduced need for hospitalisation 
and perceived to be more acceptable to patients [American Thoracic Society 19941. At the 
same time the perceived advantages of this form of therapy compared to alternative 
therapies, and the high prevalence of SAHS led to a rapid expansion of demand and 
provision in some countries. 
In a managed care setting like the NHS, where purchasers were faced with the prospect of 
resource provision for 2-4% of the adult population [Young et al. 19931, reviews of the 
evidence base commissioned by the purchasers showed gaps in the evidence of 
effectiveness available [Wright and Dye 19951. This report led to many purchasing 
authorities seeking to restrict the availability of CPAP treatment and facilities for 
diagnosis and treatment in various NHS regions in the UK [Gibson et al. 19981. Local 
Physicians were impelled to argue and win resources on a region-by-region basis [Sleep 
Alliance. 20041- 
Although physician bodies such as the British Thoracic Society initially took up the 
challenge and provided forums for debate and discussion of the controversies [Kryger 
19971 [Fleetham 1997; Pack and Young 1997; Shaw 1997; Stradling 1997; Walsworth-Bell 
19971, the lack of media interest, patient advocacy and absence of industry influence 
probably resulted in a lack of large scale national studies and the absence of a national 
service framework [Sleep Alliance. 20041- More recently in 2001, consensus guidelines 
were produced to assist in service provision and guiding research into hitherto unknown 
aspects of SAHS and CPAP use [Scottish Intercollegiate Guidelines Network 20031. 
By contrast in the USA, the existence of the American Academy of Sleep Medicine 
[American Academy of Sleep Medicine 19991, the National Sleep Foundation 
[Anon. 2004b; National Sleep Foundation 1999], active media interest in the consequences 
of national sleep habits and sleep related accidents [Leger 19941, governmental bodies 
such as the National Institute of Health sponsored research [National Commission on 
Sleep Disorders Research 1993] had created a situation for a much more widespread and 
rapid adoption of CPAP technology across the nation [Mack 1999]. 
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Although perhaps slower than in the USA, the diffusion of CPAP in Europe has been 
variable with countries such as Germany, France and Spain taking the lead with national 
large scale studies and widespread resource provision [Rodenstein 2000] [Fischer et al. 
1997]. Not much is known about the economic evaluation of CPAP in SAHS [Tousignant 
et al. 19941 [Douglas and George 20021 [Pelletier-Fleury et al. 2004] and the state of 
diffusion other than by unpublished industry estimates in Europe. 
Thus CPAP provision in the UK has not kept pace with USA, Germany and Australia due 
to a variety of reasons. Principal among them are the questions of RCT evidence of 
effectiveness, influence of confounding variables (i. e. obesity), lack of a uniform outcome 
measure and economic evaluation. This thesis addresses these issues and explores the 
factors influencing the diffusion and adoption of this new health technology in the UK 
NHS. 
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2.1 Overall aim 
The primary aim of the research presented in this thesis was to conduct an HTA case 
study of an innovation (CPAP), appraising its impact on the course of a chronic 
disease condition (SAHS) where the outcome is measured not by increased survival 
but by an improvement in HRQL and health status. The research design includes a 
clinical review, a prospective RCT of clinical effectiveness and a cost utility analysis. 
The secondary aim was to study the process of diffusion of new technology from 
innovation to it's'adoption by the end user in a managed care setting like the NHS. 
Thus this thesis aims to provide a framework for the assessment of future innovations 
in the treatment of chronic disease states within a managed care setting. 
2.2 Clinical review of SAHS in a DGH (Chapter IV) 
The aim of the research presented in this chapter was to assess the population 
demographics and the morbidity and mortality associated with SAHS in a typical 
DGH Sleep clinic population. 
To measure the change in the demand for diagnostic and treatment services over 
the 7 year review period and to assess the success of CPAP trials and compliance 
over a medium term follow up. 
2.3 Clinical effectiveness (Chapter V- VII) 
The aim of the research presented in these chapters was to conduct a prospective RCT 
to assess the effectiveness of CPAP use in SAHS patients compared to a control group 
given conservative lifestyle modification advice. 
Chapter V presents data on clinical efficacy using EDS, neuro-cognitive function 
(Trail maldng B) and polysomnographic variables. 
Chapter VI presents comparative data on HRQL using two different generic 
questionnaires and two mental health assessment tools. Generic HRQL tools not only 
examine a multi-dimensional profile of health state but by their nature make it 
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possible to compare the impact of competing technologies, a vital step in health 
policy and setting of priorities for resource allocation. 
The secondary aim in this chapter was to evaluate the validity, sensitivity and 
reliability of generic HRQL tools (SF36 and EuroQol) in SAHS patients. 
In Chapter VII the aim of research presented was to evaluate the traditional measures 
of utility / health status based on patient preferences generated by the Standard 
gamble, Time-trade off and EuroQol utility in SAHS patients for use in a cost utility 
analysis. To measure the QALYs generated by the provision of CPAP vs. lifestyle 
intervention in these patients and calculating the cost/ QALY ratios. As a universal 
outcome measure (i. e. QAM would incorporate patient preferences with the quality 
and quantity of life and thus facilitating comparison of health technology 
interventions. The cost/ QALY ratios would then be compared to other health care 
interventions and use in health policy and planning of services. 
The use of a control group (given conservative, written lifestyle intervention advice 
combined with weight losing advice from NHS dietary services) provided the added 
opportunity to assess the impact of such lifestyle modification strategy in a 
population group where such lifestyle factors (i. e. obesity) have been considered to 
confound both mortality, morbidity and a majority of symptoms of EDS and 
fatigability identified in previous research. 
The secondary aim being to assess the relationship between physiological variables of 
disease severity with patient reported symptoms, HRQL decline and change in health 
status. 
2.4 Diffusion of Innovation (Chapter Vill) 
The aim of the research presented in this chapter was to assess the factors affecting 
the diffusion of CPAP in the UK by qualitative questionnaire surveys of primary care 
physicians (entrusted with the screening of individuals in the community and refer 
them to specialist centres) and respiratory physicians in secondary care; entrusted 
with provision of facilities for the diagnosis and treatment of SAHS. The 
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questionnaire survey was designed to assess the characteristics of CPAP as an 
innovation (safety, effectiveness, advantages when compared to other established 
therapies, patient acceptability, possibility of providing safe therapeutic trials, ease of 
use by patients); methods of knowledge utilisation which may impact on the rate of 
diffusion and adoption of new technologies; innovator categories; factors affecting 
adoption of new technology within the NHS- infrastructure for diffusion of expert 
knowledge, communication systems, funding restrictions and finally the future of 
CPAP. 
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3.1 Ethics 
The study was approved by the Birmingham Heartlands & Solihull Hospital Research & 
Ethics Committee. 
3.2 Study design 
3.2.1 Clinical review 
All case notes and physiological data sets from patients referred to the Birmingham 
Heartlands Hospital Sleep Disorders clinic from 1990 to 1997 were examined. 
Subjects were classified into cases or controls based on diagnostic criteria incorporating 
symptoms of snoring and EDS, combined with evidence of nocturnal respiratory 
disturbance (i) (either on overnight oximetry with an oxygen desaturation index (ODI) of 
L2' 15 hour', 4% drop in arterial oxygen saturation or (ii) in those undergoing full PSG an 
AHI ý: 15 hour, ). 
Using a retrospective, case-control analysis, the prevalence of co-morbidity (hypertension, 
stroke, and diabetes and ischaemic heart disease) and mortality were compared between 
cases and controls. 
Secondary outcome variables were the change in the number of referrals, diagnosis based 
on ODI criteria, success of therapeutic trials of CPAP and compliance with CPAP over the 
follow up period. 
3.2.2 Randornised controlled trial 
The trial was conducted in accordance with the best practice standards as set out in the 
CONSORT agreement (details in the appendix). 
3.2.2.1 Recruitment 
All patients referred by General Practitioners to the Birmingham Heartlands Hospital 
(BHH) Sleep Clinic between June 1998 and October iggg, with a history of snoring and 
EDS were invited to participate in the study with an information leaflet (please see 
appendix) mailed with their first clinic appointments. 
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3.2.2.2 Clinical assessment & investigations 
Patients were reviewed in clinic with their partners by a clinician. Patients who reported 
symptoms suggestive of SAHS then completed the Epworth Sleepiness Scale (ESS) 
questionnaire [Johns 1991] and were invited to participate in the study and provided 
further information about the study aims and asked to sign the consent forms (appendix) 
witnessed by their partners in accordance with the Birmingham Heartlands Research 
Ethics committee requirements. Domiciliary overnight arterial oximetry was conducted in 
all patients. 
3.2.2.3 Exclusions 
Patients with neuromuscular disorders, kyphoscoliosis, hypothyroidism and chronic 
respiratory diseases were excluded from the trial. 
As shown in the flow chart, all patients who gave written consent then underwent an 
inpatient full polysomnography (PSG). Patients with symptoms of Snoring +/- EDS and 
an AHI 2t15 hourl (moderate-severe SAHS) [American Academy of Sleep Medicine 1999] 
then proceeded to the health status interview. 
Patients who declined to participate in the trial progressed along the clinical protocol of 
the unit. 
At the conclusion of the baseline health status interview, randornisation was 
undertaken. A random number sequence was generated by PC using the EPI-INFO 
software v6 (CDC, USA). This random number sequence was kept under the supervision 
of the chief technician of the laboratory and blinded to the chief investigator. Patients 
were allotted to CPAP if the random number was even and lifestyle intervention if the 
number was odd. 
Patients randomised to receive CPAP (Group D-underwent a home based overnight 
CPAP titration study using the ResMed Auto-titrating CPAP device, followed by fixed 
pressure CPAP (95% percentile) set up by experienced technicians. They were given open 
and ready access to follow up with technicians as needed, for adjustments of masks and 
pressure if needed during the three months of the study. At the conclusion of the study, 
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patients underwent a final PSG using their CPAP machine. Compliance data on usage 
(hours/ night) was downloaded from the machine and recorded in a PC database using 
the ResMed autoscan software vi. i (ResMed Inc, USA). 
Patients randomised to receive lifesMle intervention (Group 11) were given written 
and verbal guidance on sleep hygiene measures and formal dietary assessment by a clinic 
dietician. They were then given further reinforcement of the dietary and sleep hygiene 
advice after 4 and 8 weeks of initiation with repeat hospital visits. At the conclusion of the 
trial they underwent a final PSG at the end of the three month study period. 
The final step in the trial was a health status interview in the same format of the 
baseline assessment undertaken by the principal investigator. The principal investigator 
was not blinded to the form of treatment given to patients as the health status assessment 
methods had to be standardised. 
Patients were then returned to normal clinical follow up protocol. Those who were 
randomised to receive lifestyle intervention were offered a CPAP trial as appropriate on 
clinical decision. 
3.2.3 Diffusion study 
The diffusion of innovation phase of the research was divided into two questionnaire 
surveys. Both the questionnaires were designed to assess the following (please see 
appendix); 
" Innovator categorisation of respondents 
" Innovation characteristics for CPAP 
" Communication networks for knowledge diffusion 
" Factors influencing diffusion 
" Secondary data on patient referral patterns, number of patients and size of the 
service need. 
The primary care questionnaire survey was mailed to the chief executives Of 303 primary 
care trusts in England & Wales requesting them to be forwarded to GPs interested in sleep 
disorders or new technologies. 
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The secondary care survey was mailed to one individual Respiratory Consultant in each 
Respiratory Medicine department in all NHS hospitals in England & Wales. 
Both the questionnaires were followed up with a second mailing after 6 weeks for non- 
responders. 
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3.2.2.4 Flow chart of the sequence of events 
All eligible and consenting patleni 
referred to the Sloop clinic with 
Polysomnography 
AHR IS hour I 
Health status Interview 
CPAP group Lifestyle II 
group 
Auto-CPAP Wdfton 
titration 
II 
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Diet + 
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CPAP 
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Health status 
HTA in SAHS; PhD ibefis-Indrami Chakravony 2005 95 
Chapter III: Design & Methods 
3.3 Methods 
3.3.1 Diagnosis of SAHS 
3.3.1.1 Clinical review 
SAHS was diagnosed based on the following algorithm for the retrospective clinical 
review. This was based on the clinic protocol which had evolved over the study period. 
Step 1: Patients with symptoms of SAHS (snoring & EDS) under went a home- 
based overnight pulse oximetry. Patients with a 4% arterial ODI of 2! 15 hour, were given 
a therapeutic trial with CPAP [Ryan et al. igg5b]. 
Step II: Symptomatic patients with an ODI Of < 15 hour-, underwent an inpatient 
overnight full PSG. Patients with an AHI a 15 hour, were given a trial of CPAP [American 
Academy of Sleep Medicine 1999]. 
Step III: Symptomatic patients with AHI of >5 and < 15 hour, were classified as 
mild SAHS. 
Step IV: Patients without symptoms of SAHS and AHI <5 hour, were classified as 
normal controls for this study. 
3.3.1.2 RCT 
Patients with symptoms of SAHS (snoring & EDS) and evidence of nocturnal apnoeas or 
hypopnoeas with an apnoea hypopnoea index (AHI) of a 15 hour-, on their full inpatient 
polysomnography were diagnosed as SAHS for the purpose of this study [American 
Academy of Sleep Medicine 1999]. In epidemiological studies an AHI >5/hour is 
traditionally considered to be significant in the presence of symptoms [Young 19931 
however the benefit of treating patients with mild SAHS (AHI >5 and <i5/hour) is 
variable and often compliance with treatment is reported to be less than 50% [Engleman 
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igg7a]. Hence the conventional threshold (AHI ý: 15/hour) in widespread use in clinical 
practice was used in this trial, as the target patient group would then be representative of 
the patients attending secondary care sleep clinics in the UK. 
3.3.2 Health status interview (baseline) 
The baseline health status interview (HSI) interview was held in an office in the 
Department of Respiratory Physiology with a single interviewer (IQ and the patient 
accompanied by a partner. A written explanation of the signs and symptoms SAHS had 
been provided to the patient while obtaining consent for the trial a few days prior to the 
interview. Patients were requested to read this information in the presence of the 
interviewer and an opportunity was provided at the outset for any questions. 
Explanation of the treatment available for SAHS was given in generic terms avoiding any 
clear prediction of the 'gold standard or best practice option'. It was explained that the 
only way to determine who would benefit from which specific treatment strategy 
depended on assessment of therapeutic trial data and on patient preference. Although 
surgical options may be relevant in particular cases this would only be decided after a trial 
of one of the 2 alternative conservative measures, namely lifestyle intervention and CPAP 
therapy. Ibis interview was held prior to randomisation and hence there was no 
indication of patient's future treatment group available to both the interviewer and the 
patient. There was no indication given at any stage in the trial that a cross-over of 
treatment groups would be available and if patients were not satisfied with the trial 
treatment option them would be withdrawn from the trial and returned to the Sleep 
disorders clinic for further assessment and treatment. 
The interview comprised of an explanation of the concept of utility/ valuation of health 
and the utility assessment method detailed; 
Step 1: Utilities were first obtained using the SG method 
utilising a colour coded probability pie chart 
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0 Step 2: Subject was then given time to complete the battery of 
questionnaires un-supervised (SF36, EuroQOI 5D, GHQ 28, HADS) & 
Trail-making test A &B. 
e SteP 3: completing the interview with the utility derived by the 
TTO approach using a graph 
SteP 4: This was followed by random allocation of treatment 
groups based on a random number chart where even numbers were 
allotted to Group I= CPAP therapy and odd numbers were allocated to 
Group II - lifestyle intervention arm. 
3.3.3 Group 1: CPAP therapy 
Patients who were randomized to receive CPAP therapy underwent a home-based CPAP 
titration study using the Autoset II CPAP system (ResMed Plc, Abingdon, Oxford, UK). 
This system used a validated algorithm based on the flattening of the inspiratory flow 
curve to detect obstructive apnoea and hypopnoea and auto-titrated the pressure to 
eradicate these events [Teschler et al. 1996] [Littner et al. 2002]. A 95% percentile 
pressure predicted by the overnight auto-titrating CPAP study was used to provide fixed 
CPAP machines (Sullivan V elite, ResMed Inc, USA) during the trial. Standard Mirage 
nasal masks were used according to best fit after a trial in the laboratory. 
3.3.4 Group 2: Lifestyle intervention 
Each patient (along with their partners or next-of-kin) received a standard verbal 
guidance and explanation on our intention to measure the effect of a conservative strategy 
on snoring, daytime symptoms and nocturnal sleep disruption. 
A written leaflet listing the strategies for the following were provided (please see 
appendix ); 
1. Sleep hygiene 
2. Quitting smoking 
3. Reducing alcohol consumption and 
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4. Controlling stress was provided and discussed. 
Patients were then weighed, neck measurements taken and given guidance by a dietician. 
Verbal and written advice was provided on ideal body weight, calorie-controlled weight 
reducing diet and the benefits of regular exercise. 
Sleep Diary 
Patients were asked to maintain a Sleep diary which was a log book recording the 
foHowing; 
0 total number of hours slept, 
* period of sleep including duration and timing of naps if any 
0 daytime alertness score (Visual analogue scale (VAS) from alert =o to extremely 
drowsy = lo) 
0 quality of sleep (VAS score from o= poor/ unrefreshed sleep to fully refreshed = 
10) 
Follow-up appointments were arranged at 4 and 8 weeks for reinforcement of the 
lifestyle intervention strategy but no measurements were obtained. 
3.3.5 Conclusion of trial 
The duration of the trial was 3 months and concluded with an overnight 
polysomnography (this was conducted using the CPAP equipment in Group 1 patients). 
The morning after the PSG, patients completed the same battery of health related quality 
of life questionnaires, Trail making test and the concluding health status interview using 
the same format as the baseline. 
Patients were weighed and neck measurements taken. 
All patients in Group 2 were then offered a home CPAP therapeutic trial and Group i 
patients were given the option to continue with their CPAP therapy long term combined 
with lifestyle intervention strategies. 
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3.3.6 Outcome measures 
Primaty 
* Cost per QALY gained 
e Change in health utility (Ug measured by the SG method, Utt,, measured by the 
7TO method and Uq as derivedfrom the EuroQol) with intervention. 
* Change in HRQL scores 
Secondary 
" Change in ESS scores. 
" Change in body weight and sleep diary parameters (Sleep quality & Sleep period) 
" Change in neuro-cognitive fiinction (Trail Making test) 
" Correlations between respiratory or sleep parameters and health status. 
3.3.7 Health related quality of life measurement 
3.3.7.1 Short form 36 (SF36) 
3.3.7.1.1 Background 
The SF36 questionnaire was developed by the Rand Corporation in the USA from an 
inventory Of 149 items used in their batteries designed to assess general health in the 
Health Insurance Study/ Medical Outcomes study. The SF36 started life as a 20 item 
questionnaire including 17 original items and then was expanded into its current form 
[Ware et aL 19931. The 35 items in the questionnaire are incorporated into 8 subscales 
indicative of the different dimensions of health related quality of life and are then further 
summated into 2 summary scales: - Physical & Mental component summary scale (PCS/ 
MCS). There is a single item which is not incorporated in the summary scales asking 
respondents for their perceptions of health change in the past 12 months. 
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3.3.7.1.2 Scoring 
Each subscale has its own response format from dichotomous yes/ no to the six-point 
scale of 'none to 'very severe'. Although different formats are not known to influence the 
outcome varying response styles have the potential of being visually confusing to 
respondents. The scoring algorithms are designed to increase the scales ability to compare 
results across different studies. Item scores for each of the 8 dimensions are summed and 
transformed into a scale from o= poor health to loo = good health The scores are 
traditionally reported as mean scores and compared using parametric statistical methods 
without their frequency distribution, even though mean scores tend to be influenced by 
extreme outliers [Julious et al. 19951. Factor analyses of correlations among the 8 SF36 
subscales has consistently identified 2 factors accounting for over 8o% of the reliable 
variance in different populations. These were the physical and mental components with 3 
scales; 'physical functioning', 'role physical' and 'bodily pain' correlating highly with the 
physical component and 'mental health', 'social functioning' and 'role emotional' with the 
mental component. Using the psychometric techniques of principal factor analyses using 
rotated components the 2 summary scales were constructed and shown to be reliable in 
23 different population groups tested. A by-product of this factor analyses led to 
identification of io items which contributed go% of the variance in the 2 summary scores 
and hence the much shorter (SF12) survey questionnaire was launched. The subscales 
are not summed together to produce an overall score but transformed using United States 
normative population data to yield a score Of 50 with SD of lo. 
3.3.7.1.3 Steps in scoring the summary scales 
0 z-score transformation using means and standard deviations of SF36 scale scores 
from the general US population 
0 aggregation of scale scores using physical and mental score coefficients from the 
general US population 
* transformation of summary scores to the norm based scoring (50,10) 
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3.3.7.2 European quality of life questionnaire (EuroQoQ 
3.3.7.2.1 Background 
EuroQol is a generic health related quality of life questionnaire which was developed by 
the EuroQol group formed in 1987[Brazier et al. 1993a]. One of the key aims of the group 
was to develop an instrument which would facilitate comparisons across nations and to 
generate a cardinal index of health with a potential for use in healthcare evaluation. The 
original 6 dimensional format was tested in Finland, The Netherlands, Norway, Sweden 
and the UK and this resulted in a standard 5 dimensional format, launched in 1991. 
Applicable to a wide range of health conditions and treatments, it provides a simple 
descriptive profile and a single index value for health status that can be used in the 
clinical and economic evaluation of health care as well as population health surveys. 
EuroQoI has been specially designed to complement other quality of life measures such as 
the SF-36, NHP, SIP or disease-specific measures. The current 3-level, 5-dimensional 
format of the EuroQol will remain unchanged for the immediate future. 
EUroQoI is designed for self-completion by respondents and is ideally suited for use in 
postal surveys, in clinics and face to face interviews. It is cognitively simple, taking only a 
few minutes to complete. Instructions to respondents are included in the 
questionnaire. There are 4 components in the questionnaire: 
0 Description of the respondent's own health by the EuroQol classification 
* Rating of own health by means of the EuroQoI thermometer 
* Valuation of a standard set of health states defined by the EuroQol classification, 
and 
9 Background information about the respondent 
3.3.7.2.2 HRQL component 
Respondents describe their own health state in 5 dimensions; mobility, self-care, usual 
activities, pain/ discomfort and anxiety/ depression. Each dimension is described in 3 
levels represented by numbers; no problem=1, some probleM=2 and severe problem/ 
unable to perform = 3. Thus each state is described by a5 digit number, table 3.1; 
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Table 3.1: EuroQOl 5D choices illustrating a resultant health state = 11223 
Dimension Levelchosen code 
Mobility No problems in walking about 
Seýf-care No problems in washing & dressing 
Usual activities Someproblems 2 
Painl discomfort Moderate pain 2 
Anxiety/ depression Extremely anxious/ depressed 
The EuroQoI health state thermometer is a visual analogue scale where respondents are 
asked to mark off their current health state between o=worse imaginable health and 
ioo= best imaginable health state. The final page of the questionnaire gathers 
demographic data on age, occupation/ activity, sex, education, smoking history, 
professional qualifications and postcode for geographical location. Thus the main uses of 
the EuroQol instrument as recommended by the EuroQol group are; 
Comparing respondents health state with general population and/ reference 
groups 
Valuation of classified health states using preferences elicited by a general 
population survey in 1993[Brooks 1996] 
Descriptive health state or valuations can be compared with the background 
variables i. e. age, sex, education etc. 
3.3.7.3 General Health Questionnaire 28 (GH028) 
3.3.7.3.1 Introduction 
The GHQ 28 was designed to be a self-administered screening test aimed at detecting 
psychiatric disorders among respondents in community settings and non-psychiatric 
settings such as the general medical outpatients and primary care. The concept of 
psychiatric disorders emanates from the WHO's 'clinical descriptions and diagnostic 
guidelines of mental, behavioural and developmental disorders in the ioth revision of the 
International classification of diseases (ICD). The GHQ28 [Goldberg and Williams 1988] 
is designed with a view to identifying patients at a greater risk of developing a psychiatric 
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disorder. The threshold score is the premise that on independent and expert psychiatric 
assessment the probability that an individual identified by the GHQ28 will be positively 
diagnosed as having a psychiatric ailment, is >o. 5. The GHQ28 was initially designed for 
identifying psychiatric disorders among Londoners but has since been translated and 
validated in 38 languages with similar validity. The questionnaire identifies a breakdown 
or deviation from normal functioning rather than lifelong traits, namely; 
0 inability to continue to carry out one's normal healthy functions, and 
* appearance of new phenomena of a distressing nature 
3.3.7.3.2 GHQ scoring 
GHQ has a4 point response scale as shown in table and utilises either a bimodal response 
for screening or a4 stage Likert scale for profiling. The likert scale was chosen in order to 
give a more detailed profiling of the 4 dimensions. The threshold for scoring cases was 
based on 16 studies where the modal value was 4/5 for each subscale. When comparing 2 
samples for prevalence of psychiatric illness using GHQ scores the authors recommended 
statistics of dispersion (Mean & standard deviation) or proportion of high scorers in each 
sample. 
Table 3.2: GHQ28 scoring systems 
Question Less than usual No more than 
usual 
Likertscore 01 
GHQ- bimodal 00 
Rather more Much more 
than usual than usual 
23 
11 
In this study with SAHS patients the GHQ28 was used to assess the prevalence of 
psychiatric illness at baseline in each group comparing the scores and proportion of high 
scorers and then to assess the change in scores and proportions after 3 months of 
intervention. Secondly the GHQ28 scores have been compared with the main 
polysomnographic and demographic variables using a multiple regression analysis to 
determine the contribution to high scores [Singh et al. 19871. Thirdly I have compared 
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the correlation of the scores obtained by the mental health dimensions from the SF36 and 
HADS scores with those obtained by the GHQ28, to assess their reliability. 
3.3.7.4 Hospital Anxiety & Depression Scale (HADS) [Zigmond 
et al. 19831 
3.3.7.4.1 Introduction 
The HADS instrument was developed in 1983 as a brief assessment of anxiety and 
depression using 14 items divided into 2 sub-scales. In order to correct for the common 
problems of physical illnesses influencing mood states the design of this tool excludes all 
items relating to both emotional and physical disorders. The design also attempted to 
distinguish between anxiety and depression by basing on the an-hedonic state as this 
responds best to anti-depressant drug therapy. While the anxiety subscale items are based 
on the psychic manifestation of anxiety neurosis from the present state examination. 
3.3.7.4.2 Scoring 
HADS is derived from clinical experience and not by factor analysis. Dependant on 
direction of the wording of each item they are scored from 0-3 or 3-0, representing the 
degree of distress; none = o, a little = 1, a lot =2 and unbearably = 3. On summation of 
individual scores and compared with clinical psychiatric diagnoses ,a HADS 
depression 
ratings of less than 7 are considered to be non-cases, 8-io as doubtful and >11 as definite 
cases [Carroll et al. 19931. 
3.3.8 Economic evaluation 
3.3.8.1 Tools for utility assessment 
3.3.8.1.1 Quality adjusted life year (OALY) 
The potentially insoluble economic problem of infinite health needs competing for finite 
health care resources has led to a variety of utility approaches to measure the value of 
health, sometimes incorporating HRQL with economic analyses to provide a fairer means 
of distributing health care funds [Fallowfield 199o]. The QALY was developed to combine 
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quantitative data such as increased survival and qualitative data concerning disability and 
distress with basic economic data like the cost of surgery or phannacological therapy to 
provide a theoretical cost-per QALY gained [Weinstein et al. 1977]. 
Figure 3.3: Quality gained by an intervention 
Quality adjusted life years gained by an 
intervention 
100- 
01 
Intervention 20 deathl 
1 11 Without intervention 0 With intervention 
Thus the basic approach to calculating the QALY is by health status indices which are 
essentially weighting schemes. To satisfy the QALY concept the quality weights must be a) 
based on preferences, b) anchored on perfect health and death and c) measured on an 
interval scale [Drummond et al. 19971. Each definable health status from death or coma 
to varying degrees of disability or disease to full health, accounting for age differences, is 
assigned a weight from o to 1. While zero is the only practical number that can be 
conceptually associated with death, the concept of full health being i allows 
measurement in fractional terms (e. g. 0.5 years in M health = 0.5 QALY i year in 
health state valued at 0-5) and thus allows compatibility with years of healthy life. When 
the number of years an individual expects to spend in current health state is multiplied by 
the weight allotted to that health state then the QALY is derived as a theoretical 
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equivalent of number of years in full health [Weinstein and Stason 1977]. The underlying 
rationale being that individual or communities are the best judge of their own welfare and 
likely to assign higher weights for more preferred health outcomes [Drummond, et al. 
19931. 
Calculating QALYs is based on the difference between the areas under the two curves 
illustrated in figure 3.1 but this is designated the QALY gained without discounting. As 
individuals tend to value immediate gains more than gain on a future date, QALYs are 
discounted to account for this time preference. The UK Department of Health 
recommends discounting at 6% for both costs and gains and the US Treasury 
recommends a more rigorous discounting at 4,7 and lo% which is the system used in this 
study as this allows better comparability and sensitivity analysis. The method of 
discounting uses the concept of taking the gain for a year in the future and moving it back 
year by year to the present reducing the amount each year by r% of the remaining 
amount, where r= the annual discount rate [Drummond et al. 19971. 
The most commonly used methods for eliciting individual preferences and thus assigning 
quality adjusted weights for health outcomes are; the rating scale, SG and 71TO methods. 
While both the rating scale and TrO derive their weights under conditions of certainty are 
called'values' the SG is based on uncertainty and bence caused 'utilities'. 
Table 3.3: Methods for measuring preferences 
teiiaititý acertainty (utilities) `Re'sp'o'nse'm'e 
Scaling Rating scale 
Category scaling 
Visual analogue scale 
Ratio scale 
Choice Titne-trade off Standard gambl6, 
Paired comparison 
Equiyalence 
Person trade off 
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3.3.8.1.2 The Rating scale method 
3.3.8.1.2.1 Standard Gamble method (SG) 
Utility weights derived by the Utility theory of von Neumann and Morgenstern are based 
on individual decision making under conditions of uncertainty [von Neumann and 
Morgenstern 19441. Utility is a preference that an individual will have on considering the 
consequences of different courses of action. The SG method captures the individual's 
attitude to risk and thus is influenced by whether an individual is risk-averse, risk 
indifferent or risk seeking. Although it is shown that individuals are risk averse for large 
gains, risk seeking for small gains or losses, a consistent risk attitude is modelled and 
assumed for practical convenience. Unlike scaling methods of eliciting a response by 
introspection as in HRQL methods on a numerical scale, utility/ value measurement is 
based on making a choice. Since future health or an individuals' response to a health care 
intervention is uncertain the preferred method for measuring preferences is with utilities 
[Mehrez and Gafni 1991]. The only caveat being that when utilities are aggregated in a 
sample to represent societal/ community preferences the utility theory no longer applies, 
unless it is assumed that 'society' is a single entity with utilities equal to mean utilities of 
the community. 
The core of SG method is a paired comparison in which the respondent chooses between 
two alternatives with two possible outcomes: a good outcome with the probability p and a 
bad outcome with the probability of i-p. The probability of outcomes is varied until the 
respondent is indifferent about the two alternatives. The SG begins with presenting a 
written description of the health state (a scenario) under evaluation. After reading the 
scenario, the respondent is asked to imagine a hypothetical situation in which he or she is 
confronted with a choice. The options available are to continue living in the state of health 
described in the scenario, or to take a gamble with two possible outcomes, e. g. perfect 
health and death. The probabilities in the gamble are systematically altered until the 
respondent cannot choose between the certainty of continued life in the described health 
state and the gamble. The utility for the evaluated health state = (probability of outcome 
A)* (utility of outcome A) + (probability of outcome B)* (utility of outcome B). As most 
subjects find it hard to relate to probabilities, the SG is supplemented by visual aids like a 
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probability wheel (an adjustable disk With 2 colour coded sectors which are changed as 
each option is presented to the subject, representing the probabilities of health or death as 
in figure). Where a temporary health state is being assessed which is worse than the 
current state but not death, this can be set =o and the same formula used. However if it is 
desirable to relate this worse temporary state to death on the o-1 scale, a repeat SG 
approach is required [Drummond et al. 19971. 
Figure 3.4: illustration of the standard gamble method of eliciting a utility for 
a chronic health state preferred to death. 
0 
71 
Current 
state of 
health 
H 
25 0.26 
0.5 
DO. 
1 
0. ; dm 
0.75 0.76 
1H=0.75 
Since utility of death =o and for healthy state = i; Utility for health state H= probability 
p for full health. In this illustration H= 0-75,0.5 & 0.25 with the 3 probabilities 
presented. 
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When these utilities are multiplied by life-expectancy to calculate QALYs, it is assumed 
that utlities are independent, that the trade off is constant at the extremes of the health 
states and responders are risk neutral. 
3.3.8.1.2.2 Time-trade off method (TTO) 
The T170 method was developed for use in health care assessment as an easy to 
administer instrument, yet giving comparable scores to the often intuitively challenging 
Standard gamble method [Torrance, et al. 1972b]. It is not related to any existing 
behavioural theory, but to a 'value function'. It enables the identification of different 
points on an individual's indifference curve in his evaluation space [Mehrez et al. 199oal. 
The application of the TTO technique to a chronic state considered better than death is 
illustrated in figure 3-5. 
Figure 3.5-: Illustration of the Time trade off method for a chronic state 
preferable to death 
Healffiy 
1.0 Alternative 
A temative 
The subject is offered 2 alternatives; i) state i for time t (= life expectancy for the 
individual followed by death) in the current health state/ chronic condition or 2) healthy 
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for time x<t followed by death. The concept is a trade off of the quantity of life in the 
current less desirable state for less number of years in a state of best imaginable health. 
This time x is varied till the subject is indifferent between the 2 alternatives, at which 
point the value of state i; 
hi = x/t 
There have been alternative suggestions to measuring in the dead to healthy scale by 
other researchers who have used 'daily TTOs' with a trade against unwanted sleep or 
annual 170s where the trade off is against unwanted convalescence [Buckingham 19931. 
As the purpose of the Tro weighting in this study is to derive QALYs we have chosen to 
the dead to healthy model. In the event of assessing the value of temporary states, TTO is 
derived in a2 stage method with the temporary state being redefined as of a short 
duration followed by death due to a concern that imminent death would tend to distort 
the results [Cook et al. 1. However there was no demonstrable difference when the 
individuals in this study were faced with outcome in 12 weeks or 12 years suggesting that 
the TTO was applicable to different time frames. 
3.3.8.1.2.3 Reliability & validity issues for weighting 
methods 
One of the main concerns raised against both of these weighting measures is the 
dependen ce on the assumption that chronic health states are constant, that death is the 
worst possible outcome and the lack of specific input of psychosocial parameters. It is 
assumed that individuals are prepared to sacrifice a constant proportion of their life span 
in order to achieve a given improvement in their present health state, which is 
irrespective of the absolute amount of remaining years [Loomes and McKenzie 1989]. It is 
argued that a younger individual faced with the prospect Of 20 years in a state of ill health 
may be willing to trade off iLo years for improved health, while the same may not be true 
for an older individual faced with <5 years of life expectancy [McNeil et al. 1981]. This 
would tend to overestimate the value of present health of an older individual compared to 
a younger individual. 
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On the other hand, there is evidence to show that both individuals and society tend to 
value utility obtained at a younger age greater than the same achieved at an advanced age. 
This is against the basic assumption that the preference of an individual will be towards 
maximizing his utility and is independent of age. In a study to test this hypothesis, 
individuals asked to rate the value of life, regardless of their age valued a life of a 30 year 
old as equivalent to 11 sixty-year olds. On average, people were willing to sacrifice 35 older 
adults (70-year-olds) to save one 3o-year-old. It was also shown that a measure which 
increased life-expectancy by 1 year, conditional on having survived until the age of 75 
years, is given a low weighting [Johannesson et al. 1996a]. 
Unlike classical psychometric approach, where each instrument has to undergo rigorous 
testing in different settings, economic analysis instruments are based on an underlying 
utility theory and its assumptions. Even when human behaviour deviates from that 
predicted by normative theory, it is suggested that we would prefer to achieve that which 
is better and more rational rather than unaided judgement for a complex and important 
decision [Howard 1988]. 
Others have reported that preference scores for a severe pain health state were not 
independent of time, hence not satisfying the assumptions of the utility theory [Bala et al. 
19991. When patients' raw ITO scores were adjusted using information on their utility 
functions for survival time, to derive a measure of health state utility equivalent to the SG 
in a sample of 199 cardiovascular patients; the raw 1-rO scores were significantly higher 
than SG scores, while the adjusted ITO scores were shown to be equivalent [Martin et al. 
2000]. 
Conversely, in a sample Of 3o disease-free testicular cancer patients, SG scores were 
significantly higher than unadjusted TTO scores for all profiles. As the majority of 
patients (85%) were risk-averse, certainty equivalent adjusted TTO scores were higher 
than unadjusted scores, and were not significantly different from those obtained from the 
SG for three of the four profiles [Stiggelbout et al. 19941- 
Threats to validity include construct under-representation and construct-irrelevant 
variance. Construct under-representation occurs when a stimulus presented to a judge 
fails to fully represent the depth and complexity of information required in actual 
judgments. Construct-irrelevant variation occurs when factors irrelevant to preferences 
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influence measurements of utilities. Among several factors that cause construct- 
irrelevant variation are cognitive abilities, numeracy skills, emotions and prejudices, and 
the elicitation procedure. The validity of an elicitation protocol depends (i) on the degree 
to which its scaling method captures the relevant facets of utility and (2) on the degree to 
which measurements are influenced by construct-irrelevant variation. 
Discrete-state health index models provide an alternative to direct elicitation of utilities 
and work by attaching fixed preference weights to observable health states. The creation 
of discrete-state models with current technologies requires the adoption of strong 
assumptions about the scaling properties of utilities. Because of the impact of variation in 
techniques on measurements, the combination of utilities elicited with different protocols 
is not recommended in cost-utility analysis in a league table [Lenert et al. 20001. 
There is also evidence that suggests that various health status measures are at best only 
moderately correlated with SG and TI70 utilities. Results from regression analysis, 
predicting SG or TrO utilities from combinations of health status scales, typically have an 
R2 of o. 18 to 0.43- Preferences determined by rating scale methods are more strongly 
related to health status scores, but correlations are variable ranging from 0.17 to 0.46 and 
only about 27% to 34% of variance can be explained in regression models. The Quality of 
Well-Being Scale and other multi-attribute preference measures have low to moderate 
correlations with health status measures (r = 0.03 to 0-71). Health utility and 
psychometric health status scales may measure different attributes of health and are not 
interchangeable indicators of HRQL [Revicki et al. 19931. 
3.3.8.1.3 EuroQol health index 
The multi-attribute theory is an extension of the traditional utility theory by including an 
additional axiom of utility independence, which has three levels of assumptions. (i) First 
order utility independence assumes that there is no interaction between the preferences 
for one attribute and the fixed levels of other attributes and that the relative scaling within 
each sub-scale/ attribute remains constant. (ii) Mutual utility independence assumes that 
there is no interaction between the preferences for some attributes with fixed levels of 
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other attributes. (iii) The third assumption being the additive utility independence which 
states that there is no interaction for preferences among attributes at all. 
The third method of deriving weights for QALYs is based on utilising the pre-existent 
multi-attribute scales such as the EuroQol, Quality of well being scale (QWB) and the 
Health utilities index (HUI). For the purpose of this study I chose the EuroQoI as 
explained in section above. 
EuroQol scores were calculated by comparing health states based on the 5 dimensions 
and 3 level design of the questionnaire with TTO scores for 243 potential health states 
obtained by a population study (Dolan et aL 19951. The problem was that it was virtually 
impossible to generate direct valuations for all of these states, and thus it was necessary to 
find a procedure that allowed the valuations of all EuroQol states to be interpolated from 
direct valuations on a subset of these (42 health states were chosen for valuation) using a 
"tariff" of EuroQol values. Thus this model appeared to predict the values of the states for 
which there were direct observations and, thus, authors justified their use to interpolate 
values for the states for which no direct observations existed as shown in table 3.4. 
Table 3.4: Coefficients for TTO tariffs used in EuroQol health states. [Dolan 
19971 
nision i; dficie D i'm e'n i IC 
Constant 0.081 
Mobility7- level 2 0.069 
Mobility - level 3 0.314 
Self-care7- I level 2 0.104, 
Self care - level 3 0.214 
Usual acttvi e2 -0.06' Usual activity - level 3 0.386 
Anxiety/ depression level 2,. -', , -, 
'0.07, i, 
Anxiety/ depression - level 3 0.236 
N3 '0.269 
N3 signifies any attribute which receives a level 3 response 
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Table 3.5: Algorithm for calculating EuroQoI health state values (example 
state 11223) 
Full heý16 
Constant term (for any dysfunctional state) 
Mobility Oevel 1) 
Self care (level 1) 
Usual activities Oevel 2)' 
Pain and discomfort (level 2) 
Anxiety and depression (level 3) 
N3 Oevel 3 occurs in any 1 dimension) 
Iberefore the estimated value of health state 11223 
3.3.8.2 Measures of economic evaluation 
3.3.8.2.1 Background 
i. 'ooo' 
-0.081 
-0 
-0.036 
-0.0123 
-0.0236 
-0.269 
0. '255 
The role of economic evaluation in HTA includes a range of techniques that can be used to 
investigate the cost and consequences of different procedures or programs. There are 
various methods of analysis; cost of illness study, cost-minimisation study, cost 
effectiveness analysis, cost utility analysis and cost benefit analysis. Economic evaluation 
in the public sector was initially based on the cost-benefit analysis (CBA), which is an 
application of the theory of resource allocation at the core of welfare economics. 
Application of CBA was used in the public sector investment planning and environmental 
protection. It measures both the cost and benefits in monetary terms. The costs of a 
programme are measured in opportunity costs defined as the benefits of the best 
alternative programme. Benefits are defined as the best willingness-to-pay for the project. 
Using this method of analysis comparison is possible within and beyond the technologies/ 
programmes in the health care sector. Thus it is a method of establishing allocative 
efficiency of resources, provided all costs involved are known. However the economic 
evaluation in health care started off with cost of illness (COI) studies. Benefits were 
calculated as reduced treatment costs and reduced loss of production by a method known 
as the human capital approach. However it proved difficult in the health care setting to 
assess all the benefits in monetary costs. Hence this led to the development of the Cost 
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effectiveness analysis (CEA). In this system the costs are monetary but the benefits are 
measured in physical units and are studied with a societal perspective considering 
consequences not only within the health sector but beyond as well. Hence they are 
intuitively best designed to study the comparative benefits of a new technology compared 
with an altemative with homogenous outcomes. In the event of different outcome 
parameters CEA is not beneficial in allowing a rational comparison between 'unlike' 
benefits and is inconsistent with the welfare economic theory. 
The cost utility analysis (CUA) was designed to overcome the restrictions of the CEA 
method with the utility based measure of outcome. Utilities measure individual 
preferences and hence intuitively assess the satisfaction derived by people with healthcare 
services. One of the primary goals of CUA was to allow comparison of different 
technologies in various different health care sectors with heterogeneous outcomes. 
Combining a utility with life expectancy in the QALY, a cost/QALY can be estimated and 
compared between different interventions in league tables, as long as the same method of 
assessment was used to derive the utility. 
3.3.8.2.2 Costs 
3.3.8.2.2.1 Introduction 
Cost is the product of 2 elements; the quantity of resources used and the unit cost of the 
resources. Cost generating events (like hospital stay) can be usually measured in patient 
specific (stochastic) or non-patient specific (deterministic) ways. Costs may be unit cost 
for individual events or average costs (total cost/total number of patients or events) and 
marginal costs are calculated for individual extra events. While opportunity cost is the 
theoretical benefit that would have been derived with the 'next best' use of the same 
resources. Although costing can be in various ways as described in the table 7.6, the 
approach used here is partially stochastic where the average costs for the same cost- 
generating events are taken with patient specific effectiveness data available from the 
present RCr. Unlike the patient specific data which varies with individual patients in a 
trial and is collected for each patient's cost generating events; this method uses average 
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costs which an ideal patient would encounter when going through a standard diagnostic 
and treatment pathway in a typical DGH. This has been done to ensure that the cost data 
is more generisable and hence more useful in the context of HTA. 
Table 3.6: Approac 
C6'Sting aýproach 
Deterministic 
PardaUy-stochastic 
Wholly stochastic 
hes to costing [Drummond et al. 19971 
"Measurement of resource use and e&ciiýeness'data' 
Non-patient specific resource use /patient specific 
effectiveness data 
Non-patient specific resource/ patient specific effectiveness' 
Patient specific resource use/ patient specific effectiveness 
data 
3.3.8.2.2.2 Perspective 
Costs are dependant on the viewpoint of any analysis (example the NHS as a provider, 
paying individual or an insurance agency covering a new technology provision) and 
certain overhead costs which may be common for both the technologies concerned need 
to be included in the analysis. Cost data is either collected on an individual case basis or 
on a general resource basis from hospital/ institutional records. Although the theoretical 
cost of any item is the opportunity cost (i. e. the value of foregone benefits because the 
resource is not available for its best alternative use) the pragmatic approach to costing is 
to take its existing market price or in the case of the NHS the subsidised price available 
due to a bulk purchasing agreement. 
3.3.8.2.2.3 Types of costs 
Traditionally the types of costs for potential inclusion in economic analysis are usually 
classified into 5 main groups [Drummond 19871; 
direct health care costs (cost of intervention, cost of treatment, future health 
service costs, trial costs) 
direct non-health care costs (other public sector costs, patient travel costs, 
patient's opportunity costs) 
0 indirect health care costs (cost of morbidity and mortality) 
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0 indirect non-health care costs (productivity costs, future non-health service costs) 
0 intangible costs 
The costs of various investigations in this study were taken from the departmental cost 
break-down (average costs-not patient specific) and included discounted bulk purchase 
prices available within the NHS. There were no clear cut price lists available for similar 
services within the private sector/ open market hence these could not be considered. 
However costs published from other UK institutions have been included in the analysis to 
allow comparison of cost/QALY values. 
Valuation of non-market items such as leisure time is based on the price an employer 
would have to pay (i. e. overtime rates) to buy some of the worker's leisure time, similarly 
volunteer time is also calculated on minimum unskilled wages to average earnings 
depending on the situation. In this study, the patients were recruited during their routine 
visit to the hospital and underwent almost exactly the number of investigations as they 
would for a normal clinical diagnostic study. The extra 2 hours spent with interviews were 
the same for both groups of patients hence were excluded from the analysis. 
Although most cost analysis studies report real costs, adjustment of costs are sometimes 
favoured when unadjusted prices would introduce substantial bias into a study and there 
is clear and objective way of making the adjustments [Drummond et al. 19971. There is an 
argument for including costs incurred in future years as a result of keeping people alive as 
an indirect effect of a healthcare intervention. However there remains a lack of consensus 
in this matter and economists believe that an estimation of the average annual per capita 
cost may need to be added, either in primary or sensitivity analysis. Omission of such 
future costs may bias cost-effectiveness estimates against interventions which prolong life 
in favour of those which improve HRQL, especially in the elderly. 
The impact of including these future costs on the cost- effectiveness of the treatment of 
hypertension was studied in Sweden. The cost/QALY gained was found to change little 
among young men and women due to the addition of future costs, but increased by about 
$14,000 for middle-aged men and women and about $27,000 for older men and women. 
When future costs were not included, the cost / QALY gained are generally lowest among 
older men and women, but when future costs are included, the cost per QALY gained is 
mA in SAHS, PbD tberis Ifidrand Cbakravory 2005 120 
Chapter III; Design & Metbods 
generally lowest among middle-aged men and women. The authors concluded that the 
total resource consequences of changes in mortality should be routinely considered in 
cost- effectiveness analyses [Johannesson et al. 1997]. On the other hand it has also been 
shown that adding such a cost makes little difference to the cost/life year gained and such 
unrelated healthcare costs are ignored without biasing the results significantly. In the 
case of SAHS, treatment with CPAP has been shown to improve HRQL and daytime 
functioning. It is also shown to reduce hypertension but there is as yet no clear 
epidemiological data showing a prolongation of life or reduction in mortality (Veale, et al. 
2000] [Wright et al. 1997a] hence unrelated health care costs in the future were 
considered not relevant to this study. 
In the matter of dealing with overhead costs incurred within hospitals there is a simple 
formula proposed by Drummond; 
Directly attributable costs for the programme implementation 
Deduct from total hospital operating expenditure, the directly allocated costs and 
departmental costs not known to be involved with this program 
3) Allocate remainder of hospital operating expenses on the basis of number of 
patient days 
4) Undertake a sensitivity analysis 
For the purpose of this study, the costs for each investigation, clinic visit, consultation 
with dietary services and inpatient tests were calculated inclusive of the hospital 
overhead/ operating cost attributable to the particular service within the prices provided 
by the Finance department of the Hospital. Hence a separate costing exercise has not 
been undertaken. 
In this trial, the costs involved in the lifestyle arm are quantitatively less than the cost of 
CPAP therapy and inclusion of PSG costs may bias against the cost/QALY ratios obtained 
in the lifestyle arm. It may be argued that as PSG is not a standard test available in most 
DGHs it may be removed from the final cost/QALY analysis. However within the 
sensitivity analysis the impact of non-PSG (cheaper) tests may also be calculated to make 
the cost/QALY ratios more generisable. 
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3.3.8.2.2.4 Time horizon 
The time horizon is the period of time for which costs and effects are measured. The time 
horizon is determined partly by the duration of the trial, by the perspective of the 
intervention under study and the duration that the policy maker is interested in which 
may be longer than the period under study [Davidoff et al. 19961. Although the analysis 
can be performed for a variable periods of time, a long duration is usually recommended 
in order to incorporate the effect of changes in both costs and resources. Ilmiting the 
costs of analysis to a fixed period after the intervention may introduce bias into a cost 
comparison, especially at the beginning or end of treatment phase or life [Briggs et al. 
19941. In this case CPAP is known to affect a measurable benefit within days of institution 
of therapy and studies have shown the benefits obtained in the first 4-6 weeks to be 
maintained in the long term. As this is also a life-long treatment the conceptually 
appropriate measure was a product of the effect on utility with life-expectancy. However 
further analysis included a5 year treatment perspective as well as future developments 
may significantly alter the treatment options and it may not be appropriate to consider 
CPAP usage in decade terms. The cost measurement year is 1999. 
3.3.8.2.2.5 Economic welfare theory 
Economic welfare theory concept underlines all the economic evaluation exercises and 
hence it is usually argued that opportunity and marginal costs should be included and 
should dictate how they are measured and valued. Based on this concept, the benefits of 
therapy for SAHS patients have a much wider societal aspect in reduction of RTAs, work 
related accidents, better productivity and reduction of psychological distress. Measuring 
this is beyond the scope of this study as only short term gain in health status is used, 
hence to use opportunity costs in economic analysis of SAHS patients i. e. 'time given up 
from work to undergo treatment'would be inappropriate and introduce a bias against the 
treatment. While in the case of CPAP therapy, cost/QALY may be over-estimated by 
ignoring societal benefits, in lifestyle intervention a3 month trial duration may be a 
disadvantage as lifestyle changes are expected to take much longer to achieve (over 
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estimating cost/QAM. However it was decided that the current waiting list for SAHS 
patients in the UK varied between 3-9 months and it would not be un-ethical to conduct a 
3 month trial denying the patients randomised to lifestyle intervention 'a physician led 
decision' on treatment. It was felt unjustified to increase the waiting period for a CPAP 
therapeutic trial (the current 'gold-standard') beyond this time horizon. 
3.3.8.2.2.6 Discounting of costs 
Discounting is based on the concept that any goods or benefits are more desirable at the 
present than in the future and this principle is called 'positive time preference' and 
intuitively exists even in the absence of interest rate structures. This is calculated by the 
formula [Drummond, et al. 19971; 
p =, E3N=l Fn (1 + r)-n 
Where P= present value, F. = future cost at year n and r= annual interest / discount rate; 
(1+r)-n is the discount factor and can be calculated from tables/ formula. 
However in the case of this study, there is an initial capital cost of equipment like the 
CPAP machine, masks which then need to be calculated based on an annual equivalent 
cost for the life of the equipment. In this case if the capital outlay is K, and the annual 
sum E which over n years at an interest rate of r will be equivalent to K is calculated 
by; [Drummond et al. 19971 
K=E[i +(i+r)-n 
r 
The choice of the discount rate has been traditionally taken as 5% in the last 3 decades in 
most economic evaluation analyses as this was assumed to be the social rate of time 
preference (i. e. the measure of societys willingness to forego consumption today in order 
to have a greater consumption in the ftiture). This has loosely been based on risk free 
investment like Treasury bonds and their prevailing rates. In the UK the public sector 
discount rate announced by the UK Treasury is used and this is currently 6% 
[Anon. igg7b]. This is based on a social opportunity cost approach and is a general 
statement on social time preference. 
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In the USA the recommended approach is the shadow-price-of-capital approach (i. e. 
opportunity cost of a public programme is measured/ transformed in terms of the 
foregone private activities that would have to be given up). Some UK analysts recommend 
using 0%, 3% (representing real risk less discount rate) and 5% (as most studies in the 
last 3 decades have adopted this figure) but many cost-benefit analysis of public spending 
use lo% in their calculations and recommendations. The Panel for Cost effectiveness in 
Health Medicine in their consensus statement argue that a convention is required for a 
real discount rate (inflation adjusted) reflecting the societal time preference and direct 
evidence suggests a rate Of 3% and conducting sensitivity analysis with rates of 0%, 5% 
and 7% [Siegel et al. 1996]. As this remains a matter of debate in various countries, I have 
adopted the widest possible discounting rates to allow a wider generalisability of the 
results. Hence, I have evaluated costs and benefits discounted at the US Treasury 
recommended rate Of 0%, 4%, 70/6 and io%, which gives the widest possible variation in 
the present climate. All costs are adjusted for the effect of inflation at 3%. 
3.3.8.2.3 Sensitivity analysis for costs & benefits 
Sensitivity analysis for cost/ QALY ratios is demonstrated by calculating the ratios at the 
95% confidence intervals for the mean values of costs or benefits. The 95% confidence 
intervals are thus calculated using Mean value +/- standard error of mean (SEM) x factor 
(derived from the f distribution tables based on the number of freedom for the variable or 
n-1). 
Comparison has been made with costs derived from a similar NHS based study [Chflcott. J 
et al. 20001 involving two different types of diagnosis and assessment procedures for 
SAHS patients as is currently used in non-specialist hospitals in the Midlands, UK dealing 
with such patients to give an idea of the cost/ QALY rations in other real life scenarios. 
There are 3 steps in sensitivity analysis; 
0 identifying uncertain parameters 
0 specifying the range of variation by expert opinion, literature review and specified 
confidence intervals 
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0 calculating study results based on best guesses, most and the least conservative 
estimates 
3.3.8.2.4 Cost Utility analysis 
Whereas the health effect of a healthcare intervention is expressed and can be measured 
in effect terms in CEA, although the current Panel on CEA recommendations propose the 
QALY, in a CUA the denominator is always measured in cost/QALY or Healthy year 
equivalent (HYE) terms. The denominator in CUA is generic and includes a valuation of 
health status or utility in its design and excludes intermediate data like improvement in 
morbidity or physical parameters. The second advantage of the CUA measure is the 
common outcome denominator of cost/QALY allows comparison between effects of 
different healthcare intervention programs. CUA is the preferred method used when 
HRQL is the main outcome measure as in the case of SAHS [Wright and Dye 19951 
[D'Ambrosio et al. 1996]. 
CUA is not recommended when only intermediate data can be obtained, when alternative 
therapies are equally effective, when the intervention is shown to be unequivocally 
dominant both in clinical and cost effectiveness terms and when the extra cost of 
obtaining utility values is considered not to be cost effective. In the case of SAHS, there is 
a raging controversy in the literature and the public domain regarding effectiveness of 
CPAP therapy, the role of lifestyle changes and there is a dearth of clear Level I or II 
evidence on clinical effectiveness except in neuro-cognitive function, daytime sleepiness 
and energy/ vitality dimensions of HRQL [Engleman et al. igg7c; Stradling and Davies 
1997; Wright et al. 1997b]. There are no economic evaluation data of Uvel I or 11 standard 
in SAHS till date in the body of literature, [Wright and White 20001 thus the CUA method 
was chosen for this study and different methods of obtaining the weighting for QALYs 
were compared. The methods for weighting QALYs and estimating costs have been 
discussed in section above. 
3.4 Statistical Analysis 
Data is expressed as mean and standard deviation (SD). A student's t test was used at 
baseline between Group i and Group 2. The non-parametric tests (Wilcoxon Rank Sum) 
test for paired samples was used to measure the change achieved in outcome parameters. 
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The individual relationships between health status and disease markers were measured 
using Spearman's rho. Missing values were replaced by baseline values with the intention 
to treat hypothesis and used in analysis. This was then multiplied by the life expectancy of 
each patient based on the United Kingdom 1996 population census to generate the QALYs 
gained by intervention, in each treatment group. All statistical analysis was done using 
SPSS vii. o for Windows (SPSS Inc, Chicago, IL, USA). 
Sample size estimation was based on results obtained from the literature in change to 
SF36 sub-dimensions with CPAP treatment with a 95% confidence interval. The required 
number of patients was 72, but this was likely to be under-powered to detect changes in 
lifestyle intervention arm as the changes were expected to be modest. 
Sample size = [change in variable/2 x SDI ioo 
3.5 Non- completions 
In the CPAP group 8% of subjects failed to tolerate the treatment, a number comparing 
favourably with such 'failed therapeutic trials' reported in the literature (10-38%) 
[Monasterio, et al. 20oial. The number of patients dropping out in the lifestyle 
intervention arm was 18%. Two patients chose alternative treatment options in the 
private sector and 4 did not return to complete the trial. Difficulty in maintaining subject 
motivation in trials involving lifestyle modification strategies is well-recognized [Sampol 
et al. 1998]. During the design phase of this study this potential for disenchantment 
amongst patients given lifestyle strategies was expected, and thus it was our deliberate 
intention not to offer alternate cross-over to the CPAP arm (to avoid positive CPAP bias) 
during the conduct of the trial. As an alternative study design a 'cross-over' design was 
discussed but it was felt that the patients on therapeutic CPAP may be expected to notice 
a symptomatic benefit with minimum effort, hence when crossed over to lifestyle strategy 
may create a negative bias against lifestyle modification. 
For the purpose of the analysis all patients have been included (intention to treat) 
[Altman iggi], as this is the preferred statistical method to handle lost data, preserving 
the original randomisation and prevents the introduction of bias; this may undermine the 
benefit of lifestyle intervention by treating 'lost to follow up' patients as treatment failures. 
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4.1 Results 
4.1.1 Demographics 
Of the 678 patients referred to the Birmingham Heartlands Hospital Sleep Disorders 
Clinic, 618 case notes were traced. Sixty records (42 niales) were unavailable for analysis 
as they had been microfilmed and stored in an offisite storage facility, as was routine 
policy in the Trust for patients not tinder active treatment or follow tip over 5 years. 
Fifteen patients with neuromuscular diseases and significant respiratory diseases were 
excluded from the analysis. 'rhe remaining 603 patients reviewed included 488 males 
(aged 53 t 12 years) and 115 females (aged 51 ± 13 years), with a male: female ratio Of 4: 1. 
Figure 4.1: Histogram illustrating the age distribution in the referral 
population and box Plot showing the median and intcr-quartile ranges for age 
between males/ females. 
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The mean BMI among female patients was greater than the male patients (33 ±9 vs. 31 
±6.6 kgm -for men, p= 0.003). However female patients had a lower ODI; [ 11.8 (Range 
o-6o) hour, vs. men 18 (Range o-iii), p=o. oi] and AHI 114 (Range 1-76) hour, vs. men 
21.2 (Range 0-111), p=0.02], but reported a similar degree of EDS measured by the ESS 
scores (12 +6 vs. men = 12 +5). 
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Figure 4.2: Epworth Sleepiness scale scores for the population and 
comparison of scores between men and women 
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Figure 4.3: Population BMI distribution and comparison of median and 
I RQ ranges for men and women 
140 
120 
100 
0 
150 
smi 
Y axis = frequency of BMI 
X axis = BMI in kg/M2 
IITA in S1111S, - Phl) thesis IndrawlChakim-od), 200ý 129 
550 650 750 
bo 0 600 700 Boo 
CI IAPTER IV: Clinicairmiew 
loo 
80 
80 
40 
20 
o 
Cb «o 
11 FEKýLE PMLE SEX 
Y axis: BM I in Kg/M2 
X axis: Sex distribution female: male 
Figure 4.4 shows a similar prevalence of smoking, hypertension, cerebrovascular disease, 
diabetes between men and women, except for ischaemic heart disease which was 
significantly higher among men (p=0.02). 
Figure 4.4: Prevalence of mortality and co morbidity in the study population 
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SAHS was diagnosed in 361 (62%) patients of the 603 patients reviewed, with a male 
predominance (male: female 7: 1). There were 251 (30 females) patients with moderate- 
severe SAHS (Mean ODI 30 +22 hour', age 54±12 years, ESS 13: h6, BMI 33±8 
kgM-2) 
and 
110 (21 females) patients with mild SAHS (AHI 8±3 hour', age 53±13 years, BMI 30±2 
kgm-2, ESS 13±5). Table 4.1 compares the characteristics of SAHS and controls showing 
that patients with SAHS were older, had a higher BMI and sleepier than controls. 
Table 4.1: Characteristics of SAHS and non-SAHS patients; mean (SD) 
SAHS Controls p 
n 361 242 
Age (years) 53(12) 50(12) 0.001 
BMI kgM-2 32(8) 29(5) <0.001 
ESS (0-24) 13(5) 11 (5) <0.001 
AHI hour-' 25(21) 3(2) <0.001 
ODI hour-' 24(21) 3(3) <0.001 
4.1.2 Mortality 
There were 22 (4 females) deaths recorded over the 7 year period of follow up, among the 
603 patients whose notes were available for review, and the cause of death was obtained 
in 17 (77%). The mean age at the time of death was 62 years with a range Of 39 to 70 years. 
There were no differences between the BMI [29.8 (23 to 5o) kgm -2and ODI; 31 (5 to 85) 
hour'] of the deceased patients compared to the population mean. 
SAHS patients had a mortality Of 4% and a higher risk of death; OR 5 (confidence interval 
1.1-32.4, P=0.03) than controls (mortality 1%), as shown in Table 4.2. 
The all cause crude mortality rate was higher for SAHS patients (6/looo/year) than 
controls (1.2/iooo/year), P=0-03. The recorded cause of death was cardiac in 9 (53%) 
patients, respiratory in 7 (41%) and cerebrovascular/ stroke in one (6%), as detailed in 
Table 4.3 
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Table 4.2: Comparison of morbidity & mortality between SAHS and controls 
Controls SAHS 
Number (%) Number ('ý)) p 
n 242 361 
Deaths 2(0.1) 15(4) 0.03* 
I lypertenslon 39 (17) 97 (27) 0.0041 
Ischactnic heart disease 32(14) 52(15) Ns 
I)Iabctcs 8 (3) 22(6) Ns 
Cerebrovascular disease 5(2) 10(3) Ns 
Current smokers 52(22) 104(29) Ns 
Ns not significant, *significant at 95'ý/o lex, cl using X2 test 
Table 4.3: Available data on 17 of the 22 recorded deaths 
Patients Age BNll Sex ODI CPAII Co-n-iorbid Cause of 
death 
1 39 30.5 1" 19 CP. \P COPI) Resp 
2 39 31.3 m 35 WIND Resp 
3 44 25.5 M 15 WIN 1) IkCsP 
4 52 50.4 N1 25 CPAP CABG, 11-113 CVA 
5 53 25.7 M 21 - COM) Rcsp 
6 53 29.3 m 6 CPAP WIN, 11-11) Cardiac 
7 57 40.1 M 25 CPAP NIDDNI, I ITN Cardiac 
9 67 29.5 m 70 CPAP H'IN Cardiac 
9 68 32.6 NI 10 CPAP COPD, II 11) Cardiac 
10 70 31.8 NI 85 CPAP COPD Resp 
11 70 26.3 1; 5 COPD Resp 
12 71 33.1 m 60 CPAP I FIN Cardiac 
13 71 26.3 M 25 - Cardiac 
14 73 23.3 1ý' 45 RTND CCF, I FIN Cardiac 
15 76 23.5 F 17 WIN D Rcsp 
16 77 18.4 m 44 CPA 1) CO. " COPI) Cardiac 
17 82 29.9 N1 15 CPAII (: CF, I FIN Cardiac 
Mean 62 29.8 30.7 
1 ITN= hypertension, (-'OIID= chronic obstructive pulmonary disease, returned CPAP 
machines, 11 ID= ischaernic heart disease, Nll)l). Nl= Non insuhn depenclant chabetes, 
cerebrovascular accident 
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4.1.3 Co morbidity 
Hypertension was significantly more prevalent in SAHS patients; the risk of being 
hypertensive at presentation being twice as high, (OR 2, Cl 1.2-2.9, P=0-004). Though 
greater numbers of SAHS patients had documented ischaemic heart disease and 
cerebrovascular disease, these did not reach statistical significance. 
4.1.4 Referral patterns 
Annual referral rates increased io fold from 20 patients in 1990 to 200 in 1996 with an 
increasing proportion being women, figure 4.5. During this period, there was a similar 
increase in annual CPAP prescription rates from 5 in 19go to ioo in 1996. GPs referred 
263 (44%) patients to the Sleep clinic, while 173 (29%) patients were tertiary referrals 
from Otolaryngologists (ENT). Hospital physicians referred 167 (28%) patients. 
Diagnostic rates for SAHS were similar in all sub-groups of referrals regardless of source 
of referral (with 37% of ENT, 46% of GP and 47% of hospital physician referrals being 
subsequently diagnosed to be suffering from SAHS). 
Figure 4.5 Annual referral rates for men and women 
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4.1.5 Role of arterial pulse oximetry 
Fifty seven percent of patients (n=205) were diagnosed based on criteria including 
appropriate symptoms and a baseline ODI >15 hour'. The addition of PSG facilitated 
diagnosis in another 43% of patients (n=156). 
4.1.6 CPAP usage 
Therapeutic trials with CPAP were prescribed tO 257 (72%) patients of whOM 2o8 (81%) 
continued with treatment for a mean follow up Of 3 -+ 1.6 years. 
Annual follow up showed 
a reduction in ODI from 34 to 3 hour-' and ESS scores reduced from 14 to 9 on treatment 
as shown in Table 4-4. Patients' mean self-reported compliance with CPAP was 5±2.2 
hours. night . Patients who returned their machines 
haxing failed to benefit from a 
therapeutic trial had significantly lower ODI at baseline. 
Of the 22 patients with SAHS who died during follow tip, 8 had returned their CPAP 
machines failing to tolerate the treatment. 
Table 4.4: Comparing characteristics between SAHS patients continuing 
with CPAP therapy and those failing to tolerate CPAP 
CPAP continued CPAP returned P 
Mean (SD) Mean (SD) 
n= 208 n 49 
Age (years) 5401) . 5, -) 1: 3) 
NS 
BMI (Kg/M2) : 3.3(7) 3,301) NS 
ESS pre-treatment (o- 14(5) 13(6) NS 
24) 
ODI pre-treatment 34(21) 2308) 0-004 
(hour--) 
ESS post-treatment (o- 9(5) 12(6) 0.05 
24) 
ODI post-treatment 3(5) 5(8) NS 
(hour--) 
Number Number 
Mortality 8(4%) 4(8%) 
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4.2 Discussion 
4.2.1 Mismatch in service provision 
This clinical review showed the first phase in the lifecycle of an innovation as it was 
introduced for use in a typical UK DGH setting. Although initially reported as an 
innovation in 1981 [Sullivan et al. 1981], CPAP as a commercial product only became 
available in 199o, when the first patients were referred to a newly established Sleep 
disorders clinic. The rising number of referrals from 1990 to 1997 shows the increasing 
awareness among both primary and secondary care physicians of this condition and 
reflects increasing public awareness. The RCPUK working party reported at the same time 
the increasing demand for sleep diagnostic and treatment services and identified the need 
for such provision across the country [Semple and Gibson 19931. 
However population screening surveys in the USA at the same time, suggested prevalence 
for SAHS to be between 2-4% of middle aged adults [Young et al. 19931, the majority of 
whom were unlikely to be aware of their condition and unlikely to seek a referral and 
hence were likely to go untreated [Young et al. 1997a]. As almost half of all patients 
referred to the Sleep service were subsequently diagnosed to have clinically significant 
SAHS, suggesting that there were a number of people in the community with SAHS who 
were either unaware of their diagnosis or were inadvertently screened out by the referral 
process. The mismatch between demand and availability of sleep diagnostic services in 
the UK has been reported by the RCPUK working party again in 1998 [Gibson et al. 19981 
and by the multi-disciplinary expert group called the 'Sleep Alliance' in 2004 [Sleep 
Alliance. 20041. Thus the present research into the diffusion and adoption of CPAP in the 
NHS would have to examine the factors leading to this apparent mismatch. 
4.2.2 Morbidity & Mortality 
The case-control study of SAHS patients compared to controls (with snoring without 
SAHS) highlighted the increased risk of hypertension and mortality in the SAHS group. 
Snoring has been reported as an independent risk factor for vascular complications such 
as hypertension [Lindberg et al. 1998] but may merely be a marker of underlying SAHS 
[Stradling and Crosby 199o; Stradling 1995b; Waller et al. 19891. As the odds ratios 
HTA I., SAHS, PbD tbesis Indramil Cbakrawny 2005 135 
CHAPTER IV: CEnicalreview 
identified in this analysis are in comparison to patients with snoring, it is likely that the 
risks to SAHS patients are under-estimated in this analysis. 
In this study, SAHS patients had a5 times higher risk of dying compared to controls, with 
a significantly higher crude mortality rate (6/looo/year). This rate was greater even when 
compared to the mortality risk for ischaemic heart disease, certain cancers and 
respiratory diseases (3.2,2.6,2/looo/year respectively) estimated in England & Wales in 
1998 [Office for National Statistics 1999]. The predominant cause of death among this 
group of SAHS patients was cardio-pulmonary as has been reported previously by other 
epidemiological studies on SAHS patients, which have also identified higher mortality 
rates [Mooe et al. 2001] [Veale, et al. 20001. An analysis involving 57 deaths from 1,620 
SAHS patients followed up over 12 years, in Israel in 1995 identified cardiopulmonary 
causes for deaths in 53% [Lavie et al. 19951. 
Obesity among SAHS patients can independently contribute to the increased mortality 
seen, however the mean BMI in this group was only marginally higher than the controls. 
A trend which is reflected in population characteristics in UK showing a majority of adults 
examined by the 1996 Health survey for England, reported that 62% of adult men and 
53% of the adult women were overweight or borderline obese (BMI>25 KgM-2) [Joint 
Health Surveys Unit et al. 19971. The influence of obesity was thus probably only marginal 
in contributing to the excess mortality seen in this analysis. 
Daytime systemic hypertension is strongly associated with SAHS and an independent risk 
factor for increased vascular mortality and morbidity [Hla et al. 19941 [Young et al. 
1997d]. In this study there was a higher prevalence of daytime systemic hypertension 
(27%) compared to controls (17%), the risk being twice. Pendlebury et al in 1997, reported 
a 46% prevalence of systemic hypertension among their clinic SAHS patients, [Pendlebury 
et al. 1997] while in 19go Partinen and Guilleminault had reported a prevalence Of 57% 
from a7 year follow up study of SAHS, conducted at the Stanford Sleep Clinic [Partinen et 
al. 199o]. Both these studies were conducted in the tertiary care setting with a more 
selective process of referrals and hence perhaps accounting for the higher prevalence of co 
morbidity, compared to our patients who were principally referred by GPs or ENT 
surgeons. 
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The same unselected referral pattern for this study population probably accounted for no 
significant differences between the prevalence of ischaemic heart disease OL5%), 
cerebrovascular disease (2-3%) and diabetes (5-70/0, while significant associations have 
been reported in the studies from specialised clinics in both France and USA [Partinen & 
Guilleminault 199o] [Pendlebury et al. 19971. 
Smoking as a contributing factor towards mortality risk was virtually excluded from this 
analysis, as we found the prevalence of smokers amongst our SAHS patients to be similar 
to the national prevalence [Joint Health Surveys Unit and Dept of Epidemiology & Public 
Health 19971. Thus even among unselected secondary care SAHS patients we found 
strong evidence for the existence of a significantly higher risk of hypertension and 
mortality, though probably of multi-factorial origin. 
4.2.3 Role of pulse oximetry in a diagnostic algorithm 
This study demonstrated the clinical value of combining symptoms compatible with the 
SAHS [Whyte et al. 1989] with an ODI 2: 15 hour, from domiciliary overnight arterial 
pulse oximetry; a diagnostic tool with a 99% specificity for identifying SAHS, albeit with 
only a 32% sensitivity [Gurubhagavatula et al. 20ol; Ryan et al. 1995a; Wiltshire et al. 
2001]. This strategy has enabled a definite diagnosis of SAHS in over half of referred 
patients without the need for expensive PSG studies [Epstein et al. 1998]. However it is 
recognised that absence of the characteristic episodic desaturation pattern in a 'normal' 
oximetry does not exclude SAHS[Pepin et al. 1991] [Svanborg et al. 19gol and hence all 
patients with relevant symptoms and a 'non-diagnostic' oximetry underwent multi- 
channel polysomnographic evaluation allowing diagnosis in a further 44% patients. 
4.2.4 CPAP trials & compliance 
CPAP treatment was successfully established in 82% of the patients with SAHS after 
undergoing therapeutic trials, who reportedly used their machines for a mean 5.5 hours 
every night. Though CPAP may be perceived initially as an intrusive form of treatment by 
a proportion of patients and reportedly associated with considerably variable usage, the 
compliance results compared favourably with figures Of 4-5 hours per night, as reported 
from other centres [Meslier et al. 1998; Zozula et al. 2001al with objective usage monitors 
[Engleman et al. 1994c; Kaplan et al. 1994; McNicholas 19971. Compared to usage reported 
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of prescribed treatment options in other chronic conditions such as asthma, hypertension 
and diabetes, the high proportion of patients using CPAP over a medium-long term 
period suggested its positive innovation characteristics such as patient acceptability, 
which will be further assessed during the third phase of this research project. 
4.3 Conclusion 
Data from this retrospective clinical review and case-control study demonstrated that 
since its commercial availability there has been a rise in the referral rates in a typical DGH 
Sleep clinic however the numbers are still likely to leave a large burden of unrecognised 
and untreated disease in the community. 
SAHS patients are twice as likely to present with systemic hypertension and have a5 
times higher risk of mortality, which is multi-factorial in origin in comparison to controls 
with snoring. 
Domiciliary overnight pulse arterial oximetry as an integral part of an SAHS diagnostic 
algorithm is likely to diagnose over 50% of patients and contribute to the economic 
efficiency of such units. However due to a low sensitivity and the likelihood of missing 
patients with UATý such diagnostic algorithms should include a full PSG for negatives. 
CPAP treatment as an innovation has been shown to have a high acceptance among SAHS 
patients and compliance achieved is comparable with many other chronic diseases. Hence 
this clinical review set the scene for the design of a prospective RCT into the efficacy and 
effectiveness of CPAP and examining characteristics of CPAP diffusion in the NHS. 
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5.1 INTRODUCTION 
One of the early assessments undertaken in the appraisal of a new technology involves the 
measurement of its safety and clinical efficacy. This chapter presents the data on the 
clinical efficacy and effectiveness of CPAP compared to lifestyle intervention in a 
prospective, randomised study. 
5.2 RESULTS 
5.2.1 Population 
There were 141 new patients referred by their GPs with snoring and history suggestive of 
SAHS, to the Sleep disorders clinic at the Birmingham Heartlands Hospital (BHH) 
between June 1998 and October 1999. All patients were sent an information pack prior to 
their clinic appointments. This consisted of a Sleep apnoea leaflet and consent form 
including a brief outline of the proposed trial (appendix). Subjects were asked to 
communicate their decision during their clinic visit. One hundred and thirty two patients 
expressed a positive interest in the trial, while the remaining ii patients declined to 
participate in the trial and were seen within the established clinical pathway of the clinic. 
Of the 132 patients who expressed an interest in the trial and underwent full, overnight, 
inpatient PSG, 82 (58%) were diagnosed to have moderate to severe SAHS (AHLý15hour 
1) and were approached for written consent to participate in the trial. Seventy one 
patients gave written consent and were then randomised. The ii patients with SAHS who 
declined participation in the trial were returned to the Sleep Clinic for appropriate 
management according to current clinical protocol. The numbers in each phase from 
referral to recruitment and randomisation are presented in table 5.1, while the 
demographics of above mentioned groups are presented in table 5.2. 
Thirty-seven patients were randomised to Group I (CPAP therapy), 3 failed to tolerate 
CPAP, 1 subject preferred to proceed to a surgical option and another patient 
subsequently underwent surgery for a growth hormone secreting pituitary tumour. 
There were 34 patients randomised to Group H (Ilfestyle). Five patients were 
subsequently excluded due to health reasons (acute abdomen = 1, chest infection = 1, 
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initiating anti-convulsant therapy for newly diagnosed epilepsy =i and visual impairment 
= 2), 2 patients preferred to go for alternative therapies privately (CPAP & surgery) and 4 
patients dropped out without communicating any reasons and did not take up written 
invitation to return to the Sleep clinic for fiirther assessment and treatment. One patient 
found the travel from 20 miles distance for multiple visits to the hospital logistically and 
economically challenging and another patient had to be excluded due to poor 
comprehension of the health status valuation techniques and poor command of the 
language. Twenty one completed the study in the lifestyle intervention group. The 
demographics of the patients either excluded after recruitment or failing to complete the 
study are presented in table 5.1. 
Table 5.1: Study population and randomisation into groups 
Numbers % 
New patients in clinic between 1/6/98 and 31/10/99 141 10 
,0 Patients undergoing polysomnography 132 94 
Patients with SAHS (AHI ý: 15 hour-') 82 58 
Recruited and randomised 71 50 
CPAP group 37 100 
CPAP - Completed 32 87 
CPAP - exclusions total 5 
Lifestyle group 34 100 
Lfestyle completed 21 62 
ldfestyle exclusions total 13 
Total completed 53 75 
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Table 5.2: Demographics of the referral population undergoing 
polysomnography n=132, Mean (SD) 
Patients 
interested 
n=132 
Patients with 
SAHS 
n=82 
Patients 
recruited in 
the trial 
n=71 
Patients 
failing to 
complete 
n=18 
Age years 50(13.6) 50(9-9) 48(12) 45(16.5) 
% male 77 75 79 72 
AHI /hour 32(21.5) 45(28.3) 46(26) 33(23) 
BMI kgm-2 29(4) 36(10.7) 35(10) 29(6) 
Table 5.3: Showing patients either excluded or not completing the study 
with their characteristics 
Serial 
No 
Sex Age BMI AHI Reason Lifestyl 
e/ 
CPAP 
29 M 72 32 46 Excluded due to health Lifestyle 
90 M 43 31 34 Dropped out Lifestyle 
123 M 56 29 42 Logistical problem due to 
distance from hospital 
Lifestyle 
48 M 35 29 16 Opted for surgery lifestyle 
74 M 55 29 77 Excluded due to failure to 
comprehend utility/ value 
methods & language 
lifestyle 
78 F 67 38 74 Excluded due to poor 
vision 
Lifestyle 
15 M 70 35 29 Excluded due to health 
(chest infection) 
Lifestyle 
59 F 32 33 30 Opted out for CPAP lifestyle 
91 F 33 24 18 Excluded due to starting 
anti-convulsants for 
epilepsy 
lifestyle 
124 M 28 32 22 Excluded due to health 
(acute a domen) 
Lifestyle 
2 F 32 31 17 Dropped out Lifestyle 
138 M 52 36 42 Dropped out Lifestyle 
102 M 26 33 22 Dropped out lifestyle 
11 M 32 28 27 Opted out for surgery CPAP 
25 M 66 26 32 Failed CPAP 
108 M 52 36 78 Failed CPAP 
101 F 32 37 25 Failed CPAP 
99 M 66 30 43 Failed CPAP 
110 F 62 28 67 GSH tumour CPAP 
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5.2.2 Study population characteristics (n=71) 
The population (n=71) was predominantly male and middle-aged vvith a normal 
distribution (flgure 5.1 & 5-2) with a mean (SD) 48 (12) years. 
Figure 5.1: Sex (%) distribution in the study population 
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211% 
Figure 5-2: Histogram depicting the age distribution for the study population 
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The BMI distribution was skewed due to 4 extremely obese subjects with BMI>45 kgm-2, 
however the mean BMI was 35 (io) kgm-2, figure 5.3. Six percent of subjects were in the 
conventionally accepted normal range (>2o and <25 kgm-2) and 13% were extremely 
obese (>4o kgm-2). Majority of subjects were either overweight (25-3o kgm-2 = 21%) or 
obese (mild-30-35 kgrn -2 = 30%, moderate obesity 35-4o, kgrn -2 = 30%), figure 5-4-- 
Figure 5-3: Histogram depicting the study population BMI distribution 
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Figure 5-4: Pie chart depicting the proportion of subjects classified 
according to BMI (kgm-2). 
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The BMI distribution was representative between men and women in the study 
population (excluding the extremely obese male subjects) as shown infigure 5.5, the 
mean BMI in men was 35.7 (1o) and in women 34 (1o) and the differences did not achieve 
statistical significance (Pý 0.536). The neck circumference mean 46.2 (6.1) cm were 
closely related to the BMI, linear regression coefficient r2 =0.454, P<0.001 (flgure 5.6). 
Figure 5.5 showing the frequency distribution of BMI (kgm-) according to 
sex of subjects 
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Figure 5.6: plots the relationship between BMI (kgm-2) and neck 
circumference (cm) 
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5.2.3 Co morbidity 
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The overall prevalence of smoking was 27% (19/71 subjects), hypertension (HTN) 39% 
(28/71 subjects), Ischaemic heart disease (IHD) including angina and previous 
myocardial infarction (MI) 24% (17/71 subjects), cerebrovascular disease (CVA) 6% (4/71 
subjects) and diabetes mellitus (DM) lo% (7/71 subjects). The prevalence of HTN 
(relative risk 2.4, P<0-05) was significantly higher among men. The relative prevalence of 
smoking, IHD, CVA disease and diabetes and average weekly alcohol (ALQ consumption 
is shown infigure 5-7. 
Co morbidity was unrelated to BMI and age in the population as shown in the frequency 
distributions infigure 5.8 & 5-9. 
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Figure 5.7 showing the % prevalence of co morbidity among male and 
female patients 
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Figure 3.8 Frequency distribution of BMI (kgm-) with co morbidity (alongx 
axis; O=absence or I=presence of co morbidity) 
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Figure 5.9 Frequency distribution of age (years) with co morbidity (along x 
axis; O=absence or I=presence ofco morbidity) 
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5.2.4 Polysomnographic characteristics 
Table 5.4 shows the baseline home (Minolta Pulsox-7) overnight oximetry and inpatient 
PSG characteristics of the population. The ODI was lower than the number of 6 beats/ 
min pulse rate variation (PRV) recorded during the home monitoring (both however 
being within the range for moderate to severe SAHS). 
The sleep variables suggest a mean total sleep time of less than 6 hours with variability. 
The mean sleep latency was 28 minutes, REM latency was 2 hours and the sleep efficiency 
was reduced in the whole population. The majority of time was spent by subjects in Stage 
II sleep (almost 3 hours) and the least amount of time (i. e. >i hour) was spent in slow 
wave sleep (comprising of Stage III and Stage IV sleep). 
The AHI had a skewed distribution as shown by figure 5.9 showing a tri-modal spread 
with peaks at 15-2o hour', 50-55 hour, and 70-75 hour, and the Al showed a normal 
spread with a peak at 55-6o hour-,, figure 5.10. 
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Table 5.4: Home oximetry and PSG variables at baseline 
Home pulSe oximetry variables Mean SD SEM 
4% ODI 25.2 28.8 3.9 
Mean Sa02 (Pulsox) 93.1 2.9 0.4 
HRV (6bpm) 47.1 25.1 3.3 
Mean HR 67.0 8.8 1.1 
Polysomnographic variables 
NREM obstructive apnoea index 18.4 21.5 2.8 
NREM hypopnoeas index 24.3 19.1 2.5 
NREM central apnoea index 0.4 1.1 0.2 
NREM AHI 43.6 32.0 4.2 
REM obstructive apnoea index 16.9 20.2 2.8 
REM hypopnoeas index 29.6 17.0 2.3 
REM central apnoea index 1.1 3.0 0.4 
REM AHI 48.4 25.5 3.5 
Mean AHI 46.3 26.4 3.1 
Longest apnoea (seconds) 46.5 25.7 3.4 
Longest hypopnoea (s) 58.4 31.0 4.1 
Mean apnoea/ hypopnoeas duration (s) 21.5 4.7 0.6 
Mean Sa02 Clo) 91.4 4.3 0.6 
MinSa02 Clo) 74.9 16.1 2.1 
Mean Sa02 desaturation Clo) 6.6 7.6 1.0 
Sleep latency (min) 27.9 30.9 4.0 
REM latency (min) 129.0 80.4 10.5 
Total sleep time (min) 412.2 111.4 14.5 
STAGE1 (min) 10.2 8.7 1.1 
STAGE2 (min) 185.7 69.7 9.2 
STAGE3 (min) 52.9 28.3 3.7 
STAGE4 (min) 16.8 22.0 2.9 
REM time (min) 86.4 41.7 5.6 
Al 58.8 26.9 3.2 
Sleep efficiency (/o) 68.5 16.7 2.2 
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Figure 5.10 Histogram depicting the frequency distribution of AHI (hour-) 
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Figure 5.1jL: Histogram depicting the Al distribution 
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5.2.5 Interactions between home oximetry and inpatient 
PSG 
The predictive relationship between ODI and 6 beats/ min PRV is shown infigure 5.10, 
which shows a linear regression coefficient r2=0.5283, P<0.001- 
Figure 5.12: Scatter plots showing regression coefficient comparing ODI vs. 
PRV 
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The relationship between ODI and AHI is predicted by the quadratic regression 
coefficient r2=0-543, P<0.001. 
, Mgure 5.11 shows the relationship between AHI and PRV (regression coefficient r2=0-434, 
P<0.05) while figure 5.12 shows the relationship between AHI and Al (regression 
coefficient r2=0.2217, P<0.05). 
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Figure 5.13 Scatter plot depicting the relationship between AHI & PRV 
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Figure 5.14: Relationship between AHI and AI 
160 
140 
120 
100 
80 
60 
40 
20 
40 
0 4p 
ob ý» 
deý 0 Iß, db ; ll 0.0,, 
g> 0 
, de db 
0 
0 
ib 4, 
-» 
'0 
20 40 60 so 100 
AHI 
x a)ds: AHI per hour and y axis: AI per hour 
FUq -0 221 -, 
HTA in SAHS; PbD tkfis INdraml Chakwwny 2005 153 
Chapter V: Clinical effectiveness 
5.2.6 Relationship between PSG & anthropometric variables 
Exploration of the data interactions using scatter plots (flgure 5.13) shows that the age of 
subjects was not significantly related to AHI or Al. Among polysomnographic variables, 
BMI showed a significant linear relationship only with AHI (r2=0.15, p<o. ooi) but not 
with AI, figure 5-14. Neck size showed a relationship with AHI (r2=o-14, P=0.001, figure 
5.15) but none of the polysomnographic sleep variables (sleep latency, REM latency, time 
in SWS) were significantly related to sleep-breathing variables (AHI/ AT), as shown in 
Table 5.6. 
Figure 5.15: Relationships between age & AH I or Al 
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Figure 5. jL6: Relationship between BMI and AHI or AI 
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Figure 5.17: Relationship between AHI and neck size 
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Table 5.5: Regression coefficients for sleep and breathing variables 
Sleep 
latency 
REM 
latency 
Beta P Beta P 
AHI -. 151 . 357 -. 026 . 883 
Al . 310 . 058 . 055 . 
754 
Min Sa02 . 216 . 162 . 169 . 312 
Total sleep time -. 102 . 509 -. 086 . 601 
Time in stage 111 -. 051 . 768 -. 223 . 226 
Time in stage IV . 161 . 294 
1 
. 079 . 628 
Sleep latency I 
1 
1 
. 008 
1 
. 958] 
Using multiple linear regression models with sleep latency and RFIM latency 
as dependant variables 
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5.2.7 Excessive daytime sleepiness (EDS) 
Excessive daytime sleepiness was measured using the ESS questionnaire at baseline in all 
patients. There were 18% of subjects with SAHS who did not report EDS based on the ESS 
questionnaire results. The frequency distribution was normal with a mean score Of 13 (5), 
with men reporting a marginally higher score than women, Men: median 12 (Inter 
quartile range IRQ = 6) & Women io (IRQ ii), as shown infigure 5.16-18. 
[Figure -5.18: Baseline ESS scores in the study population 
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Figure 5.19: Histogram depicting the ESS scores at baseline 
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Figure 5.20: Distribution of ESS scores between male and female patients at 
baseline 
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5.2.8 ESS - relationship with anthropometric & PSG 
variables 
The chronological age of study subjects did not show any relationship with their predicted 
self-reported EDS ffigure 5.19). However BMI had a positive relationship with ESS in this 
dataset with a plateau between 30-4o kgrn-2, (cubic regression equation, r2 =0.2, P=0.04), 
figure 5.2o. The three primary polysonmographic variables of AHI, AI and sleep latency 
did not demonstrate a significant relationship with daytime somnolence, figure 5.21. 
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Figure 5.21: Relationship between baseline ESS scores and age 
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Figure 5.22: RelationshiP between BMI and ESS at baseline 
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Figure 5.23: Relationship of ESS scores with PSG variables 
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5.2.9 Summary of baseline population data 
Unlike a population survey, study subjects were recruited from patients referred from 
primary care with history suggestive of SAHS hence due to a positive selection bias, the 
proportion of subjects diagnosed SAHS and percentage of males were higher (78%) and 
8o% subjects were either overweight or obese (BMI >25 kgm-2). Men had a 2.4 times 
higher relative risk of being hypertensive than women although there were no significant 
differences in age, BMI and prevalence of smokers. 
The 4% ODI and PRV (6 beats/min) obtained from overnight home oximetry recordings 
was closely related to AHI and AI obtained. The mean AHI and AI were in the moderate 
to severe range but showed only a weak inter-relationship. Sleep parameters revealed a 
delayed REM latency, reduced time in slow wave sleep (SWS) likely to contribute to 
daytime sleepiness. 
The BMI increments were weakly predictive of higher AHI and ESS scores but did not 
show a similar relationship with any of the other sleep variables. 
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5.3 CLINICAL EFFECTIVENESS 
5.3.1 Clinical efficacy of CPAP/ Lifestyle intervention 
Baseline characteristics are presented in table 5.6 showing no significant inter-group 
differences except Group II spending shorter time in Stage I. 
Table 5.7 lists the post- intervention results in each group and their paired samples t test 
significance values. 
In Group I there was a significant reduction in AHI and AI on CPAP therapy while the 
improvement in Group II was milder. 
In both groups there was an improvement in sleep latency and a reduction in total sleep 
time. 
Group I patients report marked improvement in daytime somnolence with ESS scores 
reduced from 13.7 (5.6) to 7-1 (4.6), p<o. ool but patients in group II did not report a 
significant improvement; ESS scores 13 (3-7) to 11.6 (4.7), p=o. 164 as shown in figure 
5.22. 
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Table 5.6: Baseline Group Statistics 
Groups Mean SD P 
Age (years) Lifestyle 51.3 12.2 
CPAP 46.3 11.3 o. o82 
BMI (kgm-2) Lifestyle 34.0 5-5 
CPAP 34.3 9.2 0.897 
Neck size (cm) Lifestyle 44.9 
- 
4.8 
CPAP 46.5 6-5 0.249 
ODI (hour-i) Lifestyle 19.2_ 25.9 
CPAP 31.2 27.3 o. o66 
PRV (hour-1) Lifestyle 42.1 18.3 
CPAP 51.7 26.5 o. o87 
AHI (hour-i) Lifestyle 36.3 24.4 
CPAP 46.6 27.2 o. o66 
Sleep latency (min) Lifestyle 36.5 35.2 
CPAP 22.4 25.9 o. o88 
REM latency (min) Lifestyle 140.1 
-n-8 CPAP 118.1 83.2 0.314 
Total sleep time (min) Lifestyle 422.5 118.2 
CPAP 402 113.0 0.274 
STAGE I time (min) Lifestyle 7-1 7.2 
CPAP 12.7 9.6 0.026* 
STAGE II time (min) Lifestyle 195-4 76.3 
CPAP 175-4 53-4 0-190 
STAGE III time (min) Lifestyle 53.4 25.8 - CPAP 54-5 ý, '3 1.0 0-702 STAGE IV time (min) Lifestyle 22.6 3o. 8 
CPAP 16.1 19.9 o. 695 
REM period (min) Lifestyle 81.2 42.9 
CPAP 86.3 40.4 o. 776 
Al (houm) _ Lifestyle 59.1 35.6 
CPAP 53.4 22.7 0.113 
Sleep efficiency _ Lifestyle 66.5 17.6 
CPAP 70.0 16.5 0*447 
Mean Sa02 _ Lifestyle 91.5 5.0 
CPAP 91.7 . 13.5 0-849 Min Sa02 _ Lifestyle 77-7 11.0 
CPAP 74.4 1 .6 0-427 
Baseline ESS _ Lifestyle 13.0 3.7 
CPAP 13.7 15.6 o. 183 
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TABLE 5.7 Paired samples of patients completing the study at baseline and 
post-intervention 
sty e, ", 
ný 37 n=34 
Mean SD p Mean SD P 
Base BMI (kgM-2) 34-3 9.2 34.0 6. o 0.03 
Post'BMI' 34.1 " 912 NS 33.3 5.5 
Base neck size (cm) 46.5 6.5 44.9 4.8 
Postnecksize ýý47-5 
, 
'443 
,, 'Ns ý 45.4 3.8 
Ns 
Base AHI (hoýf-i) 46.6 27.2- 36 .3 244 ' 
Post AHI 7.7 4-3 <0.001 28.6 22.9 0.02 
Base Al (hoUr-'l) '53.4 22.7 59.1 35.6 
Post AI 18.9 6.9 <0.001 4o. 6 23.3 0.01 
Base sleep latency (min) 22.4 25.9 36.5 35.2 
y P64'sleep latenc 
-Y .2 
'31' 29 - 4 6 64 48.1' '44. 4 0.05 
Base REM latency (min) 118.1 83.2 140.1 79.8 
'Post REM latency 111.0 70-5' 'Ns 113. '7 62.3 Ns 
Base stage I time (min) 12-7 9.6 7.1 7.2 
Postl stage I time "I - '48.2' 18-3'ý Ns, 14.8' '26. o Ns 
Base stage II time (min) 175.4 53.4 195.4 76.3 
ý, -, P6 tstaixeIltime, Iý4,1 -" 
1 3.6 ,, 5 
44.1, NS 176.9, '69.1 'Ns 
Base stage III time (min) 54.5 31.0 53.4 25.8 
6st stage III time 54,3 30-0 Ns .1 
66' '35.8 Ns 
Base stage IV time (min) 16.1 19-9 22.6 30.8 
PoSt'stage IV time '15.1- 10-4 Ns 17.4, 1§. ýi 'Ns 
Base REM period (min) 86-3 40-4 81.2 42.9 
'd 
,,. 
Ppsi'REM, periO -, 
82.8 30 . 0,, 
84-ý 49.5 NS 
Base total sleep time (min) 402.5 113.0 422.5 118.2 
Posttptal sleeptirne 338.3, , 
65.3 6.6o4, 357.6 A13-9, 
Base sleep efficiency 70-0 16.5 66.5 17.6 
Y 70.0 .6 14 
68. '2 16. ,8', ' ' Ns 
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Figure 5.24: showing the baseline median ESS scores and inter-quartile 
ranges before (BESS) and after (PESS) treatment. 
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5.3.2 Change in lifestyle parameters 
5.3.2.1 Weight 
Group I patients had no overall change in body weight during the trial period; Median o 
(ranging from gaining 3.3 kg to losing 7.4 kg of their own accord. 
However in group II, the median weight loss achieved was 3.2 kg with a range from 4.1 kg 
gain to 13.4 kg loss. 
The histograms in figure 5.23 Mustrate the distribution of the percentage change in 
weight from baseline achieved. The change in BMI in group 11 was 0-7 kgm-2, (P=0.03)- 
The change in weight and BMI showed no significant relationship with alteration in AHI 
or AI in Group 11 patients. 
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Figure 5.25: Histograms of weight change post trial (% of baseline weight in 
kg) 
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5.3.2.2 Sloop diary 
Group Il patients did not demonstrate a change in the sleep period based on their diary 
records, between the first fortnight and the last fortnight of the 3 month trial period, the 
average sleep period was 7 hours/ night. 
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There were significant improvements recorded in the VAS scores for the quality of 
nocturnal sleep (p=o. ooi) and in reduction of the feeling of sleepiness on waldng 
(P=0.002) after lifestyle intervention, as shown in table 5.8. 
There were no significant relationship between the difference in ESS scores and the sleep 
diary vajdables. 
Table 5.8: Paired Samples Statistics for Group 11 
Mean SD p 
Baseline sleep period (hours/ day) 6.9 1.2 
Post sleep period 7.0 1.0 0.401 
Baseline sleep quality VAS score (0- 10) 4.9 1.3 
Post sleep quality score 5.4 1.5 0.001 
Baseline daytime sleepiness VAS score (0-10) 5.5 1.2 
Post daytime sleepiness VAS score 3.7 1.2 0.002 
5.3.3 Group I CPAP compliance 
Computerised CPAP compliance records downloaded and analysed showed an average of 
33.5 (14-3) hours use per week (figure 5.26). 
There was no significant relationship between the CPAP usages with reduction in AHI 
(figure 5.27) seen after the treatment phase or (Spearman rho = 0.339, P=0.07) when 
compliance data was plotted against change in EDS (measured by ESS scores), figure 5.28 
not reaching statistical significance. 
The regression equation did not predict a change in ESS scores with mean hours of CPAP 
usage as an independant variable. However when baseline AHI was added as an 
independent variable, the model adjusted 
R2 
= 0.238 (P=0.022) and coefficient O= 0.492, 
p=o. ol4 for baseline AHI. With the addition of baseline ESS scores to the above model, 
the adjusted R2improves to 0.589, p<o. ooi and the coefficient 0 for baseline ESS = 0-563, 
P=o. ool. There was no change with the addition of baseline BMI to the regression model. 
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The above results demonstrate that baseline AHI and ESS scores are the most strong 
predictors of improvement in daytime hypersomnolence, whereas mean hours of CPAP 
usage is suggestive but does not reach statistical significance to be a predictor of 
treatment success. 
Figure 5.26: CPAP usage 
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Figure 5.27: Compliance in CPAP patients and relationship with 6 AHI 
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Figure 5.28: Compliance with CPAP related to 6 ESS scores 
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5.3.4 Summary of clinical efficacy 
There was a significant improvement in nocturnal parameters of breathing disturbance 
and sleep fragmentation in patients on CPAP therapy reflected by an improvement in 
sleep latency and daytime somnolence. In the lifestyle group of patients there was a 
reduction in BMI, AHI, AI and improvement in sleep latency. Based on the sleep diary 
there was an improvement recorded in sleep quality and daytime sleepiness on VAS 
scores but not on ESS scores. 
There was an average weight reduction Of 3.2 kg, achieved by dietary advice in Group 11 
patients compared to no change in the weight of CPAP patients. 
CPAP usage Of 33.5 hours/ week was related to improvement in daytime sleepiness but 
failed to reach statistical significance although baseline AHI and daytime 
hypersomnolence were strongly predictive of successful treatment. None of the sleep 
variables were significantly related to improvement in EDS in both groups of patients. 
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5.4 DISCUSSION 
This chapter examines the clinical efficacy of CPAP usage in correcting the nocturnal PSG 
variables that quantify and define SAHS and also compares the effectiveness of CPAP 
against a more conservative strategy of sleep hygiene and weight loss programme. The 
data demonstrate that CPAP is more effective in correcting the AHI and AI of patients 
with SAHS, improving EDS and neuro-cognitive function. As an early step in HTA of 
CPAP, these results provide the basis for further evaluation of outcome measures to 
assess the impact of treatment on quality of life. 
5.4.1 Methodological issues 
The current definition of SAHS includes the clinical scenario of snoring and EDS 
combined with physiological evidence of sleep fragmentation due to apnoeas, hypopnoeas 
or UARS [American Academy of Sleep Medicine 19991. In epidemiological surveys, the 
usual threshold value of AHI used in syndrome definition is 5 hour'- However evidence 
from clinical studies and from the treatment of patients with mild SAHS (AHI 5 to <15 
hour, ) suggest that almost 5o% are either asymptornatic, intolerant of CPAP or may not 
report an improvement in symptoms after treatment with CPAP [Engleman et al. 
igg7b; Monasterio et al. 20olal. Even patients with AHI>3o hour, but in the absence of 
self reported EDS, fail to show a positive response to CPAP treatment [Barbe et al. 2001]. 
Unlike this poor uptake amongst mild SAHS patients, there is good evidence from studies 
suggesting that in symptomatic (ESS score >8-10/24) moderate to severe SAHS patients 
(AHI >15-3o hour-1) the uptake of CPAP may be as high as 81% in the first 3 months and 
up to 68% in 5 years [McArdle et al 19991. This was compatible with the data from the 
retrospective clinical review reported in chapter IV of the long term follow up patients 
with SAHS, where a similar proportion (81%) of patients offered therapeutic trials, 
continued to use the treatment for a mean follow up Of 3±2 years. Hence the decision to 
recruit patients to this study based on ESS>8/24 and AHI? 15 hour,. 
As the perspective of this research was to determine the evidence of effectiveness among 
patients seen within typical clinical settings, the recruitment of patients was not based on 
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epidemiological methods of random selection from populations but based on the primary 
care physician referrals to the sleep clinic. In order to avoid selection bias, patients were 
sent invitations with their appointment letters to the sleep clinic before they were seen in 
the clinic and diagnosis discussed. They were randomised into each treatment phase only 
after their diagnostic PSG. In order to avoid a potential pro-CPAP / machine bias among 
the participants the predicted success with each treatment strategy was deliberately not 
discussed with participants and there was no indication given of any crossover to the 
alternative therapeutic option at the end of the trial. 
5.4.2 Population 
SAHS is a disease prevalent in all age groups but the maximum impact of the resultant 
disability is reported by patients in the middle-aged group on work performance and 
family. This study had a recruitment age range of 16-8o years with a mean age 48 years 
which was representative of similar populations. The Sleep Health Heart Study which 
recruited over 6ooo patients older than 40 years reported a mean 63 years [Baldwin et al. 
20oll and the Wisconsin Sleep Cohort have looked at the working age group of patients 
Oo-6o years) [Hla et al. 19941. Similar age range has been reported by most other surveys 
on patients. 
There was an expected male predominance (4: 1) seen in this population compatible with 
the gender ratios reported in other sleep clinic populations. Whereas epidemiological 
surveys have reported a 2: 1 male predominance, clinic based populations have been 
typically 4 to 8: 1. [Redline et al. 19941. Women in this study were on average lo years 
younger then the men (mean age for men 50 years and women 40 years). In population 
studies women with SAHS tend to be older then men but have similar BMI, while in clinic 
populations women tend to be younger and more obese. Postmenopausal women 
(without hormone replacement therapy) often have a prevalence of SAHS that is 4-5 
times higher than premenopausal women and almost similar to that of men [Bixler et al. 
20oil. There is evidence that women tend to have the same degree of symptoms as men 
with SAHS [Ferini-Strambi et al. 1999; Young et al. 19981, yet tend to have a greater 
degree of under-reporting and under-diagnosis. It has also been argued that this apparent 
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reluctance of women to report their symptoms and seek medical attention may account 
for a delayed diagnosis and an increased mortality similar to post-menopausal women 
with ischaemic heart disease [Wilhoit et al. 19871- 
5.4.3 Obesity & weight loss 
At baseline BMI was significantly related to AHI (p=o. ool), a finding in support of the 
hypothesis suggesting that obesity contributes to the severity of SAHS[Kopelman et al. 
1986; Young et al. 2oo2b]. It is also known that obesity can be independently related to 
EDS even in the absence of SAHS [Resta et al. 2001]. ESS scores (representing the most 
commonly reported symptom of SAHS) were demonstrated to be independently related to 
BMI (P=0.04), this in turn adds to the confounding potential for obesity in assessing the 
severity of SAHS due to the overlap of the daytime symptom complex [Grunstein and 
Wilcox 19941. On the other hand ESS scores were not found to be significantly related to 
AHI or AL This highlights the absence of a simple linear relationship between the 
physiological markers of nocturnal breathing disorder with daytime symptoms. Thus a 
simple correction of nocturnal apnoeas may not be the best predictor of the effectiveness 
of therapy in these patients. 
The effect of weight loss is seen in the lifestyle group patients where there is a subjective 
improvement in sleep quality and a reduction in VAS scores for daytime sleepiness, 
although the reduction in ESS score does not reach statistical significance. There is also 
evidence of improvement in AHI, AI and sleep latency which is compatible with the 
symptomatic improvement but without evidence of a predictable relationship with the 
degree of weight loss. Hence although there is evidence of improvement in symptoms and 
AHI/ AI with lifestyle strategies, the causal hypothesis linking BMI, AHI/ AI and EDS 
remains to be established. A cephalometric study among Japanese SAHS patients found 
that in obese patients, upper airway soft tissue enlargement may play a more important 
role, whereas in non-obese patients, bony structure discrepancies may be the dominant 
contributing factors [Sakakibara et al. 1999] [Watanabe et al. 2002]. The problem may 
also lie in the way that obesity is measured as suggested in a study finding a more 
consistent relationship between waist circumference with AHI then was seen with more 
traditional measures i. e. BMI/ neck circumference [Grunstein et al. 19931. 
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Thus, for the purpose of assessing the clinical effectiveness of therapy in SAHS, the 
physiological measures are unlikely to be related to, or predict the net outcome in patients 
and thus are unsuitable for use in appraisal of health technology. 
However, obesity increases the risk of morbidity and mortality several fold in patients, 
irrespective of the presence or absence of SAHS [Anon. 20001. When present in SAHS 
patients, it further worsens the general health status and may synergistically multiply the 
overall risk of these patients. There are reports of a faster rate of desaturation in obese 
patients with SAHS compared to non-obese patients with the same duration of apnoeas. 
This suggests that abdominal obesity in SAHS patients may therefore aggravate the risk of 
cardiovascular disease. This study was not designed to investigate the effect of obesity on 
pathophysiology and long term health outcomes in obese patients with SAHS. However 
the evidence that simple conservative lifestyle advice combined with weight loss strategies 
improves AHI, AI, quality of sleep and daytime somnolence within 3 months suggests that 
this form of lifestyle modification strategy is certainly an adjunct to the holistic treatment 
of these patients and may improve outcome even more in the long term [Young et al. 
2002a] [Barvaux et al. 2000]. 
The mean weight loss achieved in this group given conservative written advice was 
modest (1.5%), ranging from a loss Of 20% to a gain Of 5% of baseline body weight. Within 
this 3 month period the majority of patients showed no change in weight. Other 
researchers have reported similarly modest weight change on conservative approaches 
[Ballester et al. 1999]. Prior to the introduction of newer pharmacological agents as an 
adjunct to exercise and diet programs for weight loss, the only success has been reported 
from surgical measures, i. e. gastric banding / bypass [Raiala et al. 1991]. Although 
surgical measures with their inherent mortality and morbidity cannot be recommended 
except in rare cases [Lee et al. 1997], there is perhaps a potential in using either Orlistat 
[Ballinger 2000; Foxcroft and Milne 2000] or Sibutramine[Bray et al. 1996] as an adjunct 
to low calorie diet in the treatment of obese SAHS patients. 
5.4.4 Co morbidity 
The prevalence of systemic hypertension in the study subjects was almost twice as high 
(49%) for men compared to UK population surveys. The prevalence in women however 
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was half that of the men and similar to UK adult women (22%) [Joint Health Surveys Unit 
and Dept of Epidemiology & Public Health 1997). SAHS has been associated with, and 
considered in the aetiology of, systemic hypertension [Alchanatis et al. 2000] [Davies et 
al. 20ooal [Lavie et al. 2000], drug resistant hypertension [Logan et al. 20011, ischaemic 
heart disease [Fletcher 1996b], cardiac arrhythmia [Peker et al. 1999], pulmonary 
hypertension [Marrone et al. 19971, cerebrovascular disease [Mohsenin 2001] and 
diabetes mellitus [Elmasry et al. 20011. There is now data from a prospective cohort study 
[Peppard et aL2000] of the new development of hypertension among SAHS patients 
under follow up. 
The causal hypothesis linking SAHS with increased incidence of vascular diseases 
involves elevated sympathomimetic activity [Mmasry et al. 20021, increased occurrence 
of atherosclerosis [Friedlander et al. 1999; Saarelainen et al. 1999] and reduced daytime 
efferent vagal tone [Hilton et al. 20011. Lifestyle factors such as smoking, increased 
alcohol consumption, sedentary lifestyle and obesity [DiaZ, 2002] have also been 
implicated independently in increased cardiovascular morbidity hence tend to confound 
the interpretation of the link with SAHS [Stradling and Crosby 19gol - 
For men in this study population the prevalence of documented IHD was 25%, for DM 
was i1% and for cerebrovascular disease was 9%. As the mean age for men was 50 years, 
the prevalence of IHD may be definitely significant in reducing the overall life expectancy 
in this population. In the case of women who were almost lo years younger then the men 
in this study population, a prevalence of documented IHD Of 22% was much higher then 
would be expected from general population surveys. It has been hypothesised that 
patients (especially men) with SAHS who also have other independent risk factors for 
hypertension, increased cardiovascular morbidity and mortality are likely to be at a 
significantly greater risk [Wilcox et al. 19981. Hence a focus on lifestyle alteration and 
tackling obesity is considered to be a logical approach to improve the health and prevent 
morbidity and mortality in such patients. 
5.4.5 Polysomnography & Pulse oximetry 
The results from the clinical review of SAHS patients showed almost two thirds of 
symptomatic patients could be diagnosed on the basis of their domiciliary, overnight 
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pulse oximetry. However as this method of screening tends to rely on the presence Of 3- 
4% desaturations for diagnosis, many patients with predominant hypopnoeas and UARS 
are likely to be missed, thus reducing the sensitivity of this technique. When 4% ODI and 
PRV (obtained from pulse oximetry) in the prospective study patients, were plotted 
against AHI and AI they demonstrated strong correlations. The PRV (6 beats/ min) 
showed a stronger relationship with AHI and AI than ODI, suggesting that change in 
heart rate may be an autonomic marker of arousals [Stradling et al. 2ooo] and hence a 
stronger predictor of sleep breathing disorder, especially in patients without 
desaturations. Other researchers have shown the potential for ODI for diagnosis of SAHS 
[Choi et al. 2oool and the enhanced sensitivity when combined with PRV in symptomatic 
patients [Gurubhagavatula et al. 2001; Ryan et al. 1995b] Although definition of SAHS 
involves the demonstration of nocturnal sleep disorder, PSG variables have traditionally 
shown little relationship with daytime symptoms, except perhaps AHI and AL Most 
patients with significant SAES generally report a sleep latency of <io minutes although 
this is more likely to be the case in Narcolepsy patients. PSG variables at baseline 
suggested sleep deprivation which then improved by almost 40% with treatment with 
CPAP and by 32% in lifestyle patients. 
Although one study has reported an increase in the mean SWS after CPAP treatment in 
the first and second sleep cycles the significance of this change remains uncertain 
[Heinzer et al. 2001]. In this study, there was no significant increase in mean total SWS 
after treatment with CPAP but the duration of stage II sleep and total sleep period were 
reduced. As these patients also had significantly reduced daytime somnolence, this may 
indeed be a reflection of reduced sleep deprivation and a restoration of the balance 
between Stage II and SWS. 
5.4.6 Sleep hygiene 
Patients in the lifestyle group given written advice on sleep improvement measures 
reported a significant improvement in sleep quality (VAS score) and daytime sleepiness 
(VAS score). Whether the demonstrated improvement is as a result of sleep hygiene and 
weight reduction strategy or merely a placebo effect is uncertain, and a question that the 
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design of this study is unable to establish with certainty. When this subjective 
improvement is compared to PSG variables there is a definite change in sleep latency, 
combined with a reduction in AHI, which is compatible with objective improvement in 
sleep quality. There were trends towards improvement in SWS and REM sleep but these 
did not reach statistical significance. Other researchers have reported evidence of sleep 
quality being affected by diurnal work pattern and nocturnal distractions such as 
television and smoking habits [Wetter et al. 19941 [Wetter et al. 19951. Although there is 
not much research evidence of the effectiveness of sleep hygiene strategies in SAHS 
patients, other studies investigating the effect of sleep hygiene measures on sleep quality 
have reported benefit from behavioural strategies in patients with depression and 
insomnia which may be sustained in long term follow up [Hauri 1997]. Among SAHS 
patients there was little prior evidence of improvement with sleep hygiene measures 
[Monasterio et al. 2001b]. In the only other similar study, the authors reportedly 
recruited an average of 65 -77 mild SAHS patients who were given either CPAP or a sleep 
hygiene and/ weight loss program. Although the patients on weight loss and sleep hygiene 
noticed an improvement in clinical symptoms, the change in ESS scores and HRQL scores 
did not reach clinical significance. Similarly in the present study the reduction in total 
ESS scores did not reach significance during the trial phase in patients on lifestyle 
intervention program. 
5.4.7 CPAP group 
Patients given CPAP therapy demonstrated improvement in self-reported daytime 
symptoms (ESS scores, po. ooi) and in objective PSG variables. Sleep latency improved 
by 40%, AHI returned to normal range (p<o. ool) and AI improved to normal (p<o. ool). 
Thus there was clear evidence of the correction of both the nocturnal sleep breathing 
disorder and daytime somnolence after treatment. Patients who spent more time using 
their CPAP reported a greater change in the ESS scores, suggesting that duration of CPAP 
use may reflect in better tolerance and greater benefit in symptom control. There is an 
accumulating body of data that CPAP treatment not only corrects AHI but also improves 
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EDS compared to placebo and oral devices [Wright and White 20001 in symptomatic 
patients. Unlike earlier uncontrolled trials this data has been gathered using either oral 
placebo or sub-therapeutic-CPAP [Montserrat et al. 2001] in a RCT design and in one 
trial compared to conservative lifestyle advice [Ballester et al. 1999]. One hundred and five 
consecutive predominantly male patients of a similar age group (53 tio years, BMI = 32 
*6 kgM-2) with moderate to severe SAHS (AHI 56 ±2o hour-1, ESS 12 ± 5) where 37 
patients were randomly allocated to conservative program of sleep hygiene and weight 
loss (Group 1) and Group 2 (n = 68) received, in addition, treatment with CPAP. The 
odds of experiencing a treatment response with CPAP + conservative strategy compared 
with conservative strategy alone were 6-5. 
In a further study with ill subjects (48% females) with mild SAHS (AHI 5-3o hour-A 
given CPAP treatment or conservative weight reduction advice and/or nasal dilators / 
nasal corticosteroid sprays. At the end of the trial period, there was no change in MSLT 
results in both the groups although the patients on CPAP reduced their ESS scores by 
2/24 and there was a significant reduction in RDI in both the groups but greater in the 
CPAP group. Almost half of the patients on CPAP reported improvement in HRQL 
compared to 25% on conservative therapy. Analysis of patients based on treatment 
response identified a group with AHI>15 hour-i and MSLT <8 min who also had 
underlying co morbidity who responded well to CPAP therapy [Redline et al. 19981. 
These two studies although initially designed to investigate two different levels of SAHS 
severity concluded that patients with significant symptoms (EDS) and AHI>15 hour-1 
were most likely to respond to treatment with a reduction in AHI, improvement in 
daytime symptoms. Both studies found little correlation between the AHI and daytime 
symptoms and polysomnographic variables remained poor predictors of treatment 
response. 
5.4.8 CPAP compliance 
The number of hours of CPAP usage may reflect on the degree of benefit obtained from 
this treatment. The average CPAP usage per week recorded in this population given the 
standard direct contact with experienced technicians, (which was the normal practice in 
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this institution) was similar to that reported by most other researchers. My analysis 
showed a significant relationship between 'duration of CPAP use' and 'reduction in ESS 
scores'. There is some evidence that patients who self-refer themselves as well as those 
given intensive follow up and encouragement tend to use their CPAP machines for longer 
durations and hence experience a greater improvement in symptom control and daytime 
function [Hoy et al. 1999]. Even with intensive support the mean duration reported in the 
above study was 5.4 hours versus 3.9 hours on normal follow up. As the need for sleep has 
a wide variability between individuals, the optimum period for sleep in humans is difficult 
to quantify and hence the optimum duration of CPAP use is also variable [McNicholas 
19971. Most studies and clinic patients usually report usage between 3-6 hours. Patients 
with less severe SAHS are more likely to discontinue CPAP treatment. The risk of 
experiencing nasal and pharyngeal side-effects of such severity that the patient stops 
using CPAP increases with age and patients who have undergone UPPP [Janson et al. 
20001. However 36/39 patients on CPAP therapy preferred to continue with their 
treatment compared to 13/46 given conservative therapy in an American study [Redline 
et al. 1998]and similar results have been reported by Monasterio et al with 62% accepting 
treatment with CPAP in patients with an AHI of 10-3o hour, [Monasterio et al. 2001a]. 
As an innovation, CPAP shows characteristics of widespread potential user group, good 
user acceptance and tolerance with minor side-effects including discomfort from the 
mask, dryness of mouth and difficulty adapting to positive pressure [Massie et al. 19991, 
which even in long term follow up does not reduce the compliance or the perceived 
benefit [Zozula and Rosen 2001a]. 
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5.5 CONCLUSIONS 
As a first step in the HTA of CPAP the data from this research confirms that it is indeed 
effective in reducing or correcting nocturnal sleep breathing disorder which is reflected in 
an improvement in daytime symptoms of EDS. As an innovation, CPAP demonstrates 
good tolerability and acceptance with mild side-effects both in the short term as shown in 
this study and also in the long term based on reports from other studies. The duration of 
CPAP use also relates to greater improvement in control of EDS. 
It is shown that obesity is an independent factor contributing to both EDS and AHL 
Conservative lifestyle modification and weight loss strategy achieved only a modest 
weight loss in 3 months, but demonstrated an improvement in nocturnal sleep quality, 
daytime sleepiness along and PSG variables (sleep latency, AHI and Al). 
As this population of SAHS patients (similar to other groups) has a high prevalence of 
obesity, systemic hypertension and IHD, a holistic strategy involving lifestyle measures is 
likely to be more successful in reducing morbidity and mortality, although the current 
study was not designed to investigate the effect on long term health. 
The polysomnographic variables (AHI and AI) of sleep breathing disorder show little 
predictability for daytime symptoms and hence are unlikely to be suitable for use as 
generic outcome measures for measuring the benefit from therapy. 
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Chapter VI: Health related quaUty ofUfe assessment 
6.1 INTRODUCTION 
With the improved control of diseases due to advanced technological innovations and 
health care provision in the developed countries, the traditional measures of mortality 
and survival became insensitive to further improvement in the health of populations. As 
explained previously this led to a change in the focus of health care provision from 
negative (eradication of disease and prevention of death) to positive health including well- 
being, mental and spiritual health and the fulfilment of life. This transformation of the 
focus of health measurement to 'quality' terms happened in the last two decades. Surveys 
have shown a substantial rise in the scientific literature measuring or mentioning quality 
of life changes in the last three decades [Muldoon et al. 1998]. 
6.2 METHODOLOGY 
6.2.1 Generic HRQL tools 
The initial controversy regarding the perspective of HRQL measurement (whether 
professional or patient's own) was decided by a spate of studies which showed wide 
discrepancies between professional or patient's own approach to their HRQL [Slevin et al. 
1988]. As it became established that patient's own self-esteem, individual preference and 
subjective measures of benefit were by far more relevant in promoting good health, there 
were further issues in establishing validity and reliability of these HRQL measures. Most 
HRQL measures available have been developed by professionals including items which 
were weighted 'professionally' then assessed among subjects in trials; an aspect which 
some purists believe interferes with the basic patient orientated HRQL concept [Kelly et 
al. 20011 [Bowling 19921. 
However there are some measures which are specifically designed to accurately measure 
the different aspects of HRQL that tend to be affected by specific disease states. Hence 
these disease-specific measures demonstrate a greater sensitivity in these population 
groups, whereas other measures which incorporate the more widespread aspects of health 
and HRQL tend to allow widespread use among different populations and different 
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disease states. From a health technology appraisal perspective, the 'generic' HRQL 
measures hold promise in measuring the impact of a specific intervention and still having 
the ability of comparison with competing technologies. 
Generic measures have been broadly divided into those which measure objective 
fiinctional status and others measuring subjective well-being (Muldoon et al. 1998]. The 
effects of health on HRQL have been further characterised in terms of physical and 
mental domains. The physical HRQL domain includes an individual patient's perception 
of the way their physical symptoms or disability impact on the various aspects of their 
lives. The mental domain focuses on the anxiety or mood states and includes emotional 
support and relationships. 
There are various questions of validity of the HRQL measures used in medical research. 
Primarily this involves establishment of the fact that a questionnaire measuring physical 
well-being should reflect accurately objectively measured changes in the physical state/ 
symptoms of the patient (criterion validity). Most HRQL instrument also have to 
demonstrate construct validity by showing that they are not only reflecting the changes 
seen with other disease related measures but also that they are not related to 
anthropological measures such as height, weight, age and sex but to other measures of the 
particular disease state under study (convergent-discriminant validity) [Bowling 19921. 
It is also known that extraneous factors such as marital status, employment, geographical 
clusters and social acceptability may influence responses to these IIRQL measures, which 
tend to make interpretation complex. 
For SAHS patients the impact of their disease on their physical and mental state can be 
profound. The chronic fatigue and daytime sleepiness can adversely impact on physical 
functioning, driving performance, work, relationships, social embarrassment, change of 
personality and even depression [Flemons and Tsai 1997a]. Disease specific measures 
such as Stanford Sleep Scale [MacLean et al. 199o] and Sleep Apnoea Quality of life 
Index (SAQLI) [FlemonS 20001 tend to be sensitive to the specific HRQL deterioration in 
these patients. But generic measures have also been shown to be effective in measuring 
the impact of disease and treatment in some studies [Jenkinson et al. 19981 [Finn et al. 
1998b] [Montserrat et al. 2001] [Engleman et al. 1999]. 
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There were two problems using HRQL measures in SAHS patients. Firstly there was little 
correlation reported between physiological measures of disease severity and HRQL 
measures and secondly variable effect sizes [Finn et al. 1998b] [Yang et al. 20001 were 
reported by different researchers [Montserrat et al. 20011 within individual sub-scales of 
instruments and between different instruments [Jenkinson et al. 1998]. Therefore for the 
purposes of this study, in order to measure the outcome of CPAP versus lifestyle 
intervention, four questionnaires were used and are discussed in Chapter III. 
1. Short form 36 item general health questionnaire (SF36) was chosen 
because it had widespread use both in the USA and UY, with normative data 
eidstent in both populations which would allow for comparisons. It had also been 
shown to be sensitive to change in certain dimensions in SAHS patients. 
2. European quality of life questionnaire (EuroQol): This was specifically 
designed for use in the UK and Europe and has been used extensively in health 
status assessment for use in economic evaluation. 
General Health questionnaire (GHQ28): for assessment of psychiatric 
disability in these patients 
4- Hospital anxiety and depression scale (HADS): psychiatric assessment 
After the diagnosis of SAHS was discussed with patients and their partners and both 
verbal and written information (Appendix ii ) on clinical and management options 
provided, they were then asked to complete the following health related quality of life 
questionnaires unsupervised both before and after the trial period. 
6.2.2 Mental health assessment tools 
Sleep disorders have been strongly associated with psychiatric illness in meta-analyses of 
epidemiological surveys in chronic disease. The involvement of SAHS with psychiatric 
illness goes beyond un-refreshing and unfulfilled sleep to anxiety and clinical depression 
[Klonoff et al. 19871 [Millman et al. 1989]. There is a considerable overlap in the 
symptornatology associated with depressive illness and SAHS. Evidence suggests that 
both SAHS and depressive illnesses have both far reaching social and physical 
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consequences including an increased independent risk of coronary artery disease [Wells 
et al. 1998] [Pratt et al. 1996]. Hence it is was considered important to screen patients 
presenting with SAHS for psychiatric illnesses and to measure the effect of treatment 
using standard screening tools like the General Health Questionnaire and the Hospital 
Anxiety and Depression Scale. 
The HADS and GHQ28 have been shown to be reliable instruments for case distinction 
and screening in general population, clinic and psychiatric populations with strong 
internal consistency and convergent validity with other comprehensive and gold standard 
measures, hence they are used in this study to assess the prevalence of anxiety and 
depression. They are also used to assess the difference in scores after intervention and 
compared with the mental health dimensions of the SF36. 
6.2.3 Neuro-cognitive test (Trail making Test A& B) 
The trail making tests are part of a standard battery of neuro-cognitive function testing 
which measures both mental dexterity and hand-eye-coordination. This involves Test-A 
which is a series of numbers on a sheet in disorderly fashion which needs to be joined in 
order and the time to complete the test is measured. Test-B involves alternate letters and 
numbers which then have to be joined in order alternately (number alternating with 
letter) with a measurement of time taken to complete. 
All such neuro-cognitive battery tests have been shown to improve in repeated testing due 
to a process of learning, however in this study they were used only on 2 occasions, 3 
months apart minimising the 'learning effect'. 
In SAHS patients Trail making tests along with other neuro-cognitive battery tests have 
been shown to be abnormal at baseline (Redline et al. 1997] and sensitive to the effect of 
treatment with CPAP even in short-term studies [Borak et al. 1996] [Henke, Grady, and 
Kuna 2001] [Engleman et al-1994b]. In common with other neuro-cognitive tests there is 
seldom a strong association with disease parameters except in patients with dementia 
[Kingshott et al. 1998]. 
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6.3 RESULTS 
6.3.1 Short form 36 questionnaire survey 
6.3.1.1 Baseline results for study population 
The baseline scores in the 8 dimensions of HRQL computed from the SF36 questionnaire 
are presented in table 6.1 with the summary scores in physical and mental summary 
scales. Figure 6.1 illustrates the distribution of the responses to questions 1&2 referring 
to HRQL status in the last 12 months and the expectation for the future. Nearly 6o% of 
the population of SAHS patients rated their health status in the last 12 months to be fair 
to poor. In response to Q2 70% expected their health status to remain the same in the 
near future and 25% expected their HRQL to deteriorate. 
Table 6.1: Baseline population mean (SD) for SF36 survey results 
Diriýinsions Mean SD 
Physical functioning (PF) 62.4 23.6 
Role Physical (RP) 63.3 26.1 
Bodily pain (BP) 6o. 8 21.6 
Energy/ Vitality (VT) 38.1 17.9 
General Health (GH) 49.8 21.8 
Social functioning (SF) 58.7 23.7 
Mental health (MH) ý6ý. O 184 
Role emotional (RE) 77.9 20.9 
Physical component 39.6 9.8 
summary (PCS) 
Mental component summary: '46. i 9.3 
(MCS) 
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Figure 6.1: SF36 question I&2- proportional results for study population 
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Qi: 1=excellent health, 2= very good health, 3= good health, 4= fair health, 5= poor health 
Q2: i= much better than i year ago, 2= somewhat better, 3= about the same, 4=somewhat 
worse, 5= much worse. 
When the scores were compared to UK population norms there were significant lower 
scores seen in all the HRQL dimensions except in emotional role limitation as shown in 
table 6.1o. 
The most deterioration was seen in energy/ vitality and social ftmetioning dimensions. 
Women scored their HRQL lower than men in mental health, social functioning and 
energy vitality while men scored lower in physical dimensions. 
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Table 6.2: SF 36 survey results according to sex compared with UK 
population results* 
SEX Study SD Populat Effect 
Mean ion size 
N=58 Mean 
men N=787 
N=13 men 
women N= 884 
women 
Physical functioning MaIc 6o-7 24.6 8, j (). 91 
Female 69.1 18.1 77 0.44 
Role physical- limitation Male 63.3 27-5 82 o. 68 
Female 63.4 20.8 76 o. 61 
Bodily pain Male 6o. o 22.4 79 o. 85 
Female 63.8 18.9 74 0-54 
Energy/ Vitality Male 39.6 17.8 66 1.48 
Female 32.4 17.7 59 1-50 
General health Male 49-1 21-7 70 1-43 
Female 52.8 22.8 69 0.71 
Social functioning Male 59-3 25-3 86 1. o6 
Female 56.5 16.3 82 1.56 
Mental health Male 65.5 19.4 78 o. 64 
Female 63.2 14.8 73 o. 66 
Role emotional - limitation Male 79.0 20.8 85 0.29 
Female 73.8 2 t. 8 81 0.33 
Physical component Male 39.3 10.5 
summarN 
Female 40-5 6-4 
Mental component summary Male 46.4 10.1 
Female 44-9 5.6 
Health survey for England 1996, West Midlands ag e standard ized populat ion results 
Effect size- difference in mean s/ SD 
6.3.1.2 Relationships between sleep, anthropornetric and 
SF36 baseline values 
The demographic variables (age & BMI)and polysonuiographic variables (AIII & AI) werc 
not related to any of the SF36 subscales except for sleep latency which demonstrated a 
significant negative correlation with physical role limitation (Pearson's correlation 
coefficient -0-341, p=o. oog) and social functioning (Pearson's correlation coefficient - 
0.297, P=0.025). 
The inter-class correlations for the physical (PF, RP, BP & GH) and mental dimension 
subscales (VT, SF, MH & RE) with an average Of 0.46, are demonstrated in table 6., j Ab 
also with coefficients for the component summary scales. The energy/ vitality and general 
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health dimensions show considerable overlap between the mental and physical 
dimensions. 
The Cronbach's a coefficient for intra class reliability assessment was 0-87 at baseline and 
o. gi after intervention. 
Table 6.3a: Inter-scale correlations between sub-scales for SF36 at baseline 
PF RP BP VT GH SF MH RE 
PF I 
RP o. 62 1 
BP 0.59 0.50 1 
V'r 0-30 0.44 0-41 1 
GH o. 62 o. 68 0.58 0.50 1 
SF 0.33 0.36 0.50 o. 68 0.42 1 
MH 0-14 0.15 0.28 o. 69 0.34 0-75 1 
RE 0.21 0.39 0.25 0.51 0-36 0.52 0.70 1 
PCs 0-75 o. 67 o. 64 0.27 0.77 0. '38 0.10 0.17 
MCS 0.01 o. o8 0-14 0.71 0.19 o. 66 0.89 0.74 
Average correlation 0.46 (ranging from 0.14 to 0.75) 
PF-physical functioning, RP-Role limitation physical, BP-Bodily pain, VI'-Energy/ vitalitN, 
GH-Gencral health, SF-Social functioning, MH-Mental health, RE-Role limitation 
emotional, PCS-Physical component summary, MCS-Mental component summar. N 
Table 6-3b: Inter-class correlation for subscales of SF36 post intervention 
PF RP BP VT GH SF MH RE 
PF I 
RP 0.73 1 
BP 0.55 o. 58 I 
V'r 0.54 0.54 0-48 1 
GH o. 6o o. 66 0.45 o. 64 I 
SF 0.49 0.57 0.40 o. 69 0.58 1 
MH 0.27 0.38 0.23 0-58 0-41 o. 67 I 
RE 0.45 o. 63 0.47 o. 61 0-46 0-70 0.75 1 
PCs o. 89 o. 83 0-71 0.54 0-74 0-45 0.11 0-: 37 
Mcs 0.12 0.24 0.23 o. 62 0.40 0.74 o. 87 0-75 
Average correlation wits o., 5: j (range from o. o, -ý to o. 89) 
PF-physi cal functioning, RP-Role limitation physical, BP-Bodily pain, Vl'-I-'. nergN, / vitality, 
GH-Gencral heal th, SF-Social functioning, MH-Mental health, RF. -Role limitation 
ernotional, PCS-Physical component summary, MCS-Mental compon ent summary 
___ 
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Patients in Group I on CPAP therapy demonstrated a significant improvement in social 
functioning (21%, effect size o. 8, p=o. ooi), energy/ vitality (16%, effect size 0-7, P 0.001), 
mental health (lo%, effect size 0.5, P=0.003) and physical role limitation (8%, effect size 
0.3, P=0.04) in the SF36 questionnaire after treatment. 
The change in ESS scores correlated with general health (Spearman's correlation 
coefficient o. 61, p=o. ool) and mental health dimensions (coefficient 0.4, V0.05). Using 
a linear regression model, 40% (adjusted r, =04) of the variation in mental health scores 
after treatment could be attributable to ODI, sleep latency and REM latency (r-= o. 6, 
P=0.015). 
The patients in Group 11 on lifestyle intervention did not show any significant 
improvement at the end of the trial period, as shown in table 6.4. 
Table 6-4: Paired samples statistics for SF36 variables before and after 
intervention 
CPAP Lifestyle 
Mean SD p Mean SD p 
Base PF 6,1.9 28,1 61.4 2,5. ý5 
Post PF 65.3 26.5 o. 658 63.9 26.7 0.756 
Base RP 59.8 31.1 66.6 25.5 
Post RP 68.2 28.1 0.037* 71.9 21.5 0.349 
Base BP 61.5 25.4 62.0 24.7 
Post BP 64.7 21.7 0.3o8 62.0 21.9 0.998 
Base VT 38.9 22.0 36.6 Iq. () 
Post vr 55.2 19.3 <o. ooi* 39.1 18.9 o. 623 
Base GH 48.6 23.2 49-7 27.3 
Post GH 55.4 23.5 0.058 47.3 21.5 0.726 
Base SF 57.7 26-7 6o. 1 26.: 3 
Post SF 78.7 22.3 0'001* 66-5 20.6 0.392 
Base MH 66. o 21., 5 6--,. o 20.4 
Post MH 76.2 20.2 0.003* 65.9 17-5 0.514 
Base RE 79-1 23.7 75.6 24.3 
Post RE 84.3 20.8 0.072 76.9 19-3 0.828 
Base PCs 39.4 12.2 40.4 9.3 
Post PCs 40-9 10-5 0.281 41-5 9-7 o. 634 
Base MCS 46.5 10.2 44.1 1 1. 'j 
Post MCS 53.2 9.2 <0.001* 46.4 7.6 0.436 
PF-physical functioning, RP-Role limitation ph ysical, BP-Bodily pain, VI'-Energy/ vitality, 
GH-General health, SF-Social functioning, MH-Mental health, RE-Role limitation 
emotional, PCS-Physical component summary, MCS-Mental compon ent summary 
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Figure 6.2 shows that for CPAP patients mean SF36 scores return to population normal 
figures in the mental health dimensions but the physical dimensions remain below 
normal even after 3 months of therapy including the general health dimension, which is 
derived predominantly from questions related to the physical aspects of HRQL. 
Figure 6.2: Post CPAP SF36 scores compared to UK population mean scores 
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PF= physical functioning, RP= role limitation physical, BP= bodily pain, VT= energy & 
vitality, GH= general health, SF= social functioning, MH= mental health, RE= role 
limitation emotional. 
6.3.1.3 Summary of SF36 data 
The SF36 questionnaire demonstrated excellent intra-class and inter-class reliability 
with Cronbach's alpha = o. 8-o. 9 among sleep apnoea patients. All SAHS patients 
demonstrated the poorest HRQL scores in Social Functioning and Energy/ Vitality 
dimensions and subsequently in patients on CPAP the greatest improvement was 
seen in mental health dimensions (SF & VF). Men had poor scores in General Health, 
Physical Functioning and Bodily Pain dimensions. Women reported their worst 
HRQL score in the Social Functioning dimension. SAHS patients on lifestyle arm did 
not show any significant improvements while in the CPAP arm, post treatment SF36 
scores were improved but did not reach population normative values in the physical 
dimensions. Sleep latency was negatively correlated to physical role limitation. 
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6.3.2 European Quality of Life Questionnaire (EuroQol) 
6.3.2.1 Euro0ol 5 dimension 
Patients reported moderate problems in mobility, usual activities, pain and anxiety/ 
depression. There were no significant intra-group differences in the distribution of 
grades of severity reported by patients, except in anxiety/ depression as shown in figure 
6.3 (Chi sq test, P=0.002). In both the groups there were moderate problems reported in 
usual activities, pain and anxiety/ depression dimensions at baseline which does not 
change significantly in either group when measured after the treatment phase, figure 6.4 
& 6-5. 
Figure 6-3: Comparing baseline EuroQol grades between 2 groups of patients 
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The 5 dimensions of the EuroQol questionnaire (1=mobility, 2=self-care, 3=usual 
activities, 4=pain/ discomfort and 5=anxiety/ depression) classify the quality of life in 3 
levels (1=no problems, 2= some problems and 3= severe problem/ unable to perform. 
C=CPAP & L=Lifestyle 
The 5 dimensions of the EuroQol questionnaire (1=mobility, 2=self-care, 3=usual 
activities, 4=pain/ discomfort and 5=anxiety/ depression) classify the quality of life in 3 
levels (i=no problems, 2= some problems and 3= severe problem/ unable to perform. 
B=Basefine & P=Post-treatment 
HTA in SAHS, PhD theju Indraml Cbakrmony 2005 190 
Chapter VI: Health related quality offife assessment 
Figure 6.4: Proportion of Life_style group patients scoring 1-3 in the EuroQol 
and the effect of therapy 
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Figure 6-5: Proportion Of CPAP group patients scoring 1-3 in the EurOQoI and 
the effect of therapy 
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The 5 dimensions of the EuroQol questionnaire (1=mobility, 2=self-care, 3=usual 
activities, 4=pain/ discomfort and 5=arDdety/ depression) classify the quality of life in 3 
levels (1=no problems, 2= some problems and 3= severe problem/ unable to perform. 
B=Baseline & P=Post-treatment 
6.3.2.2 EuroQol health thermometer 
The population mean score on the visual analogue scale (EuroQol-HT) depicting current 
health status on a scale from o to ioo incorporated in the EuroQol was 66.8 (16) 
compared to the UK population mean of 83. 
Figure 6.6 shows the linear relationship between the EuroQol HT and the EuroQol 
indirectly derived utility. 
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Figure 6.6: Scatter plot showing the linear regression between EuroQol HT 
and EuroQoI utility. 
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Euroqol utility 
The baseline EuroQol HT scores were not related to any of the baseline parameters (age, 
BMI, neck size, AHI, AI, sleep latency, REM latency). At baseline EuroQol-HT correlated 
strongly with SF36 subscales, utility values from standard gamble and time-trade off 
methods, as shown in table 6.5- 
The negative correlation with scores from the HADS anxiety and depression subscales is 
due to the higher scores indicating worse mental health state unlike the higher score 
representing a better health state perception in the EuroQol-HT. 
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Table 6-5: Spearman correlation coefficients for relationship between 
EuroQol HT and other HRQL measures 
PF RP BP VT GH SF MH RE 
Eq utility 0.7* o. 6* 0.4 0.7* o. 6* 0-3 0.4 (). 7* 
Eq -HT o. 6* 0.5 o. 6* 0.7* 0-5* 0.4 o. 6* 
PCs mcs 
0.4 -0-4 
Usg Utt. Anx Dep GA GB GC GD EqHT 
Eq-utility 0.7* -0.4 -04 -0-4 -0-4 o. 6* 
Eq-HT 0.3 0.5 -o. 6* o. 6* -0.4 -o. 6* -0.5 
SF36 scales: PF physical functioning, RP role limitation phvsical, BP bodilv pain, VI' 
energy/ vitality, GH general health, SF social functioning, MH mental health, RE, role 
limitation emotional, PCS physical component summary scale, MCS mental components 
summary scale. Ug standard gamble utility, Utt. Time trade off utility. Hospital anxiety 
and depression scale (HADS): Anx anxiety subscale, Dep HADS depression subscale. 
General Health Questionnaire GUIQ: GA somatic symptoms, GB anxiety & insomnia, GC 
social dysfunction, GD severe depression. 
* Significant at 99% level all others are significant at 95% level. 
The pre-treatment mean score for Group I (CPAP) was 66(16.6) improving to 7303.2), 
p=0.009. In Group 11 (Lifestyle) the mean baseline score of 67.705.6) does not change 
significantly after treatment 67-403.7). 
6.3.3 General Health Questionnaire (28-item) 
6.3.3.1 Proportion of cases vs. non-cases 
Using a threshold value for the GHQ-)8 total SCOIT Of 11/12 for identif%ing significant 
psychological distress/ disease in the study population, there were an overall 64/71 
patients affected. After treatment with CPAP there was a 43% reduction in proportions of 
patients with significant psychiatric distress/ disease (X2 = 8.29, P=0.004; Odds ratio 6.3, 
95%CI = 1.7 to 28.7). In Group 11, there were 32 patients Aith psychiatric distress at the 
end of the trial compared to 31 at baseline. 
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6.3.3.2 Reliability 
The inter-item correlations for the 4 sub-scales are given in table 6.6 the average being 
0-58 and the coefficient of reliability Cronbach's ct was o. 84- 
Table 6.6: showing the inter-class correlation for GHQ subscales 
GHQ-A GHQ-B GHQ-C GHQ-D 
GHQ-A 1 
GHQ-B o. 6o 1 
GHQ-C 0-56 0.57 
GHQ-D 0.53 o. 61 o. 6o 1 
GHQ-A=Somatic symptoms, GHQ-B=an)dety & insomnia, GHQ-C=Social dysfLmction, 
GHQ-D=severe depression 
Figure 6.7: Frequency distribution of baseline scores for GHQ28 total score & 
subscales 
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Table 6-7: Paired samples statistics for GHQ scores before and after the trial 
LifestYle p CPAP p 
Mean Mean 
GHQ-A Base 7.7 (3-4) 8.3(3.8) 
Post 6.8(2-4) 
Base 6.6(2.6) 
Post 5-9(2-0) 
Base 9.4(2-5) 
0-049* 3.9(2-5) 
6.945) 
0.072 2.9(2.6) 
9.7(2.8) 
Post 8.9(2.2) 0.296 
Base 2.3(2-4) 
Post 2.9(2.9) 0-031* 
Base 25.9(9.1) 
Post 24.4(7-1) 0.249 
5-8(2.2) 
3.0 (3-8) 
1.2(2.1) 
27-8(12.5) 
13-9(7-3) 
6.3.3.3 Effect of treatment on GHQ scores 
<o. ooi* 
<o. ooi* 
<o. ooi* 
0.002* 
<o. ooi* 
Group I patients reported a significant reduction in the GIIQ-total score and in all 4 sub- 
scales. Patients in Group 11 showed no change in GHQ-total score and a modest reduction 
in somatic symptoms (GHQ-A) but a worsening in the severe depression sub-scale (GHQ- 
D) as demonstrated in table 6.7. 
6.3.3.4 Correlations of GHQ scores with other parameters 
None of the parameters (Age, BMI, AHI, ODI, Al, sleep latency, REM latency) were 
significantly correlated with the GHQ scores. There were no significant correlations with 
utility measurement using either standard gamble or time-trade off methods, and only 
weak relationship with the indirectly derived EuroQoI utility index. Therc were significant 
relationships between the GHQ subscales and the SF,, 36 and HADS questionnaire, as 
shown in table 6.8. 
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Table 6.8: Spearman's correlation coefficients of GIIQ subscales with other 
HRQL measures 
PF RP BP VT GH SF MH RE PCs MCS 
GHQ A -0.4 -0-5* -(). 7* -o. 6 -0.. q* -o. 6* -o. 6* -o. 6* -()-7* 
GHQ B -0.5 -0.4 -0-5 -o. 8* -0.8* -0-7* -o. 8* 
GHQ C -0.4 -0-7* -0-4 -0.5 -o. 6 -o. 6* -o. 6* -o. 6* 
GHQ D -0.4 -0.4 -0-5 -o. 6* -0-7* -0-7* -o. 6* 
U'X Utt. Anx Dep Eq Eq 
HT utility 
GHQ A o. 6* o. 6* -o. 6* -0-4 
GHQ B 0.7 * 0-7* -0.4 
GHQ C 0.5 * 0-7* -o. 6* -0.4 
GHQ D 0-7* 0-7* -0.5 -0.4 
F36 scales: PF physical functioning, RP role limitation physical, BP bodily pain, Vl' 
energy/ vitality, GH general health, SF social functioning, MH mental health, RE role 
limitation emotional, PCS physical component summary scale, MCS mental components 
summary scale. 
U,,, standard gamble utility, Utt,, Time trade off utility. 
Hospital anxiety and depression scale (HADS): Anx anxiety subscale, Dep HADS 
depression subscale. General Health Questionnaire 
GHQ: GHQ-A somatic symptoms, GHQ-13 anxiety & insomnia, GHQ-C social dysfunction, 
GHQ-D severe depression. Only significant correlation values have been shown; 
significant at 99% level others at 95% level 
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6.3.4 HOSPITAL ANXIETY & DEPRESSION SCALE 
6.3.4.1 Cases 
There were 14% cases with anxiety disorder and 8% with significant depression in the 
study population, as shown in figure 6. io. 'Me figure 6.8 shows the frequency 
distribution of the HADS subscale scores. 
Figure 6.8: Proportions of cases, doubtful and normal patients classified 
according to ILADS scores 
HADS-A cases 
21% 
46 
D' 
50/0 
113 Normal 0 Doubtful o Cases 
The established criteria for diagnosis of cases based on the HADS scores for each subscale 
(HADS-A arl)dety & HADS-D depression) a score s7 is normal, 8-io is considered to be 
doubtful and 2- 11 is considered to be a case with significant psychiatric disorder. 
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Figure 6.9: Distribution of baseline IUDS subscale scores for study 
population 
30- 
20ý 
10. 
Std. Dev = 3.91 
Wan = T3 
0111tN= 71.00 
0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 160 18.0 20.0 
Baseline HADS-A score 
12, 
10, 
8- 
6. 
4 
2.1 Std. Dev = 3.30 
I 
Wan = 5.5 
0- 1N= 71.00 
00 20 40 60 80 10 0 12.0 14ýO 
1.0 3.0 5.0 7.0 9.0 11.0 13.0 15ý0 
Rac. plinp HAnq-n qmrt- 
HTA in SAHS, - PhD tbesis Indraml Chakrawrý; 2005 198 
Chapter V 1: Health related quality of Afe assessment 
6.3.4.2 Correlations 
The baseline HADS-A scores were related significantly to the ESS scores measuring EDS 
(regression coefficient 0.343, P=0.004) among all the baseline anthroponictric and 
polysomnographic parameters as shown in figure 6. io. While the baseline HADS-D scores 
were significantly related to ESS scores (coefficient 0.262, P=0.049) and sleep latency 
(coefficient 0-319, P=0.008). 
6.3.4.3. Consistency & reliability 
The inter-item correlation for the HADS-A and HADS-D subscales was 0.7534 and the 
Cronbach's ct coefficient for reliability analysis was o. 8594- 
6.3.4.4 Effect of treatment 
There was a reduction in the proportion of patients classified as cases in Group I and a 
consequent increase in patients classified as normal after therapy as shown in figure 6.11. 
The odds ratio for being classified as 'normal' after the treatment phase in Group I based 
on HADS criteria was 5.5 (95%Cl 1.5 to 23-9); X2=7-1, p=o. oo8 for HADS-A subscale and 
6.7 (95%CI 1.2 to 46.9); X"4-9, P=0.03 for HADS-D subscale. 
In Group 11 the change in proportions of cases versus normal subjects did not reach 
statistical significance. Patients in Group I on CPAP therapy showed a significant 
reduction in their HADS scores in both the anxiety and depression sub-scales, as shown 
in table 6.9 while there was no change seen in patients on lifestyle therapy in Group 11. 
Table 6.9: Paired samples statistics for HADS subscales before and after 
therapy 
Lifestyle Lifestyle p CPAP CPAP p 
Mean SD Mean SD 
HADS-A Base 7-8 : 4.4 7 -22 4-5 
Post 7.3 2.8 Ns 4.4 3.6 <0.001* 
HADS-D Base 5-3 3.0 6.1 : 3.7 
Post 5.4 2.5 Ns 2.6 2.5 <0.001* 
Ns=not statistically significant 
I ITA in SA I IS; Phl) thesis IndrandChakravorly 2005 199 
Chapter NT Health related quality of Zife assessment 
Figure 6.1o: Scatter plots showing linear relationship of HADS scores with 
baseline ESS scores 
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Figure 6.11: showing the alteration in proportion of cases and normal 
subjects based on HADS classification before (base) and after therapy (post) 
(Group I=GI & Group 11-GII) 
HADS-A cases 
10 Nonnal 0 Doubtful 13 Cases 
HADS-D cases 
113 Normal 0 Doubtful 
The established criteria for diagnosis of cases based on the Hospital anxiety & depression 
scale (HADS) scores for each subscale (HADS-A anxiety & HADS-D depression) a score :5 
7 is normal, 8-1o is considered to be doubtful and a ii is considered to be a case with 
significant psychiatric disorder. 
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6.3.5 Neuro-cognitive function (Trail-making test A& B) 
Although the baseline cornpletion times for the trail-making exercise was similar in both 
groups of patients, there was a significant reduction (18%, effect size o. 5: 3,1)<0.05) in 
time taken to complete the rrail- making B test in CPAP group I compared to group 11. 
Table 6.1o: Trail-making test A&B completion time (seconds) before and 
after treatment 
CPAP pre CPAP post Lifestyle pre Lifestyle post 
A 38(13.6) 34 36.6(20.2) 33-401-9) 
B 90.9(31-4) 74.4 (30-5)* 94.8(56-7) 86.9(40-7) 
* paired samples t test P<0.05 
The difference in completion time between baseline and post treatment test (8 T,, and 8 
TO showed no relationship with polysomnographic or anthropornetric pararneters. There 
was a significant correlation seen with change in health status scores as follows; 
Table 6.11: Non-parametric correlations between health status and difference 
in Trail-making scores 
Spearman's p 
coefficient 
Group 1: 6 T, &6U, 0.44 0.02 
Group 1: 8171, &8U,,,, -0-4 0-04 
Group 11: 8 T, &8 Tb o. 8 <0.001 
Group 11: 8'ft, &8 Um, -o. 6 (). ()I 
Group 11: 8 Ta &8 Utto -0.4 o. o6 
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6.3.6 Summary of HROL findings 
Sixty percent of patients rate their health to be fair to poor at baseline (SF36) while 
25% expected their health to deteriorate in the next 12 months (SF36). Compared to 
normal UK population, women with SAHS reported HRQI, deterioration in Social 
Functioning, Energy/Vitality and General Health with effect sizes >0-7 (moderate to 
severe). Among men with SAHS, the maximum HRQL decrements were in the 
Energy/Vitality, General Health, Social Functioning, Physical Functioning and Bodily 
Pain (effect sizes >0.7). 
The SF36 scale properties showed concurrent validity (physical role limitation and 
social functioning related to sleep latency), intra-class reliability (Cronbach's a 
o. 87), and good inter-class reliability (coefficient >o. 6). 
PSG measures of AHI and AI were not significantly related to any of the sub-scales of 
SF36. Patients on CPAP showed improvement in Social Functioning, Energy/ Vitality, 
Mental Health and Physical Role Limitation (SF36). 
After successful treatment with CPAP, mental dimension scores return to normal 
values (GH, RE and MH) but physical dimension scores remain lower than 
population values. No significant change was observed in the patients on lifestyle 
modification (SF36). 
Baseline EuroQol scores indicate moderate problems in usual activities, pain and 
anxiety/ depression dimensions. There was no significant improvement in EuroQol 
scores after treatment in both groups. EuroQol scores and health thermometer scores 
(VAS) were correlated with SF 36 subscales (PF, RP, VT, GH and RE) but not with SF 
dimension of SF36 (which showed the greatest change with CPAP treatment). 
EuroQol health thermometer scores improved after CPAP treatment but not with 
lifestyle intervention. 
GHQ28 identified 64/71 (go%) patients as potentially having significant psychiatric 
morbidity. After treatment with CPAP, there was a 43% reduction in 'cases', but no 
significant change in the number of patients classified as cases in the lifestyle 
modification arm. After CPAP, there were improved scores in all 4 dimensions of 
GHQ28 but only somatic symptoms (GHQ-A) subscale showed a modest 
I ITA in Sz II LV, -PbD lbesis Indrani1(, 'bak. rnor4 2005 203 
Chapter VI: Health related quality oflife assessment 
improvement in the lifestyle arm. Scores for severe depression (GHQ-D) sub-scale of 
the GHQ28 showed significant worsening in the lifestyle arm. 
HADS classified 8% patients with severe depression and 14% with significant anxiety 
at baseline. HADS scores showed a significant relation to sleep latency and daytime 
hyper somnolence (ESS scores). Odds ratio for improvement in HADS scores to 
normality was 5.5-6-7 for patients in the CPAP arm but no change was seen in the 
lifestyle arm. 
CPAP patients improve timing on Trail making test B (effect size o. 5) 
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6.4 DISCUSSION 
6.4.1 Overview 
Health care provision in the last 2 decades has not only focussed on control of diseases 
and reduction in mortality but in the promotion of positive health and a sense of mental 
and physical well-being. Hence appraisal of new innovations has to take into account 
patients' self reported health related quality of life along with physiological measurements. 
While the debate continues on the most suitable HRQL tool which will not only 
demonstrate a high degree of reliability and validity but also sensitivity to the needs of 
individual patients and disease groups, across the world various different tools are being 
used in clinical trials. 
In SAHS patients the disease severity measured using nocturnal PSG variables have been 
shown to be poor predictors of daytime dysfunction [Kingshott et al. 1998]. On the one 
hand even patients with no evidence of apnoeas/ hypopnoeas (i. e. UARS) [Guilleminault 
et al. 2ool] are shown to suffer a similar level of disability, while patients with clear 
apnoeas/ hypopnoeas at night may not suffer any daytime disability and hence do not 
respond to treatment [Barbe, et al. 20011. This complex relationship between disease 
processes as it is understood, with patients' reported disability levels creates problems for 
assessing outcome of intervention in this sector. 
Studies using HRQL measures have demonstrated a reduced self-reported quality of life 
among these patients, which tends to respond to treatment. In this study, two widely used 
multi-dimensional HRQL tools were studied head -to- head along with 2 specific 
measures of psychiatric morbidity. The results show firstly that the majority of SAHS 
patients report not only poor HRQL in almost all dimensions but also report symptoms 
suggestive of psychiatric morbidity. Treatment with CPAP does produce a significant 
change in Mental Health, Social Functioning and Energy/ Vitality dimensions of SF36- 
Interestingly there is only a small change in the EuroQol Health thermometer scores with 
CPAP treatment. Lifestyle modification strategy does not reflect in any change in HRQL 
measures, except an increase in severe depression scores of the GHQ28 instrument. None 
of these HRQL measures demonstrate any relationship with physiological markers. 
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Thus the suitability of these HRQL measures in assessing the overall impact of a 
healthcare intervention remains uncertain, especially as variable results in different 
population groups may lead to unfair prioritisation in health policy decision-making. 
6.4.2 Methodological issues 
The purpose of this part of the research was not to assess the validity and reliability of the 
4 HRQL measures chosen, as all of them had been validated and extensively tested in 
large population studies in several countries. It was however the intention of this HTA 
appraisal to assess their suitability for measuring HRQL deterioration among SAHS 
patients and to assess their sensitivity in measuring the impact of treatment. However, in 
the population studied the psychometric properties of these measures were compatible 
with previously reported results and all four demonstrated good inter and intra-class 
reliability. When the scores in mental dimensions were compared between those 
generated by SF36, GHQ28 and HADS, they showed moderate correlations supporting 
their convergent validity. Similarly there was compatibility between the EuroQol physical 
disability scores and the physical components of the SF36- 
However, the EuroQol scores for anxiety/ depression showed almost 20% patients 
reporting moderate to severe problems, similar to 14% with depression and 8% with 
anxiety on the HADS but in contrast to go% being classified as having significant 
psychiatric morbidity by the GHQ28. 
None of these questionnaires showed any relationship with age, sex, BMI or any other 
variable unrelated to the patient's condition, suggesting a good discriminant capability. 
These questionnaires were perhaps focussing on the mental and social aspects of HRQL 
affected by SAHS. This is likely a manifestation of the principal reported problems of 
chronic fatigue and daytime somnolence which interferes with work and sometimes 
embarrassingly with social life in SAHS patients [Flemons et al. 1997b] [Veale et al. 20021. 
While reports that SAHS patients, suffer breakdown of relationships and an increased 
tendency to seek comfort in alcohol and depression [Veale et al. 2002], are reflected by 
the high prevalence of psychiatric morbidity reported by the GHQ28 and HADS. Thus 
these questionnaires demonstrate construct validity, and would appear to measure what 
they set out to measure, among SAHS patients in the present study. 
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Although it can be established that these HRQL tools do appear to measure relevant 
disabilities among SAHS patients, where there remains uncertainty is in their criterion 
validity. In other words, are the disabilities measured related to the underlying disease 
process being assessed? For example when the traditional measures of disease severity 
were compared to the scores measured by these instruments, none was found to show any 
significant relationship excepta negative correlation between physical role limitation and 
sleep latency. 
A lower score on physical role limitation translates to a poorer fiinction and is correlated 
with a higher sleep latency. Physical role limitation is less important in SAHS patients and 
shows only a modest change with treatment. However, physical role limitation is more 
likely to be a result of concurrent comorbidity such as osteoarthritis (which is more 
prevalent in obese individuals) and thus interfere with getting to sleep (hence, increasing 
sleep latency). 
Hence it is uncertain whether the HRQL deterioration measured by these instruments are 
a direct consequence of SAHS disease process as measured by PSG parameters (i. e. 
absence of criterion validity). This deficiency of generic measures may conceptually be 
addressed by disease specific tools, but with a likely decline in sensitivity and the inherent 
difficulties in comparisons across the disease spectrum (a vital ingredient for any health 
technology appraisal system). In other research, when a disease specific assessment tool 
was compared to a generic tool such as the SF36 among patients attending a 
rheurnatology clinic, the disease specific measure detected more problems in patients 
with osteoarthritis [Brazier et al. 19991. However, Brazier et al found that SF36 
demonstrated a greater insight in to the patient's general health and was more sensitive to 
the change with treatment in a more diverse population of rheurnatological diseases 
[Brazier et al. 1999]. Thus, in conditions such as Diabetes Mellitus, COPD, rheumatoid 
arthritis and SAHS where the disease process tends to have a multi-faceted impact on 
general health, generic tools may show a greater sensitivity to change. 
Although, a disease specific measure such as the SAQLI [Flemons and Reimer 2002] has 
been designed specially to identify the HRQL consequences of sleep deprivation/ 
fragmentation, SF36 has been shown to be sensitive to quality of sleep in subjects with 
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SAHS [Smith et al. 19951. Even the disease specific SAQLI showed little or no correlation 
with markers of nocturnal sleep disturbance, which are considered the hall-mark of SAHS 
pathophysiology [Lacasse et al. 2002b]. Perhaps the only evidence for criterion validity 
for the SF36 comes from large population studies suggesting that patients with severe 
SAHS (higher AHI levels) tend to report lower HRQL scores in multiple dimensions 
compared to patients with milder disease [Finn, et al. igg8b], but only in the case of the 
Energy/ Vitality dimension of SF36 is there a demonstrable relationship [Baldwin et 
al. 2001]. 
There have been differences in reporting of results of SF36 questionnaire scores between 
researchers. While the predominant way has been to measure the score (o-loo) and run 
parametric tests of significance, more recently there has been a trend to report effect sizes 
(difference in scores/standard deviation). 
6.4.3 SF36 & EuroQol 
Compared to normative population data (age and sex matched) baseline SF36 scores in 
the study population showed significant HRQL deterioration in almost all HRQL sub- 
scales. The lowest scores were recorded in Social Functioning, Energy/ Vitality and 
General Health in both men & women. Men also reported lower scores in Bodily Pain and 
Physical Functioning. SAHS patients are known to suffer the consequence of daytime 
fatigue and somnolence on their work and personal life, hence they are likely to report 
lower scores in the mental health dimensions including Energy/ Vitality and General 
Health dimensions of SF36 [Finn et al. 1998a] and when using the mental health 
instruments (GHQ28 & HADS). 
In the Sleep Health Heart Study surveying nearly 6ooo subjects, HRQL was assessed 
using the SF36. Baldwin et al found that in moderate SAHS lower scores were reported 
predominantly in the energy/vitality dimensions while more severe SAHS patients 
reported a more multi-dimensional decline, although no clear relationship with nocturnal 
PSG parameters were identified [Baldwin et al. 2001]. Surveys have also shown that 
SAHS patients tend to perceive almost equivalent HRQL decline as do patients with other 
chronic diseases [Baldwin et al. 2001]. Smith et al reported lower scores in almost all 
dimensions of SF36 in SAHS patients, although mainly in Energy/Vitality and Social 
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Functioning compared to a normal population. SF36 has also demonstrated sensitivity to 
the correction of nocturnal sleep apnoea by CPAP after 6 months with Energy/Vitality 
scores returning to expected normal values but not Social Functioning [Smith and 
Shneerson 19951- In an uncontrolled trial with 29 SAHS patients given 8 weeks of CPAP 
therapy DAmbrosio et al reported improvement in energy/vitality, social functioning and 
mental health dimensions of SF36 and similar to my findings also reported no 
relationship between SF36 parameters with physiological markers of SAHS disease 
severity [DAmbrosio et al. 1999]. 
In a similar RCT, Ballester et al randomised SAHS patients to conservative therapy 
(weight loss and sleep hygiene) or conservative therapy + CPAP. They measured HRQL 
using the SF36 and found the maximum decline in Energy/ Vitality and Social 
Functioning which improved among CPAP patients after 3 months of treatment. The 
likelihood of experiencing a treatment response was reported to be 6 times that in the 
patients given conservative treatment (range for odds ratios 2.5 to 17-5) [Ballester et al. 
19991. 
The proportion of SAHS patients at baseline reporting moderate problems in usual 
activities, pain discomfort and anxiety/ depression dimensions of the EuroQol 
questionnaire remained unchanged at the end of the trial phase. The EuroQol-HT 
similarly showed a lower mean score than UK population norms (66.8 vs. 83). This 
demonstrated a moderate improvement in patients treated with CPAP at the end of the 
trial (effect size = 0.4, p=o. oog), although still not reaching population normal values. 
Compared to the SF36 questionnaire this demonstrates a lack of sensitivity to change in 
the EuroQol questionnaire, especially in the SAHS patient group. This may be due to the 
inherent properties of the EuroQol which is designed as a simpler HRQL assessment tool 
with an emphasis on physical functioning fienkinson et al. 1997c]. However, both these 
questionnaires have demonstrated evidence of HRQL deterioration even in chronic 
conditions such as irritable bowel syndrome [Akehurst et al. 2002], osteoarthritis of the 
knee [Brazier et al. 1999], stroke [Dorman et al. 1998] and inflammatory bowel disease 
[Konig et al. 2002]. 
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However in patients with chronic fatigue syndrome, both the SF36 and EuroQol are 
reported to being over sensitive to the impact of the disease on mobility and physical 
functioning [Myers et al. 1999]. In head -to-head comparisons between the EuroQol and 
SF36, studies have suggested that although it has a better response rate compared to 
SF36, the EuroQol showed a lower sensitivity for transitional health states and a floor 
effect in measurement of lower health states compared to the SF36 [Brazier et al. 1993b]. 
In SAHS patients the EuroQol has been found to be insensitive to the HRQL decline 
suffered both at baseline and after treatment when compared to SF36 and the Functional 
Limitation Profile [Jenkinson et al. 19981. Similar insensitivity has also been reported in 
patients with multiple sclerosis [Nicholl et al. 20011. It is not unusual for different HRQL 
tools to show discrepancy in measuring the condition-specific deterioration in general 
HRQL similar to that seen in this case [Crockett et al. 1996]. In a review of HRQL tools, 
the authors concluded that there were perhaps no uniformly 'worst' or 'best' performing 
instruments. The decision to use one over another, to use a combination Of 2 or more, to 
use a profile and/or a preference-based measure or to use a generic measure along with a 
targeted measure should be driven by the purpose of the measurement. In addition, the 
choice may depend on a variety of factors including the characteristics of the population 
(e. g. age, health status, language/culture) and the environment in which the 
measurement is undertaken (e. g. clinical trial, routine physician visit) [Coons et al. 2000]. 
In the case of SAHS patients EuroQol showed a lack of sensitivity and discriminant 
properties hence is likely to be unsuitable for use as an outcome measure in health 
technology appraisal. 
While the SF36 dimensions of Energy/Vitality and Social Functioning showed both 
sensitivity and discriminated between the groups on the basis of treatment response. The 
SF36 may still demonstrate uncertainty in measuring the impact of competing 
technologies in different patient groups, due to the variable amplitude of the responses 
seen in different sub-dimensions. The physical sub-dimension scores of the SF36 failed 
to return to population norms after CPAP treatment suggesting that the deterioration 
seen at baseline were either unrelated to SAHS and / or CPAP treatment did not impact 
on these dimensions. 
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6.4.4 Mental Health 
6.4.4.1 Cases versus non-cases 
Both the GHQ28 and HADS identified proportions of cases with significant psychological 
morbidity in the study population but with a discrepancy between them. The majority of 
SAHS patients were classified as 'cases' based on the GHQ28 while only a quarter were 
classified as having 'anxiety/ depression' by the HADS instrument. The prevalence of 
anxiety (19%) and depression (21%) was similar to those seen in patients with acute 
coronary related chest pain in a survey using HADS [Goodacre, et al 2001]. In addition to 
anxiety and depression, the GHQ28 also measures psychiatric co-morbidity due to 
somatic symptoms and social dysfunction, which may account for the higher prevalence 
for psychiatric co morbidity. Patients on chronic haemodialysis report a high prevalence 
of psychological co-morbidity using the GHQ28 [Petrie 1989] (far less than SAHS 
patients), although the GHQ has been reported to be less sensitive than other screening 
tools like the mental health inventory and somatic symptom scale in primary care 
[Weinstein et al. 1989]. 
The only GHQ28 sub-scale which showed a significant relationship with both HADS 
subscales was GHQ-D (severe depression). GHQ28 is perhaps more comprehensive in its 
assessment of psychiatric morbidity secondary to a physical illness then the more specific 
HADS system. In a similar study examining psychiatric disability secondary to physical 
illness there was no significant difference between the screening properties of HADS and 
GHQ28, however GHQ was considered more specific for the diagnosis of depression 
[Clarke et al. 19931- 
Compared with the mental health sub-scales of the SF36 (VT, MH, SF, RE and GH) there 
were significant correlations seen with GHQ28 and HADS scores, as has been reported by 
other researchers [Failde I. et al. 2000]. 
Patients with significant depression or psychological co morbidity have a lower utility of 
health, physical and social functioning and a worse outcome [Wells et al. 1999]. Hence 
one of the benefits of using screening tools in non-psychiatric practice [Wilkinson et al. 
1988] is that they tend to increase the sensitivity of identifying the prevalence of 
psychological distress and hence offer an opportunity for appropriate therapy. This was 
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demonstrated in a primary care survey where the diagnosis of depression and psychiatric 
morbidity was doubled when GHQ was used in screening 16oo patients and compared to 
physician led diagnosis [Smith 1998a]. 
In common with the generic tools, both the HADS and GHQ28 did not show any 
predictable relationship with PSG parameters of SAHS disease severity except for HADS- 
D (depression) scale and sleep latency. Although, sleep onset insomnia is a recognized 
feature of depressive illness, in patients with sleep fragmentation and sleep debt due to 
apnoeas/ hypopnoeas the inherent short sleep latency may even be reversed by the effect 
of co-existent depression. 
At the conclusion of the trial phase there was a significant decline in all the 4 GHQ28 and 
2 HADS sub-scale scores for patients given CPAP therapy. The number of patients on 
CPAP reporting psychiatric co-morbidity was reduced significantly. Both these 
instruments with a high specificity for psychiatric co morbidity demonstrated a significant 
improvement not only in mental health status but also a decline in psychiatric co 
morbidity in the absence of behavioural / formal psychiatric therapy. This is perhaps 
strong evidence in favour of sleep abnormality (both insomnia & sleep fragmentation- 
hypersomnia) being an aetiological factor for depression [Breslau et al. 19951 and 
psychiatric illness. Even a reversal of the sleep fragmentation for a short 3 month period 
is enough to reverse severe depression symptoms in these patients [Millman et al. 19891 
and the effect may be preserved for 24 months. 
Unlike the CPAP group there was a distinct worsening of GHQ-D (severe depression) 
scores seen in lifestyle patients, which may be a manifestation of the disappointment 
developing from a failure to improve symptoms in these patients. There is however a 
mixed picture with some patients on lifestyle strategy reporting improvement in somatic 
symptoms, which may be a placebo effect or due to sleep hygiene/ weight changes. 
HT, 4 in SAHS; PbD tberis Indrand Chakrawrne 2005 212 
Chapter VI: Health related quafity ofKfe assessment 
6.5 CONCLUSIONS 
Patient preferences, which should ideally drive treatment decisions, are related to mental 
and social health nearly as much as they are to physical health. The contribution of 
mental health to preferences is known to be stronger in patients with chronic conditions. 
Thus, medical practice should strive to balance concerns for all three health domains in 
making treatment decisions, and health care resources should target medical treatments 
that improve mental and social health outcomes [Sherbourne et al. 1999] as well as 
physical health. Thus patients with SAHS not only suffer the physiological consequences 
of sleep fragmentation and consequent EDS but also demonstrate lower HRQL scores in a 
multi-dimensional fashion. The adverse HRQL impact is mostly visible in mental health 
dimensions of SF36 (energy/ vitality, social functioning, mental health and general 
health), EuroQoI (anxiety/ depression, usual activities, pain and discomfort), GHQ28 and 
HADS instruments. These HRQL effects show a significant improvement with CPAP 
treatment but remain unrelated to PSG variables of SAHS severity, suggesting a complex 
interaction. 
EuroQol shows a lack of sensitivity to the transition after CPAP treatment and in 
discriminant properties between the treatment groups, perhaps due to the focus on 
physical functioning, except in EuroQol-HT scores. 
The amplitude of mental health HRQL improvement after CPAP tends to vary depending 
on the tool used and population studied; hence this may not be very suitable for use as an 
outcome measure in health technology appraisal where comparisons with competing 
technologies are likely to be needed. 
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7.1 BACKGROUND 
Health care providers and those responsible for health policy and purchasing are 
increasingly expected to make their decisions on allocation of resources based on 
evidence of cost-effectiveness [Kopp 20001. Similarly, when an innovation is undergoing 
a health technology appraisal an evaluation of its economic impact (both costs and 
benefit) becomes imperative for health care decision making, in the face of increasing 
costs and limited resources. Compared to the early years (pre-199o) when very few cost- 
effectiveness studies were reported in clinical trials, more recently an increasing 
proportion of trials tend to include an economic evaluation exercise as part of the study 
design. Although there are many controversies regarding the methodology for collection 
and reporting of such 'economic' data this information is considered essential in current 
policymaking. Along with the uncertainties in collection of cost data there are 
uncertainties in the suitability of 'benefit' data used to measure the impact of treatment. 
There are inherent problems in making health policy decisions based on the measured 
impact on HRQL, as there is considerable variation in the magnitude of such impact in 
different HRQL dimensions and in different disease/ patient groups. Thus the problems 
of comparing competing technologies remain in health policy prioritisation. Some authors 
have recommended a combination of disease specific measures (which are expected to be 
more sensitive to change) with generic measures (comparable between diseases) to 
produce outcome variables [Ballester, et al. 1999]. This approach tends to detract from the 
measurement properties of each instrument and may undermine their construct validity 
and reliability. 
An alternative approach to using traditional life expectancy/ survival/ physiological data 
for example survival in patients given cholesterol lowering agents [Thorne 2000] or 
improved blood pressure control in type II diabetic patients [Anonymous igg8b]) is to 
use patient-based-preference measures to assess the impact of outcome in clinical trials 
and in HTA [Nathan 20021. In combination with the current 'gold standard' RCTs, 
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patient based preference measures (i. e. health status) have been increasingly used in 
many disease scenarios as a primary measure of treatment outcome for example the use 
of recombinant insulin-like growth factor in amyotrophic lateral sclerosis using SG 
approach [Ackerman et al. 19991; transmyocardial laser revascularisation for the 
treatment of refractory angina compared to conventional revascularisation [Campbell et 
al. 20011. 
Thus when information is needed about the overall value of a health care intervention, in 
a way that permits comparison with other interventions, then utilities tend to provide 
unified outcomes mostly in the form of QALYs [Torrance 1986b]. 
Theoretically it can be proven that an optimal allocation of resources within a constrained 
budget can be reached by considering cost-effectiveness ratios (CERs). While priority 
setting in the context of compatible alternatives may refer to the selection of more than 
one, possibly all, alternatives, a situation frequently seen in health care is of a set of 
incompatible alternatives where only one alternative can be selected. 
The arbitrary value that society attaches to a unit of effectiveness (e. g. a QALY) has an 
important impact on the priority ranking of medical interventions [Ament et al. 1997). 
Because the cost-effectiveness ratio (cost/QALY) is sensitive to the method chosen to 
calculate QALYs, results need to specify the appropriate method for calculating outcomes 
in order to produce comparable results [Gafni and Birch 1993a]. This part of the research 
presents the findings of individual patient preference methods to generate utility using 
the SG, TrO and the derived preference measures obtained from the EuroQol instrument 
in a cost-utility analysis of CPAP versus lifestyle intervention in SAHS patients. 
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7.2 RESULTS 
7.2.1 Health status measurement 
7.2.1.1 Baseline population health-status 
The baseline mean utility score was lower as obtained by the SG method; Mean U. g 
0.35(0.18), compared to the TrO utility scores; Mean Utto 0.59 (o. 17) and EuroQol 
derived utility; Mean Ueq 0.73 (o. 16), the frequency distributions are shown in figures 7.1 
& 7.2. 
The mean Utt. and Ug were significantly related (Spearman's correlation coefficient of 
0.32, P=0.02), the best relationship was obtained using a cubic model (Usg = constant + 
Utto3; r2=0.293, P=0.001). 
There were no significant correlations with the Ueq. The baseline U. g and Uq did not show 
any significant relationship with ESS scores, age, BMI, AHI, Al, sleep latency, REM 
latency and the lowest SaO,. recorded during sleep. 
The Utt, however was negatively related to AHI (linear regression coefficient -0.42, 
P=-0-005), sleep latency (linear regression coefficient -0.29, P=0.04) and positively to age 
(linear regression coefficient 0.42, P=0.004). 
The individual relationships between Utt,, and age and AHI are shown in figure 7.3. 
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Figure 7.2: Frequency distribution of the EuroQol utility scores. 
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Figure 7.3: Scatter plots demonstrating the relationship bemeen TTO utility 
and age/AHI 
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7.2.1.2 Effect of treatment on health status 
TAble 7.1: Effect Of trCAtment on utitity scores 
Utility methods CPAP CPAP Z p Ufe- Life- z p 
Mean SD style style 
(ed) Mean SD 
(sd) 
fil-sclinc S(; 1 0.19 0.38 1 
Post SG 0.49 0.27 -3.5 <0.001* 0.43 0.17 -2.2 0.03* 
Baschnc'1'1*() 0.55 0.21 0.64 0.13 
Post Tro 0.68 0.21 -4.0 <0.001 * 0.69 0.14 -19 0.04* 
Baschnc FuroQ)I 0.73 0.16 0.73 0.17 
Post EuroQol 0.77 0.14 -2.0 0.05 0.78 0.08 -1.8 0.07 
Z=Z --corts and p values using the Wdcoxon rank sum test 
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7.2.2 Correlations with HROL measures 
7.2.2.1 SF36 vs. health utility 
7.2.2.1.1 CPAP group: 
The only dimension of SF36 which demonstrates a significant relationship with health 
utility scores is change in physical functioning; Spearman's correlation coefficient = 0.39 
for change in standard gamble utility AU. g (P=0-017), for change in time-trade off utility 
A Utto ý 0.382 (P=0.034) and change in EuroQol utility AUeq = 0.479 (P=0.015). 
7.2.2.1.2 Lifestyle group 
Change in physical functioning score correlated with change in standard gamble utility; 
Spearman's correlation coefficient = 0.342, P=0.048. The change in weight (A weight) 
correlated with change in the following dimensions; 
ABP 0.51 P=0.002 
A SF o. 64 P<0.001 
A RE 0.43 p=0.012 
A mcs 0.44 P=0.01 
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7.2.2.2 Utility correlations 
7.2.2.2.1 CPAP group 
7.2.2.2.1.1 Standard gamble utility 
In the CPAP group, the change in Usg (A sg) with treatment was closely related to change 
in Utto (coefficient = 0.76, p<o. ool) and the following demographic and sleep variables 
at baseline; 
A sg with BMI = 0-48, P--'20-003 
A sg with neck size = 0.56, p<0.001 
A sg with ODI = 0.53, p=0.002 
A sg with AHI = 0.41, P=0-01 
A sg with sleep latency = -0-48, P=0-01 
A sg with lowest Sa02 in sleep = -0.5, P=0.003 
A sg with A SF 36-PF = 0-39, P=0.017 
A sg with A ESS scores = 0.44, p=0.02 
7.2.2.2.2.1.2 Time trade off utility 
A tto with A weight = -0-38, P=0.04 
A tto with BMI = 0.42, P=0.02 
A tto, with neck size = 0.36, P=0-049 
A tto with sleep latency = -0-37, P=0-047 
A tto with lowest Sa02 in sleep = -0-47, p=o. oo8 
A tto with A SF36-PF = 0.38, P=0.03 
A fto with A ESS = 0-55, P=0.004 
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7.2.2.2.2.1.3 EurOQol utility 
A eq with neck size 
A eq with SF36-RE 
A eq with SF36-MCS 
A eq with Ueq at baseline 
A eq with A SF36-PF 
A eq with A SF36-PCS 
= 0.44, Pý0.028 
ý -0-44, Pý0-04 
ý -0-49, Pý0-04 
-0-47, P-=(). 019 
0.48, p=o. oi5 
0-51, P=0.009 
Using the above variables in a linear regression model the adjusted r2 for A s9 ý 0.46, 
Pý0-03 and for A tto the adjusted r2=o. 62, P=0.003. Thus 46% and 62% of the change in 
the A sg and A tto respectively can be predicted by the change in the above variables. 
7.2.2.2.2 Lifestyle group 
In the lifestyle group patients there were significant correlations seen between the 
changes in Ug with change in Utt,. There were significant relationship between the change 
in Utt. and Ug with GHQ A (somatic symptoms) and HADS Anxiety subscales. The GHQ 
subscale B (self-care) and SF36 emotional role limitation (RE) subscale were related with 
the A tto as shown below; 
A sg with A tto 
A sg with GHQ-A 
A sg with HADS -A 
A sg with A SF36 PF 
A tto with GHQ-B 
A tto with GHQ-A 
A tto with HADS-A 
= o. 66, p=o. ool 
ý -0-55, P=0.01 
ý -0-48, Pý0-004 
ý 0-34, P=0.048 
ý -0-47, P=0.04 
= -0-76, p<o. ool 
= -0-54, P=0-01 
A tto with SF36-RE = 0.51, P=0-04 
A tto with SF36 A MH= -0-43, P=0-046 
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7.2.2.3 Measuring the agreement between SG and TTO 
methods 
The traditional method of examining the agreement between two measurement 
techniques has been to plot their values on a scatter diagram and assess their correlation 
and regression relationships. 
Figure 7.4 illustrates the cubic and linear regression between the SG and 770 utility 
values at baseline. However another recommended method [Bland & Altman 1986] to 
assess the agreement between two measurement techniques is by plotting their difference 
against the combined mean as illustrated in figure 7-5- 
Thus at baseline there is a weak correlation between the U. g and Utt. (Spearman's 
coefficient 0.32, p=o. oo8) and this is shown in the scatter plot of their difference with 
combined mean, figure 7.7 suggesting poor agreement between the methods (mean 
difference is 0.24 with SEM 0-03). 
In the CPAP group, when the change in SG and TTO values are plotted there is a stronger 
correlation (Spearman's coefficient o. 66, p=o. ooi), the cubic regression coefficient 
r2=0.262, P=0.017, and the plot of the differences Asg and Atto against their combined 
means shows that that there is considerable agreement between the methods (adjusted 
r2=0.223, P=0.004) as seen in figure 7.6. 
The mean of the difference between Asg and Atto was 0.07, SEM 0.03. No such 
agreement is seen in the lifestyle treatment group results. 
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Figure 7.4: Plot demonstrating the regression curves between baseline SG and 
TTO utilities 
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Figure 7. S: showing the relationship between the difference between SG and 
TrO scores at baseline (sg"odf) against their combined mean (sgttomn). 
OLO 
-2 
-4 
00 
SGTTOM 
HTA 0 -E4HT- P&D A&M IM&W-1 CAckno" 2005 224 
Ch2ptcr VI 1: EconomiC evaluation 
Figure 7.6: illustrating the relationship of the difference between ASG and 
NTTO (csgttdf) with CPAP treatment with their combined mean (csgttmn). 
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7.2.3 COST UTILITY ANALYSIS 
t sing tht: L*Klife-expýtaIICN tables, QALN's were calculated for patients in both groups 
and are shown in table 7.2. IMere were mean 5.2 QALYs gained with treatment in the 
CPAP group compared to i QALY in the lifestyle group based on U... While based on Un. 
there were 44 mean QALYs gained in the CPAP group compared to 1.3 QALYs in the 
lifestyle group. However, based on the Uq the QALYs gained did not reach statistical 
Table 7.2: Utilities and quality adjusted life years gained by intervention 
Me QALY un. QALY Uq QA. LY eq 
89 tto 
CPAP pre 0.31(0.2) 0. &c5 (0.2) 0. -0(0.3) 
CIP" 049 (0-3)** 5.2(7) 0.64 4.4(5) 0.76(0.3) 1.9(5) 
post 
(o. l)** 
lifestyie 0-38(0.2) 0.68(0.2) 0.72(0.3) 
pre 
tAfeot* 0-43 (Wr 1(3-1) 0.69 (0.1)* 1.3(2.6) 0.78(0-1) 1(4) 
post 
1, -N - I` -W. t 
#fTA - -fAHI. * 
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The mean costs used for the cost-utility analysis are presented in table 7.3 and include 
typical costs in the present study population based on Birmingham Heartlands Hospital 
finance department figures. 
In order to compare with published costs from other NHS regions, the table also presents 
typical costs based on two methods of diagnosis; a) basic which involves home based 
screening tests and b) intensive involving inpatient multi-channel sleep study [Chilcott, et. 
al 2000]. 
Table 7.3: Costs of diagnosis and treatment (1999) 
""Diagnosis & ki 4'costs BHH Costs ' Trent basic' 
in GBP(L) costs [Chilcott, 
2000] 
Tr"'e4iiiiiisivi-e 
costs [Chilcott, 
2000] 
Consultation 75 120 120 
Baseline lung function studies 125 60 60 
Blood tests 90 
Sleep studies* 1000 -100 '406 1- 
CPAP 350 250 250 
Mask'+ iubing 9 '50 
Total 1690 620 1000 
'AnnuAc9sis'I'', " 
CPAP peripherals + service 150 160 160 
ý6116w up'consultation 75 
Total 225 250 250 
Trent basic based on oximetry + ESS questionnaire + home CPAP trial + clinic follow up & Trent 
intensive includes a limited sleep study +a wakefulness test. 
The diagnostic cost for SAHS is the same in each group- E129o. The treatment cost for 
Group I patient is (CPAP) - E4oo, and annual maintenance cost Of F-150+75=F-225. For a 
Group II patient the set-up cost was f75+33x3 = P-174. 
Assuming Group II patients remained in the lifestyle intervention program, the 
maintenance cost is estimated to be E75+33 per annum, table 7.3. 
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Hence the mean(SD) total cost of treating the Group I patients on CPAP for the rest of 
their lives would be equal to E8920 (435) assuming that the CPAP machine will last a 
lifetime compared to Group II patients E4243 (228). 
7.2.4 Effects of uncertainty 
The effect of uncertainty on cost/QALY ratios at 95% confidence intervals for mean values 
is shown in table 7.4 and 7.5. The results indicate that even at extreme mean values the 
cost/QALY remains significantly better in CPAP treated patients (as measured using the 
SG and TTO methods). 
In Group II, ratios remain robust using the ITO method only although cost/ QALY is 
greater than P-loooo at the lower 95% level for mean benefit. The utility index measured 
using the EuroQol does not show sensitivity and reliability at extreme values for mean in 
either group. 
Table 7.4: Sensitivity analysis of benefits & calculated costs per QALY 
' ' 
'C'o"s't'/'Q"A" L"Y" roup ft '6' 
UýO QALYi"g ain ed QALYs gained 
Lower 95% 2.7 3304 0.4 10608 
Mean 4.4 2027 "13 
5264 
Upper 95% 6 1487 2.2 1929 
us? 
Lower 95% 2.9 3076 -0.05 
Mean -5.2 4243 
Upper 95% 7.5 1189 2.1 2021 
ut- 
Lower 95% -0.2 -1.2 
Meaný71,. 'ýý, ",, " 4695 1 4243 1 
Upper 95% 3.9 2287 3.1 1369 
Using 95% confidence intervals of mean QALY values 
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Table 7.5: 95% confidence intervals for mean costs and calculated cost/QALY 
G oupl siýQALVý-Giý'If 6"i/0"t- r 'Co ost ALY 
u"O Costs Costs 
Lower 95% 8038 1839 3779 2952 
Mean 8920 2041 4243 3315 
Upper 95% 9803 2243 4707 3677 
use 
Lower 95% 8038 1550 3779 3678 
Mean 8920 1720 4243 4129 
Upper 95% 9803 1891 4707 4581 
vcq 
Lower 95% 8038 4322 3779 3978 
Mean 8920 -4796 4243 4466 
Upper 95% 9803 5270 4707 4955 
7.2.5 Discounting 
The effect of variation on cost/QALY is presented in table 7.6 (based on 4,7 and io% rates 
for future benefits and costs). The cost/ QALY ratios remain significant and viable for 
Group I patients when measured using SG and TrO methods. 
The discounted mean costs in group I was: at o% 8920(435), at 4% 5550(133), at 7% 
4415(63) and at 10% 3756(33). While in group Il they were: at 0% 4243(228), at 4% 
3o62(96), at 7% 2628 (62) and at 10% 2364(46). 
The effect of discounting on cost/QALY ratios for group II patients were much wider and 
did not achieve statistical significance. 
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Table 7.6: Discounted benefits and cost/QALY ratios at 4,7 & 10'Y() rates 
Discount rate QALYs in Cost/QALY QALYs in Cost/QALY in 
Group I in Group I Group 2 Group 2 
Utto 
0% 4.4 (10) 2027* 1.3(0.7) 3264 
4% 2.5(0.5) 2313* 0.44(0.5) 7291 
7% 1.8(0.3) 2597* 0.33(0.4) 8760 
10% 1.4(0.3) 2889* 0.26(0.3) 10278 
U, g 
0% 5.2(1.2) 1716* 1(0.5) 4243 
4% 3.1(0.7) 1790* 0.7(0.3) 6062 
7% 2.2(0.5) 2007* 0.6(0.3) 7072 
10% 1.7(0.4) 2209* 0.5(0.2) 8487 
Ueq 
0% 1.86 4796 0.95 4467 
4% 0.95 5842 0.6 5103 
7% 0.67 6590 0.48 5475 
10% 0.51 7365 0.39 6062 
The independent samples Stud ent's t test * JXO. 05 Group I signific antly different to 
Group II. 
Assuming that CPAP machines will need replacing due to usage related deterioration or 
need replacement due to advancing technology in 5, to or 15 years and the cost of CPAP 
rising along with inflation, further calculations are presented in table 7.7 showing the 
increasing cost of CPAP replacement on cost/QALY ratios. 
As shown in table 7-7, the cost/QALY ratios remain viable and well below the UK NICE 
recommended threshold Of 2o, ooo GBP/QAIY [NICE 20041. 
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Table 7.7: Effect of incremental cost of replacing CPAP equipment at 5y, 
5+10y and 5+10+15y on cost/QA-LY 
Discount Present value for Present value for Present value for 
rate 5y replacement 5+ 10 y 5+10+15y 
replacement replacement 
Utto Cost/Q Cost/Q Cost/QAL 
ALY ALY y 
4% 381 2471 745 2623 1091 2767 
7% 11ý 1 2792 604 2952 810 3085 
10% 288 2889 496 3037 703 3185 
usg 
4% 381 1945 745 2064 1091 2177 
7% 331 2138 604 2261 830 2363 
10% 288 2338 496 2458 703 2578 
Cost of machine present ý400, at 5 years ý'464, at 10 vears ýý538 and at 15 years L623 
incremental values of machines based oil an inflation rate of 3() o 
Table 7.8: Comparing cost per QA-LY among different treatment scenarios 
Cost per QALY 
(1990) 
General practitioner advice to stop smoking 220 
Antihypertensive therapy to prevent stroke (45-65 940 
years) 
Pacemaker implantation 1100 
Hip replacement 1180 
Cholesterol testing and treatment 1480 
CPAP therapy for SAHS 1716-2027 
CABG (1, main disease + severe angina) 2090 
Lifestyle intervention for SAUIS 3264-4243 
Kidney transplantation 4710 
Breast cancer screening 5780 
1 leart transplantation 7940 
CABG (One vessel + moderate angina 18830 
Continuous ambulatory peritoneal dialysis 19870 
1 lospital haemodialysis 21970 
Adaptcd from Nlaynard I 11111 a al. 19961 
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7.3 DISCUSSION 
7.3.1 Overview 
To make the best use of scarce health care resources the diffusion and adoption of new 
technologies should be linked to the evidence of their clinical and cost-effectiveness 
[O'Callaghan ] [Harrison et al. 19971. Hence health technology appraisal involves an 
economic evaluation exercise. Although sleep related disorders are known to cause 
adverse effects to the individual their impact then extends to the society in general. 
However, the contribution from individual disease processes, i. e. the effect of SAHS on 
RTAs is difficult to measure in an RC`l'. Thus when the impact of treatment on SAHS 
patients is measured in clinical or HRQL terms, such an analysis tends to underestimate 
the benefits on society. 
However in terms of health care provision (involving resources for providing adequate 
diagnostic and treatment facilities) the benefits need to be measured on individual terms. 
With the assumptions that firstly, any patient specific tools are likely to underestimate the 
societal effects of the SAHS; and secondlv, that any health benefits provided for by CPAP 
or lifestyle intervention that is measured using patient specific tools is going to 
underestimate the societal benefits; the cost/ QALY analysis provided through this study 
would be over-estimating the costs and hence may show the health care intervention in 
less than favourable light. 
The second issue in HTA of SAHS involves the choice of an outcome measure for 
economic evaluation. This should not only show sensitivity to the health status effects of 
the disease process and rcliability but also be generisable to other diseases and/ or patient 
groups. This comparability would allow use in health policy and resource allocation 
among competing technologies. The results presented and discussed in previous chapters 
(chapters V& VI) demonstrate the difficult-,, in using either physiological markers or 
HRQL measures for such outcome analysis. 
It is possible to use an alternative patient preference approach to measure the impact of 
health care intervention on health status. The data presented in this chapter compares the 
two most commonly used tools with an indirect measure (EuroQol). Both the standard 
gamble (which incorporates the concept of risk) and time-trade off methods demonstrate 
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sensitivity to change and reliability in SAHS patients, unlike the EuroQol health index. 
Thus QALYs generated by these methods were used to provide the 'effectiveness' / benefit 
side of the cost/QALY ratio. 
Even with a potential negative bias because of the study design not incorporating the 
impact of societal benefit of intervention, the data from the Rcr demonstrates a cost/ 
QALY ratio for CPAP treatment of SAHS patients which is well within the accepted norms 
for an economically acceptable ratio below 20, ooo GBP [Birch and Gafni 20021. 
7.3.2 Methodological issues 
The main methodological issue with an HTA involves the perspective chosen for the 
economic evaluation. Sleep disorders cost the US economy almost V billion USD in 1988 
for RTAs, 72o billion USD for public transportation accidents and 15 billion USD due to 
work-related accidents [Leger 19941. Hence the economic benefit to society of treating 
patients with sleep related disorders is also potentially very large. On the other hand, it is 
estimated that diagnosis and treatment of sleep disorders in the USA cost an estimated 
27o billion USD in 199o. Although, these figures incorporate the impact of all sleep 
related disorders, with a prevalence of SAHS second only to that of insomnia, it can be 
presumed that SAHS contributes a major portion to the above costs. No such economic 
data is currently available for the UK. 
Compared to the potentially large benefit to society, that may be produced by allocating 
health resources to the diagnosis and treatment of SAHS patients, the restriction of the 
cost-effectiveness appraisal to the health service costs only, may produce a negative bias 
against the intervention. 
However, SAHS patients seek medical advice for the relief of individual symptorns of EDS 
and clinicians provide treatment, mainly for symptom relief. Thus in health care provision 
terms, the control of a patient's individual symptoms/ HRQL/ health status assumes 
prime importance and thus may be chosen as an outcome measure for HTA. 
The main factors driving the diffusion and adoption of this new technology is likely to be 
based on individual patient and clinician decisions for the relief of symptoms. Thus 
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ignoring the societal perspective for both costs and benefits of treatment of SAHS, may be 
appropriate in conducting an HTA for use in health service policy making. 
7.3.3 Utility measurement 
In SAHS patient group outcome measures such as survival, mortality, change in 
physiological measure of disease severity show uncertainty in measuring the impact of 
treatment. HRQL measures also demonstrate a wide variation in sub-dimensions between 
tools and magnitude of responses, thus posing inherent difficulties in comparison with 
competing technologies. While utility measurement, shows the distinct advantage of 
capturing the net impact of health care intervention in terms of the patient preferences. 
Both the traditional measurement of utility (based on the von Neumann & Morgenstern 
utility theory) [von Neumann and Morgenstern 19441 and the tinle-trade off method 
show significantly lower health status at baseline in the study patients. The Us, which 
involves an element of risk with a prospect of the respondent's health state worsening or 
even death occurring if a gamble fails produces lower results compared toTFO. This may 
be a reflection of either the severe degree of health status deterioration in these patients 
or the greater promise of a return to normality which leads to risk-taking behaviour. 
Firstly, in this RCT, SAHS patients were asked to consider failure of treatment to equate 
to a health state equivalent to death. Under risk- neut ral ity (which is a requirement of the 
utility theory) the utility of a gamble is equivalent to its expected value and the marginal 
utility of living in a given unit of time is the same regardless of when it occurs. As most 
patients are either risk-seeking or risk-averse this influences trade-offs between short 
term gains and long term survival and their interpretation. Thus the proportional time- 
trade off will under or over estimate the disutility of an inferior health state, depending on 
whether patients are either risk-seeking or risk-averse [Cher et al. 19971- IA)wer U, g 
results compared to Utt,, would indicate that Utt,, tends to under-estimate the distitility of 
health state demonstrating a net risk-seeking behaviour in this group of patients. 
Secondly, it is possible that this risk-seeking behaviour in the study patients with SAHS 
may be due to their prior knowledge that treatment failure may not lead to death/ 
equivalent state, hence creating a bias towards a risk-seeking behaviour more acceptable. 
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Others have reported higher scores for U. g compared to Utt. in patients with risk- adverse 
behaviour [Stiggelbout, et al. 19941- 
7.3.4 Validity 
Similar to ESS and HRQL scores presented in chapter VI, the U. g does not show any 
relationship with any of the physiological parameters at baseline and is seen to be 
independent of anthropometric variables. Unlike the Utt. which demonstrates a 
significant relationship both to AHI and sleep latency. This suggests criterion validity for 
the TrO method of assessing health status. 
Reassuringly, the outcome measures are not influenced by potentially confounding 
anthropometric variables except Utt. (which shows a relationship with age, demonstrating 
a disproportionately higher value with increasing age). Older patients when considering a 
diminished life expectancy as a trade off for health state improvement; tend to be biased 
towards preservation of the quantity of life, thus yielding inappropriately higher values 
for the health state. This discrepancy between the U59 and Utt, is shown to be best related 
by a cubic regression model in this study and explained by a power relationship. Other 
researchers have used different survival functions to adjust the TI70 values towards SG 
values [Martin et al. 20001. 
Given that none of the symptoms, HRQL effects and health state values for SAHS can be 
sufficiently explained by the physiological PSG parameters, it may be argued that there 
are yet unknown complex relationship between the disease process and its health effects. 
7.3.5 Impact of treatment 
However both these utility measures show discriminant validity after the treatment phase 
in measuring the impact of change. The change in U. g and Utto are shown to be 
significantly related to the baseline anthropometric, PSG, ESS and baseline HRQL scores. 
Thus the greater the severity of SAHS (PSG variables) and BMI the greater is the change 
seen with treatment. 
With CPAP treatment, both Utto and U. g show a significant improvement in health state. 
In terms of effect sizes the change is larger in U,, g (Ug effect size = o. 95, p<0.001 vs. Utto 
effect size= o. 62, p<0.001). This would again be compatible with the risk-seeking 
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behaviour seen in this group of patients. The change in Utt. and U. g were also shown to be 
closely related in CPAP patients suggesting that both were measuring the same change in 
health state with treatment. 
On the contrary, among patients on lifestyle strategy there was a modest change seen 
after completion of the trial. This could be a result of weight change and sleep hygiene 
modification strategies which were seen in the patient self-reported VAS scores for sleep 
quality and daytime sleepiness. Interestingly the change in Utt. and Usg scores in this 
group is shown to be related negatively to the psychiatric morbidity (higher scores on 
GHQ28, HADS and MH scales of SF36). This in turn suggests a lack of motivation and 
resistance to lifestyle changes in these patients with greater psychiatric morbidity, making 
it more likely that such strategies will fail. 
7.3.6 Euro0ol utility 
The Ueq is derived indirectly from a rating scale and hence has its roots in the basic five 
dimensions of mobility, self-care, usual activities, pain and anxiety/ depression. If SAHS 
does not significantly impact on these particular dimensions as has been seen in chapter 
VI with EuroQol scores, then it is unlikely that the derived utility will have discriminant 
properties. The results show a much higher baseline UN score compared to the Utt,, and 
U, g, which then changes minimally (not reaching statistical significance) in both the 
groups. Thus the EuroQol utility does not discriminate between the treatment effects seen 
with almost all other instruments in this RCT. 
The change seen in EuroQol index scores in liver transplant patients at 3 months were 
statistically insignificant when patients who died were removed from the analysis, 
suggesting a reduced sensitivity compared with most dimensions of the SF36 [Ratcliffe et 
al. 20021. The EuroQol index also reportedly failed to discriminate between the 
treatment effects in patients with benign hypertrophy of the prostate undergoing trans- 
urethral resection compared to SF36 which demonstrated greater sensitivity [Jenkinson 
et al. 1997a]. The magnitude of change measured by the EuroQol is also reported to be 
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small, suggesting that larger sample sizes may be necessary to demonstrate significant 
responses [Roset et al. 1999]. 
In other patient groups, where physical functioning (mobility/ self-care or pain) is 
reported to be important, the EuroQoI index has been shown to be both sensitive to 
HRQL decline and discriminatory to change on appropriate intervention; for example for 
patients on a waiting list for lung transplantation (baseline UN Of 0.31 in waiting list 
patients compared to o. 61 for single lung, 0.82 for double lung and o. 87 for heart-lung 
transplantation recipients) [Anyanwu et al. 20011, in patients with intermittent 
claudication [Bosch et al. 1999], inflammatory bowel disease [Konig et al. 20021, fracture 
neck of femur [Tidermark et al. 2002], advanced treatment for breast cancer [Conner- 
Spady et al. 2001] and rheumatic diseases [Hurst et al. 1997] also showing good test- 
retest reliability [van Agt et al. 19941. 
Valuation studies for the EuroQol have demonstrated that ability to perform usual 
activities (especially leisure activities) has a large contribution to the valuation in societal 
preferences [Taylor et al. 20011. Hence patients with chronic fatigue syndrome [Myers 
and Wilks 19991 and fibrornyalgia may be over-estimating their health disutility, while the 
index is less discriminant to patients with moderate osteoarthritis (Fransen et al. 19991. 
As in patients with stroke, where there was little correlation between the anxiety/ 
depression rating of EuroQol compared to SF36 [Dorman et al. 1999) (Dorman et 
al. 19981, the predominant effect of SAHS is seen in the mental health related quality of 
life; hence among SAHS patients EuroQol may be less sensitive to change. It is also 
possible that the relatively small study size in this RCT may be a reason for not observing 
significant change even in the CPAP treated patients. As other studies have shown that 
patients tend to derive higher scores for their health state valuations directly using the 
EuroQol then when derived via societal preferences [Polsky et al. 20011 [Selai et al. 19951. 
7.3.7 Costs 
The costs used in this analysis were based on the 'typical cost' of each investigation or 
intervention as calculated by the finance department of the hospital, and not a summation 
of the actual cost involved in treating each individual participant. The advantage of such 
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typical costs are the inclusion of a proportion of the overheads (building, maintenance, 
labour, intellectual costs) which are then standardised for cost generating activity per 
patient episode. For the size of the hospital and the level of care provided such costs are 
most likely to be similar in other hospitals within the NHS structure and hence are 
portable and comparable across NHS trusts [Chilcott. J et al. 2ooo]. As all participants in 
the trial underwent PSG a practice which is not usually followed for standard clinical 
practice the cost generated per patient was much higher than would be the case in real life 
situations both at BHH sleep clinic and in other similar hospitals. Hence cost data 
published in the report from three NHS trusts involving two different levels of 
investigation [Chflcott. J et al. 20001 (BHH E16go; Trent basic E620; Trent intensive 
F-looo) were incorporated in the cost/ utility analysis. The additional cost of replacement 
CPAP machines at 5, lo and 15 years was incorporated within the cost/utility analysis. In 
normal practice the CPAP machines are designed to last at least 10-15 Years with 
minimum maintenance, hence such additional capital cost for equipment is likely to 
increase the cost/ QALY ratio. 
However, even after including the above additional potential costs, the cost/QALY ratio 
for CPAP treatment in patients with moderate to severe SAHS remains well within the 
acceptable norm Of 20ooo GBP/QALY in the UK [NICE 20041- The cost/QALY ratios also 
remain viable and robust after testing for uncertainty and after discounting of both 
benefits and costs. 
Both the SG and TTO methods produced results which were comparable unlike the 
cost/QALY generated by the EuroQoI method. QALYs generated by lifestyle intervention 
in Group II were very small and although the costs were still within recommended 
thresholds [Birch and Gafni 2002]. 
Treatment of obesity has been rarely shown to have lasting benefits on morbidity and 
mortality or to improve the SAHS symptoms [Shneerson and Wright 2001] (Sampol et 
al. 1998] in the absence of CPAP [Barvaux et al. 20ool, although there is a reduction in the 
prevalence of hypertension [Kansanen et al. 19981, autonomic dysfunction and better 
control of diabetes [Anon. 1998]. Weight loss on its own has been shown to improve 
health state by o. o17/one unit change in BMI [Hakim et al. 20021. The addition of weight 
reducing agents with a low calorie diet may have a better probability of success but when 
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three large multi-centre trials were reviewed, the cost-utility ratio for weight loss even 
with the help of pharmacological agents (i. e. Orlistat) was found to range between 14,000 
to 132, Ooo GBP/QALY [Foxcroft and Milne 2oool and hence remains largely 
economically unviable. 
7.4 CONCLUSIONS 
The results from the cost-utility analysis show that treatment of SAHS patients (moderate 
to severe) with CPAP even for a short period of time is economically viable and that its 
impact may be reliably measured using the QALY approach generated by the traditional 
methods of SG and 7rO. The indirect derivation by EuroQol questionnaire has not been 
shown to be sensitive to the changes seen in SAHS patients and hence cannot be reliably 
used for measuring benefit or in economic evaluation. When QALYs are used in 
comparison of competing technologies one has to take into account the method of QALY 
generation and whether this method demonstrates validity, sensitivity and reliability as in 
the case of SG andITO in this study. 
Although obesity remains a major influence on the disability suffered by SAHS patients, 
current conservative strategies remain largely unsuccessful in achieving a sufficiently 
significant weight reduction to impact on the SAHS severity or HRQL disability. Where 
weight loss has been achieved, the net benefit in health status terms remains minimal. 
Although the costs involved in providing lifestyle intervention are well within the NICE 
recommended thresholds, larger studies are needed with longer term follow and with the 
addition of weight reducing pharmacological adjuncts. The addition of pharmacological 
agents to aid weight reduction are likely to increase the cost/QALY ratios further and 
make the option even less attractive to health planners [Foxcroft and Milne 2000]. Thus 
CPAP on its own remains a largely cost effective option for the treatment of these patients. 
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8.1 DIFFUSION OF CPAP- AN OVERVIEW 
CPAP therapy was first introduced as an innovation in early 198os in Australia [Sullivan 
et al. ig8i]. It was an innovation created by an academic team led by Professor Colin 
Sullivan, mainly to satisfy a need for a new modality of treatment, for an increasingly 
recognised condition, which was less invasive, caused less morbidity, was reversible and 
would in turn hold the potential for wide applicability. 
Compared to the surgical approaches of laser UVPPP or facio-mandibular mobilisation 
CPAP provided many distinct advantages; namely a simple underlying principle of 
stenting the airway with positive airway pressure, a simple construction with available 
motors/ air compressors, tubing and moulded plastic masks, trial ability without any 
irreversible adverse effects and freedom from pain, bleeding and the many complications 
of surgery/ anaesthesia. 
As it was born within an academic hospital, with direct trials on patients providing the 
initial evidence of its efficacy, it found easy acceptance within the user/ adopter 
community in Australia without the need for extensive marketing. In 1986, Professor 
Colin Sullivan and the Baxter Centre for Medical Research started work on commercial 
production of the CPAP device which was launched in 1988. A year later the management 
headed by Peter Farrell bought out CPAP from the parent company and formed the 
ResMed Inc aided by Australian government grants Of 200,000 (Australian Dollar= 
AUSD). 
The potential for the commercial utilisation was so great in the target population which 
included 2-4% or more of the adult population that it created the impetus for the birth of 
a new industry arm and ResMed Inc grew to have 74 branches worldwide with a net 
revenue of 5o million USD in 1997/98 recording a io year annualised growth rate Of 25% 
[ResMed Inc, 20031. Although a global company, ResMed Inc has 83% of its business in 3 
countries (50% in USA, 22% in Germany & ii% in France). It has been listed as the 
Fortune Magazine's top loo hot growth companies from 1999-2001 [irasia. coM 20021. 
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At the same time as CPAP machines became commercially available outside the tertiary 
academic institutes; by 199o sleep centres in the UK had grown in number and saw a rise 
in the referrals from pripary care physicians for the treatment of SAHS. There was an 
enhanced interest in the treatment of patients with SAHS, as the CPAP treatment 
modality allowed professionals, other than surgeons, like Respiratory Physicians the 
ability to treat this condition, previously beyond their reach. The Royal College of 
Physicians estimated that there was a large deficit in the availability of diagnostic and 
treatment centres in the UK [Stradling 19931. 
There have been considerable improvements (re-invention) in technology in the last 
decade with the CPAP machines becoming smaller, lighter and quieter. The masks which 
were initially moulded to individual patients were then manufactured in standard sizes 
and facial shapes. As the seal of the mask to the face was a serious factor for both patient 
comfort and efficient delivery of the positive pressure, the traditional mask, went through 
rapid cycles of change. They gradually became lighter, more comfortable and versatile 
leading to improvement in the quality of sleep on CPAP machines. The addition of heated 
humidification has also improved patient acceptance and comfort [Neill et al. 20031. 
In the last five years there have been very few changes in the CPAP machine technology 
except for the introduction of bi-level machines and automatic titrating devices for 
general use. There exists a physiological variability in the upper airway resistance within 
the same night and over a period of time in patients depending on stage of sleep, external 
factors such as alcohol consumption or exhaustion or internal variation in body weight 
collar size. 
Automatic titrating devices were conceptually attractive but have yet to demonstrate 
sufficient improvement in patient comfort or compliance [Teschler et al. 2000] to 
warrant the extra expenditure over and above the fixed pressure type CPAP machines in 
widespread use [Boudewyns et al. 19991. These auto-CPAP machines have failed the 
request for classification as a separate device priced between CPAP and the more 
expensive Bi-level ventilators in the Medicare reimbursement classification [Sullivan 
20041. This may be a factor in slowing down of the adoption of this variation of CPAP in 
the USA which remains the largest market for these devices. 
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Interestingly there are significant differences in the annual growth of CPAP market in the 
different countries; 26% in the US. A, 15% in Germany-France, 9% in Spain and <5% in the 
UK and this position has remained unchanged since 1995/96 [Newby 20021. 
It has been reported that the facilities for the investigation and treatment of patients with 
SAHS in the UK are subject to severe financial constraints and the availability of CPAP 
treatment lags markedly behind that in other countries [Gibson et al. 1998]. In 1995/96 
an estimated 2310 CPAP units were provided for the treatment of SAHS patients and 7071 
CPAP machines were in use out of an estimated 18o, ooo needing CPAP therapy [Gibson 
et al. 1998]. A recent yet unpublished survey suggested that ioi sleep centres in the UK 
were prescribing an average 6ooo CPAP machines with a total Of 37000 patients 
established on CPAP machines. The comparative figures for year 2001 were 30,000 units 
for Germany, 15000 units for France and 8ooo units for Spain [Newby 2002]. 
This variation in CPAP provision among countries in Western Europe and USA is 
considered to be due to a variety of vital differences between the health care structures 
and funding. Although there is no published evidence on the diffusion of CPAP, empirical 
data would suggest that are a variety of potential influences. 
In the USA there are active public awareness programs such as the National Sleep 
Awareness Week [Anon. 2004a] & Sleep in America Polls. These are initiated by both 
government agencies (National Sleep Disorders Centre) and non-governmental bodies 
(National Sleep Foundation) [Anon. 2004b]. There appears to be a comparative lack of 
awareness among the general public in the UY, on the symptoms of sleep deprivation due 
to SAHS. This is usually manifest by the average time between a patient becoming aware 
of his daytime hyper somnolence or being told by a partner about breathing pauses 
during sleep to reporting to his/ her primary physician for help being 2 to lo years. 
Public awareness is dependant on media interest which has been variable and usually 
linked to sleep related accidents like after the events leading to the loss of life associated 
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with the Selby train crash in 2001 [Anon. 2001]. There has been some increase in the level 
of local public awareness and knowledge with the activities of the patient self-help groups, 
usually inspired or supported by larger sleep disorder centres (e. g. Sleep Apnoea Trust) 
[Anon. 19941- 
Since the popularity and availability of the internet among the general population there 
has been an increase in public awareness from medical/ health orientated websites 
[Bernhardt et al. 2004; Siow et al. 20031. However there are a few professionally 
supported and run web sources of information on health among many more either 
commercially orientated or not run by professionals [Childs 20041. However, this new 
technology also hides several shortcomings, such as: (i) uneven quality of medical 
information available on the internet; (ii) difficulties in finding, understanding and using 
this information; (iii) lack of access for the unconnected population; and (iv) the potential 
for harm and risks of over-consumption [Benigeri et al. 20031. 
When a patient becomes aware of sleep related breathing disorder or seeks help for 
daytime somnolence his / her contact is with his primary care physician. In the UK, there 
is a variable degree of knowledge among primary care physicians in sleep disorders and 
hence many patients are known to have waited for over two years before being referred 
onto Sleep Disorder centres. Again there is a geographical variability among primary care 
physicians depending on public awareness and the pro)dmity to sleep diagnostic centres. 
There are an estimated 25000 patients referred to 112 sleep centres in the UK annually 
with 73% being referred with snoring and / SAHS [Gibson et al. 19981. 
In secondary care, there is wide variation in the level of personal interest among 
Respiratory Physicians and Otolaryngologists who have traditionally been referred 
patients with snoring and sleep disordered breathing. Hence the facilities for diagnosis 
and treatment for sleep related breathing disorders have varied across the country 
dependant on local champions, expertise and funding mechanisms and priorities. The 
absence of a UK national framework is perhaps further compounded by a lack of formal 
appraisals from bodies such as NICE and may have contributed to heterogeneity in 
availability of facilities for diagnosis and treatment. 
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Although, there had been many studies showing that CPAP was efficient in neutralising 
the nocturnal observed apnoeas and hypopnoeas, there were few well designed RCTs 
aiming to tease out the influence of confounding co-morbidities and obesity. In 1997 a 
review into the health effects of sleep related breathing disorders and the effectiveness of 
treatment undertaken by the Nuffield Institute in Leeds in association with the University 
of York reported that there was little evidence to support the prescription of CPAP except 
in the case of improving neuro-cognitive function and EDS. This perhaps led to a change 
in the funding situation for CPAP machines in various parts of the UK leading to longer 
waiting times and fewer patients receiving treatment for SAHS [Wright et al. 1997a] 
(Stradling 1997]. 
In a Royal College of Physicians survey in 1998,34 Out Of 43 respondents from Sleep 
diagnostic and treatment units in the UK reported serious financial hurdles in funding the 
service, with 6 physicians reporting complete rejection. Another 14/43 physicians 
reported imposition of limits on CPAP provision, which were below expected numbers 
[Gibson et al. 1998]. 
Only an estimated io% of the diagnostic tests for SAHS are paid for privately by 
individuals in the UY, with costs ranging from F-6oo to F-looo. The NHS reference cost 
for elective overnight studies ranges from E204 to E2818 with a mean Of F-532 
[Anon. 2002a]. Unlike in the UY, in North America, funding of investigation and 
treatment of SAHS is predominantly reimbursed by health insurance contributions. 
Industry estimation of the worldwide non-surgical SAHS treatment market in 2000 was 
315 million USD (210 million GBP) with Respironics; holding 54%, ResMed 22%, Nellcor 
Puritan Bennett 16%, and others 8% market share. This was projected to rise to 56o, 
million USD (373 million GBP) by end Of 2001 [Mack 1999]. 
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The probable causes of the relative lagging behind of the UK market compared to France, 
Germany and the US markets in CPAP use other than the public and professional 
awareness gap described above are: 
Lack of standardised facilities and national guidelines/ practice framework for 
the diagnosis of SAHS in the secondary care level [Gibson et aL 1998] [Gibson et 
al. 19971. 
Patients being variably referred to Otolaryngologists, Respiratory physicians, 
Neurologists or Metabolic physicians from primary care, possibly leading to delay 
in diagnosis and treatment. Even in conditions where national and international 
guidelines have been widely disseminated as in the case of Asthma, the 
management of patients has been shown to vary widely [Wright et al. 20031. 
3. Restrictive governmental funding perhaps as SAHS is not perceived to be a life- 
threatening or debilitating condition like heart disease, diabetes mellitus, breast 
and lung cancer [Gibson et al. 19981. 
4. Relative absence of consensus guidelines (till the recent publication of the SIGN 
document [Scottish Intercollegiate Guidelines Network 20031), in the diagnosis 
and management of SAHS. 
5. Absence of accredited courses for training of technicians in Sleep investigation 
and reporting in the UK hence restricting capacity even of tertiary sleep centres to 
cope with patient/ referral numbers [Gibson et al. 1998]. 
6. Lack of concerted lobbying capability among medical professionals, scientific 
organizations and patient self-help groups unlike other chronic diseases such as 
heart disease (British Heart Foundation)[Shillingford 1984] and asthma 
(Australian National Asthma Campaign) [Comino et al. 19971. 
7. Lack of popular and powerful national patient self-help groups unlike the 
National Sleep Foundation [Anon. 2004b] in the USA. 
8. Classifying CPAP as equipment for loan to patients, thereby restricting the budget 
within restrictive business plans unlike drugs or masks which are considered 
'disposable' although relative costs are comparable (E250-300 for a CPAP 
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machine with a life Of 10-15 years compared to E85 X2 per annum for disposable 
masks). 
The principles of the diffusion of innovation theory provide a framework for an 
investigation of the process of diffusion of CPAP within the highly regulated and 
managed NHS health care sector. The Respiratory Physicians in DGHs who are likely 
to be providers of sleep diagnostic and treatment facilities and considered to be 
disseminators of specialist knowledge about this treatment modality are likely to be 
early adopters or early majority (in their adoption behaviour) They may provide 
insights into the early diffusion stages, innovativeness, innovation -decision 
formation, innovation period. Some of them are likely to act as change agents 
catalysing diffusion/ adoption behaviour through their links with academicians, 
social networks both with innovators and early majority and leading by example. 
While the primary care physicians, who are likely to be in the late majority, are 
dependant on diffusion reaching critical mass, dependant on local availability of 
specialist knowledge and facilities, inter-personal networks for the diffusion of 
information to assist them in their adoption decision for appropriate referral. 
Therefore the aim of the diffusion of CPAP research was to investigate the influences 
among the whole spectrum of early adopters to late majority i. e. secondary care 
specialist centres to the general practitioner who remain at the patient-health care 
interface. This would help understand the positive and negative influences and the 
rate of diffusion of innovation within the NHS health care sector. 
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8.2 PRIMARY CARE SURVEY 
8.2.1 Alm 
This survey was designed to collect and assess data on the following; 
1. Demographics of GPs and their practices. 
To assess the Primary care physicians direct experience of dealing with SAHS 
patients. 
3. To assess their opinion on the relative (clinical) effectiveness of three principal 
therapies available for the treatment of SAHS. 
4. To assess the characteristics of CPAP as a healthcare innovation. 
5. To identify the knowledge of primary care physicians on the e2dstent pathways for 
knowledge diffusion on CPAP or a similar innovation in the NHS infrastructure. 
6. To assess the primary care physician's opinion on the future of therapy for SAHS 
patients. 
8.2.2 Survey design & protocol 
8.2.3 Pilot study 
A questionnaire was designed with 4 items on demographics & practice parameters (Q1 
age group of respondents, Q2 sex, Q3 type of practice- single/ multiple, teaching/ non- 
teaching & urban/ rural). Question 5&6 established whether the respondents had 
patients with SAHS in their practice and for how long they had referred patients with 
suspected SAHS, in order to establish respondents' experience with SAHS patients. 
Questions 7-11 were designed to determine respondent's opinions regarding the 
effectiveness of the therapy options for SAHS patients (Q7), acceptability to the patient 
(Q8), ease of use of CPAP (Qlo) and characteristics of CPAP as an innovation (Q9 & ii). 
Question 12 was designed to establish the pathways of knowledge diffusion bearing the 
most influence on the respondent's opinion regarding treatment of patients with SAHS 
and the final question 13 asked the respondent's view on the likely future of treatments 
for SAHS. 
The pilot questionnaire survey was conducted among 100 randomly selected primary care 
practices in London and Hertfordshire. There was a standard covering letter explaining 
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the purpose of the survey and reply paid envelopes were provided for returning the 
questionnaires. Respondents were asked to comment on the questionnaire and any other 
free text comments they wished to offer on the subject. No incentives were offered for 
completing the survey and no follow up questionnaires were sent to non-responders, as 
there was no way of identifying non-responders. There was a 35% response from this pilot 
survey and the final questionnaire was edited in the light of the respondent comments. 
A major change occurring at this time in UK primary care was the introduction of Primary 
care Trusts (PCTs) with centralisation of the purchase decisions on innovations and the 
pooling of individual specialist interests/ skills into a unitary authority. Hence the 
individual respondents' demographic characteristics, experience with SAHS and practice 
parameters were becoming less relevant within the larger decision-making processes 
introduced within each PCT. 
8.2.4 Primary care survey 
The re-designed questionnaire version II was targeted to the PCTs and had the following 
stnicture; 
QI&2: asked whether there were SAHS patients in the practice and how long patients 
were being referred with suspected SAHS to specialist centres, to establish the depth or 
duration of experience 
Q3-6: investigated the respondent's opinion on the primary indication for offering 
treatment to patients with SAHS, the clinical effectiveness of CPAP in the context of the 
available treatment options and characteristics of CPAP as an innovation. 
Q7-9: determined current pathways of knowledge diffusion, self-assessment of 
innovativeness and views on existing technology diffusion process. 
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Qlo: asked the respondent their opinion regarding the factors influencing the diffusion 
and adoption of CPAP 
The number of items was reduced from 13 in the pilot questionnaire to io, in order to fit 
within the 2 A4 page model and improve response rate. The basic framed design with the 
same colour coding was kept as the pilot questionnaire. 
The questions regarding the demographics of the respondent and the practice parameters 
were removed as the target for this survey was the newly formed PCr. The questionnaire 
had the name of the PC7 integrated in the heading hence identification of responders/ 
non-responders was ensured, although the individual respondent on behalf of the PCT 
would remain anonymous to the investigator, thus ensuring confidentiality. 
The questionnaires were mailed to 300 PCTs, addressed to the Chief Executive, with a 
personal covering letter requesting a response from physicians with special interest in 
SAHS or with responsibility for purchasing services for new innovations. No incentives 
were offered and the reply paid (stamped) envelopes was addressed to the investigator 
(IC) at the University of Warwick. A second mailing was undertaken 6 weeks later to non- 
responders with a covering letter. 
8.2.5 Data analysis 
Data from completed questionnaires was entered into a spreadsheet (SPSS) which 
allowed grouping and calculation of frequencies and proportions. 
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8.3 SECONDARY / TERTIARY CARE SURVEY 
8.3.1 Introduction 
A questionnaire survey was conducted among 261 Respiratory Consultants in the UK 
based on the Directory of Respiratory Services published in 2ool. Each secondary/ 
tertiary care hospital received one questionnaire addressed to the physician with special 
interest in Sleep/ ventilation services. In secondary care centres where special interest in 
Sleep services was not listed in the directory, the questionnaire was addressed to the 
physician listed first, with a covering letter requesting that they forwarded the 
questionnaire to colleagues who may have a special interest. 
No incentives were offered and reply paid envelopes were provided for returning the 
questionnaire to investigator (IC) at University of Warwick. A follow up questionnaire was 
sent after 6 weeks to non-responders. 
8.3.2 Questionnaire aims 
1. To assess the respondent's personal experience with SAHS patient management 
and the hospital's availability of facilities for the diagnosis & treatment of SAHS 
patients. 
2. To assess the respondent's opinion on the comparative 'clinical' effectiveness of 
the four therapeutic options available for SAHS patients. 
3. To assess the respondent's opinion on the characteristics of CPAP as a healthcare 
innovation. 
4. To assess the respondent's experience with the pathways of knowledge diffusion, 
innovativeness and social networks within the NHS infrastructure. 
5. To assess the respondent's opinion on the factors influencing the diffiision and 
adoption of CPAP in their own hospitals and healthcare regions. 
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8.3.3 Questionnaire content & design 
The questionnaire was designed in monochrome with frames and boxes for ticking 
responses with 16 questions. The questions were in 3 groups; 
About the hospital/ firm section contained 7 questions on type of hospital, 
facilities for diagnosis and treatment of sleep breathing disorders, SAHS 
treatment facilities available, patient load and CPAP provision and estimated 
expansion in service / patient numbers. 
2. The next section comprising QS-1i, explored the respondents opinion on SAHS 
treatment, efficacy & clinical effectiveness and characteristics of CPAP as an 
innovation. 
3. The final section comprising Q12-15, explored the knowledge diffusion pathways, 
innovativeness, existence of social networks and the current state of play with 
adoption of CPAP within their institutions. The final question (Q16) asked the 
respondent on their view about the future of CPAP in the treatment of SAHS 
patients. 
8.3.4 Data analysis 
Completed and returned questionnaire data was entered into an SPSS datasheet and 
frequencies calculated along with qualitative assessment of the implication of responses. 
8.4 Industry and patient self-help group surveys 
Attempts to contact the representatives of the CPAP industry and patient self-help group 
met with little success both by letter and telephonic contact. The only response was from 
the General Manager of one of the CPAP manufacturing companies who granted a 
comprehensive interview on the industry perceptions and priorities in this sector relevant 
to the UK. 
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8.4 RESULTS 
8.4.1 Primary care trust survey 
8.4.1.1 Characteristics of the Respondents 
There were 136 responses (45%) received from mailings to 300 Chief Executives of PCTs 
in England & Wales. Table 8.1 shows the age-group distribution of the respondents. 
Majority of respondents were male with a 2-7: 1 male to female ratio. 
Table 8.1: Age group of respondents 
Group, Fr"eq'uen'c"y-"' 
<30 years 0 0 
30-39 years 20 15 
40-49 years 63 46 
50-59 year's 49 36 
>60 years 4 3 
All but 3% of respondents were in a practice with multiple partners, 58% were in practices 
classified as 'teaching practices', 85% were urban with 78% having specialist services 
(Specialist nurses, Dieticians or Specialist clinics). 
There were 94% of respondents who had SAHS patients within their practice with 28% 
having referred patients with suspected SAHS for less than 5 years, 6o% for 5-io years, 
11% for 10-20 years and i% for more than 20 years. 
8.4.1.2 Indication for treatment 
In the primary care physicians' opinion, the principal reason for treatment of patients 
with suspected SAHS was predominantly improvement in HRQL and EDS. Reduction in 
cardiovascular sequelae, reduction of risk from sleepiness while driving and improvement 
in daytime performance at work were the other reasons cited with frequencies of these 
responses shown in figure 8.1. 
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presence of increasing numbers of referrals and apparent delays to secure diagnosis and 
treatment in these centres. 
8.4.2.6 Future 
A majority of respondents agreed with the statement that CPAP is likely to remain the 
most effective treatment for SAHS in the future (78%) and is unlikely to be replaced by a 
more effective treatment (78%) or a more patient friendly option (7o%). 
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8.5 Discussion 
Within the managed care setting in the UY, the primary care physicians occupy the first 
point of contact between the health care system and the community. Thus the first phase 
of the diffusion survey was designed to examine the knowledge base and perceptions 
among primary care physicians about the treatment of SAHS patients. While the 
secondary care physicians are responsible for the diagnosis and treatment of diseases in 
the hospital setting. Any innovation or healthcare intervention is thus unlikely to be 
successful unless the knowledge of its benefits reaches the frontline of the health care 
delivery system. 
The results indicate a close agreement between the primary and secondary care 
physicians in the principal indication for the provision of treatment of patients with SAHS 
(i. e. reduction in EDS and improvement in HRQQ. Recent RCTs and the Cochrane review 
of the effectiveness of CPAP therapy in SAHS [Wright and White 2ooo] have consistently 
indicated clear benefit in these two parameters [Ballester et al. iggg]. While there is 
academic interest among sleep apnoea researchers in the link between SAHS and 
cardiovascular diseases (IHD, Hypertension and strokes) the evidence of causation is still 
lacking and hence alleviation of this risk is still not a primary indication for the provision 
of this treatment in the UK. 
Characteristics of an innovation often determine the rate of its diffusion and adoption 
within a target user community. In the case of CPAP the survey results indicate a 
consensus among all respondents on the specific characteristics of CPAP which may have 
been responsible for its speedy diffusion since its inception. CPAP offered a safe and 
potentially reversible therapeutic option which could be offered to a much larger group of 
patients with SAHS than hitherto available surgical options; thus had a distinct advantage. 
It also offered the ease of instituting safe and reversible therapeutic trials to assess 
individual responses, offered the opportunity to objectively assess benefit and appeared 
acceptable and was relatively easy to use. 
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Whereas the majority of secondary care physicians agreed that CPAP would remain the 
most effective therapy in the near future and was unlikely to be replaced by a more 
effective and acceptable option for patients, primary care physicians felt otherwise. Most 
clinical trial data on compliance report a CPAP acceptance rate of between 5o-8o% 
(similar to the results presented in chapter IV) suggesting that it was probably both an 
effective and a popular therapeutic option, and likely to remain so in the future. However 
when CPAP is prescribed to patients at the milder end of the spectrum (AHI 5-15 hour-, ), 
the acceptance rate is seen to fall to 50% [Engleman et al. 1999]. 
However, it is reported that even in patients with evidence of physiological disease 
(AHI>3o hour-i), the absence of daytime symptoms is likely to make treatment 
ineffective [Barbe, et al. 2001] and hence adversely affect adoption. Thus the absence of a 
clear relationship between symptoms and nocturnal sleep disturbance may allow for 
scepticism about the future of CPAP among physicians. 
Patients have reported dryness of the oro-pharynx, fitting of the mask and associated 
leaks, excessive air pressure, machine noise and cumbersome apparatus as common 
reasons to discontinue treatment in the absence of a significant symptom benefit. Primary 
care physicians closer to patients may reflect this reservation of patients regarding long 
term usage of CPAP, and hence may be looking for an alternative which would be more 
acceptable to majority of patients. This probably accounts for the divergence seen in the 
responses for the future of SAHS therapy, between primary and secondary care 
respondents. 
When an innovation is introduced in the health care system, one of the determinants of 
the rate and extent of its adoption is the communication pathways and networks existent 
within the system. The diffusion survey indicates a definite lack of a systematic pathway 
for knowledge diffusion from innovators to secondary care and from secondary care to 
primary care physicians. The survey results indicate a dependence on personal initiative 
and personal peer-to-peer networks along with meetings chaired by hospital consultants 
for the difftision of expert knowledge in primary care. The traditional format of scientific 
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meetings and journal articles were cited as the most important determinants by hospital 
consultants. Interestingly there is hardly any role of patient self-help/ lobby groups, 
media and industry representation in influencing the diffusion of knowledge or the 
adoption of CPAP. 
In the USA, the presence of a national body (American Academy of Sleep Medicine) and 
the mixed professional-patient led National Sleep Foundation has been shown to play a 
major role not only in public awareness campaigns but also in securing government 
funding, lobbying for legislation and setting up a national framework within the National 
Heart, Lung and Blood Institute. Attempts to initiate contact with the registered patient's 
self-help bodies in the UK did not meet with much success suggesting their relative 
dormancy and there was only 1/5 responses from the industry representatives. The 
British Sleep Society (a group of professionals) and the British Thoracic Society have yet 
to demonstrate a role in either lobbying the government (Department of Health) or in 
setting up a national framework to allow a homogenous approach to resource allocation 
for SAHS sufferers in the UK While in other chronic diseases such as asthma, diabetes 
and ischaemic heart disease there is a major role played by bodies such as the National 
Asthma Campaign [Comino et al. 1997] and British Heart Foundation [Shillingford 19841 
in raising awareness among the public, lobbying the government for resources, raising 
funds for research and supporting physicians and researchers in their efforts. Similar 
efforts by the National Sleep Foundation [Anon. 2004b] in conjunction with the 
professional bodies have raised the profile of sleep disorders in the USA. This strategy has 
been successful in establishing an professional academy for sleep medicine accreditation 
and establishing a national priority with sleep awareness campaigns [National Sleep 
Foundation 1999] and national level plans for sleep research [Phillips et al. 1996]. 
To date there have been two reports published by a specialist committee of the Royal 
College of Physicians and more recently a practice guidelines published by the Scottish 
National Sleep Group [Scottish Intercollegiate Guidelines Network 20031. It is likely that 
the current disparity in funding identified by the present survey among the majority of 
hospitals/ health authorities in the UK (identified by survey respondents as the major 
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cause of lack of the availability of appropriate treatment in SAJHS) is a result of a variety of 
factors such as; a lack of a national consensus both among professionals, competing 
interests from diseases with higher public and political profile like cancer [Clive et al. 
19951, multiple sclerosis [Nicholl et al. 20oll and heart disease, lack of patrons or 
champions both professional [Lau et al. 1998] and public and confounding with obesity 
and lifestyle prototypes in the public and professional mind [Wright, et al. 1997a]. In the 
case of hepatitis B such champions have often arisen outside of the public health 
establishments that are mandated to play that role. In New Zealand it was left up to one 
unusual and determined man to not only discover the seriousness of the hepatitis B 
epidemic but to practically single-handedly force a reluctant government to acknowledge 
the threat and act to contain it. He accomplished this by combining high quality scientific 
research with unrelenting political pressure generated by appeals to the public by means 
of the mass media [Muraskin 19951. 
The mere production and distribution of guidelines is unlikely to make a significant 
impact on the adoption of innovative therapies in general use [Grimshaw & Russell 19931. 
Specifically relevant are the instances of poor adoption of asthma guidelines [Cowie et al. 
2ool] and those for use of statins in heart disease [Goff, Jr. et al. 2002] [Shea et al. 199o]. 
If guidelines are issued as a national service framework by regulatory bodies or by 
government departments, and may be considered mandatory for service provision across 
the whole country then adoption will be influenced [Halpin, 20041. 
The present survey also found that over 50% of hospitals reported an annual expansion in 
patient referrals in excess of lo%. This rapid expansion in demand combined with the 
majority who are likely to still remain undiagnosed in the community [Phillips 
1996b; Silverberg et al. 1997], is likely to present the health planners with a widening 
chasm between existing facilities, funding allocation and spiralling demand [Gibson 19981 
[Phillipson 1993; Wright et al. 1998a]. 
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8.6 Conclusions 
The survey results demonstrate that there is a consensus between the primary and 
secondary care adopters in the UK NHS regarding the characteristics of CPAP which 
would provide it with an advantage over and above co-existent therapeutic options like 
oral devices, lifestyle intervention and surgical options. 
The three major determinants which are shown to be absent from the factors influencing 
the UK diffusion of CPAP compared to the USA are; (i) lack of a national consensus 
opinion and a champion body (whether professional, public or mixed) for raising public 
and professional awareness and hence commanding a political imperative; (ii) restrictions 
and disparities in the funding of diagnostic/ treatment facilities within the UK health 
regions; and (iii) lack of structured pathways for the dissemination of expert knowledge 
from innovators/ early adopters to the majority. 
Interestingly the lack of correlation between physiological parameters of severity and 
daytime dysfunction did not seem to impact on diffusion of CPAP; the effect of untreated 
SAHS on cardiovascular disease and mortality did not feature in the indication for 
treatment in the UK, in contrast to the USA where this is a prime driver for more funding 
and resource allocation. 
Survey respondents remained divided on the future of CPAP, with primary care 
physicians predicting a change from CPAP, and secondary care physicians thinldng this 
unlikely in the near future. 
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9.1 OVERVIEW 
Health technology appraisal and diffusion of innovations in 
chronic diseases: CPAP in SAHS 
Since the discovery of vaccination by Edward Jenner in 1798 [Jenner 18oll the progress 
of science and technological innovation in many industrialised countries of the world, has 
reached a point where recent innovations are concerned not with the traditional reduction 
in mortality; but with improvement in quality of life of sufferers with chronic conditions 
[Berwick 1989]. The technological imperative in health care, which has driven progress, is 
the beneficial impact of innovations, but there is also the added responsibility for the 
recognition and avoidance of adverse effects [Annas and Elias 19991. Technology 
appraisal was bom initially to ensure the safety and efficacy of any new technology before 
being put to common use [Banta et al. 198o]. Whereas regulatory authorities are 
entrusted with the responsibility of preventing harm to people and society, health 
purchasers are concerned with the effectiveness of innovations [Banta 1994] and 
comparison of competing technologies in order to ensure the best use of limited resources 
for the greater good [Maynard and Bloor 19951 [Rutten and Drummond 19941. 
However, even within the structured environment of the NHS in the UY, the pathway 
from innovation to adoption of new health technologies has a widespread variability and 
liable to be influenced by a variety of factors [Rosen and Mays 19981. Newell et al 
discovered that the process of knowledge generation about best practice and its transfer 
within the NHS does not follow a regulated and hierarchical pathway [Newell et al. 20031. 
The way an organisation (like the NHS) deals with technology adoption is likely to be 
either slowed down by an institutional inertia or be reactive based on short-term 
organisational goals, rather than being proactive and driven by concrete evidence [Miller 
et al. 2ooi]. One may argue that an early regulatory structure and appraisal of new 
innovations in their infancy (before they have had a chance to dif se within early fu 
adopters and be enriched by the process offeedback and re-invention) may identify non- 
starters and save vital resources being spent in unnecessary adoption. This 'early' 
regulation is feared on the other hand, to create insurmountable hurdles to 
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innovativeness and potentially slow down technological progress, perhaps compromising 
patient care in the long run. The effect of regulation may be seen in a slowing down of the 
rate of introduction of innovations when compared to the rate of expansion of scientific 
knowledge [Williams 20041. The ideal pathway from innovation to adoption is uncertain 
and various models and hypothesis currently exist [Rogers 19951. 
SAHS provided the ideal case study where the advent of a new modality of treatment 
(CPAP) demonstrated a potential for alleviating the adverse effects of a chronic syndrome 
on sufferers. The characteristics of CPAP made it possible to widen the applicability of 
this treatment compared to previously available surgical options [Sullivan et. al. 1981]. 
However, since this device became commercially available in 199o, there has been a 
variable adoption in the USA and Western Europe, judging by industry estimates [Newby 
2002] [Mack 1999]. 
In 1997, a systematic review of the evidence base for usage of CPAP in SAHS patients in 
the UK identified deficiencies in the evidence of clinical effectiveness and the interference 
of confounders [Wright et. al. igg7b]. This led to a decline in resources available for the 
provision of these devices for the treatment of patients, also leading to widespread 
regional variability [Gibson and Prowse 1997]. Three years later in 2ooo, a further 
systematic review identified six RCTs with evidence that CPAP improves HRQL among 
sufferers, when compared to mandibular advancement splints and laser palatoplasty. But 
mandibular devices were preferred by patients due to ease of use and less interference 
with sleep [Wright and White 20001. 
Till now the situation identified by the RCP expert report in 1993 [Stradling et al. 19931 
and 1998 [Gibson et al. 1998] of under-diagnosis and under-treatment of SAHS patients 
remains valid in the UK. Under-diagnosis has also been reported from population surveys 
in the USA [Phillips 1996a]. Patients in most centres; are currently subject to 9-12 month 
waiting list for diagnosis and treatment. Due to a lack of a consensus national strategy for 
the treatment of sleep disorders and availability of evidence of cost -effectiveness, 
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individual clinicians have had to negotiate local funding. This has led to a further 
widening of the regional disparity in service provision. 
During the same period in the USA, the American Sleep Disorders Association has been 
upgraded to form the American Academy of Sleep Medicine (AASM) with formal 
responsibility of accreditation of professionals and laboratories and to achieve consensus 
via research and monitoring of services [American Academy of Sleep Medicine 1999]. The 
US national imperative is further demonstrated in the form of government led research 
initiatives through the National Heart, Lung and Blood Institute funding and public 
health programmes [Anon. 2004a]. There is also a major public initiative in education, 
research and policy in the form of an active National Sleep Foundation (NSF) 
[Anon. 2oo4b]. 
The situation in the UK has lagged behind with a lack of consensus regional or national 
strategy leaving individual clinicians to negotiate funding of services locally. The first UK 
national guidelines for Sleep related disorders were produced in 2003 in Scotland 
[Scottish Intercollegiate Guidelines Network 20031- Sleep is still not an independent 
speciality discipline in the UK and management of patients is shared by professionals in 
different specialities, thus creating hurdles to a concerted approach. There is little sleep- 
related education featuring in the UK medical curricula [Stores and Crawford 1998] and 
sleep disorders do not yet feature in the government's 'health for alr strategy [Childs 
20041. There is also little demonstrable influence of patient groups, on sleep related 
health policy or public awareness campaigns [Sleep Alliance. 20041. 
Thus CPAP use in SAHS patients thus presented an ideal context for the study of 
technology appraisal and factors affecting its diffusion and adoption. 
9.2 Mortality 
The retrospective case-control study presented in chapter IV, demonstrated an increased 
relative risk for mortality and for being hypertensive in SAHS patients compared to the 
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control group. Some of this increased mortality could be contributed by the excess of 
obesity seen in this group which is known as an independent risk factor. The increased 
prevalence of hypertension is also known as an independent contributor to increased 
cardiovascular and cerebrovascular mortality [Anon, 1996a; Fletcher, 1996; Lavie, 19951. 
Cardiovascular causes dominate in the 'all cause mortality' seen in SAHS patient groups 
[Mooe, 2001; Shepard, 19921. The AHI has been linked to the increased mortality in 
studies at a level Of >2o/hour [He 1988]. In large scale follow up studies, patients below 
the age of 5o years are known to have an increased risk of cardiovascular mortality in the 
presence of untreated SAHS [Veale, 20ool. The mortality rate is the same as non-SAHS 
patients in older individuals. It is also argued that the combination of obesity, 
hypertension, diabetes and SAHS may further multiply the mortality risk in patients and 
hence need to be addressed holistically. 
9.3 Mismatch in diagnostic and treatment facilities 
Data from 199o to 1997 collected from the clinical review (chapter M demonstrated a 
gradually increasing referral number with a lo, fold increase over 7 years. This was 
probably a reflection of the increasing awareness of this condition among patients and 
primary care physicians. Similar annual growth figures were reported from a majority of 
the secondary care physicians surveyed in chapter VIII. However the total number of 
patients diagnosed and treated annually were only a small fraction of the estimated 
number based on population studies (For 25000o adult population covered by 
Birmingham Heartlands Hospital, there are an estimated 5000 men and 2500 women 
with SAHS who would qualify for diagnosis and treatment) [Young et al. 19931. A 
population based study undertaken in the USA has estimated that a large proportion of 
subjects with nocturnal apnoeas/ hypopnoeas and daytime symptoms usually remain 
under-diagnosed and treated (almost 93% of women and 82% of men) [Young et. 
al. 1997a]. 
Thus data from chapters IV and VIII demonstrate the increase in public awareness of 
SAHS and improved knowledge diffusion in sleep related disorders amongst primary care 
physicians (estimated from increased referrals). But diagnostic and treatment facilities 
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have not expanded to match the increasing demands. Diagnostic facilities in the UK were 
considered severely inadequate by the Royal College of Physicians Working party survey 
in 1993 and 1998 [Semple and Gibson 19931 [Gibson et al. 19981. Data from the 
secondary care survey presented in chapter VIII, also demonstrated the lack of diagnostic 
facilities and resources and these are reported as significant factors in the slow adoption 
of CPAP in the UK. 
One of the potential ways to increase diagnostic capability without impacting adversely on 
limited resources would be to use less expensive and home based methods thus reducing 
the waiting list for more expensive hospital based in-patient polysomnograms. As 
demonstrated by the data presented in chapter IV, almost two thirds of the patients 
eventually diagnosed and treated in the Sleep clinic could have been diagnosed using a 
combination of symptoms and overnight oximetry criteria (4% ODI> 15 hour') [Ryan et al. 
1995b]. Similar research has shown that various limited sleep studies using overnight 
oximetry and symptoms/ questionnaires [Netzer et al. 2001] [Boehlecke 2ool] are useful 
in reducing the number of patients requiring full polysomnography. Using an ODI>15 
hour, can increase the specificity of moderate to severe SAHS diagnosis to 98-ioo% 
although the sensitivity is in the order Of 30-40% [Wiltshire, et al. 20011. Others have 
used automated and spectral analysis of the pulse oximetry data to improve the specificity 
to 670/6-88% [Zamarron et al. 19991 [Vazquez et al. 2000]. This reduces the pressure on 
limited availability of diagnostic facilities, speeds up the treatment of patients [West, et al 
20011 and may reduce the economic impact of such labour and equipment intensive 
diagnostic tests [Chervin et al. iggg; Epstein and Dorlac 1998] [Kristo et al. 2001]. 
Although an oximetry based approach tends to hold great potential benefit for centres 
where waiting lists are large, there are concerns regarding the limitation of this approach 
in picking up non-apnoeic disorders, i. e. UARS, Narcolepsy, Restless leg syndrome and 
Periodic limb movement disorders. In the USA, the trend has been to continue full PSG 
but with a telemedicine approach in transferring sleep studies online to a central 
laboratory, thus achieving a 44% cost reduction [Kristo et al. 20011 [Pelletier-Fleury et 
al. 19991. 
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Similar to the guidelines on practice parameters established in the USA, there have been 
specific guidelines published in Scotland in 2003 [Scottish Intercollegiate Guidelines 
Network 20031. Theoretically these national guidelines produced by consensus of expert 
committees may provide a framework for estimating the need for facilities in the UK and 
for recommending appropriate resource allocation. However sleep disorders still lack a 
place in the government agenda for health improvement and do not yet have a place in 
established national service frameworks [ChildS 20041. 
9.4 EFFICACY & EFFECTIVENESS 
9.3.1 New evidence of effectiveness 
Appraisal of a new technology first involves assessment of its safety and clinical 
effectiveness. There were two systematic reviews examining the evidence base in SAHS 
published in 1997-1998 which had come to divergent conclusions. Wright et al [Wright et 
al. igg7a] concluded that a significant proportion of the normal population report 
symptoms of snoring and daytime hypersomnolence and hence there was insufficient data 
to justify treatment purely on the basis of improvement in daytime symptoms. They 
identified an absence of well-designed RCTs which controlled for confounding influence 
of obesity, sleep deprivation and a lack of placebo-controlled trials. There was insufficient 
trial data to justify treatment on the basis of reductions in mortality and cardiovascular 
morbidity. The authors recommended firstly that randomised, placebo-controlled trials 
were needed to examine the effectiveness of treatment options, secondly that the 
contribution of lifestyle factors (obesity, sleep hygiene, smoking & alcohol) also needed to 
be examined, and that more research was needed to evaluate the link between 
cardiovascular morbidity and mortality with SAHS [Wright et al. 1997a]. 
This led health authorities in the UK to place a low priority on commissioning sleep 
related facilities and treatment. In Bristol, restrictions were placed on clinical treatment 
of patients only with jobs dependant on safe driving [A Kendrick, 1998]. 
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In contrast, a subsequent review of a set of small number of RCTs using either an oral 
placebo or sub-therapeutic CPAP, demonstrated that CPAP improved daytime 
somnolence, neuro-cognitive function and HRQL in SARS patients [Douglas 1998]. 
The technology appraisal of CPAP presented in this thesis was initiated during this period 
and an RCT was designed to address the weaknesses identified in the scientific debate as 
illustrated here, and to compare the impact of CPAP against a control group given 
standardised lifestyle intervention. The data presented in chapter V demonstrates that 
CPAP is effective in reduction of nocturnal disease parameters of AHI, AI, and subjective 
daytime sleepiness compared to lifestyle intervention. Anthropometric: variables (i. e. age, 
sex, BMI) did not have any demonstrable relationship with markers of nocturnal sleep 
apnoea/ hypopnoea (AHI & AI). 
Although traditionally SAHS has been defined on the basis of nocturnal sleep 
fragmentation combined with daytime symptoms (of sleepiness), research evidence has 
shown only weak correlation between AHI and Al with symptoms [McArdle et al. 2001al 
[Heinzer et al. 2001]. There is also evidence to suggest that even in patients with 
(moderate to severe; AHI>3o hour-') SAHS (and sleep fragmentation), the absence of 
symptoms predicts an absence of response to CPAP treatment [Barbe et al. 2001]. Thus 
there appears to be a disengaged relationship between the symptoms / disability suffered 
by patients with SAHS and their nocturnal disease severity. 
This can create uncertainty in planning health service resource allocation on the basis of 
population estimates (based on severity markers) which may not be of relevance in real 
life treatment of patients. The assessment of response of interventions based on 
physiological parameters may be less relevant in SAHS than in conditions such as 
diabetes (glucose monitoring [Wright et al. 2003]) and hypertension (blood pressure 
monitoring [Benigeri and Pluye 20031) where they are directly related to outcomes. Thus 
the complex interaction of various factors which give rise to a patient's perception of 
disability suffered due to a disease process needs to be better understood. But it is often 
suggested that that patient generated measures should be given prominence in assessing 
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the impact of intervention and health policy decision-making in chronic management 
(Sherbourne et. al. 1999]. 
9.5 HEALTH RELATED QUALITY OF LIFE 
9.4.1 Generic vs. disease specific 
Patients with untreated SAHS report HRQL scores which are lower in almost all 
dimensions measured by different tools when compared with normal population values 
[Flemons and Tsai 1997b]. HRQL data from the RCT presented in chapter VI, shows that 
SAHS patients report lower pre-treatment scores in all dimensions of SF36 with the 
maximum deterioration seen in mental health dimensions (energy/vitality, social 
functioning, general health for both men & women) and also in EuroQol thermometer 
scores. 
When HRQL is measured after treatment with CPAP, the SF36 dimensions of 
energy/vitality, social functioning and mental health showed the maximum improvement, 
while patients with lifestyle intervention reported no improvement. 
The lower scores recorded in the physical health dimensions showed no change in either 
of the treatment arms in the study but remained consistently below the population norms. 
These results suggest firstly, that the disability associated with SAHS is perhaps 
predominantly linked to mental health and social functioning; and that the con-comitant 
lower scores seen in physical health domains are either un-related to SAHS or untreated 
by CPAP therapy. Interestingly the scores recorded using the EuroQol health 
thermometer only demonstrated a small change with treatment. 
As different disease processes produce their adverse effects within different organ 
systems of the body, there is some value in measuring disease specific variables to 
accurately estimate the impact of health care interventions. Thus in SAHS patients the 
change in daytime somnolence and daytime neuro-cognitive function would be a sensitive 
measure to use when comparing different health care interventions i. e. laser UPPP or 
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Oral devices against CPAP. However to the health policy decision-maker, where 
competing interventions are being assessed for impact on the health of the population, 
disease specific measures Provide results which are not comparable. 
Thus generic measures tend to be preferred which then can provide a more comparable 
currency for such competing interventions. With this purpose in mind, researchers have 
used a variety of HRQL tools in SAHS patients which have demonstrated changes in 
various domains as listed in table 9.1. As illustrated, there are a variety of tools which 
have been used to measure any deterioration from normal of HRQL dimensions in SAHS 
patients and the change with various treatment options. HRQL measures which have 
different measurement properties and sensitivities may produce varied amplitude of 
results in the same population group. When comparing the impact of competing 
technologies in different disease-patient groups, any lack of uniformity in responses 
would make resource allocation difficult. Tbus one cannot effectively compare the change 
in physical limitation scores in osteoarthritis in a specific population given total knee 
replacement, with mental health improvement seen after control of pain in patients with 
cancer, using a single HRQL tool. 
There is also the evidence that patients with psychosocial disability as a result of disease 
tend to report HRQL assessments which may be more severely depressed than predicted 
by their disease severity [Allsup et al. 2002]. 
The EuroQol and SF36 or SF12 are currently being used widely with population norms 
being developed from various countries. This study demonstrates by the differences in 
this SAHS population group, that they may need further refinement before they can be 
recommended for use in health policy and planning (Jenldnson et al. 1998]. Table 9.1 
illustrates the variety of sub-domain responses, effect sizes reported from different trials 
measuring the impact on HRQL in SAHS. 
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Table 9.1: HRQL domains showing change in SAHS patients 
Stud no of ati t IIR L l v 
Wisconsin Sleep 
p en s 
737 
Q too s used 
36 
Domains involved 
All except boddy 
Conclusion 
Social functioning 
Cohort Study [Finn, pain & role & general health 
et al. 1998b] emotional limitation worst affected in 
Al Il> 15 hour' 
Sleep I leart I leZh 5816 SF36 Vitality related to Severe SAI IS 
Study p3aldwin, et sleep disordered showed lower 
al. 20011 breathing scores in all 
dimensions 
jenkinson et al 90 (5 weeks on SF36, Functional Energy/ vitality, FLP similar 
Uenkinson et CPAP) limitation profile, mental & physical improvement; 
al. 1997c] EuroQoI component EuroQol no change 
summary 
Ballester et al 105 CPAP vs. SF36 Energy/ vitality, 6.5 Odds ratio for 
[Ballester, et al. CPAP+ mental health improvement 
19991 conservative 
therapy 
Yang et al [Yang, et 46 (AIII<5) SF36 Mdd-moder2te Severe = vitality, 
al. 20001 16 (Af 115-15) low physical current health 
21 (AIII>15) functioning & role perception, positive 
limitation physical affect 
Meslier et al 3225 on CPAP (9 Nottingham I lealth 75% good scores in Scores linked to 
[Meslief, et months) Profile all dimensions compliance (self- 
Q1.19981 reported) 
Sanner et al 39 treated for 9 NI IP, Complaint NII P=emotional & No difference in 
[Sanner, et al. months (CPAP) fist, Verbal energy improvement pain, social 
20001 analogue scale isolation, mobility, 
sleep & verbal 
analogue scale 
Bolitschek et al 67 (CPAP) Munich Life Physical condition, Treated same as 
[Bolitschek, et 21 (SAI IS) Quality Dimension psyche, social life, controls 
al. 19981 
113 (Controls) Ust everyday fife 
deterior2tion 
Lacasse et al 82 males 186 item Daytime symptoms, 
[Lacassc, 2002a] questionnaire nocturnal symptoms, 
limitation of 
activities, emotions, 
inter-personal 
relationships 
Reda et al [Reda et 191 snorers NIIP All 6 dimensions Energy, emotional 
aZ 20001 57 SAI IS deterioration reaction improved 
105 12 months 
post UPPp 
Walker-Engstrom 37 oral appliance Minor symptom Vitality, contentment All dimensions 
et al [Willielmisson, 43 UPPP evaluation profile & sleep improved, UPPP 
et al. 19991 more contented 
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9.4.2 Mental health measures 
Paticnt, s %%ith SAIIS in the RCY (chupter V7) reported a high prevalence of psychological 
co-morbidity with the GHQ28 and of anxiety/ depression based on the HADS 
questionnaire. A similar prevalence of psychological comorbidity is reported in patients 
presenting to casualty with chest pain and suspected coronary artery disease [Goodacre et 
al. 20011 and in surveys assessing the need for mental health services in primary care 
populations [Shapiro et al. 1985]. Both these measures were developed to identify 
psychological morbidity in patients with chronic diseases which may otherwise be missed 
and in order to focus specialised psychiatric care. By the nature of the disability suffered 
by SAHS patients in functioning at work, with family and friends and their chronic fatigue 
state, this condition lends itself to generate psychological debility, as reported by Veale et 
al from their qualitative stud), of the concerns expressed by SAHS patients [Veale et 
al. 20021. 
Thus there are 3 questions posed by this high prevalence; 
(i) Is SAHS an independent cause of psychological disability among sufferers? 
0i) Is the disabdity suffered by patients due to SAHS, liable to be over- 
represented in HRQL and health status measurements due to their 
psychological co-morbidity? 
(iii) Could the apparent lack of correlation between SAHS markers and HRQL 
decline be due to the influence of psychological co-morbidity? 
The answer to the first question is available from the results of the RCT (chapter VI) 
which shows both a reduction in the prevalence of 'cases' of psychological morbidity and 
the scores on anxiety and depression in patients treated with CPAP. Compared to the 
iinprovement with CPAP use, patients in the lifestyle group tended to have a worse score 
on depression sub-scales. Similar improvement in mental health parameters is reported 
in the early literature [Millman et al. 19891 although studies over 3 months, 12 months 
and 24 months have reported variable results. In an uncontrolled study 26/41 patients 
rrix)rtM sy`Mptoms compatible with depression at baseline, 12 months after treatment 
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with CPAP Only 5o% reported improvement in mood [Yamamoto et. aL2ooo]. A case- 
controlled study with 6o patients and 8o controls, found no change in anxiety/ 
depression after 12 months of otherwise successful treatment with CPAP [Munoz et. 
al. 2000]. 
The answer to the second question is less clear as evidence suggests that anxiety or major 
depression may result in a misappraisal of benign body symptoms in normal subjects 
[Spinhoven et al. 19971, and may also worsen the perceived health state in patients with 
physical illnesses [Sherbourne et al. 19991 [Wells and Sherbourne 1999]. Even fit and 
healthy individuals (aged 55-74 years) who reported increased anxiety/ depression scores 
on HADS were found to report lower health status after flu-vaccination compared to those 
without anxiety/ depression [Allsup and Gosney 2002]. 
Does psychological morbidity confound the relationship between nocturnal sleep 
variables and health status? There were no relationships seen between PSG variables and 
mental health scores in the study patients. The improved scores were related to baseline 
mental health scores but not to PSG variables. In another study, anxiety and mental stress 
was found to be related to AHI [Borak et aL9961 but the contribution of depression to 
symptoms of chronic daytime fatigue was found to be ten times that of nocturnal sleep 
disordered breathing in SAHS patients [Bardwell et al. 20031- 
The overlap between the symptom complex associated with psychological co-morbidity 
(predominantly depression) and SAHS may contribute to the HRQL scores reported by 
patients at baseline, hence the benefits of technological innovation may not be accurately 
estimated if such HRQL tools are used in their appraisal. Thus resource allocation based 
on such measurements may be liable to a positive bias. While the first type of patient may 
not respond to treatment of SAHS and may require specialised psychiatric input, those 
with SAHS-related psychological co-morbidity may benefit from SAHS treatment. 
The HRQL debility suffered by SAHS patients is predominantly related to mental health 
dimensions and related social functioning. Thus the SF36 (mental health dimensions) 
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and the mental health tools (GHQ28 & HADS) which both measure psychological co- 
morbidity possibly associated with or resulting from SAHS related disability and are 
closely related, suggesting a convergent validity. Thus while they may be used to measure 
the impact of disease and benefit of treatment options in SAHS patients, they would not 
be suitable for comparing the impact of treatment of other diseases or patient groups 
which may not have a similar mental health related component. 
9.6 Lifestyle factors 
Obesity and sleep hygiene factors may contribute individually to the disability suffered by 
SAHS patients and thus play an important role in planning health promotion strategies in 
this group. The initial concern expressed by Wright et al [Wright et al. 1997a] of the 
confounding potential of obesity in assessing the impact of intervention in this group has 
been addressed by RCT design (chapter VI and controlling for obesity in statistical 
analysis. 
The two remaining issues are, what is the contribution of obesity in the excess 
cardiovascular morbidity and mortality attributed to SAHS in population studies and 
secondly whether reduction of BMI contributes to improvement in health status for these 
patients. The design of the prospective RCT presented in chapter V does not help answer 
the first of these questions and there is scant (if any) evidence available from research in 
this field [Shneerson and Wright 2001]. Evidence for the reduction in mortality 
associated with intentional weight loss remains uncertain. Most large epidemiological 
cohort studies have failed to show a clear benefit in mortality with intentional weight loss, 
and have often suggested an increase in non-cardiovascular mortality [Dyer et al. 
2000; Williamson et al. 1999] [IGein 2001]. 
Does reduction in BMI improve nocturnal sleepfragmentation parameters? 
The data presented in chapter V suggests that there is a modest reduction in AHI and AI 
in these patients and a rise in sleep latency after intentional weight loss. Whether the 
improvements seen in (VAS scores) nocturnal sleep quality and reduction in daytime 
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sleepiness are a result of weight loss, sleep hygiene measures or merely a placebo effect 
remains uncertain. The change in ESS scores, do not reach statistical significance. There 
is some evidence that nocturnal apnoea frequency may be reduced after weight loss in 
SAHS patients but this is usually transient and only effective in severely obese patients 
after surgical weight loss strategies from uncontrolled trial data [Jones et al. 
2004; Scheuller et al. 20011. 
Thus there is insufficient evidence from well-designed trial data to support a major 
imperative into tackling obesity in non-diabetic, obese SAHS patients using non- 
conventional strategies. Use of conservative dietary and exercise strategies may be 
beneficial in improving sleep quality and daytime symptoms and reduction of 
cardiovascular risk factors in these patients. The contribution of newly licensed 
pharmaceutical agents such as Sibutramine (Bray et al. 1996] and orlistat [Ballinger 
2oool to weight reduction strategies remains to be assessed in this population group. 
9.7 ECONOMIC EVALUATION 
9.7.1 Health status measurement 
Unlike the HRQL measurement techniques which are basically rating scales in each 
dimension, an alternative approach to health status measurement is patient preference 
assessment using utilities. Health status was measured using an interview based approach 
using the classical vonNeuman-Morgenstern theory [von Neumann and Morgenstern 
1944] based standard gamble incorporating risk and the time-trade off method [Churchill 
et al. 1987] devised specifically for health status measurement. The third measurement 
method was based on the rating scale derivative indirectly from population values 
(EuroQol utility). In the absence of a 'gold standard' with total acceptability [Giesler et al. 
1999] most researchers have used a combination of these methods in trials and compared 
their properties in individual disease scenarios. 
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Interestingly the SAHS patients in the study reported poor health status at baseline using 
both SG and TrO methods. Both these scores showed close relationship with each other 
and with the HRQL measures suggesting a convergent validity. The health status 
measures showed independence from confounding anthropometric variables except for 
TTO which had a positive relationship with increasing age. The TTO utility was the only 
outcome variable with a significant relationship seen with the primary SAHS disease 
marker (AHI) suggesting criterion validity. 
Table 9.2 illustrates typical utility values obtained from different patient-disease 
combinations showing that SAHS patients rate their health status worse than many 
severe chronic debilitating illnesses. 
Patients with psychiatric morbidity demonstrate health state preferences which are much 
lower than most physical conditions and in line with severe physical restriction e. g. major 
stroke risk < severe depression < untreated SAHSsg < cancer with a two-year survival and 
severe emesis < advanced Amyotrophic lateral sclerosis < untreated SAHStto. Patients 
with concurrent depression have been shown to be willing to accept a greater risk of death 
than those with no psychiatric disability [Schaffer et al 2002]. This has been a cause of 
debate and concern among researchers as there is a theoretical likelihood that health 
policy decision-making which is dependant on such assessments, might over-value the 
health impact of mental health interventions [Lenert et al. 19991 over others targeted at 
physical disability. 
The utilities generated by this study have a very important difference when compared to 
SG/TTO based health status reported from many other studies. The SG utilities are lower 
than those obtained by the ITO method, although both show equivalent properties of 
reliability, sensitivity and discriminant validity. Most of the comparisons in the literature 
have found SG values to be higher than ITO values in the same disease-population 
scenario [Lundberg et al. 19991 [Morimoto et al. 20021. This has been attributed to the 
inherent nature of patients (posed with the uncertainty of the preferences and the 
possibility of death in the event of a failure) to adopt a risk-averse attitude; which may 
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lead to higher values [Woodward et al. 1998]. Conversely SG obtained under certainty or 
linked (chained) [Jansen et al. 1998] to intermediate health states may produce values 
which are more in line with those obtained by'ITO utilities. 
The differences between SG and ITO utilities is probably attributed to differences in 
probability weighting, loss aversion and scale incompatibility which usually leads to 
higher values in SG and may increase/ decrease the TTO values [Bleichrodt 20021. Table 
9.2 illustrates the range of utilities obtained in different diseases using common methods. 
On the contrary, in this RCT, SAHS patients with significant psychological co-morbidity 
(based on GHQ28, HADS & SF36) showed a risk-affinity and were less concerned with 
the possibility of death (in the event of failure) and may thus have produced lower 
preferences for their health states (compared to TrO utilities). 
Similar to HRQL scores which tend to be lower in patients with significant psychological 
co-morbidity, this study demonstrates that the probable influence of psychological 
disability suffered by SAHS patients may lead to worse health state preferences. 
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Table 9.2: Utilities obtained from different disease-patient combinations 
Study Clinical 
scenario 
Utility 
method 
Values 
Laupacis et al [Laupacis el aL ESRD-Renal SG 0.57-0.70 
19961 
1 
transplantation 
Revicki et al [Revicki 1992] Depression SG Severe=0.3, Moderate= 
0.55 -0.63, mild=0.64-0.73, 
on medic=0.72-0.83 
Stavem [Stavern 19981 
_.! 
ýpilepsy SG/'ITO SG=0.99,170=0.98 
Tsevat et al [Tsevat et al 20001 Bipolar disorder- SG/TrO SG=0.70-0.77 
cure TrO=0.61-0.71 
Lundberg et al [Lundberg, et Psoriasis RS/SG/TTO RS=0.69, rrO=0.88, 
al. 19991 Atopic eczema SG=0.97 
RS=0.73, TrO=0.93, 
SG=0.98 
Brown et al [Brown et aZ 19991 Diabetic SG/TTO SG=0.88, TTO=0.77 
retinopathy 
Smith et al [Smith et aL 2002b] Radical SG Baseline=0.9, sexual 
prostatectomy dysfunction=0.87-0.89, 
sexual urinary 
dysfunction=0.77-0.82, no 
comphcations=0.92-0.96 
Kiebert et al Pebert et aL Amyotrophic SG Stage I=0.74, Stage 4=0.45 
20011 lateral sclerosis 
Post et al [Post et aZ 20011 Stroke (meta- SG/TrO At risk=major 0.26-n-Linor 
analysis) 0.55, recovered=0.4 major- 
0.72 minor, not recovered= 
0.32 major-0.71 minor 
Kok et al [Kok et aL 2002] Benign Prostatic TTO (public) Worst =0.87 
hypertrop y 
Coffey et al [Coffey et al 2002] Diabetes mellitus SG TypeII 
Uncompficated=0.69-0.65, 
Type I uncomplicated= 
0.67-0.64 
Grunberg et al [Grunberg et al Emesis/survival in SG (healthy 6y/no emesis=0.89, 
2002] cancer patients volunteers) 2y/emesis=0.46, survival 2- 
6y=0.67-0.78, emesis- no 
emcsis=0.57-0-88 
Tengs et al [Tengs et aZ 20021 Acquired Immuno Tro AIDS=0.7, Symptomatic 
Deficiency IIIV=0.82, Asymptornatic 
1 Svndrome HIV=0.94 
- Siderowf et al [Siderowf et aZ Parkinson's EuroQol/flUI 0.58 
. 
20021 
1 
disease n-A 11 
1 
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9.7.2 EuroQol utilities 
Health state preferences derived from the EuroQol questionnaire (chapter VU) showed 
higher baseline values when compared to those derived by SG/ ITO methods; and the 
change with treatment was also substantially smaller. This apparent discordance with the 
impact of treatment measured by the other methods in the same population has been 
reported similarly in the literature in SAHS patients [Jenkinson et al. 1998]. Measures 
such as the EuroQol are now widely used in assessing the impact of healthcare 
interventions in various countries especially in Western Europe and incorporated in 
economic evaluations. 
The discordance with values obtained by other methods raises two main issues; (i) Is the 
indirect assessment tool sufficiently sensitive to measure the impact of treatment in 
different patient-disease combinations? (ii) And should societal norms be given 
precedence over patient's own assessment in matters of resource allocation? Unlike the 
directly obtained utility values (as in SG/ 170 methods) the EuroQol derives its utility 
values indirectly based on population norms. Thus the potential of administering a simple 
questionnaire to assess both HRQL and health status in one sitting offers logistical 
advantages in large scale assessments. However such disparity of results obtained in 
certain patient populations may undermine the validity of the health policy decisions 
made on their basis. 
It has been suggested that the EuroQol is 'less sensitive' to the impact of the disability 
suffered by SAHS patients Venkinson et al. 1998], while it has a variable confidence in the 
results obtained in rheumatologic [Hurst et al. 19941 where it shows moderate to high 
correlations with measures of impairment and disability; or neoplastic diseases [Conner- 
Spady, et al. 2001]. Many patients with low EuroQol scores (including some with health 
states that were 'worse than death') had high health thermometer scores. In addition, the 
1severe'value is so extremely abnormal that few patients endorse it especially in physical 
functioning dimensions. Penalty scores are applied to those with at least one maximally 
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abnormal score hence the scoring properties and distributional aspects of the EuroQoI 
may indicate a lack of homogeneity in the lower end of the scale [Wolfe et al. 19971. 
SAHS patients (chapter VII) with severely reduced utility values obtained by SG methods 
had higher values from EuroQoI reflecting an opposite phenomenon (compared to stroke 
[Dorman et al. 19971 or rheumatologic diseases [Hurst et al-19941) where patients are 
reluctant to report severe disability in physical dimensions. Thus due to the variable 
weighting of the physical and anxiety/ depression questions the results obtained in 
different diseases may be substantially different. There is also evidence of EuroQoI being 
less sensitive at the ceiling (i. e. low levels of perceived ill-health) and throughout the 
range of health states when compared to the SF36, while skewed values are obtained in 
the physical dimensions [Brazier et al. 1993a]. 
The weighting in EuroQol is derived from population studies where typical case scenarios 
are presented to normal responders and utilities obtained by TrO method. Tbus 
compared to directly obtained values of utility from patients (patient's preferences) the 
EuroQoI indirectly derives these from population perspective. While EuroQol may be 
valid in comparing the effect of different technologies in the similar patient groups, it may 
not be comparing like for like' in diseases causing predominantly physical versus mental 
health problems. Recently methods have been suggested to minimise this skew in favour 
of physical disability [Brazier et al. 1993a], however one may argue that in matters of 
health policy it is the population's imperative to decide whether allocation of resources 
should be preferably given to patients with disability in physical functioning rather than 
mental/ social functioning. 
9.7.3 OALY 
The incremental individual health preferences (utility) when combined with their life- 
expectancy generates 'the QALY gained', which has been used extensively in health 
economics and to guide resource allocation when comparing the impact of competing 
health care interventions. Compared to the conservative lifestyle intervention group, 
CPAP patients gained between 0.9 to 4.2 QALYS. Conceptually, the QALYs gained by 
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different health care interventions can then be compared in a head-to-head fashion in 
assessing the cost-utility ratios in health care resource allocation. Because the QALY 
conceptually encapsulates either a patient's own preference for a health state or a 
community perspective (when subjects are asked to value different health state scenarios), 
resource allocation based on such preferences are considered ethically justified in a 
welfarist perspective (maximisation of health benefits fi-om given resources). The 
community perspective in this study is derived from the study population by summing the 
individuals' values. It is usually argued that this method of QALY generation and 
obtaining community preferences by summation of individual values is only valid under 
the principle of uncertainty i. e. using the standard gamble approach [Torrance 
1986a; Torrance et al. 1989; Torrance 1986b] - 
QALYs generated by the three different methods (SG, TrO or rating scale i. e. EuroQol) 
were found to produce different results in this study, hence potentially reducing the 
certainty of basing resource allocation on such variable results. Since the SG method is 
based on the traditional utility theory and encapsulates the individual's health state 
preference under risk (or uncertainty) it is regarded as the 'gold standard' method by 
purists. However the utility values obtained by the TTO method [Torrance et al. 1972a] 
under certainty and the EuroQol derived index have been considered unsuitable for 
summation to obtain community preferences in the same way by some authors [Gafni et 
al. 19951 [Gafni et al. 1993c]. Similar discrepancies in health state utilities have been 
reported when different methods have been used to generate them and attempts have 
been made in various ways to resolve these differences [Hornberger et al. 1992; Read et al 
1984; Mehrez et al. 199ob]. 
The health economic theory of utility generation and cost-effectiveness maximisation as a 
predominant vector in resource allocation decision-making, is still a matter of debate and 
some authors have highlighted that QALYs do not indicate the need of patients for a 
treatment, something which is considered important in health care provision [Cohen 
1996]. 
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Thus although QALYs demonstrate the benefit obtained by treatment with CPAP in this 
study (chapter WI), the amplitude of such a benefit as obtained by SG method was larger 
than that obtained by TTO; that generated by the EuroQoI method was not statistically 
significant. All three were closely correlated with each other and with HRQL measures 
suggesting their convergent validity. 
There have only been two other studies examining the cost-effectiveness of treatment in 
SAHS patients. In a retrospective and uncontrolled study with 19 SAHS patients 
established on CPAP therapy for a mean period of 9 months, Tousignant et al [Tousignant 
et al. 1994] demonstrated 5.4 QALYs gained by treatment (using the SG approach). 
However, the lack of randomisation, absence of a control group and retrospective 
assessment of successfully treated patients cannot guard against a treatment bias in the 
results. 
The QALYs obtained were based on individual health preferences and summed to 
generate the community perspective; an approach considered compatible with economic 
theory. Although these patients had much higher health state utilities at baseline than in 
the present research (maybe subject to a positive recall bias), the number of QALYs 
gained from CPAP treatment were similar [Tousignant et al. 19941. Similar results 
obtained from the Canadian study (mean duration of 9 months) compared to those 
obtained from 3 months of CPAP would suggest a maintenance of the benefit obtained on 
long term therapy. 
In the only other published study with 46 SAHS patients (AHI>3o hour-)) in a Spanish 
Hospital Sleep clinic, utilities were derived using the EuroQol health index. The baseline 
utility of o. 74 was reported to have improved by a modest o. o73 after 3 months of CPAP 
therapy (Mar et. al. 20031. The main problem in this study was once again a lack of 
randomisation and absence of a control group. The authors have justified the use of 
EuroQol (previously demonstrated to be insensitive to the HRQL change in SAHS 
patients [Jenkinson et al. 1998]) by suggesting that they were interested in generating 
preferences and not HRQL. 
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On the basis of QALYs gained by CPAP over those gained by the control group, there is a 
clearly demonstrable 'effectiveness' of this form of therapy. This is in conjunction to the 
benefits demonstrated by other measures of effectiveness i. e. HRQL tools, ESS scores etc. 
and thus can be assumed to reflect a real impact of the health technology. 
The question which remains is whether the size of change obtained by the SG method 
(under uncertainty) and that obtained by ITO method (under certainty) can be 
considered equally robust in health economic assessments. For the data presented in this 
research from SAHS patients, both the SG and TTO utilities demonstrate significant 
relationships with PSG variables (sleep latency, oxygen desaturation and AHI), 
demonstrating their construct validity, unlike EuroQol utilities. However, the impact of 
change with treatment may be exaggerated due to the psychological distress suffered by 
these patients, leading to a risk-affinity; hence higher SG changes in utility. 
Furthermore, the SG method incorporates the concept of death in the event of treatment 
failure, which to SAHS patients may not be a 'real' possibility (except in RTAs). Hence 
utilities obtained via the TrO method are possibly more representative in chronic 
conditions such as SAHS, where death is not a 'real' possibility and patients are willing to 
exchange 'years of life' for perfect health. 
Until such time as a 'gold standard' is reached most health economic assessments may 
need to use a variety of methods to generate the utility weights for QALYs and 
comparisons should take into account the method used in order to avoid bias. 
9.7.4 Cost-utility 
While the denominator in the cost-utility ratio i. e. benefit / utility has been established 
with the results of the RCr (chapter V71), there are certain issues regarding the cost 
framework used. Primarily SAHS is a disease causing mental health and social 
dysfunction with effects on job performance [Ulfberg et al. 19961, neuro-cognitive 
HTA in SAHS; PbL) lbesu Indrand Chakramn 
,y 
2005 290 
Chapter IX: Discussion & Conclusion 
function [Engleman and Douglas 1993b], accidents [Teran-Santos et al. 1999] and 
consequent health care resource use [Rodenstein 20001 [Douglas and George 20021 
[Pelletier-Fleury et al. 20041. The cost perspective used in this study was deliberately kept 
to NHS direct treatment costs with data collected for the NHS cost of a patient going 
through the study protocol. This faithfully mirrored the 'real life' scenario in the 
Birmingham Heartlands Hospital sleep service. 
The only caveat to the above 'real life pathway' was not using the screening advantage of 
overnight home oximetry in addition to symptoms of snoring and SAHS to 'fast-track' 
patients through to treatment; this relatively inexpensive procedure may have bypassed 
the labour (and cost) intensive full polysomnography in some patients. Within the 
sensitivity analysis, costs obtained from three other NHS regions have been incorporated 
and presented in table demonstrating the stability (& generalisability) of the inferences 
drawn from the results obtained in the study centre. 
The cost analysis did not take into account the societal perspective (i. e. increased 
performance, reduced driving risk, cost of accidents [Teran-Santos et al. 19991 [Sassani et 
al. 20041 [Pack and Pien 20041, insurance claims, job losses [Ulfberg et al. 19961, reduced 
use of hospital resources [Pelletier-Fleury et al. 20041 [Pack et al. 19991 Other than for 
sleep disorder diagnosis & treatment). Inclusion of these broader costs to society would 
be likely to improve the cost /benefit ratio in further favour of the intervention [Pack and 
Gurubhagavatula 1999] [Rodenstein 20001. 
The final results obtained show that treatment of moderate to severe SAHS patients with 
CPAP over their lifespan would cost between Ei189 to E3034 per QALY gained (SG and 
TrO approach after discounting both costs and benefits) which falls below the 20000 
GBP/QALY range recommendation for highly cost-effective interventions proposed by 
NICE in the UK [Tamisier, et al. 20041. These somewhat arbitrary cost/QALY thresholds 
proposed for such decisions vary according to national socio-economic norms and 
expectations [Franco 20041. Table 9.3 presents a range of cost/ QALY ratios from a 
HIA iff JAHJ; PhD tbesis Indrand Chakravoný 2005 291 
Chapter IX: Discussion & Conclusion 
literature survey conducted recently showing that the SAHS cost/ QALY ratios are likely 
to be well placed in the top five categories for cost-effectiveness. 
There is an emerging trend for generating cost-effectiveness ratios for most interventions 
(table 9-3) as a method of changing decision-making behaviour and improving the 
efficiency of healthcare resource allocation [Alban 19941. 
In the UY, recommendations by NICE based on cost-effectiveness along with professional 
analysis is currently being recommended for commissioning health care intervention 
[Hutton et al. 2ooo]but purchasers remain sceptical about affordability of such 
recommendations by the health services [Davies and LittlejohnS 2002]. 
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Table 9.3: Cost/ QALY ratios for various healthcare interventions 
Intervention Cost/ QALY 
E 
Cataract surgery in the fliTt instance [Busbee et al. 2002] 
(S) 
1263(2020) 
Total hip replacement for >85 year olds [Chang et al. 1996] 2875(46oo) 
Low molecular weight heparin for thrombotic disease [Gould et 4888(7820) 
al. 1999] 
Smoking cessation program using nicotine patches[Cromwell et 3o97-6839 
al. 19971 [Fiscella et al. 1996] (4955-10943) 
Docetaxel vs. Paclitaxel for treatment of Breast cancer [Brown et 5384(8615) 
al. 1998] 
Carotid endarterectomy in asymptomatic patients [Cronenwett et 5000(8000) 
al. 19971 
Cardioversion + Amiodarone vs. Cardioversion + Warfarin 5813-11813 
[Catherwood et al. 1999] (93oo-18goo) 
Screening for hypothyroidism [Danese et al. 19961 5764-14122 
(9223W-22595M) 
Cervical cancer screening for HIV patients [Goldie et al. 1999] 8ooo-17250 
(12800-276oo) 
Cochlear implantation in Large vestibular duct syndrome [Bichey 11145 (17832) 
et al. 2oo2l 
Intensive therapy for IDDM vs. NIDDM [Herman et al. 19971 12500-10000 
(20000-16ooo) 
Percutaneous stent insertion for Iliac arterial obstruction [Bosch 12500(20000) 
et al. 1998] 
Mechanical ventilation for Chronic obstructive pulmonary 16427-27877 (26283- 
disease [Anon et al. 1999] 44602) 
Drivers airbag vs. passenger airbag use [Graham et al. 19971 15000-38125 (24ooo-6iooo) 
Screening for carotid atherosclerotic disease high vs. low 21956-32868 (35130- 
prevalence [Derdeyn et al. 1996] 52588) 
Screening > 25 year olds for Type Il diabetes [Anonymous 354o6(56649) 
igg8b] 
Insulin like growth factor in amyotrophic lateral sclerosis 42150(67440) 
[Ackerman et al. 1999] 
Prostatic biopsy for PSA levels at 20 mg/ml to Omg/ml> 50 year 42500-171875 
olds [Gottlieb et al. 1996] (68ooo, to 275000) 
Angiography, SPECT over Stress echocardiography, PET for 58750,46875,400000 
Ischaemic heart disease [Garber et al. 19991 (94000,75000, 
64oooo) 
Erythropoeitin for Chemotherapy induced anaernia [Barosi et al. 118533(189652) 
19981 
Transmyocai7dial laser revascularisation for angina [Campbell et 142500 (228ooo) 
al. 20011 
Interferon 0 in progressive Multiple sclerosis patients [Forbes et 1024667(1639467) 
al. 19991 
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9.8 DIFFUSION & ADOPTION 
The pathway for an innovation from the bench to the end-user is conceptualized to pass 
through a staged process of diffusion, dissemination, and implementation/ adoption. 
Using a staged model of behaviour change, diffusion is seen as a precursor for 
dissemination activities, which in turn prepares physicians to consider change in their 
practices. In the case of CPAP use in SAHS patients, the rate of adoption has been 
variable in different parts of the world. 
9.8.1 Innovation characteristics 
Prior to the introduction of CPAP as a treatment option for SAHS in 1981 [Sullivan et 
al. 1981], and its subsequent commercial availability in 199o the treatment for this chronic 
condition involved surgery, which due to increased associated mortality and morbidity 
tended to be reserved for the more severe end of the disease spectrum. Compared to the 
alternative therapies (i. e. laser palatoplasty [11ttrier et al. 20011 and mandibular 
advancement devices [Marklund et al. 20041), CPAP had a number of advantages as an 
innovation. Unlike surgery, CPAP could be potentially used in almost all patients with 
SAHS regardless of severity, it was a reversible option, it was painless, it was not 
associated with any therapy related mortality risk and even morbidity associated with its 
use was less than with surgery [Meslier et al. 19981. Yet the benefits were apparent after 
the first nights' use by the patient [Karlawish et al. 20011. 
CPAP also had a reported acceptability Of 85% [Engleman et al. 1993c] [Engleman et 
al. 1994c] [Meslier et al. 1998] [Noseda et al. 20001 [Zozula and Rosen 20ola] among 
moderate to severe SAHS patients as demonstrated in [Popescu et al. 2ooll [Meslier et 
al. 1998]chapter IV. Some patients may report discomfort from the tight-fitting mask 
[Janson et al. 2oool and dryness of the oral mucosa [Massie et al. 1999]. These are usually 
solved by simple measures such as humidification [Massie et al. 1999] and do not appear 
to interfere with long term usage [Meslier, et al. 1998] [Popescu et al. 200i]. CPAP is 
known to be preferred over placebo [Montserrat et al. 2001] or surgery [Lojander et al. 
1996] [Pepin et al. 19961 by a majority of patients, although oral devices were found to be 
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the most favourable [Wright et al. igg8b]. Compliance studies have found an average use 
of between 3-5 hours/ night for most patients on the CPAP, with almost equivalent 
clinical and symptomatic improvement [McNicholas 19971. 
From the professional point of view, the questionnaire survey results in chapter VIII 
demonstrated that the majority of primary and secondary care physicians prefer CPAP 
over surgical UPPP and oral devices, believe that benefit can be measured both in 
subjective and objective terms, and that it is relatively easy to use and understand for 
most of their patients. The primary indication for CPAP prescription was to alleviate their 
patients' symptoms. The properties of an innovation to provide benefits at a reduced risk 
to the user and it's relative ease of use, when compared to established options, may have 
a significant favourable impact on diffiision [Batz et al. 1999]. 
CPAP as an innovation demonstrates characteristics which should have favoured its rapid 
diffusion and adoption among SAHS patients and their clinicians. However, the 
possibility of a permanent cure from surgical options may seem more attractive to some 
patients (more often younger and male) rather than merely achieving control offered by 
CPAP [Gregg et al. 2ooo]. 
The post-introduction technological development of an innovation may impact on its rate 
of adoption [Andolfatto et al. 1998]. However the developments in CPAP technology (i. e. 
reduction in size, operating noise) and the use of auto-titrating machines have not been 
shown to improve patient compliance significantly to justify the additional costs [Ayas et 
al. 20041. Although some researchers argue that these auto-titrating machines may have 
a role in home-based titration thus reduce the operational cost of service provision 
[Uoberes et al. 1996] [Teschler et al. 19971 [Berry et al. 2002]. 
Unlike the first masks used which were moulded to take the shape of the individual 
patient [Sullivan et al. 1981], recent commercially available masks have limitations in 
balancing the air-tight fit on widely variable cranio-facial architecture with a comfort level 
which is conducive to sleep [Janson et al. 20001. Whether user-feedback from patients 
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would have helped to change the mask production systems and improve acceptability is 
not known and may be an issue which manufacturers may be persuaded to address in the 
future (personal communication from ResMed R&D chief in the USA). Innovations are 
often enhanced with end-user participation /feedback helping to shape and make the 
innovation more widely acceptable [Abed et al. 20001. 
9.8.2 Innovativeness 
Data from the questionnaire survey (chapter VIII) indicate that of the primary care 
physicians with an interest in sleep disorders, almost a third were early adopters/ 
innovators while half were in the early majority. Similar ratios of innovativeness were also 
found among secondary care respondents. This suggests a positive adoption bias for new 
technology among primary (and secondary) care respondents. 
As the primary care questionnaire was sent to PCT Chief Executives with a covering letter 
requesting them to forward it to GPs who either had an interest in sleep related disorders 
or in new technology or responsible for healthcare commissioning, there may be a higher 
proportion of 'more innovative' individuals in the group surveyed. When the diffusion and 
adoption of coronary stents were compared with that of the magnetic resonance imaging 
(MRD scanners or the introduction of cholesterol lowering agents in the West Midlands 
region, enthusiastic individuals (opinion leaders and early innovators) had a significant 
role in the rapid diffusion of stents [Booth-Clibborn et Q1.20001. 
Innovativeness also is known to depend on a clinician's position within a social network, 
where secondary care physicians are likely to be more innovative (as seen in the survey) 
than primary care physicians [Burt 198o]. Although physician conservatism is often 
identified as one of the primary causes of slow diffiision [Banta et al. 19931 the findings 
from this survey (chapter VIII) would make this unlikely as a cause for the slow adoption 
of CPAP in the UK 
9.8.3 Physician networks & geographical influence 
In the case of diffusion of CPAP, physician networks (peer-to-peer) were reported to play 
a major role in the dissemination of information between secondary and primary care. 
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This may have influenced an increased professional awareness of SAHS among primary 
care physicians and resulted in the increased number of referrals received by secondary 
care physicians providing diagnostic and treatment facilities, as demonstrated in chapter 
IV and chapter VIII. The survey (chapter VIII) respondents also reported an absence of a 
defined structure for the distribution of such 'expert' information from secondary to 
primary care, with a view to increasing adoption and making such treatment more widely 
available in the NHS. 
The survey of primary care physicians identified personal contact with local expert 
physicians (go%) as one of the primary ways of influencing referral behaviour for SAHS. 
This was followed by scientific journals (62%) and peer-to-peer (55%) informal contact. 
Media representation was the least likely factor to influence decision-making among the 
majority of primary and secondary care physicians in the questionnaire survey. While in 
diseases such as cancer, acquired immune deficiency syndrome or dissemination of family 
planning education, mass communication agencies have important roles [Alcalay 
1983; Gupta 1996] [McAlister iggi] [Piotrow et al. iggil. 
Diffusion is also dependant on the position of the prescriber in the social network 
structure, where 'local experts', consultants in DGHs with an interest in a technology may 
play an important role in the diffusion of knowledge on its diagnosis and treatment for 
their local primary care contacts [Burt 198o]. 
When asked about the existence of a proper structure of knowledge diffusion from 
secondary to primary care within the NHS majority of primary care physicians denied 
that such a system existed (85%). Even among the secondary to primary care, diffusion of 
knowledge the system seemed to be informal. Both lack of adequate information [Brown 
1984] and spontaneous diffusion of knowledge [Buss et al. 1999] is known to be an 
important factor in the poor adoption of technology. 
In the absence of a national framework or guidelines in the UY, local innovators/ early 
adopters are likely to have a significant role in regional differences in availability of 
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diagnosoc 1"ities and adoption ot CPAP innovation. Such examples of local initiative 
haw been kxind to be significant in influencing diffusion compared to national strategies 
in quality unprovernent adopted in "'pitals in Finland [Baptista 20001 [Brommels et al. 
199-1 
had user dem&M lot an tnno%ation is one of the factors influencing the rate of diffusion 
of technolM (Byungryong et al. 19961. Although there has been a stead), increase in the 
number 431 patients approaching their GPs with symptorns of EDS suggestive of SAHS (as 
men in chapter IV and reported by respondents in chupter V711), there is hardly anv 
vuibk influence of petimmt orpnisations in the diffusion of CPAP in the UK. 
Unlike the USA. wbere organuations such as the National Sleep Foundation 
[Anon. 2oo4b) wrield a significant influence on policy making and patient self-education in 
this fie4d, such act"wa have not yet made a significant contribution in the UK. The Sleep 
Apows Truxt [Awm. 2oo4c) (a patient led self-help organization), British 'Moracic 
SoMI). Bntah Skvp Society (an amwiation of professionals with an interest in sleep 
doordm) have bttle dewxmstrabie influence on the media, governmental agencies 
respon")Ie kw hcahh policy and reamrces, or in man education/ awareness programmes. 
In compansook. the Natumal Asthma campaign, British Iung Foundation, British Heart 
Foubdatwe AM the CY'hc Fbftwis Tru2t have an important role in raising the profile of 
the dismat to the public through ma" education, dissemination of material to the media, 
rsi-. mir fund, flir, letk-alrd rt %t Aruh, wlf hell) and influencing policy. 
9.8.5 Industry 
Comnscrvwl pcixtut-twn )I CPAP %, A., commenced by ResMed Inc in i, 49o jirasiaxoni 
, 
Nlack iw49. RrsNled Inc 20031 and since then the compan), has grown in size and 
CSPIW at a rate of Abotut 20% per annum [Mack 19"J. 11c survey results indicate 
buwevw thm uktmtry has bad little influence in the diffusion and adoption of this 
WebackW a the UL Wbenes in Australia and USA, CPAP manufacturers are 
.- lederd itir t1WW nAe 0 the sup" of research and development, maintaining 
close baks w*b the awdbral hateraft and enpjpng in sovernmental dialogue, there is 
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little evidence of such an impact in the UK [irasia. COM 2002]. Both primary and 
secondary care physicians placed influence from industry low in their proffle of factors 
influencing decision-making in the UK survey (chapter WII). 
In the news letter the Sleep Apnoea Trust has commented on the lack of industry support 
for their educational activities [Anon. 2004c]- Personal interviews with industry sources 
[Newby 2002] have identified that the slow diffusion and growth of the regulated UK 
market in CPAP devices acts as a deterrent for provision of resources for the support of 
patient awareness campaigns and research grants. 
Another factor in the lack of industry engagement in the UK NHS sector is due to the NHS 
purchasers negotiating lower prices based on the power of buying machines in large 
numbers, hence reducing unit prices and profit margins. This phenomenon has not been 
balanced by sufficient growth in number of machines in order to justify the lower prices 
from the manufacturer's perspective. Such a strategy although artificially driving prices 
down to the benefit of the consumer, has had a negative impact on the growth of the 
CPAP industry. Thus price regulation without the benefit economics of scale in a managed 
care environment may have a negative influence on the diffusion and adoption of new 
technology [Banta et al. 19831. 
Commercial promotion or marketing by manufacturers are important in expediting 
diffusion in the case of statins [Booth-Clibborn et al. 2oo, o] but there is little evidence of 
large scale marketing of CPAP in the UK and hence little impact on its adoption. 
The failure of further technological improvement in CPAP technology (i. e. the 
introduction of automatic CPAP titrating machines) to impact on the growth of the CPAP 
market in the UK has had a negative impact on the resources available from the industry 
for professional and public awareness campaigns. A study of innovation in cotton 
spinning machines demonstrated that expectations of continuing incremental change 
may have actually slowed diffusion, while potential for increased profitability from their 
adoption did not reinforce the rate of change resulting in a slow down in the industry 
[Antonelli 1989]. Hence the focus of the CPAP manufacturers has shifted towards finding 
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wider uses for the CPAP therapy in patients with heart failure, cerebrovascular disease, 
Alzheimer's disease- extending beyond the SAHS horizon [ResMed InC 20031. 
While emerging research evidence on extended roles of CPAP in such diseases in the USA 
[Yan et al. 2001] [Bradley et al. 2001] has a positive role in further improving adoption of 
such machines, there is little demonstrable transfer of this evidence in the UK medical 
community. Hence the disparity in the rates of diffiision of this technology between the 
USA/ Europe and UK is likely to continue at a potential disadvantage to the sufferer. 
9.8.6 Organisational factors 
Primary and secondary care physicians responded to the questionnaire highlighting 
financial restrictions as the most important factor responsible for their patients not 
receiving therapy for SAHS. The lack of adequate facilities for diagnosis [Semple and 
Gibson 19931, long waiting times, lack of patient education campaigns and lack of 
governmental imperative [Sleep Alliance. 20041 were also shown to be responsible for the 
slow adoption of CPAP within the NHS in the UK 
Financial regulation and the absence of incentives (in a managed care scenario) may have 
had a role in slowing down the adoption of innovations (as in the case of MRI scanners 
between ig8o and 19go), regardless of their clinical effectiveness [Baker 20011. Similar 
budgetary constraints have been found to slow down the diffiision of minimally invasive 
therapy in Europe [Banta 19931. 
Although professionals often are highly respectful of scientific endeavours, in reality, daily 
decision making is shaped more by power structures, ingrained routines, and established 
resource configuration than by current scientific findings. In most organizations, 
standard operating procedures and behavioural norms are the major influences on 
workplace practices; scientific evidence plays a minor role [Rosenheck 20011. A logistical 
barrier in the application of the research in complex organisations such as the NHS may 
require the collaboration of multiple individuals and dynamic environments with an 
extensive turnover. This may result in constant personnel changes and diminished 
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commitments. Success may depend on the commitment of key people (opinion leaders) 
within the organization to see the activities through from planning to implementation to 
evaluation [Rosenheck 20011. 
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CONCLUSIONS 
9.9.1 Contribution to new knowledge 
The research undertaken and presented in this thesis was designed to appraise CPAP as a 
health technology and explore its diffusion, and has contributed significantly to new 
knowledge in this field. This includes one of the first prospective, randomised controlled 
trials to assess the clinical and cost effectiveness of CPAP against a standardised lifestyle 
intervention strategy; the second known study world-wide to apply and assess generic 
health related quality of life, mental health tools and health status measures in this 
patient group, and the first to do this prospectively; and the only study to date which has 
explored factors influencing diffusion and adoption of CPAP in the UK. 
Thus firstly, this research has addressed the dearth of well-designed RCTs in assessing the 
impact of SAHS, and in particular the principal criticism of previously published studies 
regarding the influence of co-morbidities (i. e. hypertension, cardiovascular disease etc ... ) 
and lifestyle factors such as obesity and smoking. The RCT data (chapter 10 showed that 
CPAP demonstrated a significant efficacy in reducing the baseline AHI, AI and EDS and 
improving neurocognitive function in these patients. The lifestyle intervention in the 
control arm of this RCT was designed to evaluate the impact of this strategy in a real life 
DGH scenario potentially applicable to all secondary care sleep clinics in the UY_ The data 
demonstrated that lifestyle intervention was also modestly effective in reducing weight 
and improving sleep-related disease parameters. 
Secondly, the research evaluated the reliability and validity of 2 widely used generic 
multi-dimensional HRQL tools (SF36 & EuroQol) in the assessment of the impact of 
CPAP in SAHS patients and compared them to the mental health assessment instruments 
(HADS & GHQ28), chapter VI. Patients on CPAP demonstrated significant improvement 
in social functioning, energy/vitality and mental health dimensions of SF36. The changes 
in the physical dimensions were significantly less and remained sub-normal compared to 
population values. The mental health assessment tools showed a reduction in anxiety and 
depression scores and the number of patients classified as 'cases' with significant 
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psychiatric Morbidity versus 'normals'. The EuroQoI thermometer visual analogue scores 
(VAS) showed an improvement and discriminated between the groups but the EuroQoI 
scores were less sensitive. Patients in the lifestyle intervention arm demonstrated modest 
improvement in VAS but not in HRQL measures. There was even a trend to increased the 
numbers of 'cases'with psychiatric morbidity and depression scores in this group. 
Thirdly, the research evaluated and compared 3 different methods of generating QALYs 
using the standard gamble (SG), time-trade off (TTO) and EuroQol utilities, chapter VIL 
Both the SG and TTO methods demonstrated construct and convergent validity and 
showed improvement in health status after intervention. The improvement recorded in 
the lifestyle intervention arm was modest compared to the CPAP arm. The EuroQol index 
did not demonstrate sensitivity to changes with intervention and failed to discriminate 
between the groups after treatment suggesting that it may not be an appropriate measure 
for use in this disease or patient group. 
The direct QALYs generated in this prospective, randomised controlled trial were used to 
undertake a cost-utflity analysis of CPAP in SAHs. This is the first and presently the only 
such economic evaluation study in SAHS. The cost/QALY ratios obtained were well below 
the E20,000 / QALY threshold recommended by NICE in the UK [NICE 20041. The cost 
utility ratios remained robust when incorporating costs from other NHS regions a 
sensitivity analysis was undertaken [Chflcott. j, 2000]. Patients with sAHS demonstrated 
a risk-affinity resulting in utilities generated by SG method being lower than those 
generated by TrO method at baseline. Thus, the increment in utilities obtained by SG 
method was higher than TTO generated utilities with intervention. The TrO generated 
utilities demonstrated a relationship with age, where at extremes of age, respondents have 
been known to over-estimate or under-estimate their health status [Martin, 20001. 
Fourthly, the research on factors influencing diffusion and adoption of CPAP presented in 
this thesis is the only study of its kind in the area of SAHS, chapter VIII. This research 
demonstrated that CPAP, although known to have characteristics which may favour its 
adoption by secondary and primary care prescribers as well as patients, had a slow and 
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variable adoption in the UK compared to Australia, USA and similar economies in 
Western Europe. As an innovation, CPAP demonstrated a high rate of acceptability and 
tolerability among patients included in therapeutic trials and followed up over the seven 
year retrospective study period (chapter I10. This was also demonstrated in the RCT 
presented in chapter V where 34/37 of trial subjects continued to use their CPAP for the 
trial period. In addition, the questionnaire survey respondents in chapter VIII also 
reported the tolerability and acceptability of CPAP to be strong predictors of its successful 
adoption by patients. The majority of respondents to the primary and secondary care 
survey demonstrated a clear understanding of the benefits of the CPAP therapy and the 
indications for treatment. 
While the primary care respondents felt that CPAP may be replaced by a more effective 
and patient friendly option in the future, the secondary care respondents felt CPAP was 
likely to remain the most effective option in the near future. 
Both primary and secondary care respondents considered themselves high in the 
innovativeness scale (innovators or early majority) and gained most of their knowledge 
from local experts, informal peer-to-peer social networks and scientific journals. 
They reported absence of structured communication pathways for the education of fellow 
professionals, which may slow down the rate of knowledge diffusion and may be affected 
by geographical availability of local experts. The absence of a structured dissemination 
mechanism for expert knowledge on such systems within the NHS led to increased 
reliance on local champions and local experts and informal diffusion of knowledge, which 
may have had an adverse effect on adoption. 
The respondents reported little influence of media or patient-support groups on the 
diffusion and adoption of CPAP in the UY, This may be why there is limited impact on the 
public and therefore influence health policy makers and resource allocation. 
There was little or no reported influence from the CPAP manufacturing industry 
especially in the feedback-reinvention of CPAP loop in the UK and in increasing public 
and professional awareness. 
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One of the major hurdles in the diffilsion and adoption of CPAP was reported to be 
budgetary restraints within the NHS and the inadequate availability of diagnostic and 
treatment facilities in the UY,, leading to a time lag. 
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9.9.2 Recommendations 
1. Improving the nationwide uniform availability of diagnostic and 
treatment facilities for SAHS in the UK would help to reduce the number 
of untreated patients, improve the rapid access to treatment and have a 
positive impact on individual HRQL and benefit to society. 
The cost of untreated disease to society (manifest in losses through 
accidents, poor performance, etc. ) and the potential benefit from 
treatment provision needs to be assessed in future studies and balanced 
against the cost of treatment provision, in SAHS. This would accurately 
reflect the cost-benefit ration for healthcare intervention in this sector. 
3- The benefit of lifestyle intervention in SAHS would need to be assessed 
using larger trials, longer periods of follow up and by the incorporation of 
pharmacotherapy in the reduction of obesity. 
4. Whereas variation in the impact of different therapeutic options in a 
particular patient/ disease group can be assessed using disease specific 
measures, the concurrent use of generic measures (especially patient 
preference variables) routinely in trials would help achieve universality 
and allow for their use in prioritisation and resource allocation decisions. 
5- There is a need to investigate with population based prospective cohort 
studies whether patient with SAHS are at risk of increased mortality due 
to the condition itself and whether initiation of CPAP therapy modifies 
this risk. As the presence of obesity, hypertension and other co- 
morbidities may impact adversely on this perceived increased risk. 
Further studies are needed to categorise the contribution of SAHS to 
increased cardiovascular, cerebrovascular or diabetic risk controlling for 
the risk from obesity, smoking and hypertension 
6. Fast-tracking of symptomatic patients by using overnight, arterial pulse 
oximetry/ limited sleep studies would reduce cost of investigation and 
potentially reduce waiting times. 
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7. Conducting larger scale RCTs in patients with different levels of SAHS 
severity in order to assess cost-effectiveness of healthcare intervention 
using patient preferences (utilities). 
8. Health technology appraisal of established innovations needs to be 
conducted alongside RCrs, especially incorporating generic outcomes 
data and cost-effectiveness analysis. 
9. There is a need for further research to identify 'gold standard' in 
measuring patient preferences which demonstrate good sensitivity, 
specificity and reliability in majority of chronic conditions to allow 
comparisons. Although HRQL measures are important in identifying the 
degree and type of disability suffered by patients it is not appropriate for 
use in resource allocation as patient preferences are not incorporated. 
10. Encouragement of mutual cooperation and coordination of the activities 
of patient self-help groups and professional bodies to increase public 
awareness and improve provision of resources for treatment of SAHS 
patients. 
11. Systematic dissemination of clinical and economic evaluation data to 
adopters of healthcare innovations at various levels within the MIS, 
purchasing authorities and health policy makers may help to set priorities 
at local and national level and help achieve uniformity in healthcare 
provision across the country. 
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APPENDIX I 
BIRMINGHAM HEARTLANDS HOSPITAL RESEARCH AND ETHICS 
COMMITTEE 
APPLICATION 
Title of the projec 
y of the Prrvalence, Quali! ý, of Li n Ith c, nmm ep n A Stud ife ad Hea Eoo ic I pact of Sle Ap oeal 
H)popnoea Syndrome and the effectiveness of trralment mith nasal Continuous Pojifive Airway 
Prrssurr inpatients wiM and wiMout cardiovascular co-morbidio. 
2. BacLcground of the project: 
The Sleep Apnoea/ Hypopnoea Syndrome (SAHS) is the commonest of the sleep- 
wake disorders. Although, public and professional awareness has increased rapidly 
over the last two decades, research, diagnosis and treatment in the UK lags behind 
Australia, USA and other European countries. The SAHS is characterised by 
recurrent obstruction or narrowing of the upper airway during sleep, causing episodic 
asphyxia leading to recurrent arousals and disrupting sleep to the point of injurious 
daytime consequences. 
Prevalence studies in the adult population 2 found that 2% of women and 4% of men 
had both significant daytime sleepiness and an apnoea/hypopnoea index (AHI) of 
>5/hr of sleep; thus assuming the dimensions of a major health hazard. 
The manifold consequences' of untreated SAHS from published epidemiological 
studies with cohorts followed up for more than 7 years, include cardiovascular and 
cerebrovascular disease, (hypertension, heart attack, stroke)4 , neuro-physiological disorders, (depression, loss of memory, loss of concentration, deterioration in 
intellect, alteration in personality and impotence in men), and social consequences 
(adverse effects on capacity to work, marital harmony) and road traffic accidents. In 
patients with Congestive cardiac failure the prevalence of SAHS is estimated to be 
40%-50% contributing significantly to mortality, deterioration of cardiac fimction 
and arrhythmia. 
Nasal continuous positive airway pressure (CPAP), first described in 1981 9, is a 
simple and effective treatment. Other treatment modalities include laser palatal 
surgery and mandibular advancement devices. Their efficacy is not proven. 
Recently, a major re-appraisal of CPAP treatment has been triggered by the 
publication of a systematic review into the health effects of SAHS. 'Health effects of 
Obstructive sleep apnoea and the effect of treatment with nasal CPAP(Wright et. al) 
Investigation and treatment of the SAHS has been adversely affected by this 
document, although the authorship of this publication did not include a specialist 
physician working in the field of sleep disorders. Evaluated within the current 
concepts of evidence based medicine, much of the earlier published literature in sleep 
apnoca has been criticised for small sample sizes, poor design, lack of correction for 
confounding variables, few double blind trials and lack of stratification for severity 
of the disorder. Although there is evidence of the effectiveness of CPAP in 
improving daytime somnolence, there are few data on its effect on health and the 
quality of life. Also, there are no studies on the health economic impact of the 
disease and the cost-benefit analysis of its treatment with CPAP. 
In the light of current financial constraints, within the Health service, there is an 
emergent need to assess the quality of life (QOL) and cost-benefit ratio of CPAP 
treatment of SAHS; in order to justify public funding and release further much 
needed resources, for the management of this common and disabling condition. 
Preliminary studies have shown a tremendous beneficial effect of treatment of 
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patient's with cardiovascular co-morbidity in reducing hospital admissions, transplant 
lists and improving survival. Data on quality of life and health economics is needed. 
3. Hypothesis: 
(a) The Obstructive Sleep Apnoea/ Hypopnoea syndrome (SAHS) adversely affects 
health and quality of life. It incurs a significant cost to the individual, health 
services and society. 
(b) This can be effectively improved by treatment with nasal continuous positive 
airway pressure, (CPAP) resulting in a significant saving in Health care resources. 
(c) To calculate the cost-benefit ratio of treating patients with varying severity of 
SAHS and CCF, based on physiological and symptomatic parameters and hence 
developing guidelines for selecting the at risk group, with a potential for most 
health, quality of life and economic benefit. 
(d) To develop and validate a questionnaire for SAHS, which would be specific to 
the different dimensions of disruption of health (both mental and physicaD and 
quality of life as well as being sensitive to identify change due to treatment. 
4. Design of the Trial: 
All patients aged (18-70 years) from the BHH clinic referral population, with snoring, 
daytime somnolence, and symptoms to suggest CCF, would, after informed consent, 
be recruited into a prospective study. After assessment of baseline general health, 
QOL and Epworth Sleepiness Score (ESS), patients would undergo screerung 
oximetry and polysomnography (including EEG) to diagnose and quantify SAHS. 
Cardiac status would be assessed using New York Heart Association (NYHA) 
dyspnoea scale, Echocardiography and MUGA scanning. Patients would be grouped 
into isolated SAHS, SAHS with CCF and CCF without SAHS. Based on AHI, a 
measure of the number of episodes of obstructed breathing per hour of sleep, 
patients would be stratified into mild (AHI >5-10) and moderate to severe (AHI 
>10). This would follow prescription of formalised and written lifestyle advice, 
including dietetic support, and advice on stopping smoking and reducing alcohol 
consumption. 
Patients with SAHS and SAHS+CCF would be randomised into a double- 
blinded, placebo-controlled trial of CPAP treatment. The treatment phase would 
consist of a therapeutic level of CPAP for 6/12months. 
Health, QCIL, ESS, physiological parameters and a cost-benefit analysis 
(utilising time-trade off principles) would be assessed at baseline, and after 
completion of the double-blinded treatment phase. During this stage monthly diaries 
will be collected, recording data on health, GP visits, hospital admissions, clinic visits, 
days off work, marital relations, mood scores and employment, to assess economic 
impact of the treatment. 
Data Analysis: 
Prima1y variable for comparison is the effect size in QOL scores before and after 
treatment with CPAP. 
Secondary variable is the quality adjusted life years added by treatment with CPAP 
and cost-effectiveness analyses. 
Tertiary variables include change in ESS, AHI, Oximetry, echocardiography, NYFIA 
dyspnoea score, Health related activities, days off work, marital relations, mood score 
and employment. 
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All the variables would be compared within the group of patients with moderate to 
severe sleep apnoea, to evolve a statistically significant, selection criterion for 
prescription of CPAP to the patients with a definite demonstrable potential for 
benefit. 
Data from the generic quality of life questionnaires and the cost-benefit analyses 
would be used to compare with other chronic, disabling disorders in the Quality 
Adjusted Life Years (QALY) league tables, to help rationalise distribution of 
resources in healthcare. 
5. Patient Selection Criteria and Population Size 
All willing adults aged 18-70 years referred to the Medical & Sleep Clinics in 
Birmingham Heartlands Hospital from the commencement of the study with; 
snoring and disabling daytime somnolence or ESS >12 or symptoms suggestive of 
SAHS and CCF. Oximetry dip index of >5/hr, AHI >5/hr of sleep during 
polysomnography. 
Criteria for the treatment group; AHI >10/hr of sleep during 
polysomnography 
Exclusions; (i) inability to comply with protocol 
(ii) Inability to undergo polysomnography 
(iii) Inability to have a trial of CPAP. 
Number of patients; Based on very few published trials in the literature and effect 
size, our estimate is that 100 patients would be adequate for statistical analysis and to 
detect change in primary variable 
6. Measurements to be made & Assessment of risks: 
(i) General Health: clinical examination, blood pressure, urine biochemistry, 
blood biochemistry and thyroid function tests. 
(ii)Physiological: Oximetry, Pulmonary function tests, Capillary blood gases, 
ESS, Sleep specific questionnaire, and Polysomnography (Compurnedics 
sleep system with EEG, ECG, EOG, EMG, movement score, noise 
recording and infra-red video of sleep activity) 
(iii) Cardiac investigations; cchocardiography, MUGA scan, NYHA dyspnoca 
score 
(iii)-QOL: Short Form36 (SF36) and European Quality of life (EUROQOL) 
generic quality of life questionnaires. 
(iv)Health economics: Quality adjusted life years generated from time-trade 
off scores, with the help of scenarios and questionnaires. 
All the above parameters are measured routinely in all patients referred to the clinics 
and involve no perceivable risks. The questionnaires are simple, straight- forward and 
designed to be done in less than thirty minutes. 
The treatment with CPAP is an established safe treatment modality since 1983 and 
only very few reported side-effects are noise, nasal congestion and skin excoriation in 
areas of contact with ill-fitting masks. 
7. Names of Investigators: 
Dr. RM Cayton MD FRCP, Consultant Physician 
Dr JM Beattie FRCP, Consultant Physician 
Dr. I Chakravorty MRCP, Clinical Research Fellow 
Mr. M Hilton BSc, Clinical Scientist 
Ms. S Sapiano 
, 
Senior Technician 
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Ms. HK Rupraiý Sleep Technician 
Heartlands Sleep Clinic, Department of Respiratory Physiology, BHH 
Cardiology Clinic, BHH 
8. Duration of the Projec : 
Recruitment of patients; Nov'97-jun'98 
Follow up and replacement of drop-outs; july'98-jun'99 
Data Analysis and writing up; jul'99-Oct'99 
9. Venue: 
Depts of Respiratory Physiology, Cardiology and The Sleep Laboratory on Ward 10 
in Heartlands Hospital. 
10. Nature of Consent: 
Written Informed Consent 
11. Remuneration of the subjects: 
None 
12. Financial Interest to Department/Investigator: 
None 
13. Involvement of other Depts: 
Clinical Pathology and Dietetic Departments in the Heartlands Hospital 
(As part of routine assessment of patients) 
14. Approval of Vatient's General Practitione : 
It is envisaged that formal approval would not be necessary but GP would be kept 
informed of details of patient's progress. 
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8. He J, Kryger MH, Zorick Fj, Conway W, Roth T: Mortality and Apnoca Index in 
Obstructive Sleep Apnoea. Chest 1988; 94: 9-14 
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apnoea. by continuous positive airway pressure delivered through the narcs. 
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Dr. RM Cayton MD FRCP 
Consultant Physician 
Dept. of Respiratory Physiology 
Birmingham Heartlands Hospital. 
Dated: 280'Aug! 97 
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FORMIA 
Projects involving Drugs or Appliances 
1. Name of Appliangg: CP 90, Device for delivering Continuous Positive Airway 
Pressure. Manufactured by Devillbiss, ResMed, etc. 
2. Pharmacology/ Principle: Generation of a continuous positive pressure with a 
facial mask delivery system for ramping open the collapsible upper airway during the 
low muscle tones associated with deep sleep. 
ISide-effects: 
Noise, nasal congestion and skin excoriation in case of ill fitting masks. Used in the 
treatment of patients since 1983 with more than 2500 machines prescribed every year 
in 12 centres in UK. 
4. Projec Product licence 
Clinical Trials Certificate 
Clinical Trials Exemption 
None of these. * 
5. Supported by an Industrial CompaLly: 
Not yet. 
6. Clinical Trials Compensation Statement from Sponsoring Company: 
Na 
7. Radioisotopes used: 
Not used 
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PATIENT INFORMATION SHEET 
A study of the clinical, quality of life and economic effectiveness of continuous 
positive airway pressure therapy for the Sleep Apnoea Hypopnoea Syndrome. 
Heardands Sleep Disorders Chnic 
Department ofRespiratory Pb. Vsiblogy, Birmingham Heafdands Hospital 
The combination of snoring, excessive daytime sleepiness and a lack of energy 
is due to a condition called the sleep apnoea hypopnoea syndrome, which may go largely 
unrecognised both by the sufferer and his doctors. This condition occurs due to the 
repeated partial or complete obstruction of breathing associated with the muscle relaxation 
during sleep, causing a lack of oxygen in the body. This in turn causes the sufferer to wake 
up many times during the night, leading to an un-refreshed sleep and serious daytime 
consequences. 
Untreated sleep apnoea is associated with many adverse health effects including 
high blood pressure, irregularities of the heart, heart attacks, stroke, irritable personality, 
depression, impotence, loss of memory and poor intellectual capacity. It is being increasingly 
identified as a cause of serious lack of concentration and excessive sleepiness leading to 
accidents on the roads and at work. 
A simple and relatively new treatment option is sleeping with a mask over the nose 
connected to a small machine (CPAP) which keeps blowing air at a higher pressure to keep 
the airways open. This prevents snoring and normalises breathing during sleep, hence 
improving sleep quality, daytime performance and reversing the serious health consequences 
of sleep apnoea hypopnoea syndrome. 
We need your help in conducting a trial to find out more about the adverse health 
effects of sleep apnoea and to assess the effectiveness of this relatively new form of 
treatment. This trial may provide the essential scientific proof of the useffilness of this 
treatment and help provide for allocation of further resources to diagnose and treat more 
people affected by this condition. 
If you decide to participate in this study, you will be having the investigations which 
Help to diagnose sleep apnoea, including routine blood tests, a recording of your heartbeat 
and an overnight sleep test in a special bedroom. The test involves sleeping with an elastic 
band around your chest and abdomen and a few leads stuck with tape, to record your heart 
rate, movements, breathing and stages of sleep. If you have sleep apnoea, you would then 
have an equal chance of receiving CPAP treatment immediately or after 3 months of 
measures to improve your sleep quality and general health. Except for slight nasal 
congestion in some people there are no un-wanted effects of this treatment. 
During this study, we would request you to fill out simple questionnaires to help us identify 
what benefit you think the machine has on your health and quality of life. If found to be 
beneficial you would be offered treatment with this machine for life. 
You are free to withdraw from the study, at any stage without having to give any 
reason. This would not affect your future medical care in the clinic. The Ethics Committee 
of the Bim-lingharn Heartlands Hospital are satisfied that this is an ethical study and in the 
best interests of yourself and other patients. If you have any concerns on any aspect of this 
study please contact the Seartq! j of the Etbics Commiltee on 01217666611 ext: 4791. 
For any other queries regarding this trial, please contact Dr I Chakravota on 01217666611 
page 2513/ ext: 5796 or Dr RM CatLton IS secretary on 01217666611 cxt: 5192 
HTA is SAHS; PhD thens Indrand Cbakravorý, 2005 354 
Appendix 
FORM OF CONSENT 
PATIENT 
I --------------------------------------------- Of 
-------------------------------------------------- have read the explanation overleaf of the 
proposed Study of the clinical. quality of life & economic effectiveness of CPAP 
therapy in the Sleep A12noea Hypol2noea Syndrome, which forms part of this consent. 
The aims; and purposes of the study have been explained to me by: ---------------------- 
I agree to take part in this study and I understand that I am free to withdraw from 
the study at any time without having to give any reason. 
Signature: 
Date: --------------- 
DOCTOR 
I confirm that the above named patient has read the explanation overleaf and this 
consent and that I have explained the study to the patient and answered any 
questions arising from this. 
Signaturc: -------------------------------- 
Date: ----------------- 
WITNESS 
I confirm that I am satisfied that the patient has read and understood the explanation 
and consent. 
Signature: 
Date: 
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APPENDIX 11 
INFORMATION 
Obesity is an important risk factor for snoring and OSA. However, rather 
substantial amounts of weight loss are often required to produce a significant 
improvement in symptoms. Most studies looking at this factor show that the 
weight loss must be of the order of 20 - 30%. This can be very difficult to achieve. 
The success rate for sustained weight loss of 10 - 15% through diet and exercise is 
only about 5- 10%. 
Drugs such as Fenfluramine are now frequently prescribed for the treatment of 
obesity. A rare complication of prolonged use of this and similar drugs is a 
condition called Pulmonary Hypertension. This condition is usually fatal and there 
is no effective treatment apart from heart-lung transplantation. In cases of severe 
obesity, surgery to reduce the capacity of the stomach can result in more dramatic 
weight loss and significant improvement in OSA. However, these operations 
should only be performed at specialised centres. There are numerous medical 
complications as well. 
Smoking is another important factor. However, smoking is now known to be a 
powerful addiction. There are a number of medical aids to quitting smoking such 
as nicotine replacement and drugs to decrease nicotine withdrawal symptoms. 
Unfortunately, success rates for quitting smoking are of the order of 10 - 15%, 
even with the best programs. It takes persistence and determination to quit. 
Alcohol when consumed in excess can exacerbate snoring and OSA. Intervention 
is not usually required if a person drinks heavily on a few special occasions such 
as one's birthday. However, for alcoholics, the increase in apnoea due to muscle 
relaxation and sedation may be the cause of the "hangover". Again, treatment is 
more difficult in those who need it the most. 
Sleep Habits are also important. A poor night's sleep can worsen snoring and 
OSA on the following night. This can create a vicious cycle that leads to rapid 
worsening of snoring and OSA. 
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GUIDE TO GOOD SLEEP HYGIENE 
Good sleep hygiene consists of practices that reinforce the body's natural tendency to 
sleep at night. 
Maintain a regular bedtime and awakening time. For most people, nightly time in bed 
should be no longer than 7 hours since excessive time in bed may fragment sleep. Get out 
of bed at the regular time even if sleep was poor, as "sleeping in" can disturb sleep the 
following night. 
I. Do not nap during the day as these results in poorer sleep at night. 
2. Do not drink alcoholic beverages in the evening as this disturbs sleep. 
3. Avoid caffeinated beverages after noontime, as caffeine disturbs sleep. Limit total 
caffeine consumption to no more than two beverages per day. 
4. Do not smoke just before bedtime or during the night as this disturbs sleep. 
5. Exercise regularly during the day, but avoid exercise in the evening within 3 hours of 
bedtime. 
6. Do not use the bed or bedroom for anything other than sleep and sexual activity. If 
the bedroom is used for non-sleep activities (such as watching TV), it may become a 
stimulus for alertness, rather than for sleep. 
7. Establish a routine in preparation for sleep. Engaging in frustrating activities or 
excessive worry close to bedtime may result in arousal and prevent sleep. 
8. Maintain a comfortable temperature in the bedroom. 
9. Keep the bedroom dark and quiet. Try to screen out any disturbing noise or light. One 
of the most effective ways to relax at the end of a stressful day is to do some 
abdominal breathing. Put on some relaxing musing or nature sounds (the sound of 
rain or running water). Dim the lights or turn them off. Stretch out on the bed or sofa 
and roll your shoulders around a few times. Now you can focus on your breathing. 
Take note of thefollowing: 
-Is your breathing rhythmic? 
-Is your breathing relaxed? 
-Is your chest moving up and down? 
-Is your abdomen moving in and out? 
When you are tense, breathing can be irregular and forced. Most people also use their 
chest to breath when they are upset. The most natural way to breath is to use the 
diaphragm which pushes down into the abdomen. Breathing should be relaxed and 
rhythmic. 
Try thefollowing exercises: 
-Breath without using your chest at all. Support your head on a pillow in order to relax 
your neck muscles. -Take several deep breaths into the abdomen. Exaggerate this motion 
to give yourself a better sense of which muscles are involved. -Place a book on your chest 
and another on your 
abdomen. The book sitting on the chest should remain still. The book on the abdomen 
should clearly move up and down in time with your breathing. Practice these exercises for 
a minimum of 30 minutes each day so that the abdominal breathing becomes a habit that 
you do without thinking. 
Once you have formed this habit, you are ready to move on to the next phase. In this 
phase, you simply add a brief pause at the end of each breath. Therefore, the breathing 
cycle becomes: inhale, exhale, pause... inhale, exhale, pause... 
If you find that the worries of the day are intruding on your breathing exercises, simply 
say to yourself. "Ah ha, my mind has wandered. Let's return to the breathing task. " 
If this is not successful in getting you refocused on the breathing, try repeating a simple 
two syllable expression to yourself. Some examples are "one-two", "deep down", and "in- 
out". 
Remember, practice makes perfect. 
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SPECIMEN LETTER ACCOMPANYING PILOT PCT SURVEY 
September 2001 
4(Tltle* wFirstName*wLastName* 
4(Addressl* 
4cAddreSS2)0 
4(City* 
<(PostalCode* 
Dear 4(Title * <(LastName)ý 0000, 
Nasal continuous positive airway pressure in Sleep apnoea 
General Practitioner survey 
Although Sleep apnoea is now recognised as a common condition causing daytime 
dysfunction among a large number of patients and relatively effective therapeutic options 
are available within the NHS, there is a wide regional variation in the provision and 
utilisation of the diagnosis and treatment facilities in the UK. 
The purpose of our study is to examine CPAP as a health technology innovation and 
evaluate the influences within the healthcare structure that determine its availability and 
take up. At this time of change for the future of the NHS, vital lessons can be learned 
about the utilisation of resources and provision of new health technology innovations. 
As the general practice provides the primary pathway for patients to seek health care 
intervention, we are keen to seek your opinion on this subject. We would be extremely 
grateful for your assistance in this survey. 
We would welcome any additional comments or observations that you wish to make from 
your experience. 
Thank you for valuable time and comments. 
With Idnd regards. 
Indranil Chakravorty 
SpR Thoracic Medicine 
Harefield Hospital 
i. chakravody0a rbh. nthames. nhs. uk 
a. szczepurara. warwick. ac. uk 
Ala Szczepura 
Professor & Director 
Centre for Health Services Studies 
University of Warwick 
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4p-pc-fkh % 
CFAF UWIPY fw obs"ll" 
*0 
MIL-- 
rl-m SWM 
L Age "p <30 years 
30-39 years 
4849 yean 
_ 4&59, #ears 
60-615 yeen 
2. SCIL - 
%tale 
Female 
3.1',. PC Of P! PF#ft 
%I a hiple 1!!. 1: 1WI 
0 
1 rbom 0 
Rural 0 
4. t)ws 
Norse prScti6Mer/-WciA list 0 
. Ha,, e vem rM &my pmtkots with 
Sleep speoes in your practice? 51 
6. HOW hmq bove y!! beem refeMeAptiests with Sleep SPRoes 
< Svears 
S-10 , years 10- 14 %cars 
Is- 19 years 
-; -20-ýears 
11wrapy for Skýpmpmoes 
7. How Would you rate the following options in order of clinical 
eftcbýeeew ? I- most effective 
I deso le stratep (%% eight reduction + MeepbyCseje) 
Oral devicti/ maodibular %plints 
rkr 
IAW Palatoplaso 
& How woold you rate the following options in order of patient 
we"tabifity? I -most acceptable 
__ 
I 
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Lifestyle strategy (Weight reduction + sleep hygiene) :1 
Oral devices/ mandibular splints 
C P. A p 
Laser palatoplasty E 
9. Characteristics of CPAP 
Does CPAP have any advantages over other options 
Is CPAP compatible with normal sleep 
F-. 0 
10. Is CPAP therapy for your average patient 
Too complex 0 
Eas,, to understand & operate 
Moderately complex 0 11 
-i-I. Can the benefit of CPAP therapy 
Objectively evaluated E Ell 
Subjective reporting only E 
Both E 
12. hich of the following had the most influence on your opinion about 
CPAP therapy 
Journal articles 
Scientific meetings/ seminars 
Media 
Advertising by manufacturers/ reps El 
Information from peers -1 
Information from Hospital Consultants El 
Patient pressure 
13.1 he future of CPAP in Sleep apnoes 
e-PAP is likel% to remain the most effective therapy F, 
CPA P will probabl-, be replaced by more effective therapy 
CPAP will be replaced by more patient friendly therapy E, 
Nome of the above F- 
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PCJ QUESTIONNAIRE SURVENý 
NOW 
-I 
--ALS -I I *Way pressure owapy 
About you/ your PCT (Swuth East Sheffield PCT) 
I. Are there any patients With snoring or sleep breathing disorders in your Yes No 
nractICE? El 11 
2. If yes, please indicate how long have you/ your practice been refemng patients 
with snoring / suspected Sleep breathing disorders? 
5 years 
5- 10 years 
10-20 years 
>20 years El 
C01116111111011111 POsitive Airway Pressure (CPAP) therapy for Sleep breathing 
disorden (Vour opinion as a Primary care physician) 
3 What %%ould vou consider to be the primary reason for treatment in your 
patients %ith Sleep apnoea? 
Please tick only one re,, pome. 
Reducing excessive daNlime sleepiness 
Preventing cardiovascular sequelae El 
Reducing nsk of death dunng sleep 
Quality of life improvenient 
Better performance at work 
Avoidance of sleep related driving risk 
PsycholoWcal imiDrovement 
4. Please would you rate the following treatment options for sleep apnoea (in 
order of clinical effiectiveness) in your opinion or your patient's experience? 
/ mot eflective A, 4 leavi tVec-ttve 
Lifestyle strategy (weight reduction + sleep hygiene) 
Oral devices mandibular advancement splints 
Continuous positive airway pressure device (CPAP) 
Laser u%, ulopalatopharvngoplasty (UVPPP) 
5. Pleaw would you mte the following options in order of patient acceptability in 
your opinion? 
CPAP 0 
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Laser UVPPP 
6. In your opinion is CPAP therapy for your average patient 
Too complex 
Easy to understand & operate 
Moderately complex 
i. wrticn ot tne tollowing pattiways ot Knoweage aittusion ao you tninic naa tne 
most impact on shaping the opimon of primary care physicians on CPAP therapy 
for Sleep apnoea? / most impact &7 leasi impact 
Scientific/ professional journal articles 
Scientific meetingsi seminars 
Media reporting 
Advertising by manufacturers/ reps 
Direct information from peers 0 
Information from Hospital Consultants/ Specialists 11 
Patient/ patient group pressure 11 
8. Which of the following groups do you consider your viewpoint to a new 
innovation to be closest to ? (Groups are described using standard diffusion 
literature terrmv) 
Innovators 
Early adopter 
Early majority 
Late ma)onty 
Resistant to chanste 
9. Do you feel that a clear pathway/ system exists for the diffusion of knowledge 
about new innovations from the experts to the pnmary care physicians (with 
reference to CPAP in Sleep breathing disorders)? 
Yes, there is an existing system of knowledge diffusion and adoption in my 
A sN stem has rccently been put in place In my PCT 
Them is no clear system but some spoWic ledures/ meetings etc. El 
No sý stem except pcrsonal initiative and peer contacts 
Any othcr 
10. The current state of play with CPAP in Sleep breathing disorders; Yes 
Do you dunk majonty of patients with sleep apnoea are easily receiving the 
treamient needed in your patient group? 
If no, where do )ou think the hurdles he? 
Lack of diagnostic facilities in your local DGH 11 
Lack of adequate resources r- 1 Li 
sess of their problems Lack of patient awarer 
Lack of physician time/ initiative in the district El 
Any odwr 0 
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ýPECIMEN LETTER ACCOMPANYING SECONDARY CARE SURVEY1 
vFirst-Name* <<Last-Naxneo 
Consultant Respiratory Physician 
<<Hospitab> 
cAddress - 
Line-i>> 
cAddress-Line-2o 
cCitr> 
<<ZIP_Codeo 
November 2002 
Dear Dr 4(Last-Name)ý, 
Nasal continuous positive airway pressure in Sleep apnoea 
Respiratory Specialist survey 
Although Sleep apnoea is now recognised as a common condition causing daytime 
dysfunction among a large number of patients and relatively effective therapeutic options 
are available within the NHS, there is a wide regional variation in the provision and 
utilisation of the diagnosis and treatment facilities in the UK. 
The purpose of our study is to examine CPAP as a health technology innovation and 
evaluate the influences within the healthcare structure that determine its availability and 
take up. At this time of change for the future of the NHS, vital lessons can be learned 
about the utilisation of resources and provision of new health technology innovations. 
As a Respiratory Specialist in secondary or tertiary care your firm/ unit would be the first 
port of call for primary care physicians faced with a patient with a suspected sleep 
breathing disorder, hence we are keen to seek your opinion on this subject. We would be 
extremely grateful for your assistance in this survey. (Please feel free to forward this to a 
colleague who you feel may have a greater personal interest in this subject) 
We would welcome any additional comments or observations that you wish to make from 
your experience. 
Thank you for valuable time and comments. 
With kind regards. 
Indranil Chakravorty 
SpR Respiratory Medicine 
Royal Brompton Hospital 
PhD researcher, CHeSS 
University of Warwick, 
ichakravorty rahotmail. com 
Ala Szczepura 
Professor & Director 
Centre for Health Services Studies 
Warwick Business School 
a. szczej2ura(@warwick. ac. uk 
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Appen&ýr 
Nasal continuous positive airway pressure therapy in Obstructive sleep 
apnoea: Respiratory Specialist Survev- I 
ABOUT YOUR HOSPITAL/ FIRM (((HOSPITAL>)) 
1. Is your hospital 
DGH 
Teaching Hospital with A/E 
Tertiary Care without A/E 
2. Does your hospital have facilities for the diagnosis of Sleep breathing disorders? Yes No 
ff yes, please tick the options applicable 
Dedicated sleep laboratory with full polysomnography 
Portable polysomnography on the ward El 
Limited inpatient sleep studies (without EEG/ sleep staging) 11 
Home based sleep studies El 
Overnight pulse oximetry El 
Any other El 
3. Are there facilities 
" 
for the provision of the following in your hospital? 
Specialised dietary/ obesity services 
Mandibular advancement devices 
CPAP 
ENT surgical option locally (Palatoplasty) 
Mental health support 
4. How many referrals does your hospital/ firm receive annually with suspected snoring 
sleep breathing disorder? 
<50 
51-100 
101-150 
>150 
5. How many patients approximately do you have under your departments care with 
sleep disordered breathing? 
<100 
101-250 
251-500 
501-1000 
>1000 
6. How many CPAP Machines does your department prescribe/ provide in a year? 
<50 
51-100 
101-200 
>200 
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7. What is the estimated annual expansion in the number of patients prescribed CPAP 
machines in the last 10 years? 
<5% 
6-10% 
11-150 
>15% 
B. What in your opinion is the primary indication for treating patients with sleep 
disordered breathing? 
Please tick only one 
Reducing excessive daytime sleepiness 
Preventing cardiovascular sequelae 
Reducing risk of death during sleep 
Quality of life improvement 
Better performance at work 
Reduction of sleep related driving risk 
Psychological improvement 
9. Please would you rate the following treatment options for clinically significant sleep 
so red breathing (in order of clinical effectiveness) in your opinion? 
I= mo t effective &4= least effective 
Lifestyle strategy (weight reduction + sleep hygiene) 
Oral devices/ mandibular advancement splints 
Continuous positive airway pressure device (CPAP) 
Laser uvulopalatopharyngoplasty (UVPPP) 
10. Please would you rate the following options in order of patient acceptability in your 
opinion? 
1= most acceptable &4= least acceptable 
Lifestyle strategy (weight reduction + sleep hygiene) 
Oral devices/ mandibular splints 
CPAP 
Laser UVPPP 
11. Do you agree with the following statements about CPAP therapy? Aqree Disagree 
Has a relative advantage to other forms of therapy? 0 0 
is compatible with patient's lifestyle, sleep and home environment El 0 
Is not too complex for an average middle-aged patient? 
it is possible to provide a trial without permanent/ irreversible effects 
The benefits can be objectively assessed 
12. Which of the following pathways of communication/ knowledge diffusion do you 
think had the most impact on shaping the opinion of Respiratory physicians on CPAP 
therapy for Sleep disordered breathing? 
I= most impact &7= least impact 
Scientific/ professional journal articles El 
Scientific meetings/ seminars 0 
Media 0 
Advertising by manufacturers/ reps 
peer-peer contact 
Patient/ patient group lobbying 
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13. Which of the following groups do you consider your viewpoint towards a new 
innovation to be closest to? 
(Groups are described using standard diffusion literature terms) 
Innovators 
Early adopter El 
Early majority El 
Late majority 
Resistant/ reluctant to change easily 
14. Do you feel that a clear pathway/ system is available for the diffusion of knowledge 
about new innovations from the experts to the primary care / secondary care 
physicians within the NHS (with reference to CPAP in Sleep breathing disorders)? 
Yes, there is an existing system of knowledge diffusion & adoption in my district 
A system has recently been put in place 
There is no clear system but some sporadic lectures/ meetings etc.. 
No system except personal initiative and peer contacts 
Any other El 
15. The current state of play with CPAP in Sle ep breathing disorders; 
Do you think majority of patients with sleep disordered breathing are easily receiving 
the treatment needed in your catchment area? 
Yes No 
If no, where do you think the hurdles lie? 
Lack of diagnostic facilities in your hospital El El 
Lack of appropriate resources El 
Lack of patient awareness of their problems 11 
Lack of physician time/ initiative in general practice 0 El 
Any other 
16. YOUR OPINION FOR THE FUTURE OF CPAP IN SLEEP APNOEA YES NO 
CPAP is likely to remain the most effective therapy El 
CPAP will probably be replaced by more effective therapy 
CPAP will be replaced by more patient friendly therapy 
None of the above 
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